0000930413-15-004681.txt : 20151208 0000930413-15-004681.hdr.sgml : 20151208 20151208073050 ACCESSION NUMBER: 0000930413-15-004681 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20151031 FILED AS OF DATE: 20151208 DATE AS OF CHANGE: 20151208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZO BIOCHEM INC CENTRAL INDEX KEY: 0000316253 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 132866202 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09974 FILM NUMBER: 151274056 BUSINESS ADDRESS: STREET 1: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: 5167555500 MAIL ADDRESS: STREET 1: ENZO BIOCHEM INC STREET 2: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 10-Q 1 c83212_10q.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Mark one

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2015

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number 001-09974

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter)

New York		13-2866202
(State or Other Jurisdiction		(IRS. Employer
of Incorporation or Organization)		Identification No.)

527 Madison Ave, New York, New York		10022
(Address of Principal Executive office)		(Zip Code)

212-583-0100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 45 of Regulation S-T (§232.405 of that chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes o No x

As of December 2, 2015, the Registrant had approximately 46,069,000 shares of common stock outstanding.

ENZO BIOCHEM, INC.
FORM 10-Q
October 31, 2015

INDEX

PART I - FINANCIAL INFORMATION

Item 1.	Condensed Financial Statements	3

	Consolidated Balance Sheets – October 31, 2015 (unaudited) and July 31, 2015 (audited)	3

	Consolidated Statements of Operations for the three months ended October 31, 2015 and 2014 (unaudited)	4

	Consolidated Statements of Comprehensive Income (Loss) for the three months ended October 31, 2015 and 2014 (unaudited)	5

	Consolidated Statement of Stockholders’ Equity for the three months ended October 31, 2015 (unaudited)	6

	Consolidated Statements of Cash Flows for the three months ended October 31, 2015 and 2014 (unaudited)	7

	Notes to the Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

Item 4.	Controls and Procedures	27

Part II – OTHER INFORMATION

Item 1.	Legal Proceedings	28

Item 1A.	Risk Factors	28

Item 6.	Exhibits	28

Signatures		28

Part 1 Financial Information

Item 1 Financial Statements

ENZO BIOCHEM, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	October 31, 2015 (unaudited)			July 31, 2015
ASSETS
Current assets:
Cash and cash equivalents	$	30,642		$	18,109
Accounts receivable, net of allowances		12,763			12,109
Other accounts receivable		—			6,650
Inventories		7,582			7,396
Prepaid expenses and other		1,780			2,222
Total current assets		52,767			46,486

Property, plant and equipment, net		8,132			7,948
Goodwill		7,452			7,452
Intangible assets, net		5,707			6,155
Other assets		338			353
Total assets	$	74,396		$	68,394

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Loan payable	$	3,013		$	3,013
Accounts payable – trade		9,450			8,762
Accrued liabilities		12,357			11,297
Other current liabilities		969			886
Total current liabilities		25,789			23,958

Deferred taxes		37			37
Other liabilities		1,357			1,793
Total liabilities	$	27,183		$	25,788

Commitments and contingencies

Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding		—			—
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,068,816 at October 31, 2015 and 46,062,065 at July 31, 2015		461			461
Additional paid-in capital		325,077			324,966
Accumulated deficit		(280,248	)		(284,682	)
Accumulated other comprehensive income		1,923			1,861
Total stockholders’ equity		47,213			42,606
Total liabilities and stockholders’ equity	$	74,396		$	68,394

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(in thousands, except per share data)

	Three Months Ended October 31,
	2015			2014
Revenues:
Clinical laboratory services	$	17,090		$	15,822
Product revenues		7,687			8,002
Royalty and license fee income		400			1,000
Total revenues		25,177			24,824

Operating expenses:
Cost of clinical laboratory services		10,332			10,130
Cost of product revenues		3,611			3,695
Research and development		867			791
Selling, general, and administrative		10,225			10,285
Provision for uncollectible accounts receivable		704			541
Legal fee expense		1,601			2,466
Legal settlements, net		(6,800	)		—
Total operating expenses		20,540			27,908

Operating income (loss)		4,637			(3,084	)

Other income (expense):
Interest		(40	)		(69	)
Other		54			19
Foreign exchange loss		(130	)		(472	)
Income (loss) before income taxes		4,521			(3,606	)
Provision for income taxes		(87	)		(123	)
Net income (loss)	$	4,434		$	(3,729	)

Net income (loss) per common share:
Basic	$	0.10		$	(0.08	)
Diluted	$	0.10		$	(0.08	)

Weighted average common shares outstanding:
Basic		46,068			44,564
Diluted		46,193			44,564

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(in thousands)

	Three Months Ended October 31,
	2015		2014
Net income (loss)	$	4,434	$	(3,729	)
Other comprehensive income (loss):
Foreign currency translation adjustments		62		108
Comprehensive income (loss)	$	4,496	$	(3,621	)

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

Three months ended October 31, 2015

(UNAUDITED)

(in thousands, except share data)

	Common Stock Shares		Common Stock Amount		Additional Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income		Total Stockholders’ Equity
Balance at July 31, 2015		46,062,065	$	461	$	324,966	$	(284,682	)	$	1,861	$	42,606
Net income for the period ended October 31, 2015		—		—		—		4,434			—		4,434
Vesting of restricted stock		6,751		—		—		—			—		—
Share-based compensation charges		—		—		111		—			—		111
Foreign currency translation adjustments		—		—		—		—			62		62
Balance at October 31, 2015		46,068,816	$	461	$	325,077	$	(280,248	)	$	1,923	$	47,213

The accompanying notes are an integral part of these consolidated financial statements

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)

	Three Months Ended October 31,
	2015			2014
Cash flows from operating activities:
Net income (loss)	$	4,434		$	(3,729	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment		527			507
Amortization of intangible assets		423			431
Provision for uncollectible accounts receivable		704			541
Deferred income tax benefit		(3	)		(24	)
Share-based compensation charges		111			98
Accrual for share-based 401(k) employer match expense		166			145
Foreign exchange loss		129			422

Changes in operating assets and liabilities:
Accounts receivable		(1,376	)		(482	)
Other receivables – settlements		6,650			—
Inventories		(210	)		107
Prepaid expenses and other		442			182
Accounts payable – trade		682			(1,157	)
Accrued liabilities, other current liabilities and other liabilities		474			204
Total adjustments		8,719			974

Net cash provided by (used in) operating activities		13,153			(2,755	)

Cash flows from investing activities:
Capital expenditures		(505	)		(264	)
Security deposits and other		15			5
Net cash used in investing activities		(490	)		(259	)

Cash flows from financing activities:
Net proceeds from issuance of common stock		—			2,322
Proceeds from borrowings under Credit Agreement		22,461			22,360
Repayments under Credit Agreement		(22,461	)		(22,360	)
Installment loan and capital lease obligation payments		(125	)		(115	)
Net cash (used in) provided by financing activities		(125	)		2,207

Effect of exchange rate changes on cash and cash equivalents		(5	)		(57	)

Increase (decrease) in cash and cash equivalents		12,533			(864	)
Cash and cash equivalents - beginning of period		18,109			17,455
Cash and cash equivalents - end of period	$	30,642		$	16,591

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of October 31, 2015

(Unaudited)
(Dollars in thousands, except share data)

Note 1 – Basis of Presentation

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of October 31, 2015, the consolidated statements of operations, comprehensive income (loss), and cash flows for the three months ended October 31, 2015 and 2014, and the consolidated statement of stockholders’ equity for the three months ended October 31, 2015 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2015 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2015 has been derived from the audited financial statements at that date. The results of operations for the three months ended October 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2016.

Note 2 – Net income (loss) per share

Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three month period ended October 31, 2014, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive.

For the three months ended October 31, 2015, approximately 125,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. For the three months ended October 31, 2014, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 482,000.

For the three months ended October 31, 2015 and 2014, the effect of approximately 374,000 and 142,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive.

Note 3 - Supplemental disclosure for statement of cash flows

For the three months ended October 31, 2015 and 2014, income taxes paid by the Company were $27 and $26, respectively.

For the three months ended October 31, 2015 and 2014, interest paid by the Company was $41 and $69, respectively.

For the three months ended October 31, 2015 and 2014, the Company financed $38 and $19 respectively, in machinery and transportation equipment under installment loans.

During the three months ended October 31, 2015, there was a total of $157 in capital lease agreements. During the three months ended October 31, 2014, the Company did not enter into any capital lease agreements.

Note 4 - Inventories

Inventories consist of the following:

	October 31, 2015		July 31, 2015
Raw materials	$	1,109	$	1,013
Work in process		1,984		2,002
Finished products		4,489		4,381
	$	7,582	$	7,396

Note 5 – Goodwill and intangible assets

At October 31, 2015 and July 31, 2015, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452.

The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows:

	Gross			Accumulated Amortization			Net
July 31, 2015	$	27,838		$	(21,683	)	$	6,155
Amortization expense		—			(423	)		(423	)
Foreign currency translation		(97	)		72			(25	)
October 31, 2015	$	27,741		$	(22,034	)	$	5,707

Intangible assets consist of the following:

	October 31, 2015							July 31, 2015
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Patents	$	11,027	$	(10,879	)	$	148	$	11,028	$	(10,871	)	$	157
Customer relationships		12,190		(7,621	)		4,569		12,243		(7,398	)		4,845
Website and acquired content		1,016		(1,016	)		—		1,020		(1,020	)		—
Licensed technology and other		515		(443	)		72		518		(441	)		77
Trademarks		2,993		(2,075	)		918		3,029		(1,953	)		1,076
Total	$	27,741	$	(22,034	)	$	5,707	$	27,838	$	(21,683	)	$	6,155

At October 31, 2015, information with respect to intangibles assets acquired is as follows:

	Useful life assigned	Weighted average remaining useful life
Customer relationships	8-15 years	5 years
Trademarks	5 years	2 years
Other intangibles	10 years	4 years

At October 31, 2015, the weighted average useful life of amortizable intangible assets is approximately four years.

Note 6 - Loan Payable

borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%. In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the Credit Agreement. At October 31, 2015 and July 31, 2015, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million.

The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. In July 31, 2013, the lender modified various financial covenants relating to fiscal 2014. As of October 31, 2015, the Company is in compliance with the financial covenants.

The Credit Agreement includes customary affirmative and negative covenants and events of default. The terms of the debt covenants include:

The minimum balance the Company must borrow at any time is $2.0 million. At October 31 2015, the loan balance was approximately $3.0 million, with an additional availability of $2.4 million.

The Company must maintain a Minimum Liquidity, as defined in the Credit Agreement, of not less than $3.0 million. At October 31, 2015, the Company’s Minimum Liquidity was $11.0 million.

The quarterly Cash Burn, as defined in the Credit Agreement, must be greater than zero. During the three months ended October 31, 2015, the Cash Burn was positive in the amount of $1.4 million.

As of October 31, 2015, the Credit Agreement was amended to redefine Cash Burn and add a definition for Liquidity (the “amendment”). Under the amendment, the determination of Cash Burn during a fiscal quarter excludes capital expenditures provided that Liquidity exceeds $7 million as of the last day of the fiscal quarter. As of October 31, 2015, Liquidity as defined was $33.1 million.

Based on its current level of Minimum Liquidity and Cash Burn, the Company believes it will continue to be in compliance with the financial covenants in future periods; however there are no assurances of such compliance. Based on our ability to comply with financial covenants in the past, our ability to obtain covenant waivers previously, and our expected future performance, we believe we would be able to cure a non-compliance event and obtain a Lender waiver. The Company currently believes that the Lender would be willing to negotiate and provide waivers to the Company in the event of non-compliance with covenants, although there can be no assurances. In addition, the Company believes the effects of non-compliance with the covenants would not have a material effect on our financial condition and liquidity due to cash provided by operating cash flows and funds available under the Company’s Controlled Equity Offering program.

Note 7 – Accrued Liabilities and Other Current Liabilities

Accrued liabilities consist of the following:

	October 31, 2015		July 31, 2015
Legal fee expense	$	4,999	$	4,183
Payroll, benefits, and commissions		4,717		3,907
Professional fees		491		678
Research and development		300		300
Other		1,850		2,229
	$	12,357	$	11,297

Note 8 – Other Liabilities

Other liabilities consist of the following:

	October 31, 2015		July 31, 2015
Accrued legal settlement	$	807	$	1,220
Capital lease obligations, net of short term		305		210
Installment loans, net of short term		245		363
	$	1,357	$	1,793

As of October 31, 2015, future minimum payments under the capital leases, net of interest of $23 aggregates $579, including a short term debt portion of $274 included in other current liabilities. Future minimum payments under the installment loans aggregate $534, including a short term portion of $289 included in other current liabilities. A total of $1.2 million was recorded in other current liabilities and in other liabilities as accrued legal settlement which is further discussed in Note 13 - Contingencies.

Note 9 – Stockholders’ Equity

Controlled Equity Offering

On March 28, 2013, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sales Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to the Company’s Registration Statement on Form S-3 which was declared effective on August 5, 2010 and a prospectus supplement, dated March 28, 2013, and more recently under the Company’s current Registration Statement on Form S-3 which was declared effective on August 13, 2013 and a prospectus supplement dated August 1, 2013, filed by the Company with the Securities and Exchange Commission (the “SEC”).

On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus supplement dated December 31, 2014.

During the three months ended October 31, 2015, the Company did not sell any shares of Common Stock under the Sales Agreement. For the three months ended October 31, 2014, the Company sold an aggregate of 505,829 shares of Common Stock under the Sales Agreement at an average price of $5.38 per share and received proceeds of approximately $2.6 million, net of expenses of $82.

Share-based compensation

The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2015. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended October 31,
	2015		2014
Stock options	$	104	$	85
Restricted stock		7		13
	$	111	$	98

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended October 31,
	2015		2014
Cost of clinical laboratory services	$	1	$	1
Research and development		—		1
Selling, general and administrative		110		96
	$	111	$	98

No excess tax benefits were recognized during the three month periods ended October 31, 2015 and 2014.

Stock Option Plans

The following table summarizes stock option activity during the three month period ended October 31, 2015:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2015		1,358,104		$	3.04
Awarded		—		$	—
Exercised		—		$	—
Cancelled or expired		(6,000	)	$	3.61
Outstanding at end of period		1,352,104		$	3.04	2.2 years	$	964
Exercisable at end of period		785,188		$	2.87	1.8 years	$	664

As of October 31, 2015, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.4 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is eleven months.

The intrinsic value of in the money stock option awards that are vested at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that vested.

Restricted Stock Awards

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the three months ended October 31, 2015 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2015		21,501		$	8.84
Awarded		—		$	—
Vested		(6,751	)	$	(2.10	)
Forfeited		(1,500	)	$	(2.86	)
Unvested at end of period		13,250		$	4.04

The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of October 31, 2015, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately twenty-one months. The fair value of the awards that vested during the three months ended October 31, 2015 and 2014 was $21 and $35, respectively.

The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,309,000 shares as of October 31, 2015.

Note 10 - Income taxes

At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.

The Company’s effective tax rate provision for the three months ended October 31, 2015 was 1.9% compared to 3.4% for the three months ended October 31, 2014. The tax provision for the periods was based on state, local and foreign taxes, net of the benefit for amortization of foreign intangibles. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

The Company files a consolidated Federal income tax return. The Company files combined returns with California, Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns.

Note 11 – Royalty and licensing income

The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended October 31, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $0.4 million and $1.0 million respectively, which is included in the Life Sciences segment.

Note 12 – Segment reporting

The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.

Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. Legal settlements, net represent activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the products covered by the settlements.

Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2015.

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2015

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	17,090			—			—			—		$	17,090
Product revenues		—		$	7,687			—			—			7,687
Royalty and license fee income		—			400			—			—			400
		17,090			8,087			—			—			25,177
Operating expenses:
Cost of clinical laboratory services		10,332			—			—			—			10,332
Cost of product revenues		—			3,611			—			—			3,611
Research and development		—			667		$	200			—			867
Selling, general and administrative		5,286			3,059			—		$	1,880			10,225
Provision for uncollectible accounts receivable		708			(4	)		—			—			704
Legal fee expense		9			(22	)		—			1,614			1,601
Legal settlement, net		—			(6,800	)		—			—			(6,800	)
Total operating expenses		16,335			511			200			3,494			20,540

Operating income (loss)		755			7,576			(200	)		(3,494	)		4,637

Other income (expense)
Interest		(19	)		14			—			(35	)		(40	)
Other		4			39			—			11			54
Foreign exchange loss		—			(130	)		—			—			(130	)
Income (loss) before income taxes	$	740		$	7,499		$	(200	)	$	(3,518	)	$	4,521

Depreciation and amortization included above	$	397		$	530		$	—		$	23		$	950

Share-based compensation included in above:
Cost of clinical laboratory services	$	1			—			—			—		$	1
Research and development		—		$	—			—			—			—
Selling, general and administrative		10			5			—		$	95			110
Total	$	11		$	5			—		$	95		$	111

Capital expenditures	$	437		$	68		$	—		$	—		$	505

Three months ended October 31, 2014

	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	15,822			—			—			—		$	15,822
Product revenues		—		$	8,002			—			—			8,002
Royalty and license fee income		—			1,000			—			—			1,000
		15,822			9,002			—			—			24,824
Operating expenses:
Cost of clinical laboratory services		10,130			—			—			—			10,130
Cost of product revenues		—			3,695			—			—			3,695
Research and development		—			548		$	243			—			791
Selling, general and administrative		5,066			3,150			—		$	2,069			10,285
Provision for uncollectible accounts receivable		530			11			—			—			541
Legal fee expense		91			1			—			2,374			2,466
Total operating expenses		15,817			7,405			243			4,443			27,908

Operating income (loss)		5			1,597			(243	)		(4,443	)		(3,084	)

Other income (expense)
Interest		(27	)		2			—			(44	)		(69	)
Other		2			(8	)		—			25			19
Foreign exchange gain		—			(472	)		—			—			(472	)
Income (loss) before income taxes	$	(20	)	$	1,119		$	(243	)	$	(4,462	)	$	(3,606	)

Depreciation and amortization included above	$	357		$	560		$	1		$	20		$	938

Share-based compensation included in above:
Cost of clinical laboratory services	$	1			—			—			—		$	1
Research and development		—			1			—			—			1
Selling, general and administrative		9		$	—			—		$	87			96
Total	$	10		$	1			—		$	87		$	98

Capital expenditures	$	254		$	10		$	—		$	—		$	264

Note 13 – Contingencies

On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company could be reduced or be subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. The Company has moved for reconsideration of that decision by the panel and for en banc rehearing by the full Court. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company.

As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The litigation in the United States District Court for the Southern District of New York between the Company and Molecular Probes, Inc. terminated on May 11, 2015, with a settlement in favor of the Company in the amount of $170. Through October 31, 2015, the Company’s former legal counsel, Greenberg Traurig LLP (“GT”), was also engaged in litigation against the Company in the United States District Court for the Southern District of New York concerning GT’s request for a charging lien against another matter relating to its representation of the Company in the Roche and other cases.

On April 22, 2014, the Company as plaintiff finalized and executed a settlement agreement with Affymetrix, Inc. to settle patent litigation actions before the U.S. District Court, Southern District of New York (the “Agreement”) in the amount of $5.1 million. Under terms of the Agreement, Affymetrix paid to the Company $4.3 million and paid to the Company’s attorneys $0.8 million.

On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of GT’s requesting a charging lien for fees allegedly owed for past services rendered to the Company as referenced above. Because the settlement proceeds were held in escrow, and the amount the Company would ultimately receive was indeterminable, the Company has not included the settlement in the financial statements as of or for any periods through October 31, 2015. Any applicable amounts will be recognized when so distributed. On December 3, 2015, the Company entered into a Settlement Agreement with GT pursuant to which the Company and GT resolved their respective claims against each other. The escrow referred to above will be distributed in accordance with the terms of the Settlement Agreement, upon the entry by the Court of the Stipulation, Order and Judgement.

In 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. As of October 31, 2015, the Company carried a balance of $0.4 million as other current liabilities and $0.8 million as a non-current liability. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004-2014.

On July 2, 2015, the Company as Plaintiff executed a settlement agreement with Luminex Corporation with respect to an action between the Company and Abbott Laboratories and Abbott Molecular, Inc (Defendants) and Luminex Corporation (Intervening Defendant) before the United States District Court for the District of Delaware for alleged patent infringement. Luminex paid the Company a total of $7.1 million as consideration for this agreement and the dismissal of the litigation against Luminex.

On July 20, 2015, the Company as a Plaintiff finalized and executed a settlement agreement with Siemens Healthcare Diagnostics Inc. (“Siemens”) to settle a patent litigation lawsuit before the U.S. District Court for the District of Delaware in the amount of $9.5 million. Under terms of the agreement, Siemens will also pay the Company additional royalties of $1.0 million per annum on sales of its molecular products manufactured and/or sold in the United States during the its fiscal years 2015 through 2019 if sales of such products exceed a contractual amount. The net settlement amount was included in other receivables in the consolidated balance sheet as of July 31, 2015 and was received in August 2015.

On October 9, 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in an infringement action brought by the Company regarding its US Patent no. 7,064,197. The case was originally brought by the Company in the United States District Court for the District of Delaware. This settlement is included in statement of operations under Legal settlements, net within the Life Science segment.

The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

Our disclosure and analysis in this report, including but not limited to the information discussed in this Item 2, contain forward-looking information about our Company’s financial results and estimates, business prospects and products in research and development that involve substantial risks and uncertainties. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “will”, and other words and terms of similar meaning in connection with any discussion of future operations or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign currency rates, intellectual property matters, the outcome of contingencies, such as legal proceedings, and financial results.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements. Investors should bear this in mind as they consider forward-looking statements. We do not assume any obligation to update or revise any forward-looking statement that we make, even if new information becomes available or other events occur in the future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the July 31, 2015 fiscal year. You are advised to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect our operating results. You should understand that it is not possible to predict or identify all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Overview

Enzo Biochem, Inc. (the “Company” “we”, “our” or “Enzo”) is a growth-oriented biotechnology company focusing on delivering and applying advanced technology capabilities to produce affordable reliable products and services to allow our customers to meet their clinical needs. We develop, manufacture and sell our proprietary technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. Our pioneering work in genomic analysis coupled with our extensive patent estate and enabling platforms have positioned the Company to continue to play an important role in the rapidly growing molecular medicine marketplaces.

Enzo technology solutions and platforms and unique operational structure is designed to reduce overall healthcare costs to both government and private insurers. Our proprietary technology platforms reduces our customers’ need for multiple, specialized instruments, and offer a variety of throughput capabilities together with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused on large and growing markets primarily in the areas of personalized medicine, women’s health, infectious diseases and genetic disorders.

For example, our AmpiProbe™ technology platform can lead to the development of an entire line of nucleic acid clinical products that can allow laboratories to offer a complete menu of services at a cost that allows them to enjoy an acceptable margin. In November 2015, New York State approved our first assay based on the AmpiProbe platform aimed at providing affordable molecular diagnostics in light of reimbursement pressure. Our technology solutions provide tools to physicians, clinicians and other health care providers to improve detection, treatment and monitoring of a broad spectrum of diseases and conditions. In addition, reduced patient to physician office visits translates into lower healthcare processing costs and greater patient services.

We are comprised of three operating segments that have evolved out of our core competence: the use of nucleic acids as informational molecules and the use of compounds for immune modulation.. Information concerning sales by geographic area and business segments for fiscal year ended July 31, 2015 can be found in our Form 10-K Note 15 in the Notes to Consolidated Financial Statements.

Below are brief descriptions of each of our operating segments (See Note 12 in the Notes to Consolidated Financial Statements):

Enzo Clinical Labs is a clinical reference laboratory providing a wide range of clinical services to a physicians, medical centers, other clinical labs and pharmaceutical companies. The Company believes having a College of American Pathologists (“CAP”) certified medical laboratory located in New York provides us to the opportunity to more rapidly introduce cutting edge products and services to the clinical marketplace. Enzo Clinical Labs offers an extensive menu of molecular and other clinical laboratory tests or procedures used in patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. Our laboratory is equipped with state of the art communication and connectivity solutions enabling the rapid transmission, analysis and interpretation of generated data. We operate a full service clinical laboratory in Farmingdale, New York, a network of over 30 patient service centers throughout New York and New Jersey, a free standing “STAT” or rapid response laboratory in New York City and a full service phlebotomy, in-house logistics department, and information technology department.

Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers worldwide. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world.

Information regarding our technologies can be found in the “Core Technologies” section. We are internationally recognized and acknowledged as a leader in the development, manufacturing validation and commercialization of numerous products serving not only the clinical research market but life sciences researchers in the fields of cellular analysis and drug discovery, among others. Our operations are supported by global operations allowing for the efficient marketing and delivery of our products around the world.

Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. Enzo Therapeutics has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. This focus has generated a clinical and preclinical pipeline, as well as more than 111 patents and patent applications.

Results of Operations
Three months ended October 31, 2015 compared to October 31, 2014

(in 000s)

Comparative Financial Data for the Three Months Ended October 31,

Revenues:	2015			2014			Increase (Decrease)			% Change

Clinical laboratory services	$	17,090		$	15,822		$	1,268			8	%
Product revenues		7,687			8,002			(315	)		(4	)
Royalty and license fee income		400			1,000			(600	)		(60	)
Total revenues		25,177			24,824			353			1

Operating expenses:
Cost of clinical laboratory services		10,332			10,130			202			2
Cost of product revenues		3,611			3,695			(84	)		(2	)
Research and development		867			791			76			10
Selling, general, and administrative		10,225			10,285			(60	)		(1	)
Provision for uncollectible accounts receivable		704			541			163			30
Legal fee expense		1,601			2,466			(865	)		(35	)
Legal settlements, net		(6,800	)		—			(6,800	)		**
Total operating expenses		20,540			27,908			(7,368	)		(26	)

Operating income (loss)		4,637			(3,084	)		(7,721	)		**

Other income (expense):
Interest		(40	)		(69	)		(29	)		(42	)
Other		54			19			(35	)		**
Foreign exchange loss		(130	)		(472	)		(342	)		(72	)
Income (loss) before income taxes	$	4,521		$	(3,606	)	$	(8,127	)		**

** not meaningful

Consolidated Results:

The “2016 period” and the “2015 period” refer to the three months ended October 31, 2015 and 2014, respectively.

Clinical laboratory services revenues for the 2016 period were $17.1 million compared to $15.8 million, an increase of $1.3 million or 8%. The increase in revenue from fiscal year 2015 to 2016 is mainly attributed to an increase in molecular testing volume and new account acquisitions.

Product revenues for the 2016 period were $7.7 million compared to $8.0 million in the 2015 period, a decrease of $0.3 million or 4%. The decrease was due to the negative impact of translating revenues denominated in the euro, pound sterling and Swiss franc which depreciated versus the US dollar in the 2016 period compared to the 2015 period ($0.2 million) and declines in sales of non-proprietary products ($0.1 million), primarily in markets other than the United States.

Royalty and license fee income during the 2016 period was $0.4 million compared to $1.0 million in the 2015 period a decrease of $0.6 million or 60%. Royalties are primarily earned from the reported sales of Qiagen products subject to a license agreement. Qiagen has experienced declines in its US sales of HPV products which in turn reduces our royalty income. There are no direct expenses relating to royalty and licensing income.

The cost of clinical laboratory services during the 2016 period was $10.3 million as compared to $10.1 million in the 2015 period, an increase of $0.2 million or 2%.

The cost of product revenues during the 2016 period was $3.6 million compared to $3.7 million in the 2015 period, a decrease of $0.1 million or 2%. The gross profit margin was 53% in the 2016 period versus 54% in the 2015 period.

Research and development expenses were approximately $0.9 million during the 2016 period, compared to $0.8 million in the 2015 period, an increase of $0.1 million or 10%. The increase was attributed to payroll and material costs related to new product development.

Selling, general and administrative expenses were approximately $10.2 million during the 2016 period versus $10.3 during the 2015 period. The Clinical Lab segment selling, general and administrative increased $0.2 million primarily due to increases in selling costs and related expenses. Other segment selling, general and administrative decreased $0.2 million due to lower compensation related costs.

The provision for uncollectible accounts receivable, primarily related to the Clinical Labs segment, was $0.7 million for the 2016 period as compared to $0.5 million in the 2015 period, an increase of $0.2 million or 30%. The increase is primarily due to the increase in self-pay patient revenues. As a percent of Clinical laboratory services, the provision for uncollectible accounts receivable in the 2016 and 2015 periods was 4.1% and 3.4%, respectively.

Legal fee expense was $1.6 million during the 2016 period compared to $2.5 million in the 2015 period, a decrease of $0.9 million or 35% primarily due to the timing of legal fees and related costs associated with ongoing patent litigation.

Legal settlements, net was $(6.8) million in the 2016 period. During the 2016 period the Company as plaintiff finalized and executed a settlement agreement with Affymetrix, Inc.

Interest expense was $0.1 million during the 2016 and 2015 periods due to interest incurred and fees relating to the credit agreement entered into in 2013.

During the 2016 and the 2015 periods, the foreign currency loss was $0.1 million and $0.5 million, respectively, a favorable change of $0.3 million. The Company has loans and receivables with its foreign subsidiaries which may be denominated in US dollars or a foreign currency. When re-measuring these amounts into the respective entities’ functional currency, the Company recognizes a loss if those foreign currencies, including the Swiss Franc, British pound and Euro depreciate relative to the US dollar during the period and a gain if those foreign currencies appreciate relative to the US dollar. During the 2016 period, the Swiss franc and British pound depreciated approximately 2% versus the US dollar and the Euro appreciated by less than a half percent. During the 2015 period, all three currencies experienced greater depreciation, of between 5.1% and 5.9% relative to the US dollar.

Segment Results:

Clinical Labs

The Clinical Labs segment’s income before taxes was $0.7 million for 2016 period as compared to a loss of $(0.02) million in the 2015 period, an improvement year over year of $0.7 million. Revenue from laboratory services for the 2016 period were $17.1 million compared to $15.8 in the 2015 period. The increase of $1.3 million is mainly attributed to an increase in molecular testing volume and new account acquisitions. Cost of sales during the 2016 period was $10.3 million as compared to $10.1 million in the 2015 period, an increase of $0.2 million. Clinical Lab gross profit margin was 40% in the 2016 period and 36% in the 2015 period. The provision for uncollectable accounts was $0.7 million as compared to $0.5 million; the increase is primarily due to higher self-pay patient revenues.

Life Sciences

The Life Sciences segment’s income before taxes was $7.5 million for the 2016 period as compared to $1.1 million for the 2015 period, an improvement of $6.4 million over fiscal 2015. The 2016 period includes $6.8 million for a

patent litigation settlement agreement previously described. Product revenues decreased $0.3 million or 4% in the 2016 period due to the negative impact of translating revenues denominated in foreign currencies into the US dollar ($0.2 million) and by declines in sales of non-proprietary products ($0.1 million), primarily in markets other than the United States. The segment’s gross profit was $4.5 million in the 2016 period, as compared $5.3 million in the 2015 period, a decrease of $0.8 million primarily due to a decrease in royalty and license fee income of $0.6 million and a gross margin decrease of $0.2 million on lower product revenues. The segment’s other operating expenses, excluding legal and legal settlements, net, in the 2016 period was unchanged compared to 2015. Due to smaller depreciation of foreign currencies versus the US dollar, including the Swiss Franc, British pound and Euro during the 2016 period, the foreign currency loss was $0.1 million compared to a $0.4 million in the 2015 period, resulting in a favorable change of $0.3 million in the 2016 period.

Therapeutics

Therapeutics loss before income taxes was approximately $0.2 million in the 2016 and 2015 periods.

Other

The Other loss before taxes for the 2016 period was approximately $3.5 million as compared to $4.5 million for the 2015 period, a decrease of $1.0 million due to lower legal fee expense and related costs associated with ongoing patent litigation of $0.8 million and a decrease of $0.2 million in compensation related costs.

Liquidity and Capital Resources

At October 31, 2015, the Company had cash and cash equivalents of $30.6 million of which $0.4 million was in foreign accounts, as compared to cash and cash equivalents of $18.1 million, of which $0.5 million was in foreign accounts at July 31, 2015. It is the Company’s current intent to permanently reinvest these funds outside of the United States, and its current plans do not demonstrate a need to repatriate them to fund its United States operations. The Company had working capital of $27.0 million at October 31, 2015 compared to $22.5 million at July 31, 2015. The increase in working capital of $4.5 million was primarily due to the recognition of $6.8 million in income from Legal settlements, net from a patent litigation settlement agreement, offset by net changes in operating assets and liabilities.

Net cash provided by operating activities as of October 31, 2015 was approximately $13.2 million as compared to cash used in operating activities of $2.8 million in fiscal 2014, an increase of approximately $16.0 million. The increase in the 2016 period was primarily due to a net change in operating assets and liabilities of $7.8 million, which includes the collection in the current year quarter of other receivables of $6.7 million from the settlement agreement with Siemens Healthcare Diagnostics Inc., and a change in the net income of $8.2 million.

Net cash used in investing activities in fiscal 2016 was approximately $0.5 million as compared to $0.3 million in the 2015 period, an increase of $0.2 million. The increase in the 2016 period is primarily due to increased capital expenditures.

Net cash used in financing activities in fiscal 2016 was approximately $0.1 million as compared to cash provided by financing activities of $2.2 million in fiscal 2015. The decrease of $2.3 million was due to proceeds from the issuance of common stock under the Controlled Equity Offering program of $2.3 million in the 2015 period.

On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and MidCap Financial Services, LLC (formerly Healthcare Finance Group, LLC). The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Labs and Life Sciences segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. At October 31, 2015 and July 31, 2015 borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million, with an additional availability of $2.4 million as of October 31, 2015. As of October 31, 2015, the Credit Agreement was amended to add and redefine certain terms used in the Cash Burn covenant calculation, principally the elimination of capital expenditures from the calculation when Liquidity exceeds $7.0 million. As of October 31, 2015, the Company is in compliance with the modified financial covenants. See Note 6 to the Consolidated Financial Statements herein for a further description of the Credit Agreement’s terms, the amendment and financial covenants.

The Company continued to review all operating units to further reduce annual operating expenditures in fiscal 2016. While revenues and operating results at the Clinical Labs segment improved, revenues for the Life Sciences segment declined versus fiscal 2015, primarily due to foreign currency fluctuation. If revenues were to significantly decline, the segment could be required to record impairments of its intangible assets, which last occurred in fiscal 2012. The Company believes that its current cash and cash equivalents level, utilization of the Controlled Equity Offering program if necessary, as disclosed in Form 10-K Note 10 to the financial statements, which resulted in net proceeds of $6.7 million during the fiscal year ended July 31, 2015, and available borrowings under the aforementioned Revolving Loan and Security Agreement disclosed in Note 6 to the financial statements herein are sufficient for its foreseeable liquidity and capital resource needs over the next twelve (12) months, although there can be no assurance that future events will not alter such view. Although there can be no assurances, in the event additional capital is required, the Company believes it has the ability to raise additional funds through equity offerings or other sources of funds. Our liquidity plans are subject to a number of risks and uncertainties, including those described in the Item 1A. “Risk Factors” section of this Form 10-K for the year ended July 31, 2015, some of which are outside our control. Macroeconomic conditions could limit our ability to successfully execute our business plans and therefore adversely affect our liquidity plans.

See our Form 10-K for the fiscal year ended July 31, 2015 for Forward Looking Cautionary Statements.

Contractual Obligations

There have been no material changes to our Contractual Obligations as reported in our Form 10-K for the fiscal year ended July 31, 2015.

Management is not aware of any material claims, disputes or settled matters concerning third party reimbursement that would have a material effect on our financial statements, except as disclosed in Note 13 to the Consolidated Financial Statement.

Off-Balance Sheet Arrangements

The Company does not have any “off-balance sheet arrangements” as such term is defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies

The Company’s discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and judgments also affect related disclosure of contingent assets and liabilities.

On an on-going basis, we evaluate our estimates, including those related to contractual expense, allowance for uncollectible accounts, inventory, intangible assets and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Product revenues

Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured.

Royalties

Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues.

Revenues – Clinical laboratory services

Revenues from Clinical Labs are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected approved reimbursable settlements from such payers.

The following table represents the clinical laboratory segment’s net revenues and percentages by revenue category:

	Three months ended October 31, 2015				Three months ended October 31, 2014
Revenue category
Third-party payer	$	9,695	57	%	$	8,713	55	%
Medicare		2,996	18			3,222	20
Patient self-pay		3,239	19			2,664	17
HMO’s		1,160	6			1,223	8
Total	$	17,090	100	%	$	15,822	100	%

The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs. See Note 13 in the Notes to Consolidated Financial Statements.

Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 29% and 26% of the Clinical Labs segment net revenue for the three months ended October 31, 2015 and 2014 respectively.

Contractual Adjustment

The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue, based on gross billing rates, to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule we set for all third party payers, including Medicare, HMO’s and managed care. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors.

The other relevant factors that affect our contractual adjustment include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company.

Our clinical laboratory business is primarily dependent upon reimbursement from third-party payers, such as Medicare (which principally serves patients 65 and older) and insurers. We are subject to variances in reimbursement rates among different third-party payers, as well as constant changes of reimbursement rates. Changes that decrease reimbursement rates or coverage would negatively impact our revenues. The number of individuals covered under managed care contracts or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition, Medicare and other government healthcare programs continue to shift to managed care. These trends will continue to reduce our revenues.

During the three months ended October 31, 2015 and 2014, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were 84.5% and 85.3%, respectively, of gross billings. The Company believes a decline in reimbursement rates or a shift to managed care or similar arrangements may be offset by the positive impact of an increase in the number of tests we perform. However, there can be no assurance that we can increase the number of tests we perform or that if we do increase the number of tests we perform, that we can maintain that higher number of tests performed, or that an increase in the number of tests we perform would result in increased revenue.

The Company estimates (by using a sensitivity analysis) that each 1% point change in the contractual adjustment percentage could result in a change in clinical laboratory services revenues of approximately $1.1 million and $1.0

million for the three months ended October 31, 2015 and 2014, respectively, and a change in the net accounts receivable of approximately $0.6 million as of October 31, 2015.

Our clinical laboratory financial billing system records gross billings using a standard fee schedule for all payers and does not record contractual adjustment by payer at the time of billing. Therefore, we are unable to quantify the effect of contractual adjustment recorded during the current period that relate to revenue recorded in a previous period. However, we can reasonably estimate our monthly contractual adjustment to revenue on a timely basis based on our quarterly review process, which includes:

	•	an analysis of industry reimbursement trends;

	•	an evaluation of third-party reimbursement rates changes and changes in reimbursement arrangements with third-party payers;

	•	a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers;

	•	an analysis of current gross billings and receivables by payer.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.

The following is a table of the Company’s net accounts receivable by segment. The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net receivables. At October 31, 2015 and July 31, 2015, approximately 68% of the Company’s net accounts receivable relates to its Clinical Labs business, which operates in the New York, New Jersey, and Eastern Pennsylvania medical communities.

The Life Sciences segment’s accounts receivable, of which $1.2 million or 29% and $1.1 million or 28% represents foreign receivables as of October 31, 2015 and July 31, 2015, includes royalty receivables of $0.1 million, as of October 31, 2015 and July 31, 2015, from Qiagen Corporation.

Net accounts receivable

Billing category	As of October 31, 2015				As of July 31, 2015
Clinical Labs
Patient self-pay	$	4,350	49	%	$	3,213	39	%
Third party payers		3,139	36			3,595	44
Medicare		1,012	12			1,081	13
HMO’s		282	3			305	4
Total Clinical Labs		8,783	100	%		8,194	100	%
Total Life Sciences		3,980				3,915
Total accounts receivable	$	12,763			$	12,109

Changes in the Company’s allowance for doubtful accounts are as follows:

	October 31, 2015			July 31, 2015
Beginning balance	$	1,786		$	2,142
Provision for doubtful accounts		704			2,284
Write-offs, net		(604	)		(2,640	)
Ending balance	$	1,886		$	1,786

For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and reduces the allowance in future accounting periods based on write-offs during those periods. It bases the estimate for the allowance on the evaluation of historical experience of accounts going to collections and the net amounts not received. Accounts going to collection

include the balances, after receipt of the approved settlements from third party payers, for the insufficient diagnosis information received from the ordering physician which result in denials of payment, and our estimate of the uncollected portion of receivables from self-payers, including deductibles and copayments, which are subject to credit risk and patients’ ability to pay.

As at October 31, 2015 and 2014, the Company recategorized to collections customers whose accounts receivable had been outstanding more than 210 days. The Company fully reserves through its contractual allowances amounts that have not been written off because the payer’s filing date deadline has not occurred or the collection process has not been exhausted. The Company’s collection experience on Medicare receivables beyond 210 days has been insignificant. The Company adjusts the historical collection analysis for recoveries, if any, on an ongoing basis.

The Company’s ability to collect outstanding receivables from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the impact, if any, on the allowance estimates, which involves judgment. The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the accurate patient information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount.

Billing for laboratory services is complicated because of many factors, especially: the differences between our standard gross fee schedule for all payers and the reimbursement rates of the various payers we deal with, disparity of coverage and information requirements among the various payers, and disputes with payers as to which party is responsible for reimbursement.

The allowance for doubtful accounts as a percentage of total accounts receivable at October 31, 2015 and July 31, 2015 was 12.9%. During fiscal 2015, the contractual allowance applied to the Clinical Labs segment’s patient self-pay revenues was increased based on collections trends, which has the effect of reducing the allowance for doubtful patient pay accounts receivable. We continue to improve our patient pay collection process by billing patients sooner and by giving past due accounts to collection agencies sooner.

The following table indicates the Clinical Labs aged gross receivables by payer group which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved balances not yet written off, and 3) other revenue adjustments.

As of October 31, 2015	Total		%			Third Party Payers		%			Medicare Payers		%			Self Pay			%			HMO’s			%
1-30 days	$	29,709		54		$	18,151		50		$	4,454		57		$	3,328			47		$	3,776			99
31-60 days		6,272		11			3,773		10			684		9			1,798			25			17			1
61-90 days		4,380		8			2,275		6			493		6			1,611			23			1			—
91-120 days		3,854		7			2,899		8			495		6			458			6			2			—
121-150 days		2,673		5			2,362		7			320		4			(9	)		—						—
Greater than 150 days*		8,405		15			7,040		19			1,413		18			(47	)		(1	)		(1	)		—
Totals	$	55,293		100	%	$	36,500		100	%	$	7,859		100	%	$	7,139			100	%	$	3,795			100	%

As of July 31, 2015	Total		%			Third Party Payers		%			Medicare Payers		%			Self Pay			%			HMO’s		%
1-30 days	$	28,157		53		$	17,527		50		$	4,048		52		$	2,991			47		$	3,591		95
31-60 days		6,650		13			4,109		12			802		10			1,718			27			21		1
61-90 days		4,191		8			2,313		7			578		7			1,276			20			24		1
91-120 days		3,651		7			2,534		7			604		8			474			7			39		1
121-150 days		2,856		4			2,426		7			399		5			(3	)		0			34		1
Greater than 150 days**		7,187		14			5,878		17			1,329		18			(40	)		-1			20		1
Totals	$	52,692		100	%	$	34,787		100	%	$	7,760		100	%	$	6,416			100	%	$	3,729		100	%

*	Total includes $4,822 fully reserved over 210 days as of October 31, 2015.
**	Total includes $4,072 fully reserved over 210 days as of July 31, 2015.

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected.

Inventory

The Company values inventory at the lower of cost (first-in, first-out) or market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.

Goodwill and Intangible Assets

Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. Intangible assets (exclusive of patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications result in an issued patent, the related capitalized costs are amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed.

The Company tests goodwill and long-lived assets annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill and long-lived assets for impairment, the Company has the option to first perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is not required to perform any additional tests in assessing goodwill and long-lived assets for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it is required to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative impairment test requires the identification of the reporting units and comparison of the fair value of each of these reporting units to their respective carrying value. If the carrying value of the reporting unit is less than its fair value, no impairment exists and the second step is not performed. If the carrying value of the reporting unit is higher than its fair value, the second step must be performed to compute the amount of the goodwill impairment, if any. In the second step, the impairment is computed by comparing the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized for the excess

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in foreign currency exchange rates resulting from acquisitions with foreign locations (See Item 1A. Risk Factors section of the Form 10-K for the fiscal year ended July 31, 2015) that could impact our results of operations and financial position. We do not currently engage in any hedging or market risk management tools.

Foreign Currency Exchange Rate Risk

The financial reporting of our non-U.S. subsidiaries is denominated in currencies other than the U.S. dollar. Since the functional currency of our non-U.S. subsidiaries is the local currency, foreign currency translation adjustments are accumulated as a component of accumulated other comprehensive income in stockholders’ equity. Assuming a hypothetical increase of 10% in the value of the U.S. dollar versus foreign currencies at October 31, 2015, our assets and liabilities would decrease by $0.5 million and $0.1 million, respectively, and our net sales and net earnings (loss) would decrease by $0.9 million and $0.3 million, respectively, on an annual basis.

We also maintain intercompany balances and loans with subsidiaries in different local currencies. These amounts are at risk of foreign exchange losses if exchange rates fluctuate. Assuming a hypothetical increase of 10% in the value of the U.S. dollar versus foreign currencies, our pre-tax earnings (loss) would be unfavorably impacted by approximately $0.9 million on an annual basis.

Interest Rate Risk

We are exposed to interest rate risk with our variable rate Credit Agreement which bears interest at the three month LIBOR with a floor of 1.25% plus 4% per annum. A 3% change in the LIBOR rate would impact our interest expense by $0.1 million.

As of October 31, 2015, we have fixed interest rate financing on transportation and equipment leases.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the Company’s “disclosure controls and procedures” (as such term is defined under the Exchange Act), under the supervision and with the participation of the principal executive officer and the principal financial officer. Based on this evaluation, the principal executive officer and the principal financial officer concluded that the Company’s disclosure controls and procedures are effective as of the end of the period covered by this report. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that it will detect or uncover failures within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports.

(b) Changes in Internal Controls over Financial Reporting

There was no change in the Company’s internal controls over financial reporting during the fiscal quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

There have been no other material developments with respect to previously reported legal proceedings discussed in the annual report on Form 10-K for the fiscal year ended July 31, 2015 filed with the Securities and Exchange Commission, other than as noted in Note 13 to the Consolidated Financial Statements as of October 31, 2015.

Item 1A.

Risk Factors

There have been no material changes from the risk factors disclosed in Part 1, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2015.

Item 6.

Exhibits

Exhibit No.		Exhibit
10 (t)		Amendment to Revolving Loan and Security Agreement among the Enzo Biochem, Inc., Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc., Axxora, LLC and Enzo Realty, LLC as borrowers, and Enzo Therapeutics, Inc. as a guarantor, and HFG Healthco–4 Trust as Lender

31.1		Certification of Elazar Rabbani, Ph.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Barry Weiner pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Elazar Rabbani, Ph.D. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Barry Weiner pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101. INS*		XBRL Instance Document

101. SCH*		XBRL Taxonomy Extension Schema Document

101. CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definitions Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ENZO BIOCHEM, INC.
	(Registrant)

Date: December 8, 2015	by:	/s/ Barry Weiner
		President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director

EX-10.T 2 c83212_ex10-t.htm

Exhibit 10(t)

THIRD AMENDMENT TO REVOLVING LOAN AND SECURITY AGREEMENT

Third Amendment to Revolving Loan and Security Agreement (“Amendment”) dated as of October 31, 2015 by and among ENZO BIOCHEM, INC., a New York corporation (“Enzo”), ENZO CLINICAL LABS, INC., a New York corporation (“Enzo Clinical Labs”), ENZO LIFE SCIENCES, INC., a New York corporation (“Enzo Life Sciences”), AXXORA, LLC, a Delaware limited liability company (“Axxora”), ENZO REALTY LLC, a New York limited liability company (“Enzo Realty”, together with Enzo, Enzo Clinical Labs, Enzo Life Sciences, Axxora and each other Person joined to the Loan Agreement (as defined below) as a borrower from time to time, collectively, the “Borrowers” and each a “Borrower”), ENZO THERAPEUTICS, INC., a New York corporation, as a Guarantor (“Enzo Therapeutics”, together with Borrowers, the “Loan Parties” and each a “Loan Party”), HFG-HEALTHCO-4 TRUST, a Delaware statutory trust (f/k/a HFG-Healthco-4, LLC, “HFG-4”), in its capacity as a Lender (together with any other financial institutions party to the Loan Agreement as a lender, the “Lenders”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust and assignee of Healthcare Finance Group, LLC, as administrative agent and collateral agent for the Lenders (together with its successors and permitted assigns in such capacities, the “Agent”).

BACKGROUND

A. Loan Parties, Lenders and Agent entered into that certain Revolving Loan and Security Agreement dated as of June 7, 2013 (together with all existing and future amendments, restatements, modifications, extensions, consolidations and substitutions, the “Loan Agreement”), and certain related “Loan Documents” (as defined in the Loan Agreement) evidencing certain financing arrangements among Agent, Lenders and Loan Parties as more particularly described therein. All capitalized terms used herein and not defined herein shall have the meanings ascribed to such terms in the Loan Agreement.

B. Loan Parties have requested, and Lenders and Agent have agreed, to amend certain provisions of the Loan Agreement, in each case on the terms and conditions set forth herein.

NOW THEREFORE, with the foregoing Background deemed incorporated by reference in this Amendment and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, covenant and agree as follows:

1. AMENDMENTS. Upon the effectiveness of this Amendment, the Loan Agreement shall be amended as follows:

(i) Definitions. The definition of “Cash Burn” contained in Section 1.1 of the Loan Agreement shall be amended and restated in its entirety as follows:

“Cash Burn” means for any period or as of any date, in each case with respect to the Loan Parties and their Subsidiaries on a consolidated basis, EBITDA plus to the extent deducted from net income in calculating EBITDA, all expenses of Loan Parties relating to research and development and legal costs, minus the sum of the following items to the extent actually paid in cash during such period, determined

in each case in accordance with GAAP: (i) the greater of (x) scheduled principal payments of long term Debt and Capital Leases to be made during such period and (y) actual principal payments of long term Debt and Capital Leases made during such period, (ii) if Liquidity as of the last day of the fiscal quarter for which Cash Burn is being tested is less than or equal to $7,000,000, Capital Expenditures made during such period (to the extent not funded by permitted purchase money loans or Capital Leases), (iii) interest expense during such period (including that portion attributable to Capital Leases in accordance with GAAP and capitalized interest), (iv) taxes during such period based on the Loan Parties’ and their Subsidiaries income, (v) the aggregate amount of Distributions, and other advances, and loans to officers, Affiliates, and shareholders made during such period, and (vi) any required minimum pension plan payments. For the avoidance of doubt, if Liquidity as of the last day of the fiscal quarter for which Cash Burn is being tested is greater than $7,000,000, Capital Expenditures for such period shall not be deducted from EBITDA in calculating Cash Burn.

(ii) Definitions. The definition of “Liquidity” shall be added to Section 1.1 of the Loan Agreement in the appropriate alphabetical order:

“Liquidity” means an amount equal to the sum of (1) the aggregate amount of cash on the most recent balance sheet delivered to Agent pursuant to Section 8.5 hereof, plus (2) the positive difference, if any between (A) the Adjusted Borrowing Limit and (B) the sum of the then Outstanding Balance of the Revolving Loan.

2. EFFECTIVENESS CONDITIONS. The effectiveness of this Amendment is conditioned upon the satisfaction of each of the conditions set forth below (as determined by Agent in its sole discretion) (the “Effectiveness Conditions”):

(a) Execution and delivery of this Amendment by the parties hereto;

(b) Receipt of an amendment fee of $15,000.00 which fee is fully earned and due and payable as of the date hereof;

(d) Receipt by Agent of such other documents, instruments, agreements or information as may otherwise be or have been reasonably requested by Agent; and

(e) Payment of any and all costs, fees and expenses of Agent and Lenders, including reasonable attorneys’ fees, in connection with this Amendment and the transactions contemplated hereby.

3. REPRESENTATIONS AND WARRANTIES. Each Loan Party represents, warrants and acknowledges to Lenders and Agent as follows:

(a) It is duly formed, organized, validly existing and in good standing under the laws of its jurisdiction of organization or incorporation and is in good standing in every jurisdiction where the nature of its business requires it to be so qualified.

(b) This Amendment has been duly executed and delivered by such Loan Party and is in full force and effect as of the date hereof and constitutes the legal, valid and binding obligations of such Loan Party, enforceable against such Loan Party in accordance with its terms;

(c) Such Loan Party has taken all necessary authorizing action to authorize the execution, delivery, and performance of this Amendment and each document, instrument and agreement to be delivered in connection herewith;

(d) The execution, delivery and performance by each Loan Party of this Amendment and the Loan Documents to which it is a party and any other documents delivered or to be delivered by it thereunder (i) are within its corporate powers; (ii) have been duly authorized by all necessary corporate, limited liability company or partnership action, as applicable; (iii) do not contravene its organizational documents, any material law, rule, or regulation applicable to it (including, without limitation, laws, rules and regulations relating to usury, truth in lending, fair credit billing, fair credit reporting, equal credit opportunity, fair debt collection practices, licensing, and privacy), any provision of any contractual restriction binding on or affecting it or any material portion of its Property, or any order, writ, judgment, award, injunction or decree binding on or affecting it or its Property; and (iv) do not and will not result in any default, noncompliance, suspension, revocation, impairment, forfeiture or non-renewal of any permit, license, authorization or approval applicable to its operations or any of its Properties;

(e) All warranties and representations made to Agent and/or Lenders under the Loan Agreement and the Loan Documents (as and if specifically amended herein) are true and correct in all material respects (except for representations and warranties qualified by materiality or Material Adverse Effect, which shall be true in all respects) as of the date hereof (except any representation or warranty that expressly indicates that it is being made as of a specified date, in which case each such representation or warranty is true and correct as of the date specified).

4. REAFFIRMATION. Except as expressly amended hereby, all of the terms and conditions of the Loan Agreement and the other Loan Documents are hereby ratified and confirmed and continue unchanged and in full force and effect. This Amendment shall be deemed incorporated into and made a part of the Loan Agreement, and all references to the Loan Agreement in any Loan Document (including the Loan Agreement) shall mean the Loan Agreement as modified by this Amendment. The Loan Documents and this Amendment shall be construed as integrated and complementary of each other, and as augmenting and not restricting Agent’s and/or Lender’s rights, remedies and security. If, after applying the foregoing, an inconsistency still exists, the provisions of this Amendment shall control. Each Loan Party hereby also confirms and ratifies in all respects the Lender Debt outstanding under the Loan Documents, and acknowledges that the Loan Documents shall continue in full force and effect as therein written except as amended hereby and that no claims, counterclaims, offsets or defenses arising out of or with respect to the Lender Debt under the Loan Documents exist. Each Loan

Party hereby confirms that all security interests at any time granted by it to Agent continue in full force and effect and secure and shall continue to secure the Lender Debt, so long as any such liabilities or obligations remain outstanding and that all property subject thereto remain free and clear of any liens or encumbrances other than Permitted Liens. Nothing herein contained is intended to in any manner impair or limit the validity, priority and extent of Agent’s existing security interest in and liens upon the Collateral.

5. RESERVED.

6. MISCELLANEOUS.

(a) Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts (including by facsimile or email transmission of executed signature pages hereto), each of which counterparts, when so executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same Amendment. Signature by facsimile or other electronic transmission (including PDF) shall bind the parties hereto.

(b) Third-Party Rights. No rights are intended to be created hereunder for the benefit of any third-party donee, creditor or incidental beneficiary or any affiliate of any Borrower.

(c) Modifications. No modification hereof or any agreement referred to herein shall be binding or enforceable unless in writing and signed on behalf of the party against whom enforcement is sought.

(d) Headings. The headings of any paragraph of this Amendment are for convenience only and shall not be used to interpret any provision of this Amendment.

(e) Survival. All warranties, representations and covenants made by Borrowers herein, or in any agreement referred to herein or on any certificate, document or other instrument delivered by them or on their behalf under this Amendment, shall be considered to have been relied upon by Agent and Lenders. All statements in any such certificate or other instrument shall constitute warranties and representations by Loan Parties hereunder. All warranties, representations, indemnities and covenants made by Loan Parties hereunder or under any other agreement or instrument shall be deemed continuing until the Lender Debt is indefeasibly paid and satisfied in full.

(f) Further Assurances. The parties hereto shall execute and deliver such additional documents and take such additional action, as may be reasonably necessary or desirable to effectuate the provisions and purposes of this Amendment.

(g) Successors and Assigns. This Amendment shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto. No delegation by Borrowers of any duty or obligation of performance may be made or is intended to be made to Lender.

(h) GOVERNING LAW. THIS AMENDMENT AND ALL MATTERS ARISING OUT OF OR RELATED TO THIS AGREEMENT, SHALL, IN ACCORDANCE WITH SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY CONFLICTS OF LAWS PRINCIPLES THEREOF THAT WOULD CALL FOR THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION, EXCEPT TO THE EXTENT THAT THE VALIDITY OR PERFECTION OF THE SECURITY INTERESTS GRANTED HEREUNDER, OR REMEDIES RELATED THERETO, IN RESPECT OF ANY PARTICULAR COLLATERAL ARE GOVERNED BY THE LAWS OF A JURISDICTION OTHER THAN THE STATE OF NEW YORK.

(i) WAIVER OF JURY TRIAL, JURISDICTION AND VENUE. EACH OF THE PARTIES HERETO HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY IN THE EVENT OF ANY LITIGATION WITH RESPECT TO ANY MATTER RELATED TO THIS AMENDMENT, AND HEREBY IRREVOCABLY CONSENTS TO THE JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN NEW YORK COUNTY, NEW YORK CITY, NEW YORK IN CONNECTION WITH ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AMENDMENT. IN ANY SUCH LITIGATION, EACH OF THE PARTIES HERETO WAIVES PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS AND AGREES THAT SERVICE THEREOF MAY BE MADE BY CERTIFIED OR REGISTERED MAIL DIRECTED TO THE PARTIES HERETO AT THEIR ADDRESSES SET FORTH ON SCHEDULE I TO THE LOAN AGREEMENT.

[SIGNATURES TO APPEAR ON FOLLOWING PAGE]

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written.

BORROWERS:	ENZO BIOCHEM, INC.

	By:	/s/ James O’Brien
	Name:	James O’Brien
	Title:	EVP Finance

	ENZO CLINICAL LABS, INC.

	By:	/s/ James O’Brien
	Name:	James O’Brien
	Title:	EVP Finance

	ENZO LIFE SCIENCES, INC.

	By:	/s/ James O’Brien
	Name:	James O’Brien
	Title:	EVP Finance

	AXXORA, LLC

	By:	/s/ James O’Brien
	Name:	James O’Brien
	Title:	EVP Finance

	ENZO REALTY LLC

	By:	/s/ James O’Brien
	Name:	James O’Brien
	Title:	EVP Finance

GUARANTOR:	ENZO THERAPEUTICS, INC.

	By:	/s/ James O’Brien
	Name:	James O’Brien
	Title:	EVP Finance

[SIGNATURE PAGE TO THIRD AMENDMENT AND WAIVER]

S-1

Agent:

MIDCAP FINANCIAL TRUST, assignee of Healthcare Finance Group, LLC, acting as administrative agent and collateral agent on behalf of Lender pursuant to Section 12.3 of the Loan Agreement

By:	Apollo Capital Management, L.P., its investment manager

By:	Apollo Capital Management GP, LLC, its general partner

	By:	/s/ Maurice Amsellem
	Name:	Maurice Amsellem
	Title:	Authorized Signatory

Lenders:

HFG HEALTHCO-4 TRUST, as Revolving Lender

By:	Apollo Capital Management, L.P., its investment manager

By:	Apollo Capital Management GP, LLC, its general partner

	By:	/s/ Maurice Amsellem
	Name:	Maurice Amsellem
	Title:	Authorized Signatory

[SIGNATURE PAGE TO THIRD AMENDMENT AND WAIVER]

S-2

EX-31.1 3 c83212_ex31-1.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Elazar Rabbani, Ph.D., certify that:

I have reviewed this quarterly report on Form 10-Q of Enzo Biochem, Inc. (the “registrant”).

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 8, 2015

	By:	/s/ Elazar Rabbani, Ph.D.
		Elazar Rabbani, Ph.D.
		Chairman of the Board, Chief Executive Officer and Secretary

EX-31.2 4 c83212_ex31-2.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Barry Weiner, certify that:

I have reviewed this quarterly report on Form 10-Q of Enzo Biochem, Inc. (the “registrant”).

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 8, 2015

	By:	/s/ Barry Weiner
		Barry Weiner
		President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director

EX-32.1 5 c83212_ex32-1.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-Q for the period ended October 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Elazar Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 8, 2015

	By:	/s/ Elazar Rabbani, Ph.D.
		Elazar Rabbani, Ph.D.
		Chairman of the Board, Chief Executive Officer and Director

EX-32.2 6 c83212_ex32-2.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-Q for the period ended October 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barry Weiner, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: December 8, 2015

	By:	/s/ Barry Weiner
		Barry Weiner
		President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director

EX-101.INS 7 enz-20151031.xml 0000316253 2015-10-31 0000316253 2015-07-31 0000316253 2015-08-01 2015-10-31 0000316253 2014-08-01 2014-10-31 0000316253 us-gaap:CommonStockMember 2015-07-31 0000316253 us-gaap:AdditionalPaidInCapitalMember 2015-07-31 0000316253 us-gaap:RetainedEarningsMember 2015-07-31 0000316253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-07-31 0000316253 us-gaap:RetainedEarningsMember 2015-08-01 2015-10-31 0000316253 us-gaap:CommonStockMember 2015-08-01 2015-10-31 0000316253 us-gaap:AdditionalPaidInCapitalMember 2015-08-01 2015-10-31 0000316253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-08-01 2015-10-31 0000316253 us-gaap:CommonStockMember 2015-10-31 0000316253 us-gaap:AdditionalPaidInCapitalMember 2015-10-31 0000316253 us-gaap:RetainedEarningsMember 2015-10-31 0000316253 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-10-31 0000316253 2014-07-31 0000316253 2014-10-31 0000316253 2015-12-02 0000316253 enz:WeightedAverageStockOptionsMember 2015-08-01 2015-10-31 0000316253 enz:UnvestedRestrictedStockMember 2014-08-01 2014-10-31 0000316253 enz:InTheMoneyStockOptionsMember 2014-08-01 2014-10-31 0000316253 enz:OutstandingOptionsMember 2015-08-01 2015-10-31 0000316253 enz:OutstandingOptionsMember 2014-08-01 2014-10-31 0000316253 us-gaap:IntangibleAssetsAmortizationPeriodMember 2015-08-01 2015-10-31 0000316253 enz:LifeSciencesMember 2015-07-31 0000316253 enz:LifeSciencesMember 2015-08-01 2015-10-31 0000316253 enz:LifeSciencesMember 2015-10-31 0000316253 us-gaap:PatentsMember 2015-10-31 0000316253 us-gaap:PatentsMember 2015-07-31 0000316253 us-gaap:CustomerRelationshipsMember 2015-10-31 0000316253 us-gaap:CustomerRelationshipsMember 2015-07-31 0000316253 enz:WebsiteAndAcquiredContentMember 2015-10-31 0000316253 enz:WebsiteAndAcquiredContentMember 2015-07-31 0000316253 enz:LicensedTechnologyAndOtherMember 2015-10-31 0000316253 enz:LicensedTechnologyAndOtherMember 2015-07-31 0000316253 us-gaap:TrademarksMember 2015-10-31 0000316253 us-gaap:TrademarksMember 2015-07-31 0000316253 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2015-08-01 2015-10-31 0000316253 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2015-08-01 2015-10-31 0000316253 us-gaap:CustomerRelationshipsMember 2015-08-01 2015-10-31 0000316253 us-gaap:TrademarksMember 2015-08-01 2015-10-31 0000316253 us-gaap:OtherIntangibleAssetsMember 2015-08-01 2015-10-31 0000316253 enz:CapitalLeaseObligationMember enz:ClinicalLabsMember 2015-10-31 0000316253 enz:InstallmentLoansMember enz:ClinicalLabsMember 2015-10-31 0000316253 enz:AccruedLegalSettlementMember 2015-10-31 0000316253 enz:AccruedLegalSettlementMember 2015-07-31 0000316253 us-gaap:CapitalLeaseObligationsMember 2015-10-31 0000316253 us-gaap:CapitalLeaseObligationsMember 2015-07-31 0000316253 enz:InstallmentLoansMember 2015-10-31 0000316253 enz:InstallmentLoansMember 2015-07-31 0000316253 2014-12-31 0000316253 us-gaap:CommonStockMember 2014-08-01 2014-10-31 0000316253 enz:OptionsMember 2015-08-01 2015-10-31 0000316253 enz:OptionsMember 2014-08-01 2014-10-31 0000316253 enz:RestrictedStocksMember 2015-08-01 2015-10-31 0000316253 enz:RestrictedStocksMember 2014-08-01 2014-10-31 0000316253 enz:CostOfClinicalLaboratoryServicesMember 2015-08-01 2015-10-31 0000316253 enz:CostOfClinicalLaboratoryServicesMember 2014-08-01 2014-10-31 0000316253 us-gaap:ResearchAndDevelopmentExpenseMember 2014-08-01 2014-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-08-01 2015-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-08-01 2014-10-31 0000316253 enz:LifeSciencesMember 2014-08-01 2014-10-31 0000316253 enz:ClinicalLabsMember 2015-08-01 2015-10-31 0000316253 enz:ConsolidatedMember 2015-08-01 2015-10-31 0000316253 enz:TherapeuticsMember 2015-08-01 2015-10-31 0000316253 us-gaap:AllOtherSegmentsMember 2015-08-01 2015-10-31 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2015-08-01 2015-10-31 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ConsolidatedMember 2015-08-01 2015-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ClinicalLabsMember 2015-08-01 2015-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:LifeSciencesMember 2015-08-01 2015-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:AllOtherSegmentsMember 2015-08-01 2015-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ConsolidatedMember 2015-08-01 2015-10-31 0000316253 enz:TotalMember enz:ClinicalLabsMember 2015-08-01 2015-10-31 0000316253 enz:TotalMember enz:LifeSciencesMember 2015-08-01 2015-10-31 0000316253 enz:TotalMember us-gaap:AllOtherSegmentsMember 2015-08-01 2015-10-31 0000316253 enz:TotalMember enz:ConsolidatedMember 2015-08-01 2015-10-31 0000316253 enz:ClinicalLabsMember 2014-08-01 2014-10-31 0000316253 enz:ConsolidatedMember 2014-08-01 2014-10-31 0000316253 enz:TherapeuticsMember 2014-08-01 2014-10-31 0000316253 us-gaap:AllOtherSegmentsMember 2014-08-01 2014-10-31 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ClinicalLabsMember 2014-08-01 2014-10-31 0000316253 enz:CostOfClinicalLaboratoryServicesMember enz:ConsolidatedMember 2014-08-01 2014-10-31 0000316253 us-gaap:ResearchAndDevelopmentExpenseMember enz:LifeSciencesMember 2014-08-01 2014-10-31 0000316253 us-gaap:ResearchAndDevelopmentExpenseMember enz:ConsolidatedMember 2014-08-01 2014-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ClinicalLabsMember 2014-08-01 2014-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:AllOtherSegmentsMember 2014-08-01 2014-10-31 0000316253 us-gaap:SellingGeneralAndAdministrativeExpensesMember enz:ConsolidatedMember 2014-08-01 2014-10-31 0000316253 enz:TotalMember enz:ClinicalLabsMember 2014-08-01 2014-10-31 0000316253 enz:TotalMember enz:LifeSciencesMember 2014-08-01 2014-10-31 0000316253 enz:TotalMember us-gaap:AllOtherSegmentsMember 2014-08-01 2014-10-31 0000316253 enz:TotalMember enz:ConsolidatedMember 2014-08-01 2014-10-31 0000316253 2004-06-01 2004-06-30 0000316253 2012-11-01 2012-11-30 0000316253 us-gaap:IndemnificationGuaranteeMember 2015-10-31 0000316253 2015-10-01 2015-10-31 0000316253 enz:AgreementMember enz:AffymetrixIncMember 2014-04-01 2014-04-22 0000316253 enz:PerkinElmerMember 2014-06-20 0000316253 enz:SubpoenaMember 2015-08-01 2015-10-31 0000316253 enz:SubpoenaMember us-gaap:MinimumMember 2015-08-01 2015-10-31 0000316253 enz:SubpoenaMember 2014-02-01 2014-04-30 0000316253 enz:SubpoenaMember 2015-10-31 0000316253 enz:SubpoenaMember us-gaap:MaximumMember 2015-08-01 2015-10-31 0000316253 enz:LuminexMember 2015-07-01 2015-07-31 0000316253 enz:SiemensMember 2015-07-01 2015-07-31 0000316253 us-gaap:MinimumMember enz:SiemensMember 2015-07-01 2015-07-31 0000316253 us-gaap:MaximumMember enz:SiemensMember 2015-07-01 2015-07-31 0000316253 enz:AffymetrixIncMember 2015-10-01 2015-10-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

30642000

18109000

12763000

12109000

6650000

7582000

7396000

1780000

2222000

52767000

46486000

8132000

7948000

7452000

5707000

6155000

338000

353000

74396000

68394000

3013000

9450000

8762000

12357000

11297000

969000

886000

25789000

23958000

37000

1357000

1793000

27183000

25788000

461000

325077000

324966000

-280248000

-284682000

1923000

1861000

47213000

42606000

74396000

68394000

0.01

25000000

0.01

75000000

46068816

46062065

46068816

46062065

17090000

15822000

7687000

8002000

400000 1000000

25177000

24824000

10332000

10130000

3611000

3695000

867000

791000

10225000

10285000

704000

541000

1601000

2466000

6800000

20540000 27908000

4637000

-3084000

-40000

-69000

54000

19000

-130000

-472000

4521000

-3606000

87000

123000

4434000

-3729000

0.10

-0.08

0.10

-0.08

46068000

44564000

46193000

44564000

62000

108000

4496000

-3621000

46062065

461000

324966000

-284682000

1861000

4434000

6751

111000

62000

46068816

461000

325077000

-280248000

1923000

527000

507000

423000

431000

-3000

-24000

111000

98000

166000 145000 -129000 -422000

1376000

482000

-6650000

210000

-107000

-442000

-182000

682000

-1157000

474000

204000

8719000

974000

13153000

-2755000

505000

264000

15000 5000

-490000

-259000

2322000

22461000

22360000

22461000

22360000

-125000

-115000

-125000

2207000

-5000

-57000

12533000

-864000

17455000

16591000

ENZO BIOCHEM INC 10-Q --07-31 46069000 false 0000316253 Yes No Accelerated Filer No 2015 Q1 2015-10-31

Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of October 31, 2015, the consolidated statements of operations, comprehensive income (loss), and cash flows for the three months ended October 31, 2015 and 2014, and the consolidated statement of stockholders’ equity for the three months ended October 31, 2015 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2015 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2015 has been derived from the audited financial statements at that date. The results of operations for the three months ended October 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2016.

Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three month period ended October 31, 2014, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three months ended October 31, 2015, approximately 125,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. For the three months ended October 31, 2014, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 482,000. For the three months ended October 31, 2015 and 2014, the effect of approximately 374,000 and 142,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive.

125000

482000

374000

142000

Note 3 - Supplemental disclosure for statement of cash flows For the three months ended October 31, 2015 and 2014, income taxes paid by the Company were $27 and $26, respectively. For the three months ended October 31, 2015 and 2014, interest paid by the Company was $41 and $69, respectively. For the three months ended October 31, 2015 and 2014, the Company financed $38 and $19 respectively, in machinery and transportation equipment under installment loans. During the three months ended October 31, 2015, there was a total of $157 in capital lease agreements. During the three months ended October 31, 2014, the Company did not enter into any capital lease agreements.

27000

26000

41000

69000

38000 19000 157000

Note 4 - Inventories Inventories consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Raw materials</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,109</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,013</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Work in process</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,984</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">2,002</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Finished products</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,489</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,381</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">7,582</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">7,396</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

Inventories consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Raw materials</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,109</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,013</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Work in process</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,984</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">2,002</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Finished products</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,489</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,381</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">7,582</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">7,396</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

1109000

1013000

1984000

2002000

4489000

4381000

Note 5 – Goodwill and intangible assets At October 31, 2015 and July 31, 2015, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Gross</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Accumulated Amortization</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: right; border-bottom: Black 1px solid">Net</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 49%; font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">July 31, 2015</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">27,838</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(21,683</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">6,155</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Amortization expense</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">(423</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">(423</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Foreign currency translation</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(97</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">72</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(25</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">October 31, 2015</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">27,741</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(22,034</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">5,707</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table> Intangible assets consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Gross</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Accumulated Amortization</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Net</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Gross</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Accumulated Amortization</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Net</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 40%; text-indent: -10pt; padding-left: 10pt">Patents</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">11,027</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">(10,879</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">148</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">11,028</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">(10,871</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">157</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,190</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7,621</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,569</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,243</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7,398</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,845</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Website and acquired content</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,016</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,016</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,020</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,020</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Licensed technology and other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">515</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(443</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">518</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(441</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">77</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Trademarks</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">2,993</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(2,075</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">918</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">3,029</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(1,953</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1,076</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">27,741</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(22,034</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">5,707</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">27,838</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(21,683</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">6,155</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table> At October 31, 2015, information with respect to intangibles assets acquired is as follows: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 62%; padding-left: 10pt; text-indent: -10pt"> </td> <td style="vertical-align: bottom; width: 2%; text-align: center"> </td> <td style="vertical-align: bottom; width: 12%; border-bottom: windowtext 1px solid; text-align: center">Useful life assigned</td> <td style="vertical-align: bottom; width: 2%; text-align: center"> </td> <td style="vertical-align: bottom; width: 21%; border-bottom: windowtext 1px solid; text-align: center">Weighted average remaining useful life</td> <td style="vertical-align: bottom; width: 1%; text-align: center"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-left: 10pt; text-indent: -10pt">Customer relationships </td> <td> </td> <td style="text-align: center">8-15 years</td> <td> </td> <td style="text-align: center">5 years</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">Trademarks </td> <td> </td> <td style="text-align: center">5 years</td> <td> </td> <td style="text-align: center">2 years</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-left: 10pt; text-indent: -10pt">Other intangibles </td> <td> </td> <td style="text-align: center">10 years</td> <td> </td> <td style="text-align: center">4 years</td> <td> </td> </tr> </table> At October 31, 2015, the weighted average useful life of amortizable intangible assets is approximately four years.

P4Y

The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Gross</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Accumulated Amortization</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: right; border-bottom: Black 1px solid">Net</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 49%; font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">July 31, 2015</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">27,838</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(21,683</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">6,155</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Amortization expense</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">(423</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">(423</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Foreign currency translation</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(97</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">72</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(25</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">October 31, 2015</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">27,741</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(22,034</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">5,707</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

27838000

21683000

6155000

423000

97000 72000

25000

27741000

22034000

5707000

Intangible assets consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Gross</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Accumulated Amortization</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Net</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Gross</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Accumulated Amortization</td> <td style="padding-bottom: 1px; font-weight: bold; text-align: right"> </td> <td style="font-weight: bold; padding-bottom: 1px; text-align: right"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1px solid; text-align: right">Net</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 40%; text-indent: -10pt; padding-left: 10pt">Patents</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">11,027</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">(10,879</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">148</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">11,028</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">(10,871</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right">157</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,190</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7,621</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,569</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,243</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7,398</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,845</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Website and acquired content</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,016</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,016</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,020</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(1,020</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Licensed technology and other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">515</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(443</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">518</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(441</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">77</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Trademarks</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">2,993</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(2,075</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">918</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">3,029</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(1,953</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1,076</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">27,741</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(22,034</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">5,707</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">27,838</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(21,683</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">6,155</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table>

11027000

10879000

148000

11028000

10871000

157000

12190000

7621000

4569000

12243000

7398000

4845000

1016000

1020000

515000

443000

72000

518000

441000

77000

2993000

2075000

918000

3029000

1953000

1076000

27741000

22034000

5707000

27838000

21683000

6155000

At October 31, 2015, information with respect to intangibles assets acquired is as follows: <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 62%; padding-left: 10pt; text-indent: -10pt"> </td> <td style="vertical-align: bottom; width: 2%; text-align: center"> </td> <td style="vertical-align: bottom; width: 12%; border-bottom: windowtext 1px solid; text-align: center">Useful life assigned</td> <td style="vertical-align: bottom; width: 2%; text-align: center"> </td> <td style="vertical-align: bottom; width: 21%; border-bottom: windowtext 1px solid; text-align: center">Weighted average remaining useful life</td> <td style="vertical-align: bottom; width: 1%; text-align: center"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-left: 10pt; text-indent: -10pt">Customer relationships </td> <td> </td> <td style="text-align: center">8-15 years</td> <td> </td> <td style="text-align: center">5 years</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">Trademarks </td> <td> </td> <td style="text-align: center">5 years</td> <td> </td> <td style="text-align: center">2 years</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-left: 10pt; text-indent: -10pt">Other intangibles </td> <td> </td> <td style="text-align: center">10 years</td> <td> </td> <td style="text-align: center">4 years</td> <td> </td> </tr> </table>

P8Y

P15Y

P5Y

P2Y

P10Y

P4Y

Note 6 - Loan Payable On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and Healthcare Finance Group, LLC (the “Lender). The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. If the amount of borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%. In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the Credit Agreement. At October 31, 2015 and July 31, 2015, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million. The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. In July 31, 2013, the lender modified various financial covenants relating to fiscal 2014. As of October 31, 2015, the Company is in compliance with the financial covenants. The Credit Agreement includes customary affirmative and negative covenants and events of default. The terms of the debt covenants include: <table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt"></td> <td style="width: 18pt">o</td> <td>The minimum balance the Company must borrow at any time is $2.0 million. At October 31 2015, the loan balance was approximately $3.0 million, with an additional availability of $2.4 million.</td> </tr> </table> <table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt"></td> <td style="width: 18pt">o</td> <td>The Company must maintain a Minimum Liquidity, as defined in the Credit Agreement, of not less than $3.0 million. At October 31, 2015, the Company’s Minimum Liquidity was $11.0 million.</td> </tr> </table> <table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 18pt"></td> <td style="width: 18pt">o</td> <td>The quarterly Cash Burn, as defined in the Credit Agreement, must be greater than zero. During the three months ended October 31, 2015, the Cash Burn was positive in the amount of $1.4 million.</td> </tr> </table> As of October 31, 2015, the Credit Agreement was amended to redefine Cash Burn and add a definition for Liquidity (the “amendment”). Under the amendment, the determination of Cash Burn during a fiscal quarter excludes capital expenditures provided that Liquidity exceeds $7 million as of the last day of the fiscal quarter. As of October 31, 2015, Liquidity as defined was $33.1 million. Based on its current level of Minimum Liquidity and Cash Burn, the Company believes it will continue to be in compliance with the financial covenants in future periods; however there are no assurances of such compliance. Based on our ability to comply with financial covenants in the past, our ability to obtain covenant waivers previously, and our expected future performance, we believe we would be able to cure a non-compliance event and obtain a Lender waiver. The Company currently believes that the Lender would be willing to negotiate and provide waivers to the Company in the event of non-compliance with covenants, although there can be no assurances. In addition, the Company believes the effects of non-compliance with the covenants would not have a material effect on our financial condition and liquidity due to cash provided by operating cash flows and funds available under the Company’s Controlled Equity Offering program.

December 2016

8000000

4000000

281000

P3M

three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%

0.0125

0.040 0.030

0.0050

2000000

2400000

3000000 11000000 0 1400000 7000000 33100000

Note 7 – Accrued Liabilities and Other Current Liabilities Accrued liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fee expense</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,999</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,183</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Payroll, benefits, and commissions</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,717</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">3,907</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Professional fees</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">491</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">678</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">300</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">300</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Other</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,850</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">2,229</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">12,357</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">11,297</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

Accrued liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fee expense</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,999</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,183</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Payroll, benefits, and commissions</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">4,717</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">3,907</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Professional fees</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">491</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">678</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">300</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">300</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Other</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,850</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">2,229</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">12,357</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">11,297</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

4999000 4183000

4717000

3907000

491000

678000

300000 300000

1850000

2229000

Note 8 – Other Liabilities Other liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued legal settlement</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">807</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,220</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Capital lease obligations, net of short term</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">305</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">210</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Installment loans, net of short term</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">245</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">363</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,357</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,793</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table> As of October 31, 2015, future minimum payments under the capital leases, net of interest of $23 aggregates $579, including a short term debt portion of $274 included in other current liabilities. Future minimum payments under the installment loans aggregate $534, including a short term portion of $289 included in other current liabilities. A total of $1.2 million was recorded in other current liabilities and in other liabilities as accrued legal settlement which is further discussed in Note 13 - Contingencies.

23000

579000

274000

534000

289000

1200000 Other liabilities consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">October 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">July 31, 2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued legal settlement</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">807</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,220</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Capital lease obligations, net of short term</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">305</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">210</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Installment loans, net of short term</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">245</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">363</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,357</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,793</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

807000

1220000

305000

210000

245000

363000

1357000

1793000

Note 9 – Stockholders’ Equity Controlled Equity Offering On March 28, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sales Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to the Company’s Registration Statement on Form S-3 which was declared effective on August 5, 2010 and a prospectus supplement, dated March 28, 2013, and more recently under the Company’s current Registration Statement on Form S-3 which was declared effective on August 13, 2013 and a prospectus supplement dated August 1, 2013, filed by the Company with the Securities and Exchange Commission (the “SEC”). On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus supplement dated December 31, 2014. During the three months ended October 31, 2015, the Company did not sell any shares of Common Stock under the Sales Agreement. For the three months ended October 31, 2014, the Company sold an aggregate of 505,829 shares of Common Stock under the Sales Agreement at an average price of $5.38 per share and received proceeds of approximately $2.6 million, net of expenses of $82. Share-based compensation The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2015. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. The amounts of share-based compensation expense recognized in the periods presented are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td colspan="6" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center">Three months ended October 31,</td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2014</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">104</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">85</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Restricted stock</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">7</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">13</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">111</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">98</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table> The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td colspan="6" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center">Three months ended October 31,</td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2014</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">Cost of clinical laboratory services </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">Research and development </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">1</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px">Selling, general and administrative </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">110</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">96</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">111</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">98</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table> No excess tax benefits were recognized during the three month periods ended October 31, 2015 and 2014. Stock Option Plans The following table summarizes stock option activity during the three month period ended October 31, 2015: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Options</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Exercise Price</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Remaining Contractual Term</td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Aggregate Intrinsic Value (000s)</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 40%; font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">Outstanding at July 31, 2015</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 10%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,358,104</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 10%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">3.04</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 12%"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">Awarded</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">Exercised</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Cancelled or expired</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(6,000</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">3.61</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px; text-align: right"> </td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Outstanding at end of period</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,352,104</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">3.04</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-bottom: 3px">2.2 years</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">964</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Exercisable at end of period</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">785,188</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">2.87</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-bottom: 3px"> 1.8 years</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">664</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table> As of October 31, 2015, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.4 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is eleven months. The intrinsic value of in the money stock option awards that are vested at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that vested. Restricted Stock Awards A summary of the activity pursuant to the Company’s unvested restricted stock awards for the three months ended October 31, 2015 is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Awards</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Award Price</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; text-indent: -10pt; padding-left: 10pt">Outstanding at July 31, 2015</td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right">21,501</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">8.84</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt">Awarded</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(6,751</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(2.10</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Forfeited</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(1,500</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left">$</td> <td style="padding-bottom: 1px; text-align: right">(2.86</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Unvested at end of period</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td> <td style="border-bottom: Black 3px double; text-align: right">13,250</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td> <td style="padding-bottom: 3px; text-align: right">4.04</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table> The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of October 31, 2015, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately twenty-one months. The fair value of the awards that vested during the three months ended October 31, 2015 and 2014 was $21 and $35, respectively. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,309,000 shares as of October 31, 2015.

20000000 0.030 20000000

505829

5.38 82000

400000

P11M

100000

P21M

21000

35000

1309000

The amounts of share-based compensation expense recognized in the periods presented are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td colspan="6" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center">Three months ended October 31,</td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2014</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">104</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">85</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Restricted stock</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">7</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">13</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">111</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">98</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

104000

85000

7000

13000

111000

98000

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td colspan="6" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center">Three months ended October 31,</td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2015</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">2014</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">Cost of clinical laboratory services </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 12%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">Research and development </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">1</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px">Selling, general and administrative </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">110</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">96</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">111</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">98</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

1000

110000

96000

111000

98000

The following table summarizes stock option activity during the three month period ended October 31, 2015: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Options</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Exercise Price</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Remaining Contractual Term</td> <td style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-family: Arial, Helvetica, Sans-Serif; font-weight: bold; text-align: center; border-bottom: Black 1px solid">Aggregate Intrinsic Value (000s)</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 40%; font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">Outstanding at July 31, 2015</td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 10%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,358,104</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%; font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="width: 10%; font-family: Arial, Helvetica, Sans-Serif; text-align: right">3.04</td> <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 12%"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">Awarded</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-indent: -10pt; padding-left: 10pt">Exercised</td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right">—</td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Cancelled or expired</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 1px solid; font-family: Arial, Helvetica, Sans-Serif; text-align: right">(6,000</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">)</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">3.61</td> <td style="padding-bottom: 1px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px; text-align: right"> </td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Outstanding at end of period</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">1,352,104</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">3.04</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-bottom: 3px">2.2 years</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">964</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Exercisable at end of period</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="border-bottom: Black 3px double; font-family: Arial, Helvetica, Sans-Serif; text-align: right">785,188</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">2.87</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-bottom: 3px"> 1.8 years</td> <td style="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left">$</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: right">664</td> <td style="padding-bottom: 3px; font-family: Arial, Helvetica, Sans-Serif; text-align: left"> </td> </tr> </table>

1358104

3.04

6000

3.61

1352104

3.04

P2Y73D

964000

785188

2.87

P1Y292D

664000

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the three months ended October 31, 2015 is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Awards</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1px"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1px solid">Weighted Average Award Price</td> <td style="padding-bottom: 1px; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="width: 66%; text-indent: -10pt; padding-left: 10pt">Outstanding at July 31, 2015</td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right">21,501</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">8.84</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt">Awarded</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(6,751</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(2.10</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Forfeited</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(1,500</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="padding-bottom: 1px; text-align: left">$</td> <td style="padding-bottom: 1px; text-align: right">(2.86</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Unvested at end of period</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td> <td style="border-bottom: Black 3px double; text-align: right">13,250</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="padding-bottom: 3px; text-align: left">$</td> <td style="padding-bottom: 3px; text-align: right">4.04</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table>

21501

8.84

6751

-2.10

1500

-2.86

13250

4.04

Note 10 - Income taxes At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods. The Company’s effective tax rate provision for the three months ended October 31, 2015 was 1.9% compared to 3.4% for the three months ended October 31, 2014. The tax provision for the periods was based on state, local and foreign taxes, net of the benefit for amortization of foreign intangibles. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit. The Company files a consolidated Federal income tax return. The Company files combined returns with California, Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns.

0.019

0.034

0.34

Note 11 – Royalty and licensing income The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended October 31, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $0.4 million and $1.0 million respectively, which is included in the Life Sciences segment. 2018-04-24

400000

1000000

Note 12 – Segment reporting The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. Legal settlements, net represent activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the products covered by the settlements. Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2015. The following financial information represents the operating results of the reportable segments of the Company: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td nowrap="nowrap" style="background-color: White; padding-bottom: 1px">Three months ended October 31, 2015</td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Clinical Labs</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Life Sciences</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Therapeutics</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Other</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Consolidated</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-indent: -10pt; padding-left: 10pt">Revenues:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Clinical laboratory services</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">17,090</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">17,090</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">7,687</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,687</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Royalty and license fee income</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">400</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">400</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">17,090</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">8,087</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">25,177</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,332</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,332</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,611</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,611</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">667</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">200</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">867</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,286</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,059</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1,880</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,225</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for uncollectible accounts receivable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">708</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">704</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fee expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(22</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,614</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,601</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Legal settlement, net</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(6,800</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(6,800</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">16,335</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">511</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">200</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">3,494</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">20,540</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating income (loss)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">755</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,576</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(200</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,494</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,637</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt">Interest</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(19</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(35</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(40</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt">Other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">39</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">54</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Foreign exchange loss</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(130</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(130</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Income (loss) before income taxes</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">740</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">7,499</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(200</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(3,518</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">4,521</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Depreciation and amortization included above</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">397</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">530</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">23</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">950</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation included in above:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">10</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">5</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td> <td style="border-bottom: Black 1px solid; text-align: right">95</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">110</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">11</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">5</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">95</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">111</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Capital expenditures</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">437</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">68</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">505</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td nowrap="nowrap" style="background-color: White; padding-bottom: 1px">Three months ended October 31, 2014</td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Clinical Labs</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Life Sciences</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Therapeutics</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Other</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Consolidated</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-indent: -10pt; padding-left: 10pt">Revenues:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Clinical laboratory services</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">15,822</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">15,822</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8,002</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,002</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Royalty and license fee income</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1,000</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1,000</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,822</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,002</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">24,824</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,130</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,130</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,695</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,695</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">548</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">243</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">791</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,066</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,150</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,069</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,285</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for uncollectible accounts receivable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">530</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">541</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Legal fee expense</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">91</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">2,374</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">2,466</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">15,817</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">7,405</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">243</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">4,443</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">27,908</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating income (loss)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,597</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(243</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,443</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,084</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt">Interest</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(27</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(44</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(69</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt">Other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(8</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">19</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Foreign exchange gain</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(472</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(472</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Income (loss) before income taxes</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(20</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">1,119</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(243</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(4,462</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(3,606</td> <td style="padding-bottom: 3px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Depreciation and amortization included above</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">357</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">560</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">1</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">20</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">938</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation included in above:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">9</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td> <td style="border-bottom: Black 1px solid; text-align: right">87</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">96</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">10</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">1</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">87</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">98</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Capital expenditures</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">254</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">10</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">264</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table>

The following financial information represents the operating results of the reportable segments of the Company: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td nowrap="nowrap" style="background-color: White; padding-bottom: 1px">Three months ended October 31, 2015</td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Clinical Labs</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Life Sciences</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Therapeutics</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Other</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Consolidated</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-indent: -10pt; padding-left: 10pt">Revenues:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Clinical laboratory services</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">17,090</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">17,090</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">7,687</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,687</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Royalty and license fee income</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">400</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">400</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">17,090</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">8,087</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">25,177</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,332</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,332</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,611</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,611</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">667</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">200</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">867</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,286</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,059</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1,880</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,225</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for uncollectible accounts receivable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">708</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">704</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fee expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(22</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,614</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,601</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Legal settlement, net</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(6,800</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(6,800</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">16,335</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">511</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">200</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">3,494</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">20,540</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating income (loss)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">755</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,576</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(200</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,494</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,637</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt">Interest</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(19</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(35</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(40</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt">Other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">39</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">54</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Foreign exchange loss</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(130</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(130</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Income (loss) before income taxes</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">740</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">7,499</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(200</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(3,518</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">4,521</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Depreciation and amortization included above</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">397</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">530</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">23</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">950</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation included in above:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">10</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">5</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td> <td style="border-bottom: Black 1px solid; text-align: right">95</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">110</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">11</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">5</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">95</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">111</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Capital expenditures</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">437</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">68</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">505</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td nowrap="nowrap" style="background-color: White; padding-bottom: 1px">Three months ended October 31, 2014</td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Clinical Labs</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Life Sciences</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Therapeutics</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Other</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> <td nowrap="nowrap" style="background-color: White; text-align: center; padding-bottom: 1px"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; background-color: White; border-bottom: Black 1px solid">Consolidated</td> <td nowrap="nowrap" style="text-align: center; background-color: White; padding-bottom: 1px"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-indent: -10pt; padding-left: 10pt">Revenues:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Clinical laboratory services</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">15,822</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 8%; text-align: right">—</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">15,822</td> <td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8,002</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,002</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Royalty and license fee income</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1,000</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1,000</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,822</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,002</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">24,824</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,130</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,130</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of product revenues</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,695</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,695</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">548</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">243</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">791</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,066</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,150</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,069</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,285</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Provision for uncollectible accounts receivable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">530</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">541</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Legal fee expense</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">91</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">1</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">2,374</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">2,466</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">15,817</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">7,405</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">243</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">4,443</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">27,908</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating income (loss)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,597</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(243</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,443</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,084</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt">Interest</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(27</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(44</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(69</td> <td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-indent: -10pt; padding-left: 10pt">Other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(8</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">19</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Foreign exchange gain</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(472</td> <td style="padding-bottom: 1px; text-align: left">)</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">(472</td> <td style="padding-bottom: 1px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Income (loss) before income taxes</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(20</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">1,119</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(243</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(4,462</td> <td style="padding-bottom: 3px; text-align: left">)</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">(3,606</td> <td style="padding-bottom: 3px; text-align: left">)</td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Depreciation and amortization included above</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">357</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">560</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">1</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">20</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">938</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation included in above:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cost of clinical laboratory services</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1</td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1px; text-indent: -10pt; padding-left: 10pt">Selling, general and administrative</td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">9</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">—</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left">$</td> <td style="border-bottom: Black 1px solid; text-align: right">87</td> <td style="padding-bottom: 1px; text-align: left"> </td> <td style="padding-bottom: 1px"> </td> <td style="border-bottom: Black 1px solid; text-align: left"> </td> <td style="border-bottom: Black 1px solid; text-align: right">96</td> <td style="padding-bottom: 1px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(229,255,255)"> <td style="padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">10</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">1</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left"> </td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">87</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">98</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3px; text-indent: -10pt; padding-left: 10pt">Capital expenditures</td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">254</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">10</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">—</td> <td style="padding-bottom: 3px; text-align: left"> </td> <td style="padding-bottom: 3px"> </td> <td style="border-bottom: Black 3px double; text-align: left">$</td> <td style="border-bottom: Black 3px double; text-align: right">264</td> <td style="padding-bottom: 3px; text-align: left"> </td> </tr> </table>

17090000

7687000

400000 400000

17090000

8087000

25177000

10332000

3611000

667000

200000

867000

5286000

3059000

1880000

10225000

708000

-4000

704000

9000

-22000

1614000

1601000

6800000

16335000

511000

200000

3494000

20540000

755000

7576000

-200000

-3494000

4637000

19000

-14000

35000

40000

4000

39000

11000

54000

-130000

740000

7499000

-200000

-3518000

4521000

397000

530000

23000

950000

1000

10000

5000

95000

110000

11000

5000

95000

111000

437000

68000

505000

15822000

8002000

1000000 1000000

15822000

9002000

24824000

10130000

3695000

548000

243000

791000

5066000

3150000

2069000

10285000

530000

11000

541000

91000

1000

2374000

2466000

15817000

7405000

243000

4443000

27908000

5000

1597000

-243000

-4443000

-3084000

27000

-2000

44000

69000

2000

-8000

25000

19000

-472000

-20000

1119000

-243000

-4462000

-3606000

357000

560000

1000

20000

938000

1000

9000

87000

96000

10000

1000

87000

98000

254000

10000

264000

Note 13 – Contingencies On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company could be reduced or be subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. The Company has moved for reconsideration of that decision by the panel and for en banc rehearing by the full Court. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The litigation in the United States District Court for the Southern District of New York between the Company and Molecular Probes, Inc. terminated on May 11, 2015, with a settlement in favor of the Company in the amount of $170. Through October 31, 2015, the Company’s former legal counsel, Greenberg Traurig LLP (“GT”), was also engaged in litigation against the Company in the United States District Court for the Southern District of New York concerning GT’s request for a charging lien against another matter relating to its representation of the Company in the Roche and other cases. On April 22, 2014, the Company as plaintiff finalized and executed a settlement agreement with Affymetrix, Inc. to settle patent litigation actions before the U.S. District Court, Southern District of New York (the “Agreement”) in the amount of $5.1 million. Under terms of the Agreement, Affymetrix paid to the Company $4.3 million and paid to the Company’s attorneys $0.8 million. On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of GT’s requesting a charging lien for fees allegedly owed for past services rendered to the Company as referenced above. Because the settlement proceeds were held in escrow, and the amount the Company would ultimately receive was indeterminable, the Company has not included the settlement in the financial statements as of or for any periods through October 31, 2015. Any applicable amounts will be recognized when so distributed. On December 3, 2015, the Company entered into a Settlement Agreement with GT pursuant to which the Company and GT resolved their respective claims against each other. The escrow referred to above will be distributed in accordance with the terms of the Settlement Agreement, upon the entry by the Court of the Stipulation, Order and Judgement. In 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. As of October 31, 2015, the Company carried a balance of $0.4 million as other current liabilities and $0.8 million as a non-current liability. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004-2014. On July 2, 2015, the Company as Plaintiff executed a settlement agreement with Luminex Corporation with respect to an action between the Company and Abbott Laboratories and Abbott Molecular, Inc (Defendants) and Luminex Corporation (Intervening Defendant) before the United States District Court for the District of Delaware for alleged patent infringement. Luminex paid the Company a total of $7.1 million as consideration for this agreement and the dismissal of the litigation against Luminex. On July 20, 2015, the Company as a Plaintiff finalized and executed a settlement agreement with Siemens Healthcare Diagnostics Inc. (“Siemens”) to settle a patent litigation lawsuit before the U.S. District Court for the District of Delaware in the amount of $9.5 million. Under terms of the agreement, Siemens will also pay the Company additional royalties of $1.0 million per annum on sales of its molecular products manufactured and/or sold in the United States during the its fiscal years 2015 through 2019 if sales of such products exceed a contractual amount. The net settlement amount was included in other receivables in the consolidated balance sheet as of July 31, 2015 and was received in August 2015. On October 9, 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in an infringement action brought by the Company regarding its US Patent no. 7,064,197. The case was originally brought by the Company in the United States District Court for the District of Delaware. This settlement is included in statement of operations under Legal settlements, net within the Life Science segment. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

48500000

12500000

170000

5100000

4300000

800000

7000000

The time period initially covered by the investigation was from 2004 through 2011 2004 2000000 P5Y

400000

800000

1500000 10000000 0.20

10000000

2014

7100000

9500000

1000000

2015 2019

6800000

EX-101.SCH 8 enz-20151031.xsd 001 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Net income (loss) per share link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Supplemental disclosure for statement of cash flows link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Goodwill and intangible assets link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Loan Payable link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accrued Liabilities and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Other Liabilities link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Income taxes link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Royalty and licensing income link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Segment reporting link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Contingencies link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Goodwill and intangible assets (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Accrued Liabilities and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Other Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Segment reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Supplemental disclosure for statement of cash flows (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Inventories (Details) - Schedule of inventory, current link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Goodwill and intangible assets (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Goodwill and intangible assets (Details) - Schedule of intangible assets link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Loan Payable (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Other Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Other Liabilities (Details) - Schedule of other current liabilities link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option plans link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock awards link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Income taxes (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Royalty and licensing income (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Segment reporting (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Segment reporting (Details) - Schedule of segment reporting information, by segment link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 enz-20151031_cal.xml EX-101.DEF 10 enz-20151031_def.xml EX-101.LAB 11 enz-20151031_lab.xml Statement of Financial Position [Abstract] Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Accounts receivable, net of allowances Other accounts receivable Inventories Prepaid expenses and other Total current assets Property, plant and equipment, net Goodwill Intangible assets, net Other assets Total assets Loan payable Long-term Line of Credit Accounts payable – trade Accrued liabilities Other current liabilities Other Liabilities, Current Total current liabilities Deferred taxes Other liabilities Total liabilities Commitments and contingencies Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding Preferred Stock, par value (in Dollars per share) Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,068,816 at October 31, 2015 and 46,062,065 at July 31, 2015 Common Stock, par value (in Dollars per share) Common Stock, Par or Stated Value Per Share (in Dollars per share) Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Income Statement [Abstract] Clinical laboratory services Product revenues Royalty and license fee income Total revenues Cost of clinical laboratory services Cost of clinical laboratory services Cost of product revenues Research and development Selling, general, and administrative Selling, general and administrative Provision for uncollectible accounts receivable Legal fee expense Legal fee expense Legal settlements, net Legal settlement, net Gain (Loss) Related to Litigation Settlement Total operating expenses Operating income (loss) Interest Other Foreign exchange loss Foreign exchange gain (loss) Income (loss) before income taxes Provision for income taxes Net income (loss) Net income (loss) Net income for the period ended October 31, 2015 Net income (loss) Basic (in Dollars per share) Diluted (in Dollars per share) Basic (in Shares) Diluted (in Shares) Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments Comprehensive income (loss) Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Vesting of restricted stock (in Shares) Share-based compensation charges Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Statement of Cash Flows [Abstract] Depreciation and amortization of property, plant and equipment Amortization of intangible assets Amortization expense Amortization expense Deferred income tax benefit Share-based compensation charges Accrual for share-based 401(k) employer match expense Foreign exchange loss Accounts receivable Other receivables – settlements Inventories Prepaid expenses and other Accounts payable – trade Accrued liabilities, other current liabilities and other liabilities Total adjustments Net cash provided by (used in) operating activities Capital expenditures Security deposits and other Net cash used in investing activities Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Proceeds from borrowings under Credit Agreement Repayments under Credit Agreement Installment loan and capital lease obligation payments Net cash (used in) provided by financing activities Effect of exchange rate changes on cash and cash equivalents Increase (decrease) in cash and cash equivalents Disclosure Text Block [Abstract] Earnings Per Share [Abstract] Supplemental Cash Flow Elements [Abstract] Inventory Disclosure [Abstract] Schedule of inventory, current [Abstract] Raw materials Work in process Finished products Goodwill and Intangible Assets Disclosure [Abstract] Schedule of indefinite-lived intangible assets [Abstract] July 31, 2015 October 31, 2015 Finite-lived intangible assets, Gross July 31, 2015 October 31, 2015 Finite-lived intangible assets, Accumulated Amortization July 31, 2015 October 31, 2015 Finite-lived intangible assets, Net Foreign currency translation Foreign currency translation Foreign currency translation Segments [Axis] Life Sciences [Member] Schedule of intangible assets [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Customer Relationships [Member] Website And Acquired Content [Member] Licensed Technology And Other [Member] Trademarks [Member] Schedule of useful lives for acquisitions [Abstract] Useful life assigned Finite-Lived Intangible Asset, Useful Life Weighted average remaining useful life Other Intangible Assets [Member] Range [Axis] Minimum [Member] Maximum [Member] Debt Disclosure [Abstract] Payables and Accruals [Abstract] Accrued liabilities [Abstract] Legal fee expense Payroll, benefits, and commissions Professional fees Research and development Other Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] Schedule of other current liabilities [Abstract] Long-term Debt, Type [Axis] Accrued Legal Settlement [Member] Other liabilities Capital Lease Obligations [Member] Installment Loans [Member] Stockholders' Equity Note [Abstract] Schedule of share-based compensation expense [Abstract] Class of Stock [Axis] Options [Member] Stock Based Compensation Expense Restricted Stocks [Member] Schedule of share-based compensation expense by line item [Abstract] Income Statement Location [Axis] Cost of Clinical Laboratory Services [Member] Share-based Payment Arrangement Share-based compensation Research and Development Expense [Member] Selling, General and Administrative Expenses [Member] Schedule of stock option plans [Abstract] Outstanding at July 31, 2015 Outstanding at end of period Outstanding at July 31, 2015 Outstanding at end of period Cancelled or expired Cancelled or expired Outstanding at end of period Outstanding at end of period Exercisable at end of period Exercisable at end of period Exercisable at end of period Exercisable at end of period Schedule of restricted stock awards [Abstract] Outstanding at July 31, 2015 Unvested at end of period Outstanding at July 31, 2015 Unvested at end of period Vested Vested Forfeited Forfeited Income Tax Disclosure [Abstract] Royalty And Licensing Income [Abstract] EX-101.PRE 12 enz-20151031_pre.xml XML 13 R39.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 111	$ 98
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	104	85
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 7	$ 13

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(``@\B$>\2RS`W@$``(`=```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR M@ADJG4U^>J[O.L3ODV M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[ MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?= MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^ M:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[ M_]OXO>!P.[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^ M#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V M[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V M+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P" M4$L#!!0````(``@\B$==-=7JS0$``/H<```:````>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/%V4M.XT`4A>&M1%X`Y?L@0$08,6%*LP$KJ<11$MMR5:MA M]VTR0.%11PPBG8DMV]*M?_2I5+[O4KUXCH4H'DY:$X)NBD'W5"";LM!MY2@NW+0 M'25(:B!CS4E"6'.T%L"U<+P6`+9PQ!9`MG#,%H"V<-06P+9PW!8`MW#D%D"W M<.P6@+=P]%:@MW+T5J"WDO;::+/-T5N!WLK16X'>RM%;@=[*T5N!WLK16X'> MRM%;@=[*T5N!WLK1VX#>QM';@-[&T=N`WD8Z*T&')1R]#>AM'+T-Z&TAM'+T-Z&TCM'+T=Z.TCMI+-N=-C-T=N! MWL[1VX'>SM';@=[.T=O/]$YM,\;UGSSNNFVZ=,VGX;#H#.^4WP[Q\BFGJ?#G MS9G6>5HIAM/UXBB>IKZ'A&^_.1_^`U!+`P04````"``(/(A'W&=<@``#```G M#```$````&1O8U!R;W!S+V%P<"YX;6R]5\%RVC`0_14-EY)#8D)HTV&(9XAQ MFTP)]L1N>E;D!301DBL)"OWZKNU`##$F<"@79.F]7>][V@WI2=/JAEJEH"T' M0Y8S(4T7-V\:4VO3KN,8-H49-1<(D7@Z5GI&+3[JB:/&8\Y@H-A\!M(Z[5;K MBP-+"S*!Y#S=!&VXO2Q+/TT%9]1R)=T'SK0R:FR)OV0@>LXN(&=@Y`C87'.[ M0E+'O#]=:/($V6:67[8L6?C82K/>+V$`3 M+B,(J" MX?V@'_L#>3Z([WX^C8_&D&=+#G"C&KP=_A/C@&PE"__%8CA<\A$=P M,DH4!]Z/H_/TH[M*SBTUW!`U)J$&@WKO5W<$EG#)U`Q(4RACS@@V'C%9JU;B MHSE.&\@\I((DW#`DS340])`86ZWNO5P@7FF<:97GWY5*_G`A",5;P3&RG/!G M`80:L],GF]5044E"NJ*(JP3T&=-S2,B0TV#ZDL_"!G6)]7B6G."LQJA6P MBKU,E4APX'PB_N\Y7N(]9>>R6KK<$^E1K:C`#LC>"RS.M:!EQVXU;7?A^_CI-2.BZMAR=O'7C4 M$"YV36T"EVZ6K!$=9RS(-30B3&*%BV#J!F)2E4IRZ4&@]3U>R0'OMKXFF)(,:FC`8&#Y)&=)]6(VQK:F9*.^*J/C M6@2<6Z67&M1M-Y;]3L7."+X)!SFHH3W]_=,#95C25^Z"'JK:MIVT4ZJ+`^?L M;?[X3&>3:A-0&`E1%33'SL$L.79^G=[=+QZ2JLCRRS0OTNQFD5WS:<'SXGT_ MV8F_T7#3#_%O'1\-TG918PUG[I8TBI9+GP12$*37#K4U9^$(\TU,L+#]^`2) MYX-Z(5VV#72M]2I4=+_&:/]RXLI6UG>'U(_HY%557U!+`P04````"``(/(A' MF5R<(Q`&``"<)P``$P```'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^O MT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\ M!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&& M^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\ MW*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX M?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z M>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY; MQ/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0C MI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[ MY\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4 MX&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM M(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT, M"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[ M2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=S MFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ M@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F` M6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS< M_N\-L,+$CN'MB[\!4$L#!!0````(``@\B$=G;!@`7`(``-H*```-````>&PO MZL,&&+) M'\R8C/37SQ\$$K0L;996Y<77Q_>>>VQ?N$2U6E-\M\18@9917L=PJ53UR?/J M;(D9JJ>BPERO%$(RI/14EEY=28SRV@0QZLU\/_08(APF$6_8G*D:9*+A*H8? M>@BX^!N1XQC>G[W]U0AU_0:X=P@2E))#%@@1NC:P3,#V-+H_!CA0MK< M+L,XS]0?,LDRC:'?/8]/EP[L=C#;(Y3N;D\#250AI;#D=-Q4RQ[+/',`-E$04%TH'2%(NS:A$9:0+I0331DY0 M*3BBAG(3T1F:-L.4WID7\6>QP]T6P/F8._8A,"HVICZ(SAS*P!ZJM\WFN+=I MC^,%;=$GT-&HJNCZ,R4E9]B)==!<=+-#],$>^B1"&U:P%)(\:']3")D&L(1@ MA:4BV3;R6Z)J@5O55;#7%OL4'KOEY]1T^E,;U.@2?.GC.3JYA6X;\_F&8OOEJI86O5]KSU-1)I%W]IS2OZPQ;[6>G M^?0H2!M"%>$;#CUA"=?^[@E';6E+ZZ_ M,_;AWI@']K15VO7M(-IX7_4['5=LQ):[OTPE-#Q;&;OE'B[MNF-6*UF(L2GJ MK="^DW2[YQTK%/?2:+>1E8M>:.XC-%=9P4NW$<)OU1ZVY5)'7[^X_DHJ\4-8 M!V#&JVK&MV(0/:F(*>[\I)1>E(,H@TNS$P0[.MW!U&<9$EROF>$UWY(L7,8&&XP7GCY*);\ M?A!U(\9K;[Y)Y84=1`U MYTJ$EG3>-:7I_K1UB-M0EFV@/%#;5^\&#K@DYP,O3LOFP[4LXL=,R MWG<5!HWFLWQ^,QT/EY,QNQK>#&>C"@C4^R@HLE*X`4FT%`P&9\WC`XR[VKWN,FNI'P,#$$@Z''6A+ M>/O=F'(GE6(<)H"$//0ZS"#&G8/I@DG8W9B0]\9PS1;\F8<)B.*PJC'AZK`H M;"U*=B-Y,XVA`4TR<[^!#AUA%)8U)FS=AR`0#L:"QH2AN3?%P\:H$JKB'VSR M3PVU`,=C+V-"S.E>!L^?#K^+-8P)#^_,,U=0=D*;%?QUM(,Z^J(6YF`?8T+( M7*R;2F9%9:!FZC4.QA[&A(@CJ,80(G1QV&L)UBYIUXZ=+*FN%45CBA)"XU:6T MBW^?6.N4T+H=%6,4-CP]U?`TP2AL>$H8WH["AJ<'"P3"<%RMW_H=$[#=*6%W MZW1+>QB%_4X)OXGI1F6$!4\)P5LP02B,PH*GE.#DU*62PGZG5%EN)>$"EV*_ M4VJUT(;*L-\9]CLC_&Y'8;\S['=&^-V.PGYGV.^,\!O_0LG>SK#6&:%UV\\4 MB!AUL/*EJO=QT:4RPFYG'ZO=_R-EAOW.J*4O_DG3V6"OLXN7?=#;U@=V?U*+ M,FP,78.'G541=HMPV"_RLEY8*X3K6]A!#J*PS8,=7:W4".[--=2-9C.T)[_N M#[_^"U!+`P04````"``(/(A'.HH`[F<"``"_"```&````'AL+W=O`Z'D*'4(K%XWLB>4ZDA*^?<0=-34Q.GX'OVK25=M_X`% MV3/ZJSK)4NT6A,&)G/&5RC?6?2-##JD.>&14F&=PO`K)ZCLE#&K\T;^KQKR[ M_DL2#[1Y`AH(R!+@^K^$>"#$(R$QF?8[,WE]P1(7.6==(%JL3QL^*SC7051D M/=`_2N4DU._J5V\%R*.;#C,@=E,$,@AH$9&*/2N`[@([Y-'19X&]CX@?"\0V M@WA"CPT]>4Q/+#V9T!-#3YT?X".RQP*I%4@]^LH1\!'KQP*9%<@\^L81\!$0 M/%986865SX?.(?:0QD#2_A0RD&T`6""TMD)K7\AQRVX&LL`N&RNQ\?F)(['Q M

_8),OQGA1=[B"_F!^:5J M1'!@4G4MT[#.C$FBM@*>5,JENDW8"25GJ89]?^TGDK7WZX*]LQ1_`5!+ M`P04````"``(/(A'1:&0!-$#``!L$@``&````'AL+W=O+6JJ:)M>6)1\BW4ILHX)[JYU\[T]6]MM?I1%U3YOSUUW>8JB]O5LRZS] M4E]LU?]RJILRZ_K;YBUJ+XW-CF-06400QRHJL[S:[G?CLZ_-?E>_=T5>V:_- MIGTORZSY[V"+^OJ\9=O/!]_RMW,W/(CVNVB).^:EK=J\KC:-/3UO?V5/*1\E MH^+OW%[;57LSF'^IZ^_#S9_'YVT\>+"%?>V&+K+^\F%36Q1#3WWF?^=.7LM6E=_),?NW/O-MYNCO:4O1?=M_KZAYW'((<.7^NB';\W MK^]M5Y>?(=M-F?V8KGDU7J_3+R:>P_P!,`?`$L#$W0`^!W`4$$W.QG']EG79 M?M?4UTU[R8;99D^]O!DZZ7L>&L.+ZL?4]J]K>OJQ![V+/H9^9LEA+8%)\K,B M]2C,(HGZ_%X3L)B`53R?XI/'\7R)YZMX,<;S&`UBDE2C1,\2)?!`J(H9%@=X M$8L70;TPY$6LLL@I"VC%D1>?*LB+7+Q(Z@6/6)(L2LGX<1*U)%$T"1K*09$D M6AKLQ"/BB7KL1"].-'4BD!--7ZHV:*VD5`3]Y[$3LS@QU(E$3@Q)(OM%@&HO MI2JAA`EX*\GB):%>%/*2D"R&D95"13H1`67.8@>;F'HAM(EI'B$)<1ZH;KM9 MH8]1-P:[872:=(QGR:-23,H`-XZ!#*B;!+L!DH=CRZE/)'F`%\=31H$J,%`9 M]\S`NF!G-U2F#$]$@!_'5+:&ZO0'(5A`#XZ$C*(0P__`*`MYS#"6'ZENNW'( M9)29`C.341XF0F)4>51&JY`Z<-ADE)L"C]!28 MGHR",5$)=D-%)H2=S,&347H*3$]&R0A2&^+&(^.)#-DH.8("):C`!`7*1DS9 M]+[FMA-'3Z#T%)B>0+G(Z*+QJ7024%&PVD%2>@I,3UB#4<][769P@?MD_72& MS),C*%""XMH]^#0,F[FKN>W$L1,H.T/^)\&Q$R@[)::53T/&W'4!$I-B2D%%(<<9*Q)!?AT(E$!K`+'3:#N_P-0,+($2%EZ5"9DSKBC)Z?TE)A9G))1:"#; M`)\,5!PP8]PQE%.&2DPMSLA2]>VS/#+?/BM:G0M:F[KB[' MTX5377>V[S+^TM?KV6;'Y::PIVYHZK[=3(&PO=V]R:W-H965T&ULC97+CILP%(9?!?$`L;F3B"`U5*-V46DTBW;M)$Y`8S!C.V'Z]K4-<1D# M25C@"_]_SG>,96<=9>^\Q%@XGS5I^-8MA6@W`/!#B6O$5[3%C?QRHJQ&0@[9 M&?"68734IIH`'\(8U*AJW#S3B19+` MD`13$JO873!*$O7%1E`_%LT3PD6BT!"%4Z+`(@HGB6R4>XI%AL@P1%.&T&*( M'C+<4RPRQ(8AGC)$%D/\S!YY(%HD20Q),B6)+9)D4FLROT>>$"X2I88HG1(E M%E$Z213&,$Y3ST(OYH4^'*WV(M':$*VG1*E%M'Z6:%XX0P1&AUZ+SO@78N>J MX"GE^ZJ/S1*G`,BAU8RFO-#`@^"=5-9)_U)WT_$+2]W5OF\LS_`5!+ M`P04````"``(/(A'*CHZ#LL#``!+$0``&````'AL+W=OA9\+\Z7;BB(MYMXCCL6E:G;PM918TYOJR_\=2_8(!D5 M?Q7FWB[NH\'\N[4_AH<_CF\K-G@PI3ET0Q5Y?_DP>U.60TU]RS\?E;HVA\#E M_;/VW\9T>_OO>6OVMOR[.':7WBU;14=SRF]E]]W>?S>/')*APH,MV_$W.MS: MSE;/D%54Y;^F:U&/U_OTCV*/,'\`/`)@#IC;\0>(1X!P`7+,='(VYO4U[_+M MIK'WJ+WFPVCSUU[>#)7T-0\W0T?U.;5]=TVE']M4;^*/H9Z'9+>4P"CALR+N M*_>V`,\6=D#"X;\-[*DB8Y^W(.83/$!#N4<+Q?Q3I!XEV=0' M&=,,)>)1)0K@)1207RDP(?":\:FX".A7SMS:9]2-PHN?D89$RCERXU7I),#-@D2$Z52$0X@Z'G/)081YR"CM@ MB<1(],DRS52`'T=%3K&H,!8Y)9Y,!5DO5+463`5PD3LP1HC3U"/_'BC%J9YCR>W=OH8&]U M-QT$Y]+Y^\`7&,ZXJ'S'7_?3*=]5L]U<\[/Y,V_.1=U&[[;K3]#CX?ED;6=Z ME^RE7R`7DQ_GA]*&PO=V]R:W-H965T&ULC53; MCILP$/T5Q/LNUY!-1)"65%7[4&FU#^VS0R:`UA=JF[#]^_H"#H5(Z4ML#^>< M.3.Q)Q\8_Q`-@/0^":;BX#=2=OL@$%4#!(EGU@%57RZ,$R35D=>!Z#B@LR$1 M',1AF`4$M=0OHE;"F_<$STAB/\I`;/AX$?^%'AOZT;J0%#D@>.= M6P)4M(QZ'"X'_S7:'S.-,("?+0QBMO>T]Q-C'_KP_7SP0VT!,%12*R"U7.$( M&&LAE?CWJ'E+J8GS_:3^U52KW)^0@"/#O]JS;)39T/?.<$$]EN]L^`9C"1LM M6#$LS*]7]4(R,E%\CZ!/N[;4K(/]\A*.M/N$>"3$CN#RW"P;D64!7KJ;27PD7=J'B-]7U?Q$LU M0NR+O\D4>8=J^(%XW5+AG9A4K\D\I`MC$I3)\%GUJU%#SATP7*3>;M6>VW=O M#Y)UTQ1SH[3X"U!+`P04````"``(/(A'PA7\;'P"``"Z"```&````'AL+W=O M2/=)"XR9]557#5W:!6/MPG'H MKL`UHB^DQ0U_'MAU&^YY45PYP7>C4J&SL+.WGWKHL)2=6E0U^ MZRQZJFO4_5WABER6MF=?)][+8\'$A).ECN+MRQHWM"2-U>'#TO[N+?)$('K` M[Q)?Z*AOB=RWA'R*P<_]TG9%"KC".R8B(-Z<\1I7E0C$A?_(F#=)01SWK]'S MWBW/?HLH7I/JH]RS@B?KVM8>']"I8N_D\@-+"Z$(N",5[9_6[D09J:\4VZK1 MU]"63=]>AC>Q*VEF`I`$H`@`S!)\2?`5P8>SA$`2@IM"-$L()2&\*\FC#1/28W86*%<;A?HVF@3(-1@$`&2#33 M`Z;I,5&/":"GF9YB?!`D4/.TF<*^@3B`,="\3W%>K&OFAKP`')7QH7U?V?>G M]CU7L^^/9$)IWX7`A>%SI4`I!08ES=`FF"H%OK:]\B>@AZF$*I70D(JV`*MP MH@*CT'NN`I4*-*AHQVD-)RJ3HN3SF(>)1"J1R+#%-9'7:&I7JT@^"WF81JS2 MB`WUT-9V%?_'29MB?!"ZD?9EV$QA_*2Y((@UYU.9#^XFR MGQCL:U_%56(\:7'LZ6?:&7W36W3$OU!W+!MJ;0GCOX?^SW`@A&$>U'WA6[G@ M%PDUJ/"!B6[$^]WP;QT&C+37FX*ZKF3_`%!+`P04````"``(/(A'DF<#4BL$ M``#R$P``&````'AL+W=O)(1E\[JZM.WMQ?>;P\446?.ENIFR^^=4U476=I?UV6]NMYM?2?*N]YEX46?W?SN35XW6E5A\WOE_/ ME[:_X6\W_MSN>"U,V5RKTJO-Z77U5;WL,>PE@^+OJWDTBW.O-_]653_ZBS^/ MKZN@]V!R#=[D^=]I*[G?Z>@ML^^X?+\(_KO0[J=_;>L,?LJ_^=Z M;"^=VV#E'JKP9?KW#O6FKXJ/)RBNRG^/Q6@['Q_A/ M$DS-Y`8P-8"YP=R/W`"G!F@;Z"'3T=F0UV]9FVTW=?7PFEO6/VWUTLGK/D@7 MN3_I!ZK+J>F&:[S[OE4JVOCO?:!)LUMJ8-3,"K^++G8!'UWL@#6'SQWLN2(. MGO>`J#\T['E,V""`('*(*% M(@A0I$5Q!YQW24S+ZUY0I;&+&XM%D+"84#<"\5"%M&`(LC7$H0,:P:(10,"1 MP\H&+-$`>4Y(5P23Z)/9,`AI2H(*(IL,P#8?''5LO`>0;H4B7!`@TXT!32 MD@(<5@`ZHHL948:10^D!RS00F(:4:2"MX21'HL[)$EJRH4`VI&1#SJPU*\Y[ M4:4<9CM:M*&`-J1H0X%9@AVN`G`ISVC!AGS-IY`N^I"OY];,C*1Q\;+XD!4( MJ2DAD;.O&QFZOMD+LG7B@DBTB$0!D9HB$@5$)BJ@15&2Q=JE"J$E)0JDI.ND M'2X9.'Z&8Q"QY90@4U&8TD\Z?[&54ICZ/&PQ-=ZANI?MN%TQWYVWL;Y"OQ5# M[N_4RW[6]6V53'L\9RJJC6=R^!+Y_)BLN-\D9M3 MVY_&W7D];DF-%VUU^]AAF[?YMO\#4$L#!!0````(``@\B$=[-H(EH@$``+$# M```8````>&PO=V]R:W-H965T&ULA5/+;J0P$/P5BP^(&6"R MT8A!RF0590\K13GLGCW0@!7;S=IFR/Y];`,.2D;*!7)#,W.(!R?UK4DEF7ZHZ:00-K`DD*FJ7I+96,JZ0J0^U9 M5R6.5G`%SYJ844JF_Y]`X'1,=LE:>.%=;WV!5B6-O(9+4(:C(AK:8W*_.YP* MCPB`/QPFLXF)]WY&?/7)K^:8I-X""*BM5V!NN<`#".&%7.-_B^9'2T_THL76C"G+2:;,1%!G?K5%MG:XI1]H6??T_/H,-_0\\5A\;U` M$06*C4"Q".P_C7@-<_NI"=WLJ03=A:MC2(VCLO/FQ6J\G?=9.),/>%4.K(/? M3'=<&7)&ZTXV'&J+:,%926_V">G=^XF)@-;Z\(>+]7REYL3BL#Z0^$JK=U!+ M`P04````"``(/(A'=@$9N*0!``"Q`P``&````'AL+W=OY5]1V=:932BIH.:#M*\X M/L$\PLX+EBA-^))R,!;50J%$\8]I%5U8Q^G/-IUIEPGI3$@CX38)QJ=&P>8# MM[S(-8[$]-R?W6;OX-J+.&4?^+F=1>.FGZKG8I/=Y.SLA6;,<8U))TQ$,*=^ ML46ZM#BFW^CIS_1M=+A=T;>SP]N?!;(HD*T$LEG@UY<1+V!VR92#QE1;_`5!+`P04````"``(/(A'6`BSJZ(!``"Q M`P``&0```'AL+W=O;4= M@"/O2FI[I)US_8$Q6W6@N+W!'K3_TZ!1W/G4M,SV!G@=24JR+$F^,<6%IF41 M:\^F+'!P4FAX-L0.2G'SYP02QR--Z5)X$6WG0H&5!5MYM5"@K4!-##1'>I<> M3GE`1,`O`:/=Q"1X/R.^AN2Q/M(D6``)E0L*W"\7N`UY.+OTX.$FB'CE$(2Y MO47KIY^JES+=IP6[!*$9<]IBL@FS(IA7O]HB6UJ`V3?VG"-GNJP+3QZEA2X:#=M'EK=;V==_$0V2>\+'K> MPA,WK="6G-'YDXV'VB`Z\%:2FSTEG7\_:R*A<2'\[F,S7:DI<=@O#V1]I>4' M4$L#!!0````(``@\B$=/'GPLHP$``+`#```9````>&PO=V]R:W-H965T5HIR2,X>:,"*[69M M,V3_/K8!!V5'R@5W-U75U7Z4$^HWTP-8\BZ%,L>DMW8X4&KJ'B0S-SB`8UKD_,P./*%YY8WMG-DU(`RT; MA7W&Z1T.#JZ]B%/V@9_;631N^KEZJ?*\I!>OLT!.6T@6(+N( MH$[\:H=L[7#*_J-GW]/S:##?T/.Y^W[_O4`1!8J-0+$(W'X9\1KF[DL3NME2 M";H+-\>0&D=EY[V+U7@Y'[)P))_PJAQ8!W^8[K@RY(S6'6PXTQ;1@K.2WNP3 MTKOG$Q,!K?7AG8OU?*/FQ.*POH_X2*L/4$L#!!0````(``@\B$=(%J$0HP$` M`+$#```9````>&PO=V]R:W-H965TX,]:/^G0:.X\ZEIF>T-\#J2E&1YEMTRQ86F M91%K3Z8L<'!2:'@RQ`Y*;$9)#0T?I'O&\2?,(^R#8(72QB^I!NM0+11* M%'^;5J'C.DY_]@OM.B&?"7DBW&71^-0HVGSDCI>%P9'8GH>SVQP\W`01KQR" M,+>W:/WT4_52;O9W!;L$H1ES6F/R"9,0S*M?;9$O+4[Y)WK^-7V;'&Y7].WL M\/O7`KLDL%L)[":!V^S#B-"O9S9Z2SK^?E$AH7`B_^=A,5VI*'/;+`TFO MM/P/4$L#!!0````(``@\B$=]`K:>HP$``+$#```9````>&PO=V]R:W-H965T M6C&-&^N`[`DU>MC#O1SOO^R)BK.M#"W6$/ M)OQIT&KA0VI;YGH+HDXDK1C/LGNFA32T+%+MR98%#EY)`T^6N$%K8?^>0>%X MHCNZ%)YEV_E88&7!5EXM-1@GT1`+S8D^[([G/"(2X)>$T6UB$KU?$%]B\J,^ MT2Q:``65CPHB+%=X!*6B4&C\9]9\:QF)VWA1_Y:F#>XOPL$CJM^R]ETPFU%2 M0R,&Y9]Q_`[S"(]GA_N/!?)5(-\(Y+-`_F[$6YC#NR9L MLZ<:;)NNCB,5#L9/F[=6U]OYP-.9O,'+HA&PO=V]R:W-H965TX,]:/^G0:.X\ZEIF>T-\#J2E&1YENV9 MXD+3LHBU9U,6.#@I-#P;8@>EN/E[`HGCD6[H4G@1;>="@94%2[Q:*-!6H"8& MFB-]V!Q.NX"(@-\"1KN*2?!^1GP-R<_Z2+-@`214+BAPOUS@$:0,0K[QVZSY MT3(0U_&B_A2G]>[/W,(CRC^B=ITWFU%20\,'Z5YP_`'S"+=!L$)IXY=4@W6H M%@HEBK]/J]!Q':<_^X5VG9#/A#P1[K-H?&H4;7[GCI>%P9'8GH>SVQP\W`01 MKQR",+>W:/WT4_52;O;[@EV"T(PYK3'YA$D(YM6OMLB7%J?\/WK^-7V;'&Y7 M].WL\.YK@5T2V*T$=K/`_:<1KV&^?6K"5GNJP+3QZEA2X:#=M'FIFF[G0Q[/ MY`->%CUOX1:?D/4$L#!!0````(``@\B$<%[\,(H`$``+$#```9````>&PO=V]R:W-H M965T\9\M(7,>S^H\T;7!_$@X>4?V1E6^# MV8R2"FK1*_^"PT^81KB-@B4JE[ZD[)U'/5,HT>)M7*5)ZS#^^99-M.L$/A'X M!8&-C9+-[\*+(K)>':;?8#;*!*48Q#G#A9=F'ZLGHO-?9:S.SF![*\TN(_4$L#!!0````(``@\B$?;4Q3Q MH@$``+$#```9````>&PO=V]R:W-H965TK#[K,#`UBU/=0VH?OWM0VXJ!NI+WAF..?,&5^* M$?6;Z0`L^9!"F6/26=L?*#55!Y*9&^Q!N3\-:LFL2W5+3:^!U8$D!V\Z931-20\,&85]Q?()YA)T7K%"8\"758"S* MA9(0R3ZFE:NPCM.?73K3KA.RF9!%PET@T*E1L/F+6586&D=B>N;/;G-P<.U% MG+(/_-S.HG'33]5+N=GG!;UXH1ES6F.R"1,1U*E?;9$M+4[9?_3L9_HV.MRN MZ-O9X>YG@3P*Y"N!?!:X_3;B-#OOLW`F M7_"RZ%D+OYENN3+DC-:=;#C4!M&"LY+>[!+2N?<3$P&-]>'>Q7JZ4E-BL5\> M2'REY2=02P,$%`````@`"#R(1\20(GVC`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK+3N(8L($Y0M(<"00[MF996 M$A&2JY"4E?Y]24IBA,1`+N+N:F9VEH]B1/-B.P!'WI34]D@[Y_H#8[;J0'%[ M@SUH_Z=!H[CSJ6F9[0WP.I*49'F6?6.*"TW+(M:>3%G@X*30\&2('93BYM\) M)(Y'NJ%+X5FTG0L%5A8L\6JA0%N!FAAHCO1^W.7BX"2)>.01A;F_1^NFGZJ7&ULA5/;;IPP M$/T5BP^(62_;1BL6*9NJ:A\J17EHG[TP@!7;0VVSI']?VX"#DI7R@F>&<\Z< M\:6#+$CDIQ\^\,$J=3MLO6PK/H>A<*M"IIXC5"@;8" M-3'0GK*'W?%0BX3O.?@BVTVP2V$%@BW.?1^-PHVOS&':]*@Q.Q`P]GMSMZ MN`DB7CD$86YOT?KIY^JUVMVSDEZ#T((Y;S%LQB0$]>HW6["UQ9E]H+//Z?OD M<+^A[Q>'^\\%BB10;`2*1:!X-^(MS.%=$[K94P6FBU?'DAI'[>;-2]5T.Q_B M(=(W>%4.O(-?W'1"6W)!YT\V'FJ+Z,!;R>\.&>G]^TF)A-:%\*N/S7REYL3A ML#Z0]$JK_U!+`P04````"``(/(A'J(QK0Z,!``"Q`P``&0```'AL+W=O2 MF2OL0;D_#6K)K$MU2TVO@=6!)`7-TO2&2L954A:A]JS+`@S24HPU$1#H84N&@[+1YL1IOYUTX1/H%+XN>M?"'Z98K0TYHWE-3V2'OGA@-CMNY!<7N#`VC_IT6CN/.IZ9@=#/`FDI1D M>99]8HH+3:LRUIY,5>+HI-#P9(@=E>+F]PDD3D>ZHVOA672]"P56E2SQ&J%` M6X&:&&B/]'YW..T#(@)^"ICL)B;!^QGQ)23?FR/-@@604+N@P/UR@0>0,@CY MQJ^+YGO+0-S&J_ICG-:[/W,+#RA_B<;UWFQ&20,M'Z5[QND;+"/2+<9='XW"C:_,H=KTJ#$[$##V>W M.WBX"2)>.01A;F_1^NGGZJ7:?0S)B&85[_:(E];G/*_Z/F_ MZ45R6&SHQ>+P/_KOD\!^([!?!/(/(U[#%!^:L,V>*C!=O#J6U#AJ-V]>JJ;; M>9_',WF'5^7`._C!32>T)6=T_F3CH;:(#KR5[.:6DMZ_GY1(:%T(/_O8S%=J M3AP.ZP-)K[3Z`U!+`P04````"``(/(A'Y/KP+:,!``"Q`P``&0```'AL+W=O M&])UI2;+F80GC'4^$1`?"'P6PV,?+> MSTJ]^.1W>\29MP`<&NL5J%LN\`"<>R'7^-^B^='2$[?QJOXS3.OR_%J@2`+%1J!81BP_ MC7@-<_NI"=GLJ0#=AZMC4*,F:>/FI6JZG?=Y.),/>%V-M(='JGLF#3HKZTXV M'&JGE`5G);LI,1K<^TD)A\[Z\,[%.EZIF%@UK@\DO=+Z'5!+`P04````"``( M/(A'CD*^[<`!``![!```&0```'AL+W=OJQ;I70&I/ MX@QG:9IC3JA(RL+G7E19R,$P*N!%(3UP3M2_$S`Y'I--,B=>:=L9E\!E@2.O MIAR$IE(@!=@<3KE#>,!O"J->Q,C5?I;RS6U^UL)3L#ZU-9XM-$U1#0P9F7N7X#%,+>R=8 M2:;]$U6#-I+/E`1Q\AY6*OPZAC=Y/M'6"=E$R"+A+O6%!R-?Y@]B2%DH.2+= M$_?O-@<+5T[$*KO`]6U+U+;[D+V4F_O;`E^3`<'U?I#H%$E!V'"&,1L/&):K,/I0$``+$#```9````>&PO=V]R:W-H965TW? MUS;@HC927_#,<,Z9,[X4HS8OM@-PZ%4*98^X;(91#0T;A'O2 MXV^81]@%P4H+&[^H&JS3-3HVCS M)W.L+(P>D>U9.+O-P<--$/'*(0AS>XO63S]5+R7-\H)<@M",.:TQ-&(V"4&\ M^M46=&EQHE_H]'OZ-CGE)LV+U73[;RG\4P^X&71LQ;^,M-R9=%9.W^R\5`;K1UX*]G-#J/. MOY^4"&A<"&]];*8K-25.]\L#2:^T?`=02P,$%`````@`"#R(1XKO"F^C`0`` ML0,``!D```!X;"]W;W)K&ULC5/+;MLP$/P5@A\0 MRK13IX8L($Y1M(<"00[MF996$A&2JY*4E?Y]2>H1P3'07L3=UO&EEW)&VWG<'QES9@A;N#CLPX4^-5@L?4MLPUUD052)IQ7B6?6):2$.+ M/-6>;9%C[Y4T\&R)Z[46]L\)%`Y'NJ%SX44VK8\%5N1LX552@W$2#;%0'^GC MYG#:140"_)0PN%5,HO/F+=7E=C[R=";O\"+O M1`,_A&VD<>2,/IQL.M0:T4.PDMW=4]*&][,D"FH?PWV([7BEQL1C-S^0Y946 M?P%02P,$%`````@`"#R(1\V%]FO)`0``X`0``!D```!X;"]W;W)K&ULC53-;J,P$'X5BP>H@810102I:56UATI5#[MG!P:P:F-J MF]!]^[4-N(A%RE[P>/A^9L#C;!#R4S4`&GUSUJI3T&C='3%610. M5$)RHLU6UEAU$DCI2)SA.`P/F!/:!GGF5U(.K:*B11*J4_`0'<^I13C`+PJ#6L3(UGX1XM-N7LM3 M$-H2@$&AK0(QRQ4>@3$K9(R_)LT?2TMZ0\QO,#40F(%"\&4>Z*B5UKPF1(@3K['E;9N'<8W]^%$VR;$$R%>$?!H MY,I\(IKDF10#4AVQ_RXZ&KBT(D;9!K9O4Z(RW8_9:QY'88:O5FC"G)>8V&$B MC\!&?=,BGBW.\3_T^#9]YRO<+>B[T3U-;@OLO#SC'<^&5MYT+!5(69.'57(*R7"MDH#G@NWQ_W`9$ M!/SA,-I5C(+WD]9O(7FN#S@+%D!`Y8("\\L9[D&((.0;OT^:GRT#<1W/ZH]Q M6N_^Q"S<:_&7UZ[S9C.,:FC8(-RK'I]@&N$Z"%9:V/A%U6"=EC,%(\D^TLI5 M7,?T9[>9:)<)="+0A7";1>.I4;3YP!PK"Z-'9'L6SB[?>[@)(EXY!&%N;]'Z MZ5/U7-+\5T'.06C"'-<8&C'Y@B!>_6(+.K&ULG55=CZ(P%/TKA!\P_0`$#9*,;B:S#YM,YF'WN6H5,BUEVRJS M_W[;@H4H"<87:2_GG'O/Q=[FK9!?JJ14!]^0*JD90<'(DS@"%<`$ZJ.BQR%_N012[.FE4U_9"!.G-.Y+\-9:)= MARB\!CZK4ZEM`!0Y\+Q#Q6FM*E$'DA[7X2M:;5%L(0[QNZ*M&JT#6_Q.B"^[ M^7E8A]#60!G=:RM!S.-"MY0QJV0R_^U%AYR6.%Y?U=^<75/^CBBZ%>Q/=="E MJ1:&P8$>R9GI3]&^T]Y#8@7W@BGW&^S/2@M^I80!)]_=LZK=L^W>9+"G31-P M3\">X/-,$Z*>$`T$USK05>9\_2":%+D4;:`:8K\V6AFXM")&V2YLHXPG9=K5 M12\%QC@'%RO48S9C#'88Y!'`J$^FP-<4&WQ'OTFPO4>D<#Y#Y$U$(W[,'K5=IF8MNZ'?;;1HKG>8OTB+_U!+`P04````"``(/(A'FM>9 M8P,"``"R!0``&0```'AL+W=O&(]=.K-F7&*I3KR"Q(]!UP;$B4H"H(, M4=QV?EF8V"LO"S9(TG;PRCTQ4(KYWP,0-N[]T+\%WMI+(W4`E05RO+JET(F6 M=1Z'\]Y_"7?'7",,X%<+HYCM/>W]Q-B[/ORH]WZ@+0"!2FH%K)8K'($0+:02 M_YDT[RDU<;Z_J7\SU2KW)RS@R,COMI:-,AOX7@UG/!#YQL;O,)60:L&*$6&> M7C4(R>B-XGL4?]BU[;$$^$^$Y(3*76F:GK*Y:X M+#@;/=%C_;'#G8)S+:*4]48W2M4D5+ML]%I&<5"@JQ::,(-W-G(-VPD"QOY.D>:+Y*@V5V@P"]F1@BO8D,G[?_FHFX,O43Z+BWB M!S6>[#2YRY1%CR_P$_-+VPGOQ*2ZJ>:2GAF3H"P&3^IS-&J`N@.!L]3;7.VY MG2GV(%E_FY!N3)?_`%!+`P04````"``(/(A'$EUI8>`!```N!0``&0```'AL M+W=O$FBT;LH#:19$L M"@19I&O:>K*(<%!)VDK_/B0U5)6%>F,.NO?R/)IDT0GYH1H`[7TRRM7>;[1N M=PBI'P M*CUU90S+/P>@HMO[H3].O)%+H^T$*@LT^2K"@"LBN">AWOO?PMTQLPHG>"?0 MJ5G?L^PG(3[LX*7:^X%%``IG;1.P:6YP!$IMD%GX]Y#Y=TEKG/?']!^N6D-_ MP@J.@OXBE6X,;.![%=3X2O6;Z)YA*"&U@6=!E?OUSE>E!1LMOL?P9]\2[MJN M_Y('@VW=$`V&:#*$R7\-\6"(%P;4D[FZOF.-RT**SE,MMG]VN#-R:4-,LNW8 MC3(U*;-=_>RMC.*T0#<;-&@.K)$F^W)4549R'CU&R$>60W>WK)LV7QVA%%&^7 MYP#-CG:++_`3RPOARCL);6Z)NR"U$!I,8/!DP!OS>$T#"K6VW8WIR_X^]P,M MVO%UFI[(\@M02P,$%`````@`"#R(1[GB[D[>`0``$04``!D```!X;"]W;W)K M&ULG53;CILP$/T5BP]8$R!0101IDZIJ'RJM]J%] M=F"X:'VAM@G;OZ]MP*%9JEWU)1X/YYPY,[&=CT*^J!9`HU=&N3H&K=;]`6-5 MML"(>A`]%+G+/`QVP9)X[II6VP0N`JTYP)*$^!H^[PSFS"`?XT<&H5C&R MWB]"O-C-M^H8A-8"4"BU52!FN<(9*+5"IO"O6?-6TA+7\:+^Q75KW%^(@K.@ M/[M*M\9L&*`*:C)0_2S&KS"WL+>"I:#*_:)R4%JPA1(@1EZGM>-N':$"<(=)'.0+-G?-_(.Z)].]M[)_HV3*/F`0.H% MTO^;1>8%L@T'\=TPMC#)71&\.H(,9..NID*E&+B>SIK/^MO_&+DC?(,7>4\: M^$YDTW&%+D*;B^#N0"V$!F,E?#`3:\W[Y#<4:FW#S,1RNK+31HM^>8#\*UC\ M`5!+`P04````"``(/(A';-"9F-,"``!*#```&0```'AL+W=OR>W<1)4`%G ML=-T__W:0&P:4V'E$FPS,\_8>%Y-\@MKW_B14N%]U%7#5_Y1B--C$/#MD=:$ M/[`3;>2;/6MK(N2T/03\U%*RZYSJ*H`P3(.:E(U?Y-W:E?Y.%@]NT`PP.H!TT9]HA&APBX]`=7=!GUNWK&Q&DR%MV\?B)J*^- M'J5YJX+(R&J@#DKNB!0@'@+@FU/H;9K.!O4RB,8D# M)AEADLYF`2C-HGE.JCFI`R>U."E*DGD*UA0\030S1S>?'ULDNXLCA MBF4ZES.5)8ZE>5$*LN;5)96*H!Q[(!!H2GC;(+VJV^,G4"W>S?I: MMLU]DVO"%/F)'.@OTA[*AGNO3,@&LNL=]XP)*I,,'Z2L'&5CKR<5W0LUQ'+< M]JUN/Q'L=.W<]=^'XC]02P,$%`````@`"#R(1]8Y@O&ULG9=-19DUM_(D*O7+7M9EUJK;^N`WIUIDNSZH+'QD+/;++*\6 MZV7_[*%>+^6Y+?)*/-1>U1NV<+;B7UV+MI'>?DN MQAJB+N%6%DW_U]N>FU:6;R$+K\Q>AVM>]=?+\$O"QC`Z`,<`G`(@_&]`,`8$ M1H`_..OK^IJUV7I9RXO7G+)NM>%.R>LNB(K`Z0+G%S@+#X8702?)PBF!,$L03@F"(TR!DW5:_B@ MX3P$HQ1*E00.U823F9`P$QEFPMEKHEYS@\@"P_.&DD&<.,Q---F)"#NQ82>R MWA-QQ@TSMBB&66$?6HDG*S%AA7^>@$\)^'6-DDP)$H=&2:PZ`1B:LT&K'!HE MG8#&7QN!YB&`7-HE5'TKO`P,8%`B%Q6&F9D`L*,P_2" MQ@IM$LZV'>BP2J/HW;<1C+G;D"*7+9`F M#5*D,=<(;83D-`Y?`M2$08(PL4LU MF@H87]DLF@K(79J%6\5BFEKK8ZL"A@Z00DT8I`ACM8O-CAMDW.I>0@:IT_QH MQB#%&*MAYO`8MM$^R5:>E_J"TE[(5 M*B.[51UT5*?8Z:80^[8;5!*N\/`(``'$(```9````>&PO=V]R:W-H965TW:($]#:F-I.V+Y];4,,"I:"<@FV M^7YF!H9)WG'Q*2M"5/#%:"-W8:54NP5`EA5A6+[PEC3ZSHD+AI7>BC.0K2#X M:$F,`A1%*6"X;L(BMV?OHLCY1=&Z(>\BD!?&L/BW)Y1WNQ"&MX./^EPIL6:DD35O`D%.N_`5;O=P8R`6\;LFG9RL`Q/\@?-/L_EYW(61B8%04BHC M@?7E2MX(I49)._\=1$=/0YRN;^K?;;HZ_`.6Y(W3/_5153K:*`R.Y(0O5'WP M[@<99&*LQLE#!C^ZJ]U8Z]=?V<=#30_`0T$Y`B]#^B-;)C? ML,)%+G@7R!:;AP>W&BZ,B%8V"Y.W#E'J[/O3:X%2E(.K$1HP^RD&60QT"*#5 MO1;H9K%',SIZ3%^Y"%<3>MS3D_5C@=@)Q!.!U9#BZK%`X@22>01I?%&G@I#'@<_6$:)1`"RKJ!6T6^(P=`CTM,BNJ#Q3'"WS&1H+Q7"*+%DB,K023 M)ZLZ-@KT=\VE)R4669Z+?J)V&\4;V\#WOW+*/X#4$L#!!0````(``@\B$?9 M,QJ(V0(``)P+```9````>&PO=V]R:W-H965T)U^9P M%&HBJLK(Q.V:CO:\87TPT/TZ?$*/&XR51"M^-O3"9^-`+?Z-L7?U\GVW#F.U M!MK2K5`I:OGXH!O:MBJ3)/^>DEJF"IR/K]F_ZNW*Y;_5G&Y8^ZO9B:-<;1P& M.[JOSZUX99=O=-I#IA)N6E]?:E%794#NP3\5*MO&SU*^:"2R,QJH`Y*[HG+ MXQIG/RJY!FL-,HI(9@<1^(IXQHMP?`O8`(KB/B$QFTAF\$4`($"(@1`@`7(@ MD`;?AZ#8%EP,I$C:5#D<:<1MAP,I'`O&RCR*'%D:QPE M0`KW#D`BXG$)D+4"!'@!<:\!2A>7.HE1,K_5H[-Y"/^]*.L<"+`.@MU%98N2 MQKXEC:QY(,`]R.*"+NT#I[XLZQ\(,!"R^/G)%ZS$>U_60Q!@$&11$,6"A9`W MS'H)`HR"N%X_B>8P#PJV7H(!FR!N[4VBFRWY?E78^@D&K(*X7C^)YJS<]_2P M]10,V`5Q:WT2W916@B!8-&N&.CH<=)/(@RT[]V+L>LRL:42?=!\:67E5GNH# M_5$/AZ;GP1L3LB73W=B>,4'E@N('67]'V2J;EY;NA1KF/X(MCIV@N; MAKSZ"U!+`P04````"``(/(A'CCE:R@T"```_!@``&0```'AL+W=O=?E)QT1*EA^("9"\H.5M3RP"*H@UH2=.%96'GGD59\*MB34>?12"O;4O$ M[SUE?-B%,+Q/O#276ID)4!;`^I>'NWA$%+WL:VZ6P[C$^R M:+*M&]!D0,X`XP\->#)@SP!&,EO79Z)(60@^!+(GYF7#K98+$Z*33<=LE*Y) MZNT:9V\ECJ("W$S0I-G/-!80 MVX#,8]R/DLY*4BN)\SSW"ED1P0P_)HD=2;P@P9&/$L]62<954IAZ*$L1SJ/T M,4KB4)(5%.RA)$N4''HD2\TF_8_7NW$@FP5(ZFW\?K.LUC^'AX\U_^1('4>Z M/"69QY$NUH!9XH,L10BA_#%)=B?99XMS!A%._".PHH(H]\\`F'WK/;G0[T1< MFDX&1Z[TM6%OC(IS175B]*3?9:UO&ULG57;CILP%/P5Q`>L,78BRLCYHT?&^70K0[`/BYQ#7B3[3%C?Q2 M4%8C(9?L`GC+,,IU4$V`ZS@AJ%'5V%FJ]UY8EM*K(%6#7YC%KW6-V-\#)K3; MV]"^;[Q6EU*H#9"EP,3E58T;7M'&8KC8V]_@[@@]!=&(WQ7N^&AN*?,G2M_4 MXF>^MQWE`1-\%HH"R>&&CY@0Q225WP?2AZ8*',_O[-]UNM+^"7%\I.1/E8M2 MNG5L*\<%NA+Q2KL?>,@A4(1G2KC^MN_1,D0MAS@ M#@&N"8#^?P.\(<";!(#>F<[K&0F4I8QV%F^1.FVXDW"F2"2SFJA"R9RX+%>_ M>\L\QT_!31$-F,,8XVJ,^QEQ7$#$!@*D@447KG'ACN*]P46P3N`9`F]$X`\$ MX22-'M-H3*0Q29A,$IECXCA<-^(;(_Z"D6ABQ!^)!!H#95NMJP1&)5A0V5#P MT!"$7RMX9`BB!0>38AZB69ZNMZX1&XUXK@&=B48\TPBB9%TD,2+)AG].,D\D M\M=%H/-H,V:^Y\?3H MP.@>:]$%_T+L4C7<.E$AKT1]&Q:4"BP)G2?9%:5\JLR"X$*H:23GK+^\^X6@ M[?TM,@]B]@]02P,$%`````@`"#R(1TZ/>T0,`@``V`8``!D```!X;"]W;W)K M&ULG57;CILP%/P5Q`>L;]P2$:1NJJI]J+3:A_;9 M29R`UF!J.V'[][4-<1!!)=D!^J9$P'GS5OU"8LM6[7`*A] MR6JJ7D3+&O/D*&1-M9G*$U"M9/3@2#4'&,($U+1JPB)W:V^RR,59\ZIA;S)0 MY[JF\N\KXZ+;A"B\+KQ7IU+;!5#DP/,.5/ZJO[-M6OL M[ZAB6\%_5P==&K,0G@PNR+$"\ M`!D)1$X@RB9=])#&05('021.)XW,@-+5`TXB[R2ZX'XN2P2+Y`L M9Y&,VHP=)(/3*.XQ"&.X;"3U1M*9*.)E@MAFJD8%.Z'-<>9.LJ,0FAE!^&+^]:6Y9OR$LZ.V96IJV1^\_42+]GJ/^,NL M^`=02P,$%`````@`"#R(1]1!0*?8`@``-PL``!D```!X;"]W;W)K&ULG5;1;ILP%/T5Q`<$7PP!(A*II)VVATG5'K9G-W$25,`9 M=IKN[V<#,<1V5[0\!-LY]YQ[C7UR\RMK7_F)4N&]UU7#U_Y)B/,J"/CN1&O" M%^Q,&_G+@;4U$7+:'@-^;BG9=T%U%80(+8.:E(V_R;NUYW:3LXNHRH8^MQZ_ MU#5I_Q2T8M>U#_YMX4=Y/`FU$&SR0,?MRYHVO&2-U]+#VG^`U1-D"M(A?I;T MRB=C3R7_PMBKFGS;KWVD3CC6YI52DFJ?Q[(!TU5>!T?&/_TI4K MTW\AG&Y9]:OGA[(I1(_V/4K'6J(%>&.5;S[]G87+EA]"_&]FKSW MS[+IGM?^EQ0-8>Z`<`@(=8#6<0?@(0"/`=$_`Z(A()H;$`\!L1$0]+5W._=( M!-GD+;MZ_$S4>8*5A+>*1#*K@7H5X?"']ZML&0Y(';XIHP!133-AA0"," MR>Z4"&\216B%A_<"6QN1H'O(HX,DO8<\V1`,Z>>)8KT7>$*`!X+L`Q*HX1G$:SI$:;0$X!D^!^/5!\?=Q[$I9%_^U&%TP:1;J&E[[/HT[NW8I1']?ZE>U;W@ M0ZBZ#6.]@-6V[^A&FDU^)D?ZG;3'LN'>"Q.RE^G:F`-C@LHLT4(6=Y)=K)Y4 M]"#4,%%5]WU=/Q'L?&M3=:^\^0M02P,$%`````@`"#R(1ZA>)>`4`@``5P8` M`!D```!X;"]W;W)K&ULG57;;J,P$/T5Q`<4044BR?60J.>E(Q3+-61GSS1H&WK@C.DHQ_[<'POJ=Z[N7P'M]JJ0.>%GJ65Y14VA$S1J'0[ES MG_WMP4<:8A"_:^C%9.]H\T?&/O3A9[%SD?8`!'*I);!:SG``0K22ROQW%+WF MU,3I_J+^8LI5]H]8P(&1/W4A*^46N4X!)>Z(?&?]*XPUK+1@SH@POT[>"(Z%'\.:]V8M1^>)&BDW2<$(R&P!)OG/B$<">&5$)E*!V>FKA]8XBSEK'=$ MB_7;]K<*SK6(4M8;W2A5DU#M&J+G+`S7J7?60B-F/\4$!N-;A*?4[Z8(+BGV MP0T]^)K@<(N(T7*&T!813OCA6$2\+!!9@6@B$(T"R:P+`Z8QF'CH@N_/"KG% M;))E'ROK8W7'QV998&T%UM_K1&P%X@89+7L([$^DEL? MT0/?Q,8*;+[7"1]=KP9ZH!0G3]0<<&Y(E'C(]Y<>Q67E MIHG9>^%IPLZ2E!6\<$><*<7\SPX(:[9NX%XW7LM3(?6&ER:>Y>4EA4J4K'(X M'+?N<[#)@E!##.)G"8T8S!UM?L_8FUY\S[>NKST`@8/4$E@-%\B`$*VD(O_N M1/N8FCB<7]6_FG25_3T6D#'RJ\QEH=SZKI/#$9^)?&7--^AR6&C!`R/"/)W# M64A&KQ37H?B]'$)E,6V8%(BL0#02B3B`<5:'%5`83MU4(1I7* M;C'KU;R/A?6QF/`1S0LLK<#RL4K$5B"^HQ+Q(,O%Z']HZ_`OQ*RT\(]W:1OL[?5V8EM?+I$F- M3_`#\U-9"6?/I&J&9.@+/I/ZHP5ZD*S"P)'J:>QFO.VQ;<+R>KKC66O MS?0O4$L#!!0````(``@\B$>F&&T%6P(``"X(```9````>&PO=V]R:W-H965T MU#3$(+`7U$FPS\SXSFGB&K*?L@Y>$".>SJ5M^<$LANKWG\:(D#>8[ MVI%6OKE0UF`AM^SJ\8X1?-9.3>TA`"*OP57KYID^>V-Y1F^BKEKRQAQ^:QK, M_AY)3?N#"]W'P7MU+84Z\/+,,W[GJB$MKVCK,'(YN"]P?X2A,M$6ORK2\]G: M4<&?*/U0FQ_G@PM4#*0FA5`26#[NY)74M5*2Y#^CZ,14CO/U0_V;3E>&?\*< MO-+Z=W46I8P6N,Z97/"M%N^T_T[&''2$!:VY_G6*&Q>T>;BX3H,_AV?5ZF<_ MO$G`Z&9W0*,#,@Y^K`,?0#K,KUC@/&.T=WB'5?'@7IHS)2*5U4+E+4/D,OOA M])[[09QY=R4TVASG-DC;0&/A274K`CT01[1R]X/DN8!O8O1G`OXHD#X7"(Q` M,!,(!H$0+)(<;%IM$PY)^F$"0?`<%!I0:`'!!2B<@9+!9K>%$AE*9*&@!25: MI?,E`@`\Q\0&$ULP_@(36Y*)-OP[$D-)+)1@04ELM4&;:I,:4&H!A0M0^I^U M@6"Z4&`#QVH4;>#,+BZT2*QN+IPE%&NC--J2#YHXR,))EARTJE"RJQQ9W"GIKQ="XS:D9C2](SX/)/,\Z?"4_,;M6+7=.5,BIH@?*A5)! M9"Q@)V,IY?`VFYIT]E\(N3_`%!+`P04````"``(/(A' MV&6#JR<"``"*!@``&0```'AL+W=OB$_%05I3KXXJQ1V[#2NMW$L3I4E!,5B98VYI^3D)QHLY7G6+62DJ,K MXBQ&`."8D[H)R\*=OU!7!:Q MKSO6G#:J%DT@Z6D;OL+-#CJ)4_RN::=&Z\`VOQ?BTVY^'KY-K\1 M3FU3#`JXJLU&C2[L08Y#?2*V+@O M(M`-L4.S\@0GCPT2WV,R,D@&@]5C@Y4W6(T,5KU!"B8A>TWC-*G3()B")X*F M'I,N8.`$DXXPN=/D4?Y$&.PI>$[!Z82"9V%><)8^$2;SF&P!@R>8;!;F!45/ M4')/R18]8>LU[`Y!/,>BE,CA]C(+B_36`!M)Z^3F`6""8H M?2(0'+VW<$[*IL_T(!IG6D5@^K3%HUG!J3R[D:B"@[@TNA\*_M2/W5?D9LU= M7A8M.=-?1)[K1@5[H_,A\&OV'TI.TR,VO9C\I^HT5[ MF_S^\U/^!U!+`P04````"``(/(A')K3OELX!``"F!```&0```'AL+W=O9'+Y9QSST4@'81\4PV`1A^H4-%IW1XQ5T0`G MZD%TT)J52DA.M)G*&JM.`BD=B3,$CYH2V09:ZW(O,4M%K1EMXD4CUG!/Y M+P]13C`'PJ#6L3(>K\( M\68GO\I3$%H+P*#05H&8X0IG8,P*F<+OD^:MI"4NXUG]A^O6N+\0!6?!_M)2 M-\9L&*`2*M(S_2J&GS"UX!P6@BGW146OM.`S)4"T: ML](%D()-,NK$SF6YAXU<@6)KEO9.^-[#<$]BLC6YC'51&\^/\<9.WN MA4*%Z%L][K'/^JOW%-GSL\KGYDJ.-^@FDZ4=J>$WD35M%;H(;4ZG.YB5$!J, MQ?#!>&S,H^$G#"IMPX.)Y7B/QHD6W?PJ^*&ULG53;CML@ M$/T5Y`\(OL7>1HZE3:I5^U!IM0_M,W'&%RT8+^!X^_<%;!,WL;JKOA@8GW-F M#C!D`Q>OL@90Z)W15NZ]6JENA[$L:F!$;G@'K?Y3Q9YQGM%FQ:>!9(]8T3\/@#EP]X+O#GPTE2U,@&<9]CQS@V# M5C:\10+*O?<8[(ZI05C`SP8&N9@C4_N)\U>S^'[>>[XI`2@4RB@0/5S@")0: M(9WX;=*\IC3$Y7Q6?[)N=?4G(N'(Z:_FK&I=K.^A,Y2DI^J%#]]@LK`U@@6G MTGY1T4O%V4SQ$"/OX]BT=AS&/TDTT=8)X40('2%(_DF()D)T)<36Z5B9]?65 M*))G@@](=L0<=K#3<&%$M+*9F(W2GJ3>KC%ZR:,TS?#%"$V8PQ(36DS@$%BK MKZ8(YQ2'\(X>_IW@>(](_8\S1,Y$M.!'DXF'CP5B)Q`O!.))X,O-+JQ@'CY1 MY=8EV=X)A-M/""1.(/D_FZD32%B/PX@(R M$)5M3(D*WK=J/&07=;W_&)H+?!,_Z#=A;.&K3)YUI((?1%1-*]&)*]T>MC-* MSA7H`OV-WNQ:OUIN0:%49IKJN1@;>5PHWLW/DGL;\S]02P,$%`````@`"#R( M1VGKF#>F`0``KP,``!D```!X;"]W;W)K&ULA5/; M;IPP$/T5RQ\0LV:WB58L4C95U#Y4BO+0/GMA`"N^$-LLZ=_7%W!0&BDO>&8X MY\P97ZI9FQ<[`#CT)H6R)SPX-QX)LG.`*G@RRDY3,_#V#T/,)[_!:>.;]X$*!U!7)O)9+ M4)9KA0QT)WR_.Y[W`1$!OSG,=A.CX/VB]4M(?K8G7`0+(*!Q08'YY0H/($00 M\HU?%\WWEH&XC5?UQSBM=W]A%AZT^,-;-WBS!48M=&P2[EG//V`9X1`$&RUL M_*)FLD[+E8*19&]IY2JN<_I3%@OMINYWMU\+[+/`?B.P7T8L/XR8,"IB#@GSH079[*@$T\>+8U&C)^72 MUN5JOIOW-)[(.[RN1M;#+V9ZKBRZ:.?/-1YII[4#;Z2X.6`T^->3$P&="^&M MCTVZ4"EQ>ER?1WZC]3]02P,$%`````@`"#R(1[VL.@LR"@``8$0``!D```!X M;"]W;W)K&ULG9Q;3R-)$H7_BL4[X[Q?6H`T#1K- M/JPTFH?=9S<48(TOK&V:V7^_ON%(\AQ!K%\:<)^RH$57T5&'OOJ;;GZ:_T\ M#)O1W_/98GU]\;S9O'P;C]?WS\-\LOYE^3(LMO_SN%S-)YOMGZNG\?IE-4P> M]@?-9V-G3!K/)]/%QYC.A\5ZNER,5L/C]<6O]MN=#76GV4O^-1W>ULWO MHUWT/Y;+OW9__./A^L+L@AAFP_UF]QR3[8^?P^TPF^V>:OO2_SD^J[SH[L#V M]_=G_VU_OMOX?TS6P^UR]N_IP^9Y&ZZY&#T,CY/7V>;/Y=OOP_$DXNX)[Y>S M]?[?T?WK>K.X$X'G%Z''^"/!WCM M`>%X0)`#PCXUAU/9)^)NLIG<7*V6;Z/URV1W?=AO6_EJ]R3;9][]LLOL-@GK M;7X/C_Z\\25P_CNX/#7?<"7RKN M4)'-US'X4RI\<[P_'*\XAW`Z/C3'A\/Q_4D<)(N])!^RE$TUW8D052S.?1U+ M/,42,1;?Q1*;5XD'22JY"P5%Q1A%).D42<)(NNOK-L&+!-/G!#76&,7;FT^! M9`RDOX@SO(B+-O"EEKX^OIZ.KW@N792WE23,^[YFF,IZ M15ZM$808C*;T>##P0CY9VT5#534JHFF`9C&:VD=C\;)._=M,1+DJ@&"=Q.(@ M%E]2'XPC[X%SL0^'RHHF.8(XZR&@8OMX/)ZW"7TT*(I!DQS!I45>EIZ7-N!) M)P.7#:I<2(J"L@),B\3T/0V_VPADOK39]$$C-"]3T<#*"C8M B>`IAGBUX1H")0BZK_GQ08ZLB$J&G17SZ`HQ`-%ZV M9#P&0U0A*VZ03OCI#.:V*JX6)]!S"#U?^$V"#0+"":BJGB?G4#/$>A5348$ M4^Z\5LP)7)RB&7,$+J0;8S)=.^8$+XXT9'TY.^0&C8?(E/$(7ES"#"N`Z80( MCO13?0_BL%5B30B5J;H0)WAQB!>\USK"%]>K[IC*:.XG3ACCD#%PIW4(CVQ* M'PR*HB8U7@#CL4&#.ZW'UJLCXAV3**K2"Z8\8JI?;-YZ0JGD?=\.,5DL-BOB M$51Y1!7<9#WV73E"-"A2-&:^67LB\53W5R_(\Z2?Z@O2(\LN+;S/1.0TB17< M><0=W.L],.>QB^IY>NNQ/\JAARX173I-%0HP/0+3UWY1[A&% MOO8='1-%S1LDM/2X`E7U'%X(YY%PT!_=>J17@`Z5B%Q4]*=!$!<0<2XJSB<( MG(*%E*CF/X*3@#B!J4L@.,&Q"U'IYBY!D!)PK0>3EX#+.!R]$)%N]A*:V1CI MQWK2!N1.,9@:5%5=:@1/(>);K;B]!P%+(&.M'G`!F4%F'E2EF7D$04L@O5B_ MG@D(C00S#R**07$;"D*6H.G#`G98WL3^1L145E750JF@Z,,"6\3UL9!)F8(. M41`5%5U8Q!;KTO7M,A%I(A'21;):A%8A8H.EG&)$(6(D#5;/H$AZ)Z@2(MK> MI!55$@6(D0R_>@9%,OR*N5\@$)6-57$'CD+$&(!!JHXO-D-^TF7!VTA6B_VU M332:S0:A823#JIZ&D7"N+WBBN=2D1$@829,%HYV(E".C':92C7:BP#`B#*'_ MC$BY'"JDADR]K&;N%86%DJ(+/`B&J531"*+2F:/T)%A)"JPD!`8[(:92 MG9!@)2FP-1MZF>S4E=)GGJB< M20J@9T%&)AU-WU)FTJLD:`&(ROFL`%@6_&0R@.I+/B-9?*@0#:I"T%R560"4 M"8!@OY_LU+%PB$P9CT`HX\1=5?:Y<3!@

3Z;:^BF"JD"X)WAX$$)G2 M$95N2E<$4X5L#/;0+&12#G=R(M)-Z8HPJI"I5L_,@BT0,TDQF=(E)<`KV"II M;MBE,5HAIF"7LA!,D5U**E/M4A:!52'.K1Z;!2E$YH94I6F(JJ"J$N=6OV"H M2"'T2A&1RBM5A565#:7ZUJJRA1IZI;A,XY6J0KY*9E?]Y+"2L11XI8A(Y96J MPM"J:/0J:_3`*T54.J]4%8)6)"C.#RO91=3-#ZO0L2I6D96M(B/LX#%9KD;1 M@54!9%6L)*O*E4542E=6%3[6,Y>250!921\';R59)&)^B4BSG*F-JY7,ZGLX M5C)Y@H(C:TV-0\RTGE;2Q:%'S)!Y/3&),9EJE+B]P30A(2&AT7T7?;CZHD.C M+9GN^V0TGDG3^%L-&WOUS=2[ZL.67<0D$9776`Q-XV\UQ$>AF2I:TQA3#?(- MYXKOJH\N(7#M$I5+&N^EB4U`Q)RJ6:]9TQA*#5F`ZE+3V$`-,S&`@]@00QT?*KY))C6`,]6?9I" M:IWK%M=]RK0TU4CLYBPMI'&!M'RF^228IJJ)W]P'U6<+FDJTZ!Q0IJ6I1.+M MAK3<6>+;5IUR4ZV65:OF3MC:MNV95B';.JZ9Y9J<\EE#8MMXJ:W#2@PJZWWC MIK8.!\6Z4W;M9S_8O1%.V9%AL>:%FBISI,J"YD[>^*7M!\/T_W7*3740ES.I M=V9@MM`.$)5F=&4;D[-U6&C!J-+;%)$C3;8N,TT1,7F&HG5-QC%!-\V)EW+7+JZ M4VXJC?ATV2D3FQLTET14-/U/X]2UQ*H;C*:W;&RVUI_;6S;^6$L-LI@8TC=B MD1"5BAZ-1=9ZK%F5Y<@V)EGKSVTO&W.K)>Y6DIE`6D?\J!P1J<)IBC9@T0;5 MTK'QRMIP;H/96%PM\;BRQ&#S"*7$3*Z:8-K/,V)A!Z,IQ\:9:HDU59F6IAR) M.Y6E!1M,1`P1J1#3N%,ML:<&S>#--K92&\YM0QLSJ"5N4):8M@T]?@"?5!*J M8)4U;KZ&83ZLGO;?9[$>W2]?%YO#EQ2<'CU]:<:O;O'[[\X_+%9OEP?O\_C]*4B-_\#4$L#!!0````(``@\B$?MX3UP8@0` M`(L7```9````>&PO=V]R:W-H965TT%H\DASWO/UHLTHFRPFA2RPQ?RU&7Z?# ML6H:W.7"'>QVIU1EY2G/G$+MGV;?V?Q-0B-I%7^?U+4=L] MS;PF!Y6H;=6XB.N?#[562=)XJB/_VSO%F(WA^/GF_:7M;IW^>URJ=9[\<]I5 MQSI;;^;LU#Z^)-6O_/JJ^C[(QN$V3\KVK[.]E%6>WDQF3AK_Z7Y/6?M[[?X3 M>KT9;0"]`0P&P#XUX+T!MS40O8&P-9"]@1P,F/C4P.\-?%N#H#<(;$G/,<-$VQ>RXO&2>VY>6B64SWS9;VHNM:/ MI?"BA?O1..HUJ[$&6@T/Y;UF8VK8H'#K#,@TX);&"@QSP;S[$&M*P^XUSY0& M[C4_*`V_U[Q0&J%UV2+G5TJC#=T;I?&_'CP^S"$?.>"]@^!K!V)P($8.1.\@ MU$:DTV2M1K8:BQSE$$(2(?1U)HT0^I!_IGB8A#\DX9M)@#9C/WPCA,5"#H80 M`1%"6Z2;8!0BZ$*`]+ROPX1#F)`(HZWS56B&";3>;D)S5D.;3*(ADXC(1*-I M%9ECZGF>GDMDYGNG>I@,\["<>40Z%FN$C2HBFX83`W0!1!92KZHP<>P9DL\X M$2BK!S8A\50I]C\_@I0FG.\E>RQY];6#H$416$!40"JX*8 M>$H5R+L@>!?^?7_7PCRE@L=L@X-*ZNQ'F%V9= M1RWV%H%P"8J;4`_DFQ3;?>T(Q$M0>$46+A`O,1$O@7@)"B]C'9G?@/4ZLLA5 M(C:2P$9:C)A$;.1$;"1B(RVPV4@2&WT=N:-;NE05A_:.MW2V^26KNO2&UN$> M^7M[C:RUK]C\A1'M&S9_[6X%T?UR<8X/ZJ^X.)RRTGG/JRI/VVO%?9Y7JD[> M^U9#<%3Q;GA)U+YJ'H/ZN>CNBKN7*C_?KKZ'^_?E_U!+`P04````"``(/(A' MD\`Q\\PV``#MZ@``%````'AL+W-H87)E9%-T&UL[7W9BS M^149"BJ&'0&6:E]D6Q'5)%NBS6ZV2;84NHK[`%:A2$A50!D+V>68!__#]8LC MYOZ)3<@`12*+4WD'J;M1N9X\Y^39\P]IFHD\"O^:!V=Q'F5__&(X MZGTA/F[64?K'+QZS;/OU5U^EB\=@XZ>=>!M$\,LJ3C9^!O],'KY*MTG@+]/' M(,@VZZ_ZW>[XJXT?1E]\\XOLF_^\!7VX7X#\3:.LL<4^BR#9?G7ZT76$8.>)_K=WJC\XWFP MZ(ANO^9'M1Z_>CT_S>_3+/$7V?\N]Y2-;X*'$%O`$._\3>"T>O>_KL7KR^NS M[R[>BLMW9[7SW^VV3N=>]_0OY6]G>9)@^S=ANO#7XL?`3Q`FXMS/G/ZGI]W) MZ:!7L_*S>+.!'=YF\>(73]P2V,5UGJ49P"*,'LK=YK#.):WUS=IW?EWYZ]3= MO9P).B6PV$LXNX_BS\&NKIWU1Z@P^^AWOVM$7QL=WL!'9^?EEG+>RK9_<5#F[/K= M[?75Y?G\[N)X?1]MV^YX67T!+/&2>B.\3X)MGZX%,%'X(HI MD!(N-\:!RRWOX@P.8%'8L3L:,-\)M;_$,:4?E'M_&\?(Y7*_= M)0,]/X2P&3E596\)@+T$]O>O MO_^3L";;.8<"Z"JW)B^`XTZW!Z>0"*"L//B]\//L$1#];]"B/_*ZW2[^)V_G MWXLHEG\5(?(WP/1$Q/5W1_&N:9AJXDY5G(>HRDSTM1B.O>YXZDU[8^%G`OAE M?`^'HO@,M:#Z(PT:>4Q[D4PVF^[ODT\_>2] MCZ3Q&&0A7!;I*V#RQ^*K&MG,025]M.($X'<>K]=^`A0.^Z^]N*IM7;Z6R:=,^[$.^O8,_WEZ\@P.^?B.NWU_2>.>O0?Q"W%_#`'#]BE703%]U8UUO48*$5PF9Z@8@)63K@*ZT2DF# MP1\[8*X_"#Y&<;*.T]0A-;Z#51,YV"OGS$`*"@"QJ^6>\L.VGX:(E M^SH/USG>6>U:_P"P>L3F_A.<&$#+7D>!.34LBM7/QI74-&G@<&?7;]_?7'QW M\>[V\OL+U+ZOWUZ(DZOKV]M7K;66Z]I[6X+>V93"'A8O%SL49Z-TS?8$?_ES MGK+`5\':Z^9HMV?<\NW=]=F?O[N^.K^XN?TW!V+#YI,`S2>B M8"]I#0K[[A$_O0TV(&@Y9A%+@'HO!:@S%J!JN]P$F1^BJGSA)Q&@25H_^/79 MI9AG61+>YQFI"UDL6%2I[4/\QD6\-2J"4ARL5TM5.PO_]O:QB!,)'?`'B0>5 M;0W\@HA:[O\]L"ED>W!;(,=*P@52`,ET371`GT_O_318$KH"'C'*`0]+'EPF M8X&@T7Q6`X+&/DTT.;_]3KRYNOZAO>&`E/\5Z.ZI6"7QQKH[?+B]GJJ5SKDA M-$02N-9B4*H`8R*'=\+/^)%,"UMDTGA*]SMQDB,LP^A5NQG/`R#?12CI'&_C M#5JQ_L8?^.ZOU^E=:UNQ3I$FV&W=[) M+Z]$L-FNXQU@Z,;/0!*IN>W/Z&HD4=$"#RU-"F+U%H$**TTUWS6_IV09L(2+ M%O8!3VE=KJ)OK#/[]?<&GOWN<+S9A]UA]"090`.N*99*9P,,-Z]0RVX#V#=: M)9?!-D[#K,$BI;9`%:+(%BJ_8*>0PP&)6HI.2"O MJQ"?K%X@<"?Q,UT6.7#51)P!ZH>9F#\D05!%3S?!UM\Q.VC7X3("L66])IOI M&BU8;'YDN*\#(!@1WZ_#!Z90-7@M9`U2V*A2!3/'MKQ:@92.X-'R*%JBQ4(2 M(++XMN91$%H36OK),N"_O1+A`?UK[;#`S.^#AS"*Y,W%-]XAW0-$SKJ.*"BF M^/-[-'P!*T2@N$BN@".#K0@[H*/F7B])D&EUH.C!Y7L")?^D^GIM'\7`]1[ MQ(!TNR0(DSYIL._"!<1&8]3I?!B0E:!T,QKV( M_A:+UV&,GC9/P+%U"&Y(Q<^/()+O3N-G%)G2_#X-EZ&?$+NC7E?A*A"WBS!` M2[?\IK7M*_]>?8/5)OXVR+-PD4KW%WR]"4B5OKHZ\X12$$$+W:&![SG,'@'= M`OS[!M4=O)=@1?8BA+:UP+7JI[2Q?_W]/\X8*/_Z^__%SOH#=(!/'8)<`5CW M4NH@3R*.`U.5!2>/!B]TLR`+'23[A09>DP3O&924[$R*;=DC\`9'=,G7F8%FB"IXN)$4GHI'T!>!:001K'D9=,09R$8^W3W&_8HCKN(XBY#T MEIJ^/;EV6(K<#-U:?A216%-%:%MTSR2R'1!:LB3\(I3V#?UO`1"+<(ORAK2L MP!SP>[#-N"_NY$.$T"?G)%*8V0@<_1)E)3:';\*,#LE![LH%IB#^K@'Q@;L' M/DT%?7[.HP4!@M;I8%?E0`K>._0%,AH53-X$5`0H$6<2P/&BVX%5,+E#3:[_ M3,6==A8?$MX=>4%IT>^A!6EL35$, M%8WW78%]N@(;5B38KN-J6J9%$DB6DE8T6X9:0$)@/9<-3%&.FKXM,#JF)K', MB:49[;LCYH`6\GC48>'<.&<5'C1J[<#OE](VY2RO8C6X91P^]3>HOP'2(X!: M].1K91D3XMG"PA9.`E@6NC$+,"#R8&-!O&4D0ZMM2"BQZ"U+NQQ"X.(H./78@5NRWL,[G@"VHFI\3 MO_/7BWRMU>`#@'[(DH/L8A(G:60%W3S7R.JIQ MOMVR&0$.V(@5;!"Q)38C%#8.07K-&V@F+J1UHH'EZL:>*`QBU)=T/P\>@,;T M@EV\$'=L9P7YQ15KEG("'^MQ?T)]COMCKX`^XJ4X&TJO3?6<0!/'PQY/.9X5 MI_P4*E$3L&`![8\'4YZE-RN118C"Z^(11*>$W8]DZT=!B7%9F_>DT2$L&172 MCC@W%U4KUDHR&VW>!SHC7]H*5C::"!.K(.T3OK)M'#I-"1#+D`1&:)O1'E"S M@\^UD]5%3>TL'&\@D.KF]111'1A#9#($,K%BM@I_1RDT3#436\48'H9>JB,; M&DHL.[KQG]$@"C*!OP;$$SVOUYW1G]W>X.B'./D%#X!L6R!/]+S9="B0D_:/ MWJ!/]A&@+)V_P,J]X70&_Q],>T?'8N*-IGV!?PYF8R>>1\5UL?Z_SPI<:&V% M?LW9,-L*_@>,L8]-C4A4;-Z"F->$[104@0)&DE["-OLD(4N+OT$-#L_R04Z& M_(!#;P!=J:]M`Q%I\,!*<@B'.?&&HSZK"?8,4GV1]WW-?,Y^6.^&7Z2VG3HR M3<%"HU:"#?U4HF'Z]=&W"7H6/0GWA2XT[$XZ?>\\70@T)DR M]GJCT5'!@R"-^'`<_Q`GPSZVXS^.&MV5)[,)M)ST8?@1M'6.B18P`2:,"P!L M'PQI`2-OTIT()_*P).B-QC/\VA\. M\.M@-J6OT^'HZ(?@/@7-E'U`"[@!DH`C^_"4D5V,85;ZXQ6=!RZE2Y_@#_IT M=,51+("[P>(QBM?QP\[R6(P`/B?#X8"/9M2;XK]P59/)T1W&3F[\Y)<4N,]L M!HN#8YG`X8D9M!O`'#.<:C;"WC#E9'S$7H[&HVQ"M"KZ]0I6'#(0R(L3J=&0 M3*H]1@I.)2KXD`:K'"/<@&*<0(,DP-P"),?<-*L[P>DI0`T5[E3(/VU8J9_Z M\B<55F(6VNO*)D/Y9^6V*_55:W4D>TO"1,)PN2$"H""!_=9.W[OM-S'U<=PJ]I3B^L(Z#4*X`9#,`R*T@-)#<3\4&X`=@>*^V4$2?*?ESRUK"^!3+,0V$N,N1*.V*%<=IC5*PP?Z,T M]9#[F,<1)ZQT?X>6\,<%ZAIO6!)$AI-O/32.ZX5=H0"5O)*71VF5GKP#@/N& M,JSN/%A0G`*9>3SE#&(#A.74\A]\E!5%L`X9.S[,4:=1L/04.[4O M.-J!?<^H:R85^19I\'C:Z8H-W)-D9LW48')"](?N4-E:H';Q(`UZA<7Z)M## M6C?*HD-K9!GJ1*ZFI=D-XSI(I8AZV@.XB%,VT!WWISW!2IZ\;)%@T*P*%$5[ M5;2454"](R[Y!W-)VRNTU%@6RMEJI[!QP:.M_`4#`915OJ M\O7U#7D:)=7XJ$+&9!WI=?JC+\5VG:>T,%!#`>]H9#]Y8-(#)/A2^R><0K@0LFE*C%F'Z;F<$XZ$-`5T%FPJ(2$#D$;EK*0V)31+5B':`Z.IXK*M&;)99 MRS2=%N(C_`<8Y8%Z'P\,";IBK7%;-RX%Z4\Q:U"]MPE<2&3S1O&6@02+((L9 MM/C0N>VH*TR!B^?TI+V'R"8/UTMF<*P*!.1A1/^"BHZ1+-,BI$?BSA'N#>WL MVW6P?`@L?YM40Z4Q<57@^-5\64GD()&2L(!>+A_(B@26)Y;<]'P+P#]@_S)^ M@E"9MBCQF+YJ6M_X<&_G&]")GX)UJHTO>8IR`+;$`-UB@W4(?6%YNR)3=QBN MH0K=0XT2KBK\;LI=@?8):+;L@'3L;$F9E/DJ)?$2&`4RE4QB"'$0S>J7P+#Q M]P!]JF3!$+0T-'K*F-\E!B!C@!X[7@DG1.JOY26"<%Z'2.VD:/CDWX)SNG`` M:_R4T:F,K^`P*G+1^5J=U)P.%U8R+U[6IVW%+W[/`7PI_#C M/0`;\)"B\+:6EQ]_\J-?DGR;+79R"2G<':@[64/^G"\?K+P>$RR%BD`2K\D= M4>O45G=$*+ML@,,:?V71_:HW]-OC.L\`.]QH(B>8._CT]1$)6!K;E9//WML& MEB.Y(@H@^"D+-P$IY'V;?Q68K`4DBLI1(Y-!K"`WVTQ076$%7/:?_'#M2UF' MI([.4,\J-U!8+&H;)%KZXJW-9)<_5]!HH73`F"0T?EUGD3MULEG$PCX@@C-:_U;D,0OLE>:V6FI M'"_PI`TK1DP[[EDGT$P@92RG\]_P(DB0XCU:4W."!/S'V^>0!62L!I!*J/=5 MJC.J&1WQ05^2^@=/(C_2`LI?4DHPLTG_HZ]6'<)G8L/(>VP6 MIH30XXF1V34)KOT4'=T[;58IS%@/1S.\A1*$2X-!IV?.X;42$5&=TK&4>//@ MN"XZ(J`M?+-I_A[D5>@(?")C^9<3'G-R/Y+DUY;98=-5CE!3`26_%X_Q/WE"`C#+!L#3S136YE#+5LR`0B*@S8Z74#,]N6$!]EZY;WQ/7$(U M!I@"MB<4@_(4QGF*@B;G,296:(#>C+JM@&D%"F+X5^/"&@O; M-/Z]Y%92D.)U%`1"=9YKZVP(]RSY2\^+)T:TCP'3#W%&M[@EI^B-*NE5W6(E M+:"T8(*Q=2VCVAWG#X_R'!?(Y4M'29J%8N4U*&82@>--WDT= MVJUL0[I?:16?[-N9D&_AX`V*BD#Q0WU!3BJ<.!9#;S:;T9^]Z>`(=H\GY:D0 M_%0&&>I(*'0"37H3,?!FW!?2=QX5?9STQGDR/ZA("Q:#;Q?^DI;+G M34==T??Z_=G1,=JE!Z,)F[G[LXGC4^(^#:?N-*#IWVC$Q^#H)&?Y]C:__UD: M=M]"*\Z#O('[=[/=4T+%G>40*^24SM\=P\G*/_1T-8*4\AD!GE.RA0-0^]VC MLYI8\%07G$@?,6(.100XJ9'H][I'Y:CRRL;]X4@,Q@,\2'6.WF0VJ+W(Y=6A MA.U2H+NM(]-:S9Q&>4+I=V!,""`#C"8S3XKS+,A8"R2AWS*.'/[%VLXR0WZX)E#8:URRJL:#IKNZ*Y[4?O]+6$A:(0Y@TE^X:06J";3T)V MY3ILTN[!59Y01PSAR%.9@<'!YACF<6;7A'!#6:R8XG^3UT*;-CQ!/6W6]SF$ M1F=$H^62%'*TANOL.@)>@ERO/VWA4F@8Z/8MCJ6-[L7XAELR2E3K$'B<"6*D MB@Q43SH022OG"GOP4(F0P'BHV-AFB\Y;@05N^@_^\F2DA6U9MSOPD7V'KZ@9BR+#@"3QG-' M#FR-SMO4(WC6$+T>9K3(AF8P9HC8C9)+5CG&WH.JO$C">YLI=A5>MTZO.3BN MO3I,NQQ)SYH4[><];5&S=.P<1]"4@$=ACG)W")"4'!U1_,PF%N`::/`M&'N) MC@EX[.1AMYG,S*3,1O0"D;%V&0(B`=^A))<(;;_:@,<7$F!=2I;<53'@UE/' MO+425Q/T7:?BY'9^@YDQ99QPOV"U0!1O;3,K[]*SUD!-)8KRKPP\MOWPVNJP M6,G8>!<_1.0'5-JW3"61]ED<.PD*\0-W#C",4 MNHM[G,!5C.)8#\,C9E/V/2DQ4G`J.KD^``2:"RNKEEF_]NW8>U6F;3])T$CL M(BXRX1!.&R2+"*0CP&UM?BADF]4E/^V!0IMR)@@<_*]>':%`EJ-R69**JB0` MQ*Z8C6UHOHNEX]).6I:QPM:A+RLO&(T$>V([.Y)U7S/#0X)-J\\QWZ"CZV\8 MFE5@D9RAN6M>1\TR0-60:*:C6/1?YNKB.;JV4P;*F3"H"TP]QM%!ISL\FB,= M07\$_3&%#5U\#))%F!:^G2%%DFP4)S(082E.QA3C_8J&&O?*$Q=R,6GBOC6Q MZ'=DF`P>WWBHIF5UO]Q[,AV!1HR10_W.%.BH,]5]Q^-AHY&7Q7*IW11K&B#. M6O2$QAT9=Z^9&\H3NR"K8!OU68)D_>P:([1V,CHQ/7)WY)LV'DL3D:2(GG7. M5/%$O!RTR8]MGO;ZX$!/?/((I1&9E![O%7"A4.#1-&^2_"&M!7IEX7U M[!G(:'>*"=(V^18AK,%2P/":.V7OI<8,JR^3(`:C:BAL!4.3IM;$9L M)RD4$5GF)"M"4`DZ%4*[&ZD(%T5W9M5NK,G;KL@/J*^%)7^[`\&@9?)`9?N] M:?U=RA2PTESF!8Y)L0`J@SG1]8D9%4K&B30C@*3D+V/7@95SCB(.!3N5K@$K MBDJK'Z`!T66)!XEW@QP9(4_Q29BSIZA2FL[T'%M=;@PC"UFFHF`.&O$TBT^1 M+BD3D94%U$E,(`0&T0`N<`!!(7';#2@R>]2;VQ:*G;5%:\3F7F?V)9&H+V/B M!IWAEP>,,I187P!!L1!32A-I)D;B`$:S+*3`NI(A\80(6NW&_@J.%`!9JM"C M>EE!PZU`Q9&?EB"[#-'P8Z?':52AI6@G$F6N4DH"C$&L5JU/7O<4E+4*EB2* MXS9SDNH3:>08`&!-6)=T6C$:6=Y,S1ME7")/(3.YJR9?^!'*7D6VJM+UB)/+ M$-V,ZT6L>3$OAKW!%1F81/U5Z*OE*TDF$H6L'N\$9VM\D[@&U$57VAR3W=H-PD M99/;&2P&)HY"WQ-O8>GA@PR(?A<\BQ\QLXA*#;!C756,4&'.Q6@W=GX4"G+@ MS*#(`3U1F*@>R<)RM1R',[N5-4U!QKJVZAN;,![07T(TY/*%?1\\D!E-H"D,<0U(M929B`F\J15\D]#J M0J[50]*NCH@#E):#Z^2PU/C32-262\("%6O%#<)$LQV.0J#<$O@P!WI>B_Z0 M6.'T4*-L32*D=H(D$LP2L,8*:N#EFC#+ZM2Q%:A42J<\+&/*]87(L]3W5TYPENG8:?FH^'=I6^)@PJ_+E7Q*Q7X0OG=68H/D0569 M;\;>"(SB(0(9&A1,;>^1R/=(.1""DB#0=XVVOIU[JU4GM$GS$`5:1OD*@(PQ M3IX4-I)?`BK+(K&>F+)E6]J"!+D!(.94@5K&+@9)Q95J[5=/C8$9-&Q29Z\R M];:4<*`'628Y!FB`SH8;B#9;4PLO\$6QQD7QO!.\<)KE(1DB)%A M'!78V!%N(`0L/%?EGY;!*I#V$_O`JL.^C:U8K=?L`%A)AG%%H?3E+TD\\DE, M!'4KTO*9O/XD?ZA8GK:EHAO/;DR.20LI=-T9!H>.R8]3=__EDL?&J%)&,X:T MN0]81C$%A+1+J'BC-!#9HU\`,/W;I&)32O+:5_%.\%>4NE8K8^+0!(AQ4(F9 MV=I3!^,Z9%&I4FP_17>GJZG._JT`N!@K+ MD91E4[P0*K`1([_BYXZNPJ8J.L%*%F&@35%5/$/VHJ`H_NAHG7G77)'J;^4Q^/RC7AY:\3;SR=Z-;TKZ/F\O#4<-@U MT\#?C^3,4Z]KC=8?>;W)Y*BB0GP['TJOZPT&_<)V^--1775X:C/PQB3E_L/\ MJ]D-,QY3PJ[66&7G]Z1@3A$/%I(M9R3+# MF=$;`Y1' M8M3K$50&WG`VA+]YHV'WJ*;,O)B,1EB883*&!=)T)]P-D[S'@\E1==WY(YUX M=]+#='/8#RUQ,**$>UPE=QR*`8,9UC0:ZB3\0L5Y[MH;%#9+_SS:6WP>26'8 M)8(84EBBW,4Q[@,SQE]1J.*HWSMJKENL&2\@]!/&.0YFB%VC09=MU(AI`_0# MC;I'M7$(A2)].$Y+BCD6O3+U-Z/^<:$YFM!;>22[5*CB'[0-]$_JE'CR4%J_ MD=/RJ*KZ+H)S@)`93S5@^/^C[J@%$QW^9DP4`UGZ93#2QSHF.L6R);HU_:L- M$^V1Z5>S-OS7D9Q]5A@1U--I?_A)C!3)H,1(X=->1CH;V8QT-FK&IA&5BL`* M#\3`9NW\VR.O.T9&VAMU%8'`EQDQTNGAC!0IS>+_HV&OBHWV)*7TO<$$Z\X, MQ^,&?@B'TIL@:\"H5-C>T,-J$OV)-^M.:SDB>J!'0/PG_2&7#_&X!`4PE.YT MJ#E;`TOL8S&1OJQ!@JST!,"B^O7%R50RNCY,-7-Y(J;$R\Z3OLT3Z9^M>.)) MGYE@S^OUF"L.N9(%[F;<5PQRW$4WVJ&,D2)U1^.N#);HXU]F@^G_!VS1-&^' MPC.+D0([F&"\AF:)73T__801''4B'*U:USD:96'.RN MJ;J:/*`Q0J6W1+=C%=-+EDA<%RS9Z,J4SS,*NL&XMK(^\D#)*.>3HSD6>Z8H0WO]BC248(6N@N]\#!V!J2*90$BUNE4` MBIK]I(B&7"X)!N_`S34WYI0IGCJ M%_R`F9[:">+:J2J#\[@H&09`WYN)T\QGJZR&-Y>UZ5LF>/:IZ]`(Y.?I*E3% MGE$I7YOP31M1%J;(,R`E!V7=![;-'Q:=DC"P`,K8:!=\B'&TN+"`D8'#XWOC M8C0U,A*`$?"(`-.T%$]1/JJS,%D@/WKRI44+D<2",N7&+E@ZP7@'#ENA2".R MP*G=+!6/6FC6I9(89"PSUGCH.';M34P5G..$WV,A0Y[ER*`R-')Z:8:"KH%V MRH+DC+GW"X&%W'UR;,AF=*BT?9JT.FM0Z,3&<@F6-%]@M!(6:2)6#4>*"1R< MS\.E";#&0HGB*6!=]_2LTNMB&0>I-%YQ^J::.@GTI'[1B+1$_L,A7?2`<0CS M+#36RFE5&,T\?\`,;:4Z%/:$01S1@\_HNNL'W M":")]A]\N[G_3M]&*B1'AJC*UF]C$'?SM0]7AF+:?%\`UZ,6,K(<`XZ`!*3L MHY&4;D:$&5*XS1.K8T7W=D9,")_XE9>QVAY3)H:;@`Y5H M0."3(X+YH^1Y%!LC=U\X%YZ'O(C(3]"TF;#1&*`J2;FR8YE&=,]]Z[$N2G*M M<_H`YX(4#DB1A#9I@R`DWT'`E".T^^H<700G)99@P(\G=V7(5EE`R[`KK`:# M61/-.6S#IUP[@T--T_=D+&.FDJYD2#P9KX'E29$V"LTGZFN7TNJW6:MKB>72 M(H5%60^8&>C@JC+_ER!R;GYT8,:JZH#91VJPL#?H%'*0QL6,)J2Z_1L6DC3^ MF;K[XAEI$F54Z/>+F2YT+R3L-I%U\3=4ULML$=_'"JCPM`,E$_I6A8D*N>&+ M6:3\:!XU(%$OR%AT5-?_H*L+AD?\`F$Y(.NBG[KV- M5QK*`R@Z)`^Y0MF*G=`>E1BP$WHL7E890W^.0\KO9\HP\V%B"3("_I9"UV4N M@\]<[AQ!Z9I^9B\/\[H%$R3L*8/@-;J#[('L.@@)!TWK,[?(^`4I0EXLJ MT\'.6=Q&3P>@RN)F5F8FEI;PG^*D[.RJJ%(F.?UO?^D6]-!@ABC9;]#4 MDP8@-WR;P$Z@XP/H:3[@SH.XNGI/]^&W=S(S2ETKU1=[Q;WR*X+:(AA<#_$# M4+Q2&07'[PM2.%H8F+7X$6M:4G"T=3>6#>R:2C6`-O@L4V\Q>=FFHA*74RY) MX^=D49P"T)C#`'*0V]P^[E*PSWRUVFT"@,-'A3RQ;*T8A`UZ+E^E/?0JZ*X( M:6\/B%5J7+&\I8MN([LLBZQ*8Q=CLE(\S2ZX>'I)#SD>=@8%M:FB$9TU'%^< M1,&.\B*F9G9E&.EW*\[`^^1#>!\DOX31Q1K(19DML*_U6=;G+)E=Q`G3&/"[ M7R)0X7$A=J<*2\TK`'_\$.#Q>'@(5G-)?:7RM;XZ]EHN9,_X29CA82&=`!.D MNH/3L^]/!]/>I%,8GL[M>&*%5&'R1;K`JEKE'`@#8RL:LTC3G%-?)&E2[[`F MA332X&-@SU+(POHWQC"94,&8P,$V7SX+QO(YF3H[XK5YP,%&!)T,2^E?C\%Z M:79D[AQ)%`7%AX0%S"R1M@$93"%M&;I6$^C618:!)XV`JB#>KN11`P$2`F&!OE0%IRH'JF-EGK"\*7%]7U$,#0R&=O2J7NI0< M?VLV,B_2V+=W!0PQ64PV*D,C0'VL;T=P"1,K9*^LU["^@MC,-[]$PX*%BXSE M:J_6QD3%NUQD:;'Y6]5>/)%OI60/_P)118?.2&,(=(Z7?`PS::;ZL?B6WKJ.USC+G-E)HDV155 M%LXWP$-N)=5X6*U`IHE?1@1;P*5OI74>Q8#KRV^Y$!D"52^$T)JE7>2V?B(K MK,IJC.J&XA*Z,B#.Q/=\N,6'E(FU$_W+-2B1X`+HNO:ZJGN;#-;9$3\\8KRQ M7_F6#@NN,K'3#[G418@_K?6Y/:#`&9DZ!<7=D,T:(\7C19Y:P>LQE\B55N25 M'ZXID#Q6;QBJ($>*(%NJ=Y*VC[LT!)*.R'1N-*0@S0P%NP\HR@P#+%:H$][4 M+DIA5,75XY'1Q&B;T!.@JDT(R+IDJ@/OU%$7D7(1LTLOL`HV&*`1@[C%Y^HV M58J@(6QS(170]$\Y&G+H$3K4".HN:0[71+;`YC(6\SR5.8(IZ,@@\#(F4P[[ M8:K#H*<4`V8]7K:W6BC7/\;- MJJJ8N-M"_'6ZIXJ-+>1Q572JFU9JO5/2ITI"6*!A>8/'3@S-7I2LZ6Q7N<;W M%->CF\F!"F)'NA2WS6[-&562I4#3SN-#3/%SJGM_? MQUF&%,@>L`I4SA":4 MC39UZ1AN*\]BJ3@JE3>JM`99.<*T'/=- MUF$,;F:@,8.A="?W%O2+>3Y\,=D5[95/8M_#T.[SMK)T&POO,(STE[$"9MG) M9U7HK$6?:&GCZ38R1/V%2BBL,7%U*LFXM?M)@D]"/`!;,$O4"KU422HW/+#)J:A!=B'E&, MSY1%]"IN3J=*)?!RY[ET^9%,G=T2B MKYRL.>5&(&56ON/GZ3JL/U$W<6CVW'^[9_M:PD\6*@].KXB1N6_QO1">%OI^ M?NCNTQ^Z:S[$7^G,/K^F]S_C-;TF9)*OX2$WX*=\YP@09N,O1JS_H<_W?7*E M]%8\O&K4EY[3Y[KE;K'O-F?@]GKA"?SWK2S>JOIS&UB?V?D-E,R`:H2=`?%> MEKN<6^4N/3'G+&LI!-OMG1$I89@*4'V"]/-?M.YH$^@O9'%8Y5BJA6(9VC=F M?^_9TL=@_@3P?JZ-^FO51FTZ\?H#MDN=(G6IJHB_YI%^+I/ZGU@F]65HX)3- MI"#-\D>T`J6?C".?2W%^2BG.O:6,6MV^;LVB2R/'>WAOJA:_"B/X7'SB<_&) MS\4G/A>?^%Q\XG/QB<_%)SX7G_AD*#1N7:-APW]J,LG`9HN_X":T^ M"U"XR2IYJ8[V,B)1.I=9-M%3)@\E1;#B*.9DC"F/K1471UVLVT_=:BX* M!2[M]<15Z_%J%G3)5IVW].1%.PC;"M^^MK?ZA3.9^"G+AE`FJ1W,8+W<:J/& MA]MS<7*,)!SBNUMQGL+$#=7LJ?)"N'0;2'Y5_:,Q\5[1PXC$B>B7B7,%&5< MD2'Y6AN2V3+[&BLS-CKYK?W9:F9H'/LJ,K0M`/8,TU`FVO;C.Q18=..7?W8\ M^8_(I#57A76\`:,'BX["OBB@"AZ&4;`].G:)"O$/MP30$(OQJ,'\I MB'^U"9L.XDTC.G@!>]E]!)N#(.I.5/NL;PH^Z[KF*J1A M3D]C2\_YF0QIJ.ND@QCN3!##7/NGZWI9/O*Z)B\\<>VS?Y*UC7TK%N$_8XY& M#&L7;%#N-:IF?'84`ZP8:#=P[N9^=5<^G0HV57,8*DRA_/VM?"Y9]1/_+@Y$ MNFG-P/['3QRX5P,UE%#T*_`55ZB+X%RMZ@RH(%/ M8U<*?+9OCM>14#BI+(L`DBX70NAU^J,O.;D$4S%,`NN&]VY>=K MYW885`U&.1P\+AYQ_]R8@!,!7MH!GE8?L=D85\\31PRG%=A1G M;(O9BK$8M&Z]DQO-4E].6&KZJQ`8.U57NN&<)X3'RP>1X5J'#G"&NMWK/'%D MAKJ.NL,GSRC59`E#TMHN+'O&BQ=TX+@OB(*S.'M5B%I;P;.J;[TZN#].S>E1 M#E5K$5QVL-[7-$:3N.+T\^H02A\0F6%-0GQKU=^^Z`M)J[7"K3T2+.P-/]*E M,%C&4$2[6;G9?DO)P=MN1@=;2JW/J/TU MT*;M7(V&PAJD:7?F%O;4@ZL>XNUB"_?+A^?!HJ,=5@<.V@2<,ZK$RB9%0#<_ MP0@@2HE:2J0SME),UST'OH.!.=I:ZZQ4R9O7^(X?4A*=+E_A ML"E]_?O_-5^A0"2'Q:S>NU@K&%:]WPFZGXW6IG*U$/2,Q*__P M'2:[*R.[6:UM@G?$$:`/+-R\NXPH=91K^M@6!LJ;&_I?E<=@HQ;\DR8I(SQ M"I5I%5`=RYX4G>;^E)WF1X_#/;N078?\EEX"1]3'4 MPKF+1S5;+KGJ2L-(VG&%)0*86>&J:/QV+$]2HF)X]%*EE3,@]5[W]/;=!?;= MMS=0N[43XE>=M>EN8;!4$%R-(6"?EZKLC/N$6_:@/=[O3(!U>S!_.HFX3*X1 MVLUI!N[%S^YN6QY4[FY5G*GI)(S+^]QR>5\HM*@[&.4"_]9R@<^++G!%+K_2 MZ=KAV=NU3SD'7ZDWNN$$*0#8VR>C+C(M?HTD`IAAJCWC>U91K]XUANK^>XT? MOJF3*^!6A'O7#5S5>,_DQ5C?EBLN=*HQ,(O)0"S]W4%#P?S'KKC7$(Q>M]ZF M3H[4PP5N^K-^Y7KWS.^L]R",KPDF;T3I0W"Y+EB]'J&E:%$'6/ZYPE$H(\OK M^ND6K@FZ+NZ\;JC:'JZF9T4UZ1-PSE<_=&YB'MB0BN)IA.8J*=KZF7Z?X%8_ M45[JY"FSJ&L@GKDVT4%GZ'YLOR#SV/85/0EO!VW4+F10:5YN?)>ZUKSTEBN& M.$?41C(%:JCV<[ZAI\W0SMENSM)(N.WW_*Q8(+W][+&J['=R14'9 M-R8S_*X<7F0A++MS7)\G%8H7 M7"F^;L@+KM(-%W*<5L0-R!J4]6%I%3"IB^%6-1%K0\AU54B+_MM"IN#UV`N: MFG77V.5TT>UZ]Y==Y[DZB.=7+QK="O7LFNF5AR*=&-=82?8'JN3E=!'?X?M' ML7@=5,:E[T/Y=Z!>U6"]B:M2!CMB$`>MWO*7'3X>5]"U^BG7YPW7^'7,,-TJ M/0\#DS?\EAM;.!U$WL_D/D2Z6G7U5BMB`/<15/7.J]&S:OA]:#_7A3SJ(8B[ MY-^8:;5AHA51B?NV6M6E?OE?I6GVS?\#4$L!`A0#%`````@`"#R(1[Q++,#> M`0``@!T``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q0 M2P$"%`,4````"``(/(A'2'4%[L4````K`@``"P``````````````@`$/`@`` M7W)E;',O+G)E;'-02P$"%`,4````"``(/(A'7375ZLT!``#Z'```&@`````` M````````@`']`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4 M````"``(/(A'W&=<@``#```G#```$```````````````@`$"!0``9&]C4')O M<',O87!P+GAM;%!+`0(4`Q0````(``@\B$=QC).(/@$``&D#```1```````` M``````"``3`(``!D;V-09 M7)PC$`8``)PG```3``````````````"``9T)``!X;"]T:&5M92]T:&5M93$N M>&UL4$L!`A0#%`````@`"#R(1V=L&`!<`@``V@H```T``````````````(`! MW@\``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@` M"#R(1SJ*`.YG`@``OP@``!@``````````````(`!L18``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`"#R(1RHZ.@[+`P``2Q$` M`!@``````````````(`!HA\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R(1Y)G`U(K!```\A,``!@``````````````(`! MAR@``'AL+W=O@L``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M"#R(1U@(LZNB`0``L0,``!D``````````````(`!FC```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R(1WT"MIZC`0`` ML0,``!D``````````````(`!)S8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R(1]M3%/&B`0``L0,``!D````````` M`````(`!LCL``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`"#R(1ZB,:T.C`0``L0,``!D``````````````(`!/D$``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R( M1XY"ONW``0``>P0``!D``````````````(`!S$8``'AL+W=O&PO=V]R:W-H965T*[PIOHP$``+$#```9``````````````"``9]*``!X;"]W;W)K M&UL4$L!`A0#%`````@`"#R(1\V%]FO)`0``X`0` M`!D``````````````(`!>4P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R(1YK7F6,#`@``L@4``!D````````````` M`(`!NE(``'AL+W=O`!```N!0``&0``````````````@`'T5```>&PO=V]R:W-H965T MYXNY.W@$``!$%```9```` M``````````"``0M7``!X;"]W;W)K&UL4$L!`A0# M%`````@`"#R(1VS0F9C3`@``2@P``!D``````````````(`!(%D``'AL+W=O M&PO=V]R:W-H965T5!*N\/`(``'$(```9``````````````"``91? M``!X;"]W;W)K&UL4$L!`A0#%`````@`"#R(1]DS M&HC9`@``G`L``!D``````````````(`!!V(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R(1TZ/>T0,`@``V`8``!D` M`````````````(`!K6D``'AL+W=O&PO M=V]R:W-H965TH7B7@%`(` M`%<&```9``````````````"``?]N``!X;"]W;W)K&UL4$L!`A0#%`````@`"#R(1V*^P=XL`@``0@<``!D``````````````(`! M2G$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`"#R(1R:T[Y;.`0``I@0``!D``````````````(`!G7@``'AL+W=O@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`"#R(1[VL.@LR M"@``8$0``!D``````````````(`!GGX``'AL+W=O$]<&($``"+%P``&0`````````````` M@`$'B0``>&PO=V]R:W-H965T3P#'SS#8``.WJ```4``````````````"``:"-``!X;"]S:&%R9613=')I =;F=S+GAM;%!+!08`````.``X`#H/``">Q``````` ` end XML 15 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended

Oct. 31, 2015

Oct. 31, 2015

Oct. 31, 2014

Revenues:

Clinical laboratory services $ 17,090 $ 15,822

Product revenues 7,687 8,002

Royalty and license fee income 400 1,000

Total revenues 25,177 24,824

Operating expenses:

Cost of clinical laboratory services 10,332 10,130

Cost of product revenues 3,611 3,695

Research and development 867 791

Selling, general and administrative 10,225 10,285

Provision for uncollectible accounts receivable 704 541

Legal fee expense 1,601 2,466

Legal settlement, net $ (170) (6,800)

Operating income (loss) 4,637 (3,084)

Other income (expense)

Other 54 19

Foreign exchange gain (loss) (130) (472)

Share-based compensation included in above:

Share-based compensation 111 98

Clinical Labs [Member]

Revenues:

Clinical laboratory services 17,090 15,822

Total revenues 17,090 15,822

Operating expenses:

Cost of clinical laboratory services 10,332 10,130

Selling, general and administrative 5,286 5,066

Provision for uncollectible accounts receivable 708 530

Legal fee expense 9 91

Total operating expenses 16,335 15,817

Operating income (loss) 755 5

Other income (expense)

Interest (19) (27)

Other 4 2

Income (loss) before income taxes 740 (20)

Depreciation and amortization included above 397 357

Share-based compensation included in above:

Capital expenditures 437 254

Life Sciences [Member]

Revenues:

Product revenues 7,687 8,002

Royalty and license fee income 400 1,000

Total revenues 8,087 9,002

Operating expenses:

Cost of product revenues 3,611 3,695

Research and development 667 548

Selling, general and administrative 3,059 3,150

Provision for uncollectible accounts receivable (4) 11

Legal fee expense (22) 1

Legal settlement, net (6,800)

Total operating expenses 511 7,405

Operating income (loss) 7,576 1,597

Other income (expense)

Interest 14 2

Other 39 (8)

Foreign exchange gain (loss) (130) (472)

Income (loss) before income taxes 7,499 1,119

Depreciation and amortization included above 530 560

Share-based compensation included in above:

Capital expenditures 68 10

Therapeutics [Member]

Operating expenses:

Research and development 200 243

Total operating expenses 200 243

Operating income (loss) (200) (243)

Other income (expense)

Income (loss) before income taxes (200) (243)

Depreciation and amortization included above 1

Other Segments [Member]

Operating expenses:

Selling, general and administrative 1,880 2,069

Legal fee expense 1,614 2,374

Total operating expenses 3,494 4,443

Operating income (loss) (3,494) (4,443)

Other income (expense)

Interest (35) (44)

Other 11 25

Income (loss) before income taxes (3,518) (4,462)

Depreciation and amortization included above 23 20

Consolidated [Member]

Revenues:

Clinical laboratory services 17,090 15,822

Product revenues 7,687 8,002

Royalty and license fee income 400 1,000

Total revenues 25,177 24,824

Operating expenses:

Cost of clinical laboratory services 10,332 10,130

Cost of product revenues 3,611 3,695

Research and development 867 791

Selling, general and administrative 10,225 10,285

Provision for uncollectible accounts receivable 704 541

Legal fee expense 1,601 2,466

Legal settlement, net (6,800)

Total operating expenses 20,540 27,908

Operating income (loss) 4,637 (3,084)

Other income (expense)

Interest (40) (69)

Other 54 19

Foreign exchange gain (loss) (130) (472)

Income (loss) before income taxes 4,521 (3,606)

Depreciation and amortization included above 950 938

Share-based compensation included in above:

Capital expenditures 505 264

Cost of Clinical Laboratory Services [Member]

Share-based compensation included in above:

Share-based compensation 1 1

Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member]

Share-based compensation included in above:

Share-based compensation 1 1

Cost of Clinical Laboratory Services [Member] | Consolidated [Member]

Share-based compensation included in above:

Share-based compensation 1 1

Research and Development Expense [Member]

Share-based compensation included in above:

Share-based compensation 1

Research and Development Expense [Member] | Life Sciences [Member]

Share-based compensation included in above:

Share-based compensation 1

Research and Development Expense [Member] | Consolidated [Member]

Share-based compensation included in above:

Share-based compensation 1

Selling, General and Administrative Expenses [Member]

Share-based compensation included in above:

Share-based compensation 110 96

Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]

Share-based compensation included in above:

Share-based compensation 10 9

Selling, General and Administrative Expenses [Member] | Life Sciences [Member]

Share-based compensation included in above:

Share-based compensation 5

Selling, General and Administrative Expenses [Member] | Other Segments [Member]

Share-based compensation included in above:

Share-based compensation 95 87

Selling, General and Administrative Expenses [Member] | Consolidated [Member]

Share-based compensation included in above:

Share-based compensation 110 96

Total [Member] | Clinical Labs [Member]

Share-based compensation included in above:

Share-based compensation 11 10

Total [Member] | Life Sciences [Member]

Share-based compensation included in above:

Share-based compensation 5 1

Total [Member] | Other Segments [Member]

Share-based compensation included in above:

Share-based compensation 95 87

Total [Member] | Consolidated [Member]

Share-based compensation included in above:

Share-based compensation $ 111 $ 98

XML 16 R33.htm IDEA: XBRL DOCUMENT

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	3 Months Ended
	Oct. 31, 2015
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	5 years
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Weighted average remaining useful life	2 years
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	4 years
Minimum [Member] \| Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member] \| Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years

Stockholders' Equity (Tables)

3 Months Ended

Oct. 31, 2015

Stockholders' Equity Note [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended October 31,
	2015		2014
Stock options	$	104	$	85
Restricted stock		7		13
	$	111	$	98

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended October 31,
	2015		2014
Cost of clinical laboratory services	$	1	$	1
Research and development		—		1
Selling, general and administrative		110		96
	$	111	$	98

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity during the three month period ended October 31, 2015:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2015		1,358,104		$	3.04
Awarded		—		$	—
Exercised		—		$	—
Cancelled or expired		(6,000	)	$	3.61
Outstanding at end of period		1,352,104		$	3.04	2.2 years	$	964
Exercisable at end of period		785,188		$	2.87	1.8 years	$	664

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the three months ended October 31, 2015 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2015		21,501		$	8.84
Awarded		—		$	—
Vested		(6,751	)	$	(2.10	)
Forfeited		(1,500	)	$	(2.86	)
Unvested at end of period		13,250		$	4.04

XML 19 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Schedule of restricted stock awards	3 Months Ended
	Oct. 31, 2015 $ / shares shares
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2015 \| shares	21,501
Outstanding at July 31, 2015	$ 8.84
Vested \| shares	(6,751)
Vested	$ (2.10)
Forfeited \| shares	(1,500)
Forfeited	$ (2.86)
Unvested at end of period \| shares	13,250
Unvested at end of period	$ 4.04

XML 20 R37.htm IDEA: XBRL DOCUMENT

Other Liabilities (Details) - Schedule of other current liabilities - USD ($) $ in Thousands	Oct. 31, 2015	Jul. 31, 2015
Other Liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	$ 1,357	$ 1,793
Accrued Legal Settlement [Member]
Other Liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	807	1,220
Capital Lease Obligations [Member]
Other Liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	305	210
Installment Loans [Member]
Other Liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	$ 245	$ 363

ZIP 21 0000930413-15-004681-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000930413-15-004681-xbrl.zip M4$L#!!0````(`.0[B$=/SCLPPHX``*$/"0`0`!P`96YZ+3(P,34Q,#,Q+GAM M;%54"0`#B\UF5HO-9E9U>`L``00E#@``!#D!``#L7>MSHSBV_WZK[O_`S:V: MNK=JW`&,C9WI]I;;26:SDTZR<69G]W[I(B#;VL;@X9&.^Z^_$@\;!`)A%#\( M6[4]W5CH_'1>.CHZ$A__\KHTA1?@N-"V/IU)'\0S`5BZ;4!K_NGL]VEG/)W< MW)S]920(__D?'_^KTQ%^!19P-`\8PO-:@)/_\9;_*W2$B;U<374HW%@>^E7W MX`M`SRS4,?HW^GWA>:N+\_/OW[]_T%%35X<.<&W?T8&+'PB=#J(@;(A,'(!) M7`A?;$NX!+H@JH(L7_1Z%U)7^/UI(LBBU`M?0F^\/CNF@,9AN9_.$H3PXP^V M,S^71;%[#BW7TRP=G(4M+U[-@L;_O(76M[@E=&U%EM2BOL,6\0N^VYEKVFKS MPDQSGX/&T0_G&'U'E#I=*7XE8LKFE3PFQ6T-L&T7X'"!_F%NOYRC'W#72KIK MW`168`RP?J1:HW_;F'R`6A+3'1L$E*C7_GGX8X(CWGH%W%R6!+_D\,1$,BC` MC7]^UMR$0,GVW[M!:VDX')X'OVZ:NGGM4*_2^3^_W$[U!5AJG0U?8LT4A(^X MDPLW^/T1S(2@TPN,_].9"YDVLI57 M3X#&IS-=_#IV[V==Z5[W\`LA3=P,-026![WU:/,`/8(&?CB#R+8"-"`UGE@? M)C>_G8U$]+^NU)=[W8_GV]>2_9]O"<2/5L"!MI$F&;##&P5RDD0DIX_G\;-- M3]OWPC&>1X,5R;4H1>B$@R(&H;Q M1S1!7DP]Q`?\^M6?/L*)HPO;0O]TQZ_0/1O%S3(C_'B>2V(+`@DDQG5P3]`C MY#4V#.@A-FCF@P:-&VNBK:"GF5O9-4QZA>.E2E(X2EGV"5D^`D^#%C"N-,=" MH;3;4`/,'^9)6:%*6J&N^TO?Q,N/>V\!'#QT!RPP@U[`#5H:+<%&F(V2)?/` M"TSS.(US0`NY6C-]&S,]>-PXI$J\#8J:)&=)I`J:(9IJEMP/%DX=7@LDNA94 MF,T;I@[',9T?7CGD=&HM?P9HENP/M2[FE!;L$A)K7?E!5L:'6GW8"J>D@*2F=/OXA\U)VH-@V/(E MT(]TTRFMXG)'E.L/FIX/^`/`^0(9]?@%.-H-=@!%P]R?[1]$]M2RBZ_WOH M-L:&YWYD:OU(*_4&^WF%:NLW%N+''#Z;8.RZ`*WQEK;CP1\:9LY#0.3$]G8G M"S0>M/Y$RU/;1]U;\RO7@TO$O<_KI_4*I!>QK,-O$Z13%;=W,(9F.H06#HX MY0G_L^]""[CN-.S-W7J![`!/K+9&[E/MN15>LW;R9)5(.+8"/O;\OCP@1/:` MQHR&>'K2NH86],`M?`$&.5%^7G_1_FT[09B5GE)3HSVIY+X$&;"5G"G4;'8 M%6=VMYI)=&&.Q"%(S\]D^T2)MN*]O"BY62U9-W* M+=01DX#Q!/2%99OV?(W&&M0"--LEAZN4XK&?5.#;S::`6LD>6+*<;+9/V.R3 MHQE@J3G?3NYDQTY1$SG<-]W3>PO+)`]CM?+;D_PXV1_]I%5!0/_U"^+5TE^^ M"Q'77=A4`?B(]X;2Y%.LIA.LK5P'SR1W"XZ`%:FB]MJJXIY4,'=VEI[G*4S3"4TNF*>2=5*WX3BF7II"E<+<+,P M+!KGR1GA@*SI:*5X@K8X9`JI3B@@I_O0RO'3,9I=3R3,KA78<=?X]^+:M_!< M^@FY#%NF'E!KKREZLW-'ASB4UNO2DW\-/6W\CJX6Z"GT@Z:M=$_>=GL% M%\BF[E$XO;BB1,KYXVOT&;1>GVK+K;3?5-H'L6VUX*I@U[N?)=*XMJ-YMK.> M`N<%GN1YQ/">LHT2W-IZL"I/Y*R9AMS@X^&]04%`WJK#(=7A(-YA6#07`,W1 M%V-$`;P`TUX%"Y[7%2ZGWNA"`Q1A>Y]EZ8#W5<5U"%7HTZNXIL!$)C(/OXQG MXA,PQA*9#)I+-?PAO(A%;A.5HM+0FUSDUZ=?+M:JQW&IQT&\!SW1UUYQT:P5 M19^>Z:/4<#5'U/NM>3F\TZ??-#:Q+=3*O.#K#9HJ;?-S8VS:!>.>;1Z28`\Z6]N>T^=YP-SOOTZZ8!3[L^>U^9 MH#;5L@'4Q5(3M/6-\B.M>ZVCN2JG M#"\UH]-J[KXT]YU=FZO23Q17T]R"]4VKO/M0WG>[`%/IAZ,KA@V4Q%NKOWL+ M&]Y7P*O2\_U/]N:KG?GA;`-T,D@0VBQ?)VW#5#[Z1M]T2.I;;A#:ZEL;7%;6 MMX*=CX2^%86.K=ZU<>&NVD??C$G-KGE17ZMU;3176=]4>@%P6[W1J$(=M:C6 MNZW>:)2HZ77<;?5<0]H'_EN:W>:.@QC0&]^+JMWCC>C?'W%6X,BNYZ:*LW MCE5)WU>@-*!_,9OA_->[V/GF<@ZN.2G)@V@I_;H-%BU]#UN$QZBE[\V7]O@< M"6PKX0Z_I?W.0E7Z%2AM/=%)*>_[30G0\_AM/='IZ.][#!OHVQ)M/5'#ZXD. MHF\%>R-M/5&SZXD.H6]#^@9-6T_TKNJ)#J)]]*VBMIZHX?5$!]&W:-?G;[XE MBR+6-S'ZZS%><9YDEXC8U6=D5]BV*]9G5[3_<&>_("'(F%W17X^=79+BS:'<;YRY823NBQ' M?_TZGCL@F)'BL'(V6R^!Y\!7-$^>FE5`+_J.SD1SDY^]2H^1UZ1N`'@1?$KK M*F!+@EZ6A_N+&!7V&1RUE>7ZRA5^B$L.YVVD4@_`^0:M*W,)G).IPJ#*,C.8 M?7V;*8@89+&^JZ1?BC+UGU'K%VAMOR1_ M2IM+W*1 BCAJ*G=.B48F"3;^F5Q"CY=`V>H^6_&$<*&6_QSG2(VPPM5YJA M.:R")%$BED&M+(]G+2.)!5<[$(Y<>R4=^7N37%U/GN1@LSUY-TZLF;%6Q1][ MO/67T`*O)Z1&U/`\-92BT)R_2%5VD4;?@*PM4H4JTBG$"]Q3V@2BBC0UE,:+ MM$<5:2KHS!/P<+WZ>7'\_BAL.T/OY_X=[*[!^"X M"\T![MF6$09\08)+C1J_9Y+8%031`D+9/2_RB#&K@L\MSX'>L@VU;0=)'O>E6K)D)6^,N@S4WUP;!0; M>.L'4[,\Y-:P2PN..=;3]X'4)?E.IY,S_^P*J\PBALJ@#JQ?;=OX#DVSCB=0 M>FG.Q'WN2*YLQ!7(W5@>6CI!Y`]#C4$\N'K53=_`YUKJC[RGBBKACLKI9=QQ M/8AE\X34Z]6%&$PM46O;TFM[D6YWD)VZR/YSI%D91PEONKWN3CC")K4LAIS' MPBY'E0F527_0'2H,A&ZAA8OH'&#`6H(5I31'D_UFIF=6HF52K$0TCML>M#4. MDYX`0&0P5(AHK(,,+4@E;!FI?K@/)\8%Q"[5G:$(/`@ZQ@R1W>RJ)*)]* MGLWM@J@LJI?DX>Z(`F_!E4/#_C#KCRA8ZD(ITQXBX&*&PI4AX-J]"_!#*#GQI/VFFC+9]I,ZVH9)8[`RCQP+6"D:G'AE43Z&CH5 M+G#*/(TZS`DU6.`DVM0Q)%4:D)/DIM]L,,!$LLQVD.U2;8ADAEI&!ZW)0QN8>K;^K7IJD>R_3N>E MX#,FC2H3'ULH(@1VI9F/FC0N+$FV@IZFIEX MLX[WEGNB2D0;I?1RDJZU,)8YY01SI%T/90DG$4JE3R1(=T*9:!3,&8CQ*P M"P@/=>)C46@5?S]#$VZ=*7,H9]+N54CG+2)X02_=TB",O2[T0+$7MFD`Q\4) M-&]=QP^J,K%"S78_JD._S!/*?;%?C7YBJD;S)%=N9',?9<0*%QF5X57.F%2' MEYZ@'S3GW@F.0!O!Q/,`G"G>"$V!W.XH,S-3/AN)'_`V>C6RN:EI;G@+N/M6 M>(-6[MCW%K8#?P!CB[,J1V_NKG'<*HJ979X"`&6#^)[YDMVZ:F'F;*9P*"0 M*!F,YU,C5P35,5$O;<]@Z@V(FI+JF/#6,30`JF* M(;"M*5IM$4D;RHC!D%,RNZ_6&O&HK"6_NY<&9`5/454AQQ0L?, M,74H[8R.[1)C3G8FRVG)LA'GCKB"5GI*?`L\S@SNKN/"B/R`6F$RD1\DP[GZ%S]T@BXAO M.P^NR>03I8@]91LRY1,:U4'"+CMU*`[8D&SJ%^)&V\T4/G%MGR@FR2%$*E1% M+,QLZ73%@<(`)GO2P0U*#,)&-X@T6G'RT>B.DE9H&K&<(Q]5,;&SB:A:8\04 M[,O=V9:=YBG/";E'2*^08D:K=L;'/OWFE/LQXT-S"X!S*ZQ"T]=/CF:YFA[< M<1EYN<]@AMJ4[*RRJQX9P%<`D+/.X02?74L55>8(?^L`,/VPD,A'(HL\A&U% M;X?M4!_`O7I%093M&-#2G/6-!Y9!T1=ZT[&#F(NKHU!ZLD18Y9L!SCB;@["F M@ELGM\/?E#=YS$%=1%;]&07:L^)*$_9%''D6)9=4SH15&1*[AR-*2@HPI4'= M`8]W9*%TT]-!BD2.B3-#J*!YJCPLPI"B'Y<)Q7M&GS47ZDR;54P\";:MI`26 M7'K<,#$Q"6'JB!_$02FH8E27T/0]8.R15Q'%'"VJ@XT3SS;@4L#^0+/?`CT> MOR`G-P=W/K[JX7Z6V1\A1+P[$\/P7NRG2_GUE;5L-0ZLJ2KI$X&NB`""ZMZF\:"#'3]2HT:V$*._\0F[A M:0U`/0(0I=`_'US.00'>^/H$/K)Z/A]87MT]YVIKE61<>:UY/M9,U7HY"YG7 M)/3K[]GX6+Y:RG(PK$-*>L+0A![1.MB!NA<5%XZ_:T[H(Y&OG0&(/^#BEM@S M_=+W M7&(30GD$NCVW@E[*ST")5,94LF>)V!A_ZS&1%\4V M79W@88+86L&%)!/WRK-%%^ERR=)52,53+94P,<<7M2!U"4@5(XS,<4G^",GO MI#''&)D3B+RC'ZE',F_G*(,\UL?`QDN`^M9A8%%\=N)D\HJ`+0&24:S$V/!'\-O]C+PKB<\ZC3QF64@R&V[LC)`]H]*5ZB",[W]XR[V.3I<0 M:2')[(*R!D;V-2]1_,D",F=F^DR&#V\2S>23RCBQRH"8N34<,.'9U,,$5_5H M)@H,MD&6(DK?KI8KTUX#YXOFZ0NNY7W1@K@`ZMWH?))<8AHZ._G,I1]<@+-[/Z)^ICIP MO/#)^LPIT'T'>NM+L+)=N(UR^>CY=EW+3CFU2.0#N$(:\+.88'KG@[TLZ M"G%7`3O]3,#(!WH%3]++E-KN"AV]HP-@!-7A>.M8LW1\P3C;E8OL5MC-?-BC MA&S^5R8V[^![T%V6"];9EXGQPE:#;U6P)7FHBBAP!5EKJU0%(\4O7T$+V_@8NG>0G M.WU6EUX1>@5-)=(_-:!?S69`]^YG5Z_Z`G]<\U'SP+V5_R$T/GQ/<[T*_;Q3 M!9S@LVLYD)FD:I0\==5PP^K/H)Y<$N& MY=UI2\"JJ:.KN_^[%S[?W$_^>O5%N+F;?#RG=3E*D+RT=1_/*D_K%3LI2>S\ M/>P^^?HH-9;HFQ;7T-4U\U]`55^%"@(UU7G@_^,OQ=-[2TSG^-#>^7&7KS0I#$E2>,':B9/PM_!>8+\*"N_2Q,-G.?H_ZM''?[FST;@EX2=MN?KEOU\1N>XO0@!4L&?"`W)9:%A!10Q^ MX]R/WSU?Q7][=L[CO_*%^+0`@J9'=0P1MUS;A$9@.[,P]M9,1!,]")8^`K3P M]P6!X$6O!AH4]=_ M=J$!-;RK^W/XUBV<`6&J0V#IFV<3$UIH%*9PJSW'SQ!:1UL!'PW/#3H/GCX" M?#VA<'L[^1G!-TV`%PK`7`NV(WR'WD)`AH?_OK0=@(%B1$D0@A.5<@G_W]Z[ M,+=M9(G"?Z4_EU,EUZ44@F_:,ZJ293MQUK:\EC+9[*U;*1!LDDA`@,%#LO+K MOW.Z&T\")%XD0;*W=F9DDD"?=Y]7]W$MHCH,L9!5VIM;3IWPH^D;?-WZ3^!= MT1]=(;QQ@DY4`_,^Q%E0ZN):``X(H(5CWKM*BZ`DMA@`L<M1B%-'!^R,RPGAPR`Z#QU>["IA2H8;H+A\"&!@LD86"/ MHI/%7Y(-$,+C1%I00_S';PCEC;&%UF4W.*O>5(=EKD"*V)/6"F3!,G&QI6JJ M<[8T@&881`W+/>3B::%KBT!`3YP'L=SW!#LNK8$:0O"1]E[Y"%"AR94&H"S%-Z M16ZIC?W(\+L9`A:\<699KHD&8@K&%#CGV;0E8`=0!#*@1_AKTP-X4K5RA05^ M6_P.M-*>,D%C\J^&QG`%A-#T%7;%S/FM<+`&?$]7+G\6,?G51.H3=M,UR%B( M",C`%/L'IBC_UE)W&9/6I#P50&=A>09H``7"J6PI>.9/SV1M_QS.-3%+?9%/ M[V?8X8080?#R')==)"C39)L">W$+8*W@/H9K*CU^XY`;3E[N`('1(!^`"6!; M+_\+`#'@X0!(D>!'V\&LD`B;"1M(Y>!=<=MUWTU`O0!KP(@,:@2Z#,C#1L6- M+->&=&K`>]P%_!>NP1?UY3)F*0HK(1`P4!&=R>$4K#$:5GRQ&UF'+;]4GY&U M]/N*:@Q6L=R,.0@!KU`$HV@/KE+WN3"$6]O.U^N"R0L2'F"S?VM@'K\I.W\G MOO/CA;0Q2XTF@[!X:._[/[]*PMCSW'1>D1N0:R%?OK3AVKAFFB"+Y]+%&;:P MJ;BE8PV\%&@097R]@W$_JB0C4(XG^4XYM9CF1'VD%8@`B"YH09P&3+_9W@EZ MRI44W^"Q$A8L90?'%\6O)E13/8?B?@7+.!9Y\BVJ"N]G2()ZIFM4_9+S(;]! M`=*L5K;U'2)Y%_TRI=-O0,?V/[8_J(;F\=-A*!H%6'M%\H/< MXTY8*+Y93+R(>H$"1/@:@G^!1=0A?+6%P?2[P#4P_1G84F'R(FKZ!++:&W60 MK@V4@(@_B4]0EF]&C.*"T1WVF&#@KY4>0P:IM/(]^A;;U"+:&J4^?.X;"\:! MN+\N9`I]/<^&[=JA"4XR:8KEYN5M;LRW^"O2U^/?U- M1/]#W^2C4)V/)KH[GBM._"3?>;/$K75;8B[[S';B?A:6B+OCY,XX/^D7K6H" M??U05>H[WPO>\EOAJA*DT\Y*^/_QJU#PQ/GSK,.DB7[86H!/-NWM@R!*)D$^ MFN"7?D:=S"$<.Z+'FMNX%YID.IU_1)+4F^G13?8W'JM\9%;(\M-"Z>U>5[!: M],&PGNZ]U8I?(:T:[X+(W&E>=-$EER0*;"2/P)SE6*XF3`?M/=0HYRZ(3=;% M:SH)'F'P8PT1PO-]^V5GR)YYV1FT8AX#PPA7YSOMY`CP%9>CIN(*3M[+GL)1 M'8SCJ#;?[?/1X(D,^/W+[HCCHHP3?IZ.63-MH9O4?N8I2+P5`A,SW!6CD9;9 M*:RHFR#FAL$^,2SXZ;ZH\2Z,7G-%0BPEQ1BI@C.*Z@I:^5+I#UE&C-^A0`S6 M;:#.X7TLRW-%"BV3(/=49_DP^*W+*(59;O@X<[$M/FE>`YEZD3"[;A>#4/VDRU!E#E`X[&#S:O&8J3QD16^$+PJ9N$GE$^KEW<00(RUPKA"O M&=;3;S\,8-NRWKH0\T.9SZ'2-\\IZH%3%#D]NG=G)WI8%JL`NA,D)V:6`=83 MK/GK3%A<=MY:HX:Q4J?H%@NHQ`+L&V>E:NO?1'&86#9LC9=8$E57#GU-_+_> MD"=]ZBY>DW'[AS-2!8D"`DTLU[66:2]A#T\9[IBR,2?.BK.)?YCXW1J;+F?J4C>>7V]A M%/LI3Q,B,,;T#1'$O>2@`0U6WR/RE`Y+$AJ@*7#"%/!T4MA0#4;4)I^$&MO! MWQ#!6!_LMX8*F@?`$U9L"E&(N`5SZYZ'3&K4Z_C_]Y%3,[ M&P@@[.)@\$,AO*-L,^C,%9_H6"T'2ERB<0T%$'_!#6X(UC?UB6`2')=Q\C-, MP-LM`FX.H=^^HE*-0"$,+W/JOK]NI_S"-LIEN++24MKCO&:P;K3322\9O1M& MMY5N$QE=N]G[;:&[--O%*KM153=OOUGV7YC@6.%I*J>`@:M3V'="BVI*5I>` MCT>]?':D^9B>,R.QXMUI$",;XY=5,E:I7FU1"_8!Y^8NZ!1-V-337"?OAE(` M]'(1RH:U-X<..]WA]@]50I=ZK=XHMWM7-?"IS]&3XG(H<>F.E&:+RT'=Q23* MW3)&=,<[:PJ,.U`(>"N96M[$H#N)C`X!3T(7AJW^J),;J%3).#;;*46EK*AT MQX.&BTJ:W11_\*^PVI)9[MY4[EJ[4%L##]$S*%ZK+IX2IVH?V*60AGUL;#MYBB]E@;63A`6!4&)73*\#T5:ZY8'`V!_'V['( MOPHI(,A-AR*V0C9+<@.RA1P="-(J`>+'$C]9>`MA>8KTP,--!R2V0@V`;*%( M#WRG,H#@IT^Z8=R8T^24ZR8?7>S';XOSL>"7J09X$)4APDS,/@\VWKCII_QC MEQG&SI^'V.`EBWAQDB;N7RJL7706NQ/71QQ_J#JB M]N\<_@`IZ&7)*K\L\1]!T?4N/&=I80?]FB7?__Q/> M1;XU*I(\/Q3/6:R4G^5?J)N3C+)/@V]NO7&),FV!?%7,92I6OY:5^C+UKV%K MU!WE3B?(IHSC9?5%1VD-1MW#H?Y*ZO/.F3QH*?WF_R"GOS43YGCE[T.@5VIOJW(\F^$V!?8X*E!C1/638$FR;1 M6`U->^9WQ1IK28RZT)"=,35VQER,A_M)-%7WU:6('$9$ALEND<;U3DEI:8ZT M7'3Z330HQQ(3UM*)EZP0[V,7ECU6I;.BPYY2WL+*AKPS$A:($%KM;L[30+N3 ME#UX;%)"RDE(OS5L#W,#U?"635X;W]D5\8F>H`9?%+_6YY,O.422Y#UPHT\= M!?_-)7\EC;Z[NWBCF'>5[?$6JM:?"9DSR_-[(W"EF.$X]2>S92:^]+908I+VT2&=`>FF1&LN:^BW2 M?ORN732B8O!5-`?[5<6)];DODA!+=7ZHD."/]%C5D;'PKTO[8:.<*$JKW4EF M'*H"65P3CY9^%TJ[-1K&[K*H".&KHA`>']&4WJA.\,Y(W)BZ)INP)?T*JJLB MU;60T/6'^U/7VKV'(I7>ZBV]MYX#<%";'\0%_]=9Z*OD(<"\^:0BH%80JDVL M[[24<7M/0#6:$A?#UJ"3+/26`>I5FM0?`P5ZK?X@]Z5=)RP)H!.=7K*']2PI M<8$WS.0_$G:2.C'JY3Y$4Q*DQL33U7?'W^C$@=V877FA:G][NDVG_.80,YFN M."(AP#N,!SL6@F.@PT4*(<[+'&2?-CI3D1'[2 M-3P*.H4'M84)$,R?V99IN0MJ9^8N&LW^?MXFD%,V`KU$V'!6!J#(.903%H*^ M,I**T$NTS)^7(A0HMS5E_RL;,M9R0O7!5J=TJ=I_5;M,K0(WBQ3BQ MM1D5XW&!T]5;FQVJUHG.DPL7G59[6*7GM8YJTWF2?JR,*LBF%/[J'.A"H#N6 M)NC0)DAIC?M=:8(.0'H%C'\R";HO!3AHWJ.6L\\/EJL:Y:F7Y]QA0:Y'#_GE M[+FH:87M1XW+,&-'=O64*9]R;K=&VI\2LKORJ>9#W-41-_\*_V)N=)G]JU M5L'B`[RU=]WK3?..*T4M67Y]T'F<=J0[QXH5UF07%B)LHA__.K0F6<00Y]1+I_BY!H(-0#`C[/]./$?^1&7"OZ1*S!I M("LZ2B-9\1L[8P8&1`7XU3DE&V@?\*EV*&RZ5'43QPYY<='8*@7E5:.L##2T MQI/;L-7$N_16>[))8>LN$NY*.4:72I\\4]5V-IJ?H\%G.S)Y,6E0GFO?\AZ6 M03?(^/E)Q*$QZ31=MH_-KM]AEULLU#@%DZZTMQOT8\&EMP>1)\V(AO$FN:>D MAQIQ$?&V.55<=X&![=JH2A87KU:V]5V'H)H:SQ`B>S8G8/KTS7!2:[$1K&L3 M7'&^JTL_Z8\T^3@/?]B,S/CIT4I+4X@([ M6+835BK]>%Y##>6$4LE8OI?)":5'SW,YH717D8V<4+J^X@E,-)032L^&U7)" MZ1DP64XHK>@$53^)*B>4UK^PG%!ZXAQMQHA+R;ZC9E]C@J5*^XV<4!K)M9[G M0$$YH52*B)Q0*J5%3BAM1$PH)Y2>V4A!.:%4"HN<4"HE1$XH7>\G"_N42C8= M%>BY]:BY#G3%XF>I?X?-\[=K*O\XAFLYPH;A_R^(=%=1:94TY>J MX?S[Q67WQ75G..J.VNUVGH8K#L`U*0!RI(T@E@FN&0EE,.KF12(#I&M2!*\O MU*T9AX'2[^=%`59?YT(4&13"^",;H1UD-NUMA[O7B5-^,QB!N%/SGTT8/H0) MFIOIGY[C8L=;#@6H@LEXR!`I#]EU/MSB%$I_W\Z0'';R()D'Q&(*LVENEF$N@40'?,%&&>;B./3!72EEF%''HEY!+;W'!::6 M'T-'9RD+D<9+Y[^LE!YF6$3@XRKZ*N\!J$93 M0@XREX/,`YV0@\Q]G9"#S.4@=2CY3$5"#C(/54,.,I># MS.4@\VU)EU,V`G*0N=P1Y2!S.""'&1^,-++0>:' MYH`<9-X$+LA!Y@LJ4EX/,Y2#S;BJ_"JG2('Z@M=AK#]_H91XMH`<2@B_<8`16EWJ->T>O@ZA.G3D(-1+/J MC3F]$:VJM[Q3-6M?4`8%)6J7\K1';+)EJC[F=!-"51B=3M'=8Y?,V2,V^V!. M;^UZ,=Z_]A"TKP%F;#YYQF5C2FZMWP-SJF+3R[^S5&?.-F-<%1EQ>UR? M3*W?)5I4IHH&&;N4J:K8]/+?BKA[F:J*S+!8!%*?3`T2RA`V%F5%W42 M=RE$A<%O#W/;U=U+35'HQ_D5N&8Q&2;D>QNDW78G=Q"T!S$I"KXR[C=HPRH, M?7N8VU'E(4-M@I*(FYM_E^TV@)MV;^T6>$O?45L'\Q-1;O-OF-\&<--ND]\" M;^F;X^/UE%\=.O,,?,KY8-DL^H)(#+,4):\JOG%)\H;9%M'-F64O.8N>='=! M;.JLJ.82UX+O?&`=_W+CX&BLCA^)RXV=U[$248';C=/O,,Z^]SA:]8K<6OR@ M+P'$+_2)?+.6JMGB'[2(F#D1N^PX\U+D>.-XHO3E-RMMJRDF^Y=<:Q6L/\!! MRNL=1FF=2)4ZQ+)ZJ();7M*NS\VQ8H4UV0SI1#7T"3"VGA"2K/:U-<@,SO4U M,2@Z`17E$?_@*D8,?49C@@O"#@#PJP-_G/B/_(A+!?_(U0360%9TE$:RXC=V MGQ\8%A7@5^>4;*!]P*?:H;#!GP-C;-K5)07C7*RD!#S]/D-FPU\2[] M6B.R26'K/I"U*^4872I]\DQ5V]EH?HX&G^W(Y,6D03W%^Y;W,.K<(./G)Q&' MQJ33=-D^-KO.LK2Q$.043+K2WF[0CP67WAY$GN3I/,P;*1?)8_COG-%$%G"4 M.05K0S?!'Y]AH:6W%(G"ZZ^CW_.D!T(@\B<',P$?EP-<_1X#7.D7ASP.NE]' MWI`5\8.!&QX+9*'4:Y=!"9"(XE`%G-S9\DP,E$P,UK++<;#+"$V-E"\$=Z@P+W,#-D?;,M)0A-*?KN$Y.^,`66QZ.U&]-_1B?M.=S3#:(LR-I_O'%L&.MPM1" MD*6L%YP[D_SBF90,6>*UVV*SX6ZMY4HUGPG;H#&I:KH648E#-0__^8T^6L8C M9B,8Z'C/TCU^I;O/Y&9N4XJC$#?Q(53=Q:)WN.L3Q)HX^U55;QS0JRPN_-_^QR`.(EKJB'J#-\K\JF7NJ MK0+8=HN]YV>J&NY"4VU*0*I44Z/D)W!#5RWRZ=/M.JB?*#B1]JLK?#%)P@T+ M+W1M0>CW%4BI`]0A[ZC&!!EI.&B1E6T]ZE.*>6@;,`+0V4Q@.FWY<_IN#=`"\*3))W7"4&%*)T81`DOF8D#F M"C/C+T=7;0*^DH%I<]7U7R86U`WDT(K:Z'F!UCCL?3%@T:G&?0G6B\`-H+SL M1=Z,O]1-S::J$[P\X15#IB.XX'J.S9CDN?T5GI!#DP(2B[*B\#`(OL$") M&:Z8U0KP3E#]BGSD7\!SGLG&&$8A]%P'+,24IAW MC=*IPWX5O`:B$X?B1R;RE,YF5`-F6_Q=7"3@E/;^^^$1M>+=1' M)3/#`A2!G,I5I_\#61F>PP!;K0R0._9F9CKP)R`$/R`<[+WTD7(^(-X@::IG MN)P8N@\H+@2//R-%0H'IPEM"IH/AL/%%^%NN<`&75,.Q""@MJCM`:EKF):BX MX9?N9I1)2_NJ#^\#L09`3&^90A%!",_T&PLD@`* MM2`TI>,WH)L3,!#DVVC5'#`*7V@/9@]D!D0,BX,8^H^()M("92 M'5P/4`@ZG5.^C3!Y55>Z"R\`1QX<"5@[NBFE[Q@H^P`1L%-C_K]J`U:@\*S` M^<@O]PW6TT`S8(=R.Y]R`\?]Q8P"YX%)23:`IQ9M(@@H`Z0WX$O M)T!LD$-X`K8+W%I,01'X2C7_LKV5JST+$!S8U4`7GB.O_-.;"D^`N4UL`;;' MH*=K6\95/$WUT8Q9,^'W&5P!EM94G^G`^$>0:0NV@QESF1CD`2=Y60-=-@N^ M=]"&Y3@,_+P-0QR5O3JM>9")>?V\RJ@>(S;%2HU/#`"7CI6BM&Q.`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`C:>*8@=?BJSK-RMDH7H31*C!HTX-,/=\F,NLFVRP^-4,BFTH-1]%:>X] M[HX.K7+^;10_KK=YH8#_'*>)97\#]?S*;']N"?S:_>P3)?:"]:X&!H'IN+:' M3L4[ZFBVOD*2W\SH3OHZB$?#3]"BS^_LY\)PH'-8':305UR^+K8I]F+'YEE4_?/,"& MM-19^>0#1>T1[0!UB4>[O\74YH)FF]T53NO;:`$V^\*W/-"CV>UL,[MKRZ8T M?Z4]]\T_P5/GQM;IY=C8LE?>XBH(5(.HX!LO.K(8L3S,W9P43ELV0NN\3]^* M8*<\P(I2%&*QYG5.6#'08F%M.1C;H'1;8?/7N-Y*0/^7-1"NMX5NB:62XOAA M(R;O_2+_+8_UWT=#_9)`#UY<#]>871Z,;28L@?\N,$*%ZRK%^+`%I63KJ(:) M,4?T+[+[N#3;H]-/.@^G=>HTN0%S&$E2==\0`3R)0,^B.W[JP]>)R+=[;]CT M(30B$`(QP>UR@QP5._T.#-Q%03CE'NGU,^O!*=(Q'FW/FZNOEH;G^?SL4W); MSWFDY=QSY[0YEI=/K"\9@3&FX:'Z(N-;A,.W)Y4NJWQ>)S7$M:-=CKI):-WPV@E_QR2?3*Z=LM7Y"Z"O5HXB$"PH-(B M$VK2F<[*4-@*B^DEQ\%.VMPFKT[QWPEUJJE=72(_5'*.FVH^IN?,R&YKG'=N MV%XP;8RSME_S95LSRNP4]].[&[?8)H2HYV2!4C]&QRA[V7I-WNB\&G#5 M!&_;$/5=BLG>H5J;`C_JM_,RJ6HBN;ZLF127PXA+IP66I]GB/-L\S&%) MLYUDR[FYZ`URI;J2UIMIP\L\UU]0=MQ%D0:>&-(%!E@TM*LGR4K9V-/,5@_9 MV'-.W):-/;*Q1_9[R,8>R6C9V-/`NI-L[)&-/9*1LK%'-O9($9>-/4>,GFSL M:::#)1M[]K(;-ZT=1'+R5#AYC(Z5;.PYETX-V=@CQ44V]LC&GMH5X@QZ-61C MCQ26,VWL";MY\C?A)"X(\W^.)=+(,Q6OMNJ^N.Z-Q^/@2J7-JUS7`8XBP/G% M,U+!44;=8N#XI'V_7!G6,Z7?^(2R>HDT5(:QV^FV+I9REUXE`+>0K3MN5P=0 MD#N:Y?U`ZY&Q^-VJFQ=*NYBK)%Q;J#88CLK`%1%-/]]T8T[?A=FF6F6O&[GR MK."JUVDFI`Z0MTEC'2#[3&&!\;JUK$Y8!6*Y&/LWKU0G9%OHUX&PH3ID1W)M MW2A^;1V_GNZ0U])Q"$[\4CK9O'H,[8RR>?634X"\&:6!WJN@9- M5AYE7^,N^AI'>3N#9//J\3)9:74ZN2LOLGEU%Q9.W*$-3ZL.C8Y";Q&3,N?8 M65BVR\;[RGZ+>JOT21?@F%$]9TYV%-EOL0-35DL'!@ZJ40V##07!"<];[9HL MN#>NX-[KK^_0S2FV2U%ICJAT!]TFBXKLRY"E]OV4VE/:,II6:)>BTA!1&8Z[ M#1>5W#T9.RTA98W2%F.5EV)*]4I]1F_3B4S8U:)!=NB!ZF)@(IO:WND2=3ZW M*83?U"$O^\-Q"WX@)ET1->*NDBF=N&2%/KN\$,\YQ&+E--=2"S:]@ MQT*"'\2^@/_/R."2IX6N+8CN`/ML]N!4=S3/PM]ZMD-ZFL$]F]A)81N+[3VBL\K.Q MV]L!&RMSL3;\P`+GY%]J_]]]:"DK3-CLK/<,)=Z>Z(@,6RF3\):\S:Q`WT?H M4,B+S&0OB.P%D=R6O2"R%T3V@AR\34#V@IP!DV4OB.P%.=L.`MD+4\>T%XU2EO06E[#79CV:Z?*-NE M%[O2*W6CQ"T/R853+G4H!-L@?BZ]$&Q*IY-RG#X&7'G`AKDJUAGU30B9=P;8 M*$&Q0H!UE-U1;)RK.KP&46\;J:K(5[^=H%8^H,`]VR%0VVZ)@"UQ5TS:<@V$ M`B:VR-+W+EBGA66`_7?>_^WI[C/V)C7Y[H=Q_.Z'*`+A%^,WA&/#C/8^;X)@ M+_?_T%G>$]Z($QSH5,!$[F8S>(D2?=79!;%9:WR0?=_6=.;=68\N?Q/P#250L[\!SV%G7.EHB^GC\< M>^L5^37H0TRL'D=_J3X3"S%DS7\.Q?$;,Q!XXNI+2H`D^+_X"(1("L$_&4'%@J:(-=YPC!($.TA0IDG>!+; M.GW>J)%!)+A*]ZK]@T^`$!H()1T'0+$T2J>L[Y+JCR!,7A8[XHOJ#C$MUR\9 MP'.`R%+]"U:`+[D`B"4Y_-O>&Q`'GA)/K#S;\0`EQMSUYSC>F,'3343(6P&Z M^#NJVH8.:\&;+M17[",$"/\-FU0"+,>;_$FUS#6`G!<3_@Y_)4'5M%]/`AY8 M=E3>F%:L\'F7D0K,/]5-CKB`XPD^`M6&_0!@1/(Z6'E.DB!5?K_1N>ZX-H?L MW@5:<-!-\L&RE^3^LBM:7[&_%K8F0T4S0H'@F@LLQQ_"IN$Y+NDSN]-F&J:B M;#@K^(V'5%JM#*&44\;NI*7"1Y86X(""9+J`0LCP=*T3K7'U08]@(#";P!?0 M^T_XT,]TM*/`/C>F5V#O&)LI`!LV'K__KBU4<\Y^Z*O9NM:^OXVK[/XVD7?` M@66D8;W72E(RQI% M]\7-=QXC"3,_"T`(5,QT%P[A7%L_F!!%=:I/F8E&KG&KG,Z,#8;Y@Y"&[6OW MXFL[X/PEV4OZ[7YKU!D7AH.H+GO7(_@;H'6A?/2ONJ/(_HPB&FQCP<:&5G\% M__H.'KE+P2Z][%P-?*D*RD%B4B'[^<`6'-=0[7AWZE/J@W\,-04*]EIM_OD M*WR5<)^X!3&Q+6OFX98[I8YF MZY/H:9"V;U.P@Q@K%]Z-:7KPV#>*!V>"+4YI M7_Y78'AG$.;!3Y[!B1&:YK<0,A7G/@/#\"O#/CC4@@];)OR449IYQ@)-I)7# M_&?3>B(3=/W`=--I"Y7D40>\@]4Y70%I"FZ=CAW/5%Q`ZK300H/FV?#75`<] M`^,/?R)E/,-5D0;(-7XD!Y32@2]8H34B(/![(1.@D1`C\TV?I20=:DY7:=_H ML#-/P$RWINB>LP,(B`%*O2-ZUYW#WU@X.N\^]>W%ADT]RH,]]"A' MQ3&Y>W.9$=W(B8;TVJMZA6E70[6T09)R^CWN*>WLS>MFEVPMP=9>X]G:F%ZW M@QU2N(_Z5_D-N&Q/E(2)#8?O895D6@F7]RC1E3;QF:`]2H05I/U MF:X10S'D(P8@4D6!5:T5Y+X3,\1\ZQLCD>-"^9PYFC>U M)R\.JE)F#->]IP;X6O,6F5,3CZ_Q3N,I7H[/#Z$\4E(_2V29J,XR4?R^K:;5 MB*2H-$=4QH.SJRA6O!-(5@>/K.PCJX-23&1UL);JX!>+T.\:=1SBJM_)!!S$ MF>Z*D]F1(SK3U#.9P9&=]*.9S,_GAXC'<+'^Y, MX5HEUEO"KX'&3N)4(1[TQ@LN-E(^@_"'KZ(J[;)EU!.HH9Y^">4NI?.^>344 MR=>B?/V-O2E11[_A9]!CG[W_3FU-=^(??L5#ZE(F2LC$D7'_&UVJNBEN70H^ M999-\9/&HE M3K8UGP)'S/.B9?#Z>-V].CXV5_!IPCZ"9L#Q0YD:73[YV%8[+B_R92$^:()[ MA]O6#=XHP_W#>EW9J8U*]3A380T^M+HGS`3I=$_$J-_7+>1W.+=D^P.?LO&`Z.Z7?O6 M(%O":FT)NQBTVNW\`SMWUQ7V*B=9#BDHN\,^;_*K3@C6LF`#)9^N-J>1M`R' MZWU;47FI%[QZ,V=;%\B;0ML3#L<88=5R4TVB1D3QCN>9Z/O9^79[)"V'Q<5_ MC],H.VN5I<;U(#9-:G9'A;)[;Q4(ME2@I##49G#7J+X%G,Y5ATT;<)I/A9-6 MB?$@>1-#X[3B6(+]6GP.D>IE3<+2YS@RGV,XZK>44:///#1-8D[:N':N1D,I M#(WP-T)PE*N1]#P:H!R#X_0\R-X/B-VP&QK3I^ZYEJL:9.:YGDWC4YXTO.0I M]7!B M'C\@9<$_Q4PP_)GM=ZX'-UWRJ::./TP+IXKA5YH`?!*?5`5?&O21FN+6P7T. MU]+]'F\QJ1<`%^0"6.ASXO@81\9=X!A!8(Z@/?R+#8OE?ETX=`MP%%.WG`W# M2PW+X7=WXD)B(B&'P%"!W:ZMLF35E`TMCKY=-_U#AN)S*EH*Q%N6GN'J*T,/ MQY&:'AL]R;C/6,]1X6@<[CAAY")^?K*0=<0=\DSAC3A!&)`\.#B8:XRN9PK) M2)]@&`[)RS&)$[6C2=/:QHDCB/DZ%TAT+VC$*<0Z#KB4/.)2X[F54%'*%BF* M'RXY#]+F/K;%>)!R2F^/G&A,-2=ZK>7.3N_D.K]3H5BXX^;ZSN;F^H[2ZK=S M5I-W"^GNB9C_;HNU=(E^ ML.P9U==%>U^-5-LZ*TMT5]>S6%**T(NJ1OB MCJG;F'VHEGKPKV:8.,PL!A>&HVZMCI92ZSWY4FBYMD5V5`%LBFKRJBKE6U]UY?P<^,9:S1*4*.!)STS4D79 M6"G*S$B+$62QA]<*-*SS>HH[(.772`GX(RE)_T1(-I=E2,N0[R(%Q9CJALL M4X\E@+F-E00`E_[M87'!KP[8UI*A#>@HY*.)J4N\31QO6F3E@!B)E5:W/<:3 M*,$:J5*5COB_?O2J09V;.?"-C6_P3-W]1F?_?N$Y MTQ<@;B::"/:!UO[CQKF;=16`&`%]`5JE`7*&\^\7E_T7UYTV_[]__5A@O6L2 M@_(KM9&((+-WLUMKN=0=!P3]J_J,K+@S.;[^.T-85X!W`MC.'Q^`.\J--T=8 M'ZQ4L+LOKMM7[:X`N=#BM5.WKPCROJ,:JD=-Y&4@QF3GH^-X=/J.*>U79@[N MF3Q^H4_L*R>$D@MJ$M`8:7LA:7M_(-4LDZWRF:)&19'X^.7#B^M^NS_JC!/2 MO!6BZPBI16H?\618W\UX+3)*6GA)K:!W`/"K[HB3/@.`ZQ!$]F^?-3?F-!0F MYSVONSL;):$DE)<@SJ-.("(YH+CV9=AGQWM6IWY0O[_E5^$B'(P7;W'WN8UL M/A]T4S6Q2'G#*Z[Z9IQRJ6,;U#$4C4JPA.JY<]2Z6=S:'VK+E6$]4WK/YX>E MO^F+)5P+7HM\P'TO^CT.)H.=Y'<*:/D.!1!;C^JBB?]T"<5"#7+<"NEJ\@/\J^Y"=JPU-?>A-._GW['/[D M*Q\,S%;B;L)'$]QWCS5QW6&4\+!032&8`6"10JI?Q!9[2W##:.124;Q&U,DO M4QV4J>8BDJ*=#(K)=D`G24`%.+R4\-$4<@Z1"[L!5*F\+>&^VE%B$K@K6-?4 M\1!$R;6A(5&Z_0,2I8Q(?V%A'CALS#F\\6,\L(D_L0AOL^.[P4HQWU:!^&Z= M(#N`<]T#N-<6=.H9/'")F3AX9GV-R/SR&P-B1?9KL=P:O/@6Y^TS!K4/"$40 M8.8V1@_!D'4G"+'3\AGA^/5D2ZP_:4&T:6)JPZ;1=KMH]BGH^$G[D&7&Y##U M?5P.7C1A*X>IRV'JIWIQN1RF?JILE/ZMWIY/V&-]Q,.]^9!-.*D MNI25*MMJMWSOV9&.-SYH"^".;U(XTDM@&C?K5HY$EF)R/B.1(Q6&0^3]-U76 M60'^R<3^&WV%C[Z_O_L:?:MH/=G8_]+-*B7\(2I%Z;TO$'*FEXGS`G6]2Z1Z MF4T]&Y$:]:OBM&-F]3.9%88A;*4,!(?5\=LA=H-,KN7#3NG6P+[=X9>[_@T; M;'-U*W?!>CRJ79E""YRK*R5J=I.M.BVKM`VKOK-*>-EMEE7;?5=IP.?1KT`O0P&=`T(FA`N=4 MU[*?P5%ASI)#-"BZ5.E^!_.2YF8AXIJ9\ELM!?9Z%?J7(KTK$5-*6H5!HC='8](57N M<]OGI`Q9N)?]'5),9']']?Z.FJN+_HTJ_D+B23I-?W&>4ODPLQ$`E[Z;W8KT MWZ<@^R=PR6SGB-9J\P&X`[1&&RYC.6*TQIL:&UB:X\:)4.U:# M=J8,BI#H)QX0`6XWL7#(OQ$G`S^E70K#NM%3,IE6";WQH"S_ZL:P=#_*X62N M;/-)?H@S^DW2GXM>@2/N#'JN<&Q_K;&$C=N!7<4A\8E+_MR=],L`_7L'TZ\$ M?!W;!QO3&`(25KXSY!1:0TZ_,GR7:5AR=>=#042(W_C'Z[/")(RL=.: MQ:&X'UQ/%?LTZIC]?=Y)W_1\#F"CY-V![5##AV-&RPO7E>7D61KW/,P][J=CO;>JB:5"G)MFX\%XW:Y]:Y"=KK5VNEX, M<'Y:;G7=7;/KJYQD.:2@[`[[O,FO.B%8RX(-E'RZVIS^^)V/&:Y=7NH%;[*PS%&6+5!TKCKDF:JVTWPJG+1*C`?)"V8:IQ7'$NS7 MXG.(5"]K%)8^QY'Y',-1OZ6,&GV4JVD2<]+&M7,U&DIA:(2_$8*C7(VDY]$` MY1@-B?_&,C'&Q_1$$UC6, MB\T",&O(#?,WI>RPS\:N0_4''6\0HUY%()E"#>H8/YX6[?@W;NF1ED-UO;2(9&1J,3K#45\9C>JC MPQI\]=O=R!([-CD8,>^$-'LV.=DK9ZFQDM_D*+]WQIT:;4X)8--TK!X(XKJL M5#`X@S2#LQ,@^5T7__K_+B_)__WM\W]Z_^___H^V\K[_;O;'TW^&C_/?G\U? MWWE//PWM\?"_.G_^^O#L&,-'[9^V\8O[X]??OW_Z^.7'_I>?/W_O+W[];^/F MW>*+^W7R_-O*_#;\-O_?/S]HW]_^[_+VL_//WQ\_T-NWVMM?>_/?QI_^]W\_ MWIO/G<5LI`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`9#V+):4(O:@J8R=R2U93 MCZ'D]ZV*'C\!#1TEYS3LF+J-V8=J:>G\U4\8;>KG+`Q'W5H=[8:L]_!ZH>62 MISBZP*]V297I[OKD5C4V%`2WO(:OO3A!Y%[R8JY]T;AZ?U6M&>0Z"ZGO__;@ M_1]-6-MCT\3OW`6U'Q:J*:H)7RQA%FIIR>HH_78=?1]%P:ZKUII_W42%ZB=X MM?M.=>D'5;?72]3E.K@PK[!78FY%:OTV]9T!Q6.I^GN$,#9!TWCX!^,;O6( M:=ZNKTN,HO9/W5QBNR_Z![%2[:(+MG4OQ%W#X`#DPU:_OCH@=^D(?#0U:TD?U._O=$R@MZ$^6&Y M('0VHQJ;/JL'F!`;OL;KERCK`7$M,J%$7:T,@`M;,_P^D)EG&.S$T15Y6.A. M\&9L_O`<_N24`DQ+W:3LB<@:*]MZU!T<5`-OFU"3SG27X-@:]L9+U[JSOKVT>;(.E=[(/Y#5@]-2,Z`CB&B1?IG MGE2'*%?C'T#281F;$[-[U?NAP%MZR)_F%6`[_WGP+.`+]TD!F'@Y*79OA2",07 M`913'7Z$5)B!IG/!]\63P02_4YG$@Z%PB*;:]C.\@W4T^("J7&%^O;J_(C,Z M94.8$5\/!\3Q90'T+E!X!=*DVKJ!HY.HWS*EF^I$-["9"CZP_4E^((>@>&() MCF/JXIIJFI:+>A0\BE]J*N@)+NN9&K5=%0BF@V+:U.#8P%(S#S=V)`W3/:%! MH`&H5PX^RPB%N@S:QYH.@&_X3\>;S71-IZ;VW")/"QT`?;(\`T<^L5=%C0+# M2340(Z;9@CYIN.Q9O\A,!_$!LP`FG^7+<4`7^2``C!HM"H0R8W(FGH6?3,`" M3<5/0.9UH-@MH`NHF3J`\QF(H\]5D]$.ITG];ME_D7O4!O;1+?(=A5)PB9D? M?:J#E*!HLUTO]AE;F3@45!??X01OBBB4#TXZ0=-&F.Q#?._K4O#0-U@9 M!T^:&D@OW]==0;U[7_IC/PZ]BQ6L5,;W[;ZX;E^!;H["WB1>#N['U-/8GC3Y$^3'WU1]D#S8]PQ_6Q=' M\7Q'8P7"9#+7\`8V9H-T>LRY&5V1=ZF##3-=*F0::G#<'<;]&-N)!"+/_I;B MP4NXIQ32"R`"-]BVOC,W%Y!_V;[JD:5N&&S@(KS_I7+5#CZ`H&S%E<4(=F!P M9F$!P\,5=4ZP*,LRO0QP\95G\/"!Z)R$S7Q!\$33ZI M$XA>8HK68OH*+[/5%?5@93]$B3X36%`6/TTI!B+JW+0@T-7@.SY4VC=F"W"@ MP9Z"SXSZM5RBE#UOB'M2]1XDB@UX!OB6JNG-\&B2[4,+U/B+@A4-S"ESV_EL M:/:#U4*UEZK&\$'WW7-<,`OVIN@K0H$`!A`Z_O[8RZ?AZ&G_9`GS='E`&;QD M:GMSC'>FS%6/+TWHHVIX+/D04);:\(8E7OP>2QZ M1=CT=-@OA#%E@>'VYQ@F7%BP<<&)2+;VAOGQX0?3-RSHT!UF^6&;6%G,FY_S MD<[L56ILJ#/\"('BIA[E`(,^E8T59A&7%=FL4B1V'Z'5)]CB#0CP>`2-FR\0 MR[-M/UTSPXQ2YADAS+48!N63&$$,@7O"';)8#.23)B06[)3@*#BX\3%B3ED8 MK[*\AF6*7177$T&4V/[(.IRXF>H0T2*<5O3'3A3&J&BB>9A0\#]4?[(S9X'E M1&@N5G*HZQILFQ=Y#N`/BO^ZL'/NAGX/#ZH7ZB/EBX%'04$6(&!^SB9DNO(O MU!CMV;\#]P.I3U8&J#=WW.!/S!?,9N')K,`P:-8CH[,`(8+Y[PLTR#B17SU6RFORW_F;*OK$TXG7RFFV#4=9:D81;>Y3ZQT"J'@1LF[N!3SW`WDCTN2Z\S,3K8-/+\ M)PA+'R&LV@1H6D^P4XLE^#_2<$_O$-YV"`[9P`5A:S3&F#<)7,;,?KN*\*:= MG"MUD"_/*;Y\L*8>YLN"/^\IOX#TOOO*54(<[4-7-HO@9BVMY'N3^(SNQ47>2&)(8DAB2&$;T/R*4DZ."(`ZS;O?9+3Y>A-EV&J/DT,C#W8_S.[I5QJT M+73,ND-#4E)24E)26L?CFX19?5_]RDN@Q!9AV`9Q:;Y/)2^*E(G,<%59E*6-M-2M5O MLSD/3O3:N:^;DQR0NB`Y(3EQPE:I,1%M+1Y*'3,VST/>UI,G4N7WS()1JYT, M0Z3AE5N@Y(3DQ($YT>FWE&')P>7-\D8*9TTV-3=5RK??!2.-3$K)& M)]!D4X%@N=2!!D&YKH"0FAITE':1@2((<7E-.*.KXEG&9 ME=PW3D(;!H.1AQ3PT#OFMMN,[O M2!D/&VMRL.59*D"WU>Z/)1U.PS+6L4TJK=&HAIG,1R\02KO5Z?1W#=0)A0Y? M8^-3/!.O`L2;O?&>07&=HR/N_623/3=0MM&",6R/SMZ/O$B,C"T'T5[GU1QQ=K%U4>[&XSW!$^CB0`>1U5IEWO!J0B#TAHHN2?*GS8= MVF=<>:CE3$]R[`";.I";S^?9P"U;Z9O"B8M!:Y2WZ%"0!:^D$D@ED)R0G&BR M.6I8D%J+1_)@N>"16&L'>LJ+]AE(GC)H=;O]G4B>5/Y\+.CG[X*2'-@)!SKR M[ID#:[B7RN$!.IE$0JL$5\Q*'4U'&/E,$72JR[_JP"XF0+]3GKN.RNCZ:* M*B=-CU8G+O*6C0OB?O@@H:C;OXDQC69A'4G.H]?A;O+0V'F20=KVY)ZO2#+` M8_W=NS[-\NCK[U+^8-D4WDGH=VVAFG-*L%2Z?-.%;O7'.W+.D>XUT7VL# MK%/DR[M^)TWR;JNOC'*B(BE>`\5[K7Y'.8!QJ>14["B;+?L?3RMW)XDAB2&) MT1QBU!Y([B[172JH?$=7-M5TUE_)+Z=?6H#*/_P#B"X-;TKATXFUZ:;ZLW5% MNN/D$'H9Z.R%\/T*&25)^`J$SRXZ2P;LA0&=KB3[`<@^[A_(X,BH\[@]2$D, M20Q)#$D,>>J.+7V_4&UZ.5$=B"HU:XF'[A*QIF[R\8TZ5+6U!:MM3>DC-:P5#L*)8BK%_NC$_B0( M(25#$N1$"=+@**.6\X'WU("@8]XB#VG_E,,-\#AK.UM*QR0:H MY=>1<^K1*3^B2[9&5>G%+&E*3Y?HF;9T1QR039D'[PZ49#^(P<^?_Y9-F4>2 MHY(M`9(8DAB2&$TC1NVA8\..`MZJ*QUG<[-)"%/=]>R-[3-GZW3TDH.6I+>W M'\(/1A6H(LDN@TO)`,F`4@FN=O\P%C_-Y1!_\*]4`)V]!OXUL7_T_V2?$XT: MA@!'`-?F_\.^<5:JMOY-"LG`6S'4E4-?$_^O-^1)G[H+="#:/[PA,\L4S@2Y ML775:)&?J?%(T0MJD7O5="[OJ:W/TL+>O?M1IO5DJRNQ!/]'&N;I:?[4YH$( M+Y$)^,?#PJ:4+($L"X>`+T6GY$YSK0FU25=I$51DQKZ)_U1VAK`BO%'!TRA. M,]F&0RY#`(N`^)AB]8Z`*!^L:2!EPK^YPI1"^EO1"\X5@C"-()_4B9-%\#+D M+H1""7)+$:@B`I_T&8VQ_U[3J>F?!9`B<`8B\+"@L"SU8`/)Y+KD^^GQ/9SM M(M7\#-A]:YGL*]6ETV-4\V9E%#<=^2YTXN*1FAYU7F?*N4PG2V)(8DAB2&(< MO`15I'M1Y'QZF/*I?C#O-N^A[:T`=7ZHP%4_D96"4T:*,0^-1C]L;EOIMT:= MSF8_I3"0Q85P;_0K#=H6.F8EQB4E)24E):5U/-RI@,-=BO+5MJ:>YA);A&$; MQ*7Y/M6QG]^MXZC[J-5N=\J\IP'X2X&0!-D?0?:A*0>-P+8W_I4ZS/[->E8- M]YF=83<@_C(=2F;4GRV7EZ#G>8Y1GN1M"B<4T/X*L\\D%Z0^2$Y(3IR896I6 M9'M>I]E2$QEGZ9F/90PK0S9)D!P$Z?3`9O1V#=3AH]B=S1>X6U%\KSGGY]B< M1"/*46T@LL@NB2&)(8G12&(T*[*HUHO2L$$"M08A[9928%;FJ6N&]#4E021! MFF4\#A^-U+)[K#9T7AP/RZ4.)$=\MP;Y;W<[83I(P9`$.;RFG%#4(4?3G+0V M]'NC3$XVF09U]"QV>MVCQ%TJQ`X),APK.Q6*(P\CBHZ4.1[&]UOMP4!ZT.`? M*?W<4P].F`XG81EKV29!,<92(##-U!GEOV*M*?O#00_Y/.J.;IED9MG$,_%B M-JJY.M[ZIFH:`.DZQ*8:U1_9#7$;*-MHP>C'DX_GJ1S)*^[/DPPGL6E(@NPT MX#ZK^**6HS^?Z!PB#3SL([JE\DO2>?9RQV/88N21O?35Z9]3Q27U=T+]S#U' M[?,\0JDY,#>.=!K]9(\D%S8OQX,6^-VSD:$YK@G M19(BYW6F6)YUD<20Q)#$:"0Q:@])]]N!$QX=YC=?D0O#]=4MB M2&)(8DAB'&]#Y>YN%,*A,>*5,O.CG;!$XP%)9WLOKODOWCT111[VPUXB)^#JT9::%#7C\=3I(^QK21 M-'`HTZ,$0.>ETM*^)Y6B0%?>"9-!&>^<#(?WX^MO1_Y@V13>2>AW;:&:XITWVM]4^*^LY)WFOU!IV/1[0]S:X,,:VHD?'^PL_A=$C[W)6R2 MZ/LA>C)9);K[>0'`I,I(8DAB2&)(8!]]F#C-P68/]".$C!NP5L%%9 M]C-QJ/VH:XE;@G3E?!9!'%B1!3IL@1V$OFA6*5-HOY*#EQJE` MK0>:Y-8II4(2Y.!JTK"HHI93?T6',A\SF97Y;)`\ZG8#\ M2TX<6A=&0TGW@^X`97OR3V,Z6BT=FFP66GYM.:?^'$6V15&"4>ZJ$)'N=#9FC@Y"]DD-1)(DAVS%E`X`DAB2&),;!B5%[$-F` MPWZWZDK'P=ILCL%4=SU[8[/,V;H9G7[^64G2OY,!_;&378:3D@'GS8#.X$`6 M/\W-$'_PKU0`G;T&_C6Q?\0___6CYUS.577U^I[.L9GI&UWAH7US_DYW-,-R M8%]_`'C>&I;VU[7_NG_Y#WWQEA-JW\WX4_A^\1J'>*8.+YO]^\4*7O&":):) M>+%/M,X?'VQKJ=QXXT%_]\0:94TY>JX?S[1?O%=3<$+WNE:[(& MUKVVH%//H'>S)%8?S9EE+]DID;?/XLL`O[Q`7C\L*)E9AF$]X937F6ZJIJ:# M,Z2';R=*G M[@+=P?8/;X`*IG`-R8T-)&B1GZGQ2-&/;9%[U70N[ZFMS^)5CKAL[K&@8EI/ MMKH22_!_I.&>[F^GMH)$=!/Y@'\\+&Q*R1((LW`(^,9T2D!P+)!>TE5:!"6( MJ>/$?RH[QUL1WJ@AT2C.F=F&0R[##HN``)EB]8Z`*!^L:2!EPK^Y6IA"^EO1 MR1]3E$_JQ,DB>!ER%T*A!+FE"%01@4_ZC,;8?Z_IU/1/ M;""97)=\/SV^A[-VI)J?`;MO+9-]I;IT>HQJ7GM6>&>']`N=D7FDID>=UYER M+DL"DAB2&)(8DAA'548469\>)GVJ'Z6\S7OD?BM`G1\J<-5/9:7@E)$RSD.C MT0^;"U/#5GNU??5K[8U M]327V"(,VR`NS?>ICOW4=1WW%$KUVZW5-R0.J"Y(3D MQ`E9I<9$M+5X*&5.1)^GO*TG3Z3*[YD%HU8[&89(PRNW0,D)R8D#0N.-7!SL$ZB<:G)&2-3J#)I@Y)#$D,28Q&$J,Q$6T-O4\- M&SM2ISPH[5:WV]D34(VFA*S/28)(@C30>!P^&JEE]UAMZ/0Y'I9+'4@0I-L: M*(D)"V=)!RD8DB"'UY03BCKD\*J3UH;!(&=FMV$TJ*-'MM/.6?)L&.Y2(79( MD-&.%>+(PXBB`ZF.A_&PL8X&9:S*B2E`M]7NCR4=3L,RUC+JM34:Y6Y':QC^ M-:>9.IW^KH$ZH=#AJVT]Z@[>:3BS;.*9>!4@U5P=[QE4-0V`=!UB4XWJC^R& MR0V4;;1@#-NQD1!GJ1P7R;M+2T'T:H.9:33Z)[%92(+LU$CT=FHDCCRN^$3G M$$S@^3'1$'6TN\%X3_`TF@C@<525=KD7G(HP**V!TMO`S3.B0_N,*P^UG.GA M^X1#7=>@6(9H$9.ZN?E\G@W8L.!5GP2BJ!5`+)"0I@U:WV]^)Y$GES\>"?OXN*,F!G7"@(^^> M.3`'NJW>N$#A0G)A1WK0ZO<.DB-(D$OW.37!B6XR0C[R,2@F$_9TAXPHHP;/6'L@T5*\B)Z.BL:L@7:9') M65&@UQIT&WTML_3_#[Z72V)(8DAB2&(<5Y_D[BZ5PSFV02P@ZE"OI$!([9#$ MD,20Q&CP)E(IB51@B_B(0ZFIXQXI@R^46'?]607$R1;J<]9QV5T?31553IH> MK4Y5&@*)RZ4;G*T=VT\D`>G MI!9(3DA.--L>'3XBW>B3=,OX)!^C76MD0F?@H_CE*U?]ON%N\HWT[=8O@O!* M,K6\B9%2IPO7>ID/WD(K)+O#>N7EKKMKW3]IPK=ZXYRY9TGW&NF^U@98I\B7 M=_U.FN3=5E\9Y41%4KP&BO=:_8YR`.-2R:G8439;]C^>5NY.$D,20Q*C.<2H M/9#<7:*[5%#YCJYLJNFLOY)?3K^T`)5_^`<071K>E,*G$VO33?5GZXITQ\DA M]#+0V0OA^Q4R2I+P%0B?7726#-@+`SI=2?8#D'W3AYNL-1)9B(HDAB2&)(8EQ\*WE M MVTKED9R=T%\.DY%'TYK)B81[N",.C/N2[@>U_\IAAOD<-)RMI6.3#5#+KR/G MU*-3?D27;(VJTHM9TI2>+M$S;>F.."";,@_>'2C)?A"#GS__+9LRCR1')5L" M)#$D,20QFD:,VD/'AAT%O%57.L[F9I,0IKKKV1O;9\[6Z>@E!RU);V\_A!^, M*E!%DET&EY(!D@&E$ESM_F$L?IK+(?[@7ZD`.GL-`H+_(!HU#`&#@*C-_X=] MXZQ4;?V;%#J!BV*H*X>^)OY?;\B3/G47Z#6T?WA#9I8I/`AR8^NJT2(_4^.1 MHNO3(O>JZ5S>4UN?17V:&/Q[])U,Z\E65V()_H\TQ--3^ZD-`Q'^P1(3_.-A M85-*ED"5A4/`?Z)3YUH3:I*NT""HO8]G$?RH[*U@1WJBP:10GF&S#(9?R MPR(@/:98O2,@R@=K&DB9\&^N*J60_E;T?[,/;/(C`_^3.G&R"%Z&W(50*$%N M*0)51."3/J,Q]M]K.C7]_G\I`F<@`@\+"LM2#S:03*Y+OI\>W\-Y+E+-SX#= MMY;)OE)=.CU&-6]6%G'3,>]"IRP>J>E1YW6FG,L4LB2&)(8DAB3&PU-X*4.>'"ESU\U@I.&6D%?/0:/3#YE:5?FO4Z6SV4PH# M65P(]T:_TJ!MH6-6,EQ24E)24E):Q\.=!#C<12A?;6OJ:2ZQ11BV05R:[U,= M^YG=.HZWCUKM=J?,>QJ`OQ0(29#]$60?FG+0"&Q[LU^I`^S?K&?5<)_9N74# MXB_3H61&_7ER>0EZGF<7Y>G=IG!"`>VO,.],4&L0TFXI!>9CGKIF2%]3$D02I%G&X_#1 M2"V[QVI#Y\7QL%SJ0'*L=VN0_T:W$Z:#%`Q)D,-KR@E%'7(-A?+_5'@RD!PW^D=+//>G@ MA.EP$I:QEFT2%&,L!0+33)U1_FO5FK(_'/20SZ/NZ)9)9I9-/!/O9:.:J^.E M;ZJF`9"N0VRJ4?V1W0JW@;*-%HQ^//EXGLJ1O-;^/,EP$IN&),A.`^ZSBB]J M.?KSBV4M?G?XY55Q2?R?4S]QS)"?VS(E. MJSM,M@E++NR?"[UD9FMO7&AP.%N+:\)F6Q)KK9V[O-TY`X'$(T=*;"2)M`E[ M9L&PU5L;$2"YL'?+'*]`2@[LG0.]5B_)`\F%_>O!L#5NYVQ$:(Y[4B0I"BMP)N+9$A4!J!7&PC9;.S3PI'SHD"WU1[5<;-$*@6DNW_<6[$!*(,]4H*A]0420Q)#$F,!F\HA?-'!;:%CS@5DCKND3+U MHI.S3>`$0V%Y)ZO_+MD_'DT1]*BWM>U(I"G3EG3`9E/'.R7!X/[[^=N0/EDWAG81^UQ:J.:=DKNIF;M:> M9_.9/"[2%$Y<](;Y?8*"/$@V2$C:2RV0G)"<:)8]:E8DNM$_Z9;Q3SY&6];( MA,[`7_&+5J[Z?<-UM!MIW:U?'.&59&IY$R.E.A>N]3(?O(566$N!YK_:.)M' M->^)ITQPI:4H.?-,!>E=W>Z>,MW76O^DJ.^!T4[[8&[<$^ M*5[)I2B2S9`]C[+V+HDAB2&)<7!BU!Y&UIO:+A4ZOJ,KFVHZZYWDMPXO+0#_ M'_X!Q)"&-Z7PZ<3:=`7QV3H>W?XPMS;(L*9&PO<'.XO?)>%S7\(FB;X?HB>3 M59+L>R'[N)ML(]D3X65T>=R>HB2&)(8DAB2&/%&W/NIFH=KT;K#027(B.)(8DAB2&)`1N593\3A]J/ MNI:X)7C',E#'**CDD)?S50!Y9$$2Y+0)Y]LL=L7N:W1?*@TPG(O^3$H75A M-)1T/^@.4+8G_S2FH]72H77EG/JSU%D6Y1L`6P"T3.MZHXXD!W@2F[L M105&N:=*2++7V9`Y.@C9*SD419(8LAU3-@!(8DAB2&(S-S;+G*V;T>GGGY4D_3L9T!\[V64X*1EPW@SH#`YD\=/<#/$' M_TH%T/';?_WH.9=S55V]OM<6=.H9]&YV3^?8R_2-KO#,OCG_:,XL>\F.4[Q] M%E\^`&!O#4O[ZUJ\]E_!>U2#.M_H(S4]>B]:9[]0EWBF#J^<_?N%YTQ?$,TR M$3?V@3;H_O'!MI;*C3<'6>T_6%WE3G/QSS]N14/N)W7B?*;+";5?D"G5]*5J M./]^<=E]<:T,V^,V_%\$DW0(KJO#VA]-LG\FE8:O$WE%[@Q!NU9%= MJD>GKPRW@Q:'#8\_H-WG-FAW#&UWNYT8:/&%U_:2`G!5,LWEX&*VYMXRICN3 MLNY`45+@"A9>E[("D%4B67'(_)9I,##OPH;I]WSVXJVL9$'?:[0-`7$461A5H++HA?^*]D/#$3:P3,@_H52Q2OS,: MQ&UE+GC2-I[*B%2S%.W^N"F(#+(1N3$,-@9)1!%9^\1HU"Z+3-VX5-M7.IU^ M*41B6'RUK4?=@>CK@V6_@Z#3G7G&C:99'A!P9YHQ;(]BD&\"8IWP94&NI`.7 MO4(0UT/C2I%,NQC$<9`_T;EJ@).^.QF(6Y1@O9*@5.-MIY,%3`FB5#90`Z57 M(SB5;,R@K62R*0;+3ZIN?K(2+@7:WHNC^8*(9TTVH3[MS:_IQ?4A9 M^[H2=-72K_WA8#MXU:A713$NDYJQ`_BJ*L?EFG;L`,A*2==!=U@4/G\R^*[C M827N\B66K0!5->6I5M<7\S:*4!JYS7S\U&AN47R[3BF(PRP&J]YZM@WY;32A5XDG-*(6['8($RP-?/6"MV`X! M'/XT_]T##IS[K)N6K;O/OD$#IS+^EO=_>_#U9^HN+/CF$7["U&)W[N2:I=T; M3NN;<2/(6>P1SL;QOI.154B9$$8*QPXJD))YNWD.G%4%0:OE/(%5C:#M96ZOM9%1% M12@%5[[S1U6DK#L8KSW$/;2_GC(;C3(ASM&7V MN@>`N(HL#,=*:8BKGUVI9)'Z[4%C3D95LQ1*(@M^0$1&[4Q$CJKH\2IT_&H^[E)9XGN]W0)830>&X\11WIK/XU1T,[>?A*AX5J.2:>V/"Y_5 M*$J^*IIQF52-^N&KK!V7:^JQ`R)6T9#+;GN4Y\10Z;,R8?S`@SR04UOB:.U$\-F?=*C7 M89<$K27"&"3]T;.G:L60:-`>')*B]9ZBJ+2E=/N-.))3K=@[:,21G$JF4RF% M0:WPUU"_.SP2E0S#N#NJ0Y"J]PR/E`U8G-*1HE&VWI_6D:)1-Q/1C7T3N9OX MRQY+J!O/7B4\=\7-^O'L9^)9]Q&Q<4,P'M2$<;[-)'$#_>'0SO:NZCXN-1Z4 M1+EVG+,WT8*'I1IS_FNTP3DK=%BJ]/&OFA$:9WMKQ0]+E5:VVK'*=GR*'98: MC^J1O!H.Z%0K6R3NBCK8>:GJ)R,: M39W$&;6LDUTOKG'0U2HV8FMFF6)X);FQ==5HD9^I\4AQTF:+W*NFLSY[ M0Y:J/=?-UZ0=F;<%;_/PCR^62XG2)>%PM>X;$H*JB]F7GO_0CRO_KXG]H_]G M?7#=F>07SZ1DV"(07/9:!$P90<55S6>BFE/RWOS'(BA_Q!?`%OEH:E]PG]8U%U[GV2Z963;[4?"Q-4.\30ITL`SC^=)Z,MG*$T>?ZJK]3!YL:Z5_ M]P%[6NC:@DRHIBXI!_V!:@O3,JRY[H-/+K[_7GSY^>/^*+?"D.D35 M_O9T&UX^@9>"45]:Y(/NP!\<>U>?Z5KP@M_OW[]^^'SWB@"$'^C$]A"4+A)2 MZ5WAXR!KRY4!:`%VAD'G\%[=G-G(:7;/-%#`T;^3%9`+LW$VW@(-7Q+7(N^^ MW!"'_NVA2,`GSK/CTB7`;J@3BF0W/QK;WY3[6GX[^D;_R57!$3SB_7( MC`11.HRL\-\J^=,#,H/$?:%/Y&?UD9JX.(-7!9*"+'-=+Q;\.Q0#^"A1U7 M99/Z0GH/.;G!RKNZP5[BHG/`GT!IP%W=F>E4D&2FF\&WP.>HZ&B69TQQ-9`! M3X/5@$3P+]#>/T'U\=<`M*-/0$@UT)6E0V9@DI&*\*X5`D:Y,'S&T)8HG(!] MWU*A:0$:@=6@@%9@93[0*88,Y%:W-;10CRIS3KB01*@,\H3[#_8&`X!+("=3 M0'@#D-M%3>+83'VKI07&;`9_H*ZM^+8$SSF<&#[F"Y"H)5!TRGYN4]AYP&") M?#>74@`F6!Y,#E=!DQJ,K_@4R-Y$-35X>@&A/<(F?L:8RM!GBZ+&J282UD0U M@ZT.GJ)\A2@W&/\9^34PY0Z\A1MO8*D1W#U_1=XSH9\E;0!J1/AD"VADJL*6 M32W*OP?[I-/'<&F`S%]4!7,W-]&&JF@2IVB1@-"@LRZJA@[K:('4BF6O]K`) MWCA,A+RY!TJC<`6-4PTX2&S^LR\ABL!!NP' M?SE3I'&R%RSF*]I;A/Z6F'G[$GGU'-;XY\)=L!]K,A@RQ M24!W$^YB(;T0/%?]BYIK'@EL<"O+G-)@O^$(.:%<*EVV;01@\XVC&]TXMF-. M$EJ#P*]ARI=FJT'X8#$:=:+[O-BF"*\B?!M9A(T=QB]+9 M3]*DU5<`^"0%;/&ML_`W9.:=4I=[N[Y_TFW[^RN^AD+8#I"'0*8]/0.GW'H* MX090".H708$6Y M\8Q:B:G'=M,U-C`NWJQL<'LZHW57`W=A=&'0V['GGB_H*2@Q9'W/Y9D$[^)@ M)<7Y3PN\-O#NN#Z%ZX%P,SO"/W/$D&6F<.L2Q+TU)OWC*!?7!9Z)H"^V:!MW MLJ5-J/N$EC`94X;;%83QDR`D`W=K"7XDKFIQHBF*C\:3[B[0?PB']`"8,_71 M"D*7P$WAZPE_%[Y\J0S;B*1M>?-%H*!=)<[<%$G#L=7P2P,/_:#?!_$.N!4_ MV8`2O&$.4:<*0C0GGSY]C>^T/STDMMDG?\-*=R)2=JP:N1!1JBA@W)Q`A.GP M%ZE$6S#7:`Z@T1`HU>0AI?"'HT$J=T@@;'&`(1&O=@V+4.;YNW#_<_;AV86Z MG+#'0AC!G+#X7)_->`RC_R."/_H=1!1)'Q,Z=0[<9W\Q@;R9S9Z7%$C^W1=A M2_S:-U-1+FM\@YJP1A?.W:O[JP136UNX>9$,H&]\D&(REZ(&_2O%#QNO0*ZF M+$U@+QV?9\&+6A&\``]]+:1[V;OJQB+0E!_%!0UDQ[)-^NR0E^VK40#&'A-< MG7:*`+0J2\!7:O^EF^\-,!1^^@F?C7P,L*H&_#*>/B,7W+J`R?_+M)Y,!"3Z M4$K&[17PWII3E(U63`(BSR7M#H*(GI*(M%5?"C--?N?R^Y(&5[%7L^$YN7PJAV($L@L=33;>B(KSW8\#!*%4(54Q[0>N.&X5(8U M0^.4-&8L7L>CHB(/!V2WGH3CNE+!RCG^52@V-8679B5-!!'G<".>T7> M"F#8WAS*B,@(..2)!034F(:HA3NR4,U8G,F<*\]P_62/#F MF*I+WS+!5T>"K%8&*"#F;3@F3A#G8ZH#XGQ4I*<%4!\V/IX_F:`^Q;WR;LHV M#-NDRW@`>@E"2R*C^6[BZO?30TQ4>.8W*=/P(]`!RQ">E6[[*H&4302-/!A$ ML>9^D9#'6!(3>1_@&D&,I9,T#=Q\EGMA`++46=3*IN'2(MY*1$OP+W#D1(XG MR&ZQ!UU]Y1EL*VF1.PPE&'*_8`J191GW8$QC$608B3$913MY[TU6%C55\LY# M77H``[I-#'3 M>$]NQ.X6-T<"/-])>P]F)G-7!\F!%__IF=PZ!Z(#D%^1WQ8Z*ADQ/:8Q\-S* M0N<"]9A'&=S0V*KN,"G4\2LC$*,Y1@3*4]187;(FE*1METMGAT=+(S)BC5AR`L+A@:% MU93\RBS!TBSG")@]*JQ/!`L6W(3TCD./O&,+8QXJ6`#3*BQGP;,$#O6MN<_S MN`1K%C^'A/;*IWQ(-&:O[NG*%=F/=$]2&'6^4<8D^!CN7^=@M%`RM=+I@XM%?H-K"T'2]I6-@"%IBVSI#=J(:S+PCMNVK7N@'.WYPPXY/H>NO3G3T_RE/R40]7_RU MRK)@R5\_^[XYQ&RNBG8!*QA+Y#\S>E&@EA`BL^U6%"UQ<](T:C!9!A(\+_UB MWH_,SWF&?<9W`\-LVTLE4D^:8.,&WXXN]%=(+HRQV2Z/#&=I!D1&&`%>-N$I M::%BT>(*_GNM`.M'DBC!GN/XWE0+%H05V6ZRXA8XA%%35SK6GT!;5%:560`. M+Y5V7-I47]X9>R\8`*K+HLTXX70G1K05RQ?^P*W^>-Q,)I;KDJ`+V=<:\7F0,F*Q$+EXYQ:0L M]1$\\"H6UQ3M6'@'POZ$]6WF+(O-,24E>15`Q&/C*+:BEHH&9!C&Y(155Z(5 MPJ"8'!+_*"@#V*E'M#)%2(T)5(LJ^U_$?CG`&-:1_ M6"!S4FI=XH&XAQDF9]24]`SPE?6R;(YZ-PO%>M)E'-K6U*2+&L8`/I)AB1[M M4HR0H4&TV:VR.B]'@06/V"@6&("OB!X<&B;V$TS5+8.TJ]\R@@5<;P::Z=F< M';A/.)8Q34\_3D-'`=\7,;8.8WO4_QIC^3A8WO$@K`I6I=\Q/$;'010Q/-5O M4.!F$SV`E+V=!<$BP`4`^7;+PP_L3%9;,?^FFK'QI-R05NZ!YDXR'NN&!H\8RV3'B;+'_1$GZT MR#&WPLXST186U338/%8>4I=Y1Q#M.8'ELI"O*BM&>C;/LDT\![81)]';(KH\ M_'?`)X$#*XI+Z&U&$UD._"L,\EFHXT5*!H[?<2,,H&FY&/M,]4=]ZC&Y`=[[ MTCR?HPRZX-4MU$6])-Q2^7FO%02L?%5;P.3$Q2&5H9$; MX#(;2U-Z:?'6A,B/N9HX-WX*\J/?;?8KN-M?>'`?M-6NX)W)UFW1K?J+9Z*_ M^&!UV^+/:!-M^\7U((2W.`CQ2][Y9W?)V'@A^PW^^+Y18FH#@B]L5ZQ#06$E#\F8!1V4;`#1`D[W%(O.!7TP^< M;[A-WM2KWXM3\H^/8*J6O(&*W?0/96\<`)+97)T`5.GX@.9>-T5.4#6_\5CTP?H4.':1A.LF4HO3 M9@+"+&"QTWZX3M.M2Z\=FTK[40Z!\$^(K6S>6=_IB#__")+)_K&4P!,`/R!= M/OI*0CRR@4J[UC7HQ6=;9_C$QK,!]6+`+L-(7/2:"592,=.PS7.`IE8,1CE8 MD'D:Z#TK3KRC;%/;"/.0&9(.WR\`TD@=+AVN83L!6&RMN*'X&,W(?N4)C?CR MV6,-_82L@.*Z]C0PMRDI(%Z'"*01/16/#5,+8WC\\1G@7GI+'RN$B@.2O=1U MA*+O'>XX3BBSL1J(JB=UX,RE[ MF9H=7W/#UB!^^,4RM?KAR[8\:\O&U3ULU!1GL]")*[6;Y38+27\AZBX4`B>J M9/R3NUGX@EN>9?[&4]#@@_`O/EAV87>BI*5((MJ.ZF-5@".*(#1(P[ZM.8V^ M,@<14>FR8-CL?Y=A>.?%=?NJTPZTOGZ84VXZ+V$?-D0]<5;F-@A%MB:EO6'H M:$+BU._QO4G)LS?5X;XJ[:X?P1H^D.+//T2V.L,;*>2IU@)I+Q-2D:=-AW2< M#+GR0RH&A8EY4CN!3DG*8'S-DI+7SP0F9MP2H*'@]8LX1?D!&F0#%)7]%(#& M>0%*.9Y<)`Q2VL.L>#-/U#!(;MX;P/"M_K]^_#ZQ#<[B_Q]02P,$%`````@` MY#N(1W(\#V%(#0``!*T``!0`'`!E;GHM,C`Q-3$P,S%?8V%L+GAM;%54"0`# MB\UF5HO-9E9U>`L``00E#@``!#D!``#M76USVK@6_GYG[G_PS7ZY=W8H(6DV M3:;M#B])RFY2LD":;79V=H0M0(V1J&1>G%]_)6,#!@N_8-F0\J4E8.N1SB.= M,/^;_]ZW MK.%EL3B93-[H_%&F(PH9&5$=,O&%5BAP!&T.4J500%QJ=P1K-:AKQ^?:RUD^/2V>PE_H:)\',',*CQMF#VX6@);-JAYAM">\63X^/3HO?@ MT>S)RZGXPO?\Y-1YNG1Q<5%T?IT_RE#0@[S84O'/N]N6WH<#4$"860#K`H"A M2^9\>4MT8#G2#:V7)GU"_%7P'BN(KPJED\)IZ4F+`)NYI3 M]4O+'L(/1PP-AJ:HD?-=G\+NAR.(7PI"A*7C61$_\2_^H?]PQA@QD2%D7P&F M:$FK#Z%UI(F"'YIU7QOX.T205Q0_%J7O%I54K\X[Z0"V+/YY`''L&JZ^7O2Z M7[JU%,."PC[$C`^(&6;*W2J),82L;(A*2+ MN/[`%J&V/J*4?VJ#CAE)?F%%I":_LJ[3$31,!#K(1!:"+'(=9:\6/Z93M84, M&.R)/D[AD%"+ZW6$NX0.')W4L=T?$X@V>K$+<>O`U$>F\\PM;X&O;7!J06Q` MPVN=@$NB;Q8CF0.:1/>!F$(9$^IAF*`#S0]'(U;H`3#\I\P8M%AUUE7\4G;K MX6CE+F`=1S6[[Q6%^(O0M)CWC4-(X;CD:NB?@@&*6U15C+HR=@;?U?<1&@.3 ME\C*5A50:G,VO@!S!%4T(1KPG'(_Z67J;R.@NE='_G&-<;\-=)\HLM%@ULT* MB&MO[_TN)8,0)BT26WZ$&I!RO^A(FT#4ZUOBHZOGXOHA`5?^3NOK_S2<&7]-@VU=,\M.$#&U73(?4RHL-L'`^UXCY=( MQR7@+*W./JN'.I=C)\0/6>8;.^;N: MZN9(K.BI%'LDW%W50M&$)K&ZV_B<+AS!NF)WM",7?(<`3Q$BXS^;0S M%0V5@=LM)69W:=DD):G)2,1'RR+ZVRK&/EV&#E/OAVU-<&DK63+!G?S>56!>0^04<=5,$06,)>`E;B`X:A+)GIW M^8DB/:G"3<17$UJ`3]",*T`QPCW&?='10`@'&ESW(UW--#8"ZE[P%45ZZ>KC M)03'"`2$'MT2)A;'&EUNM!7-MV)5(6\7)^+0BRO8-/?WEDQY&1O9V-Q0S+QY MBRH4R3QBDVW;LU8%/;5AN>9]<26&ZZ/2R*[5.,WDOB8P(6O",<0CJ&CO;Q5B MBYG*33U,@F!H;`;7L[;"FT0;%BST_'\!$IC M*,YS<`_3C7%A;<*G!1$$*WEQN\DUXRZ0-Y+53*U]"#G-!,+E[I]9^Z4B56Y; MR-P9M"WN!J@3^@(B-XV61.Y+DDEY/;()&>2U%G'(-:X$3.($W+C54C,UW@2X M%V,A1&8I+U!"TQ01(,Z1-Y-#EHT!PHA9HK)CJ)"IB,CY.6GQ6(LJR%3WO^XI M&2-QKO&:T!H9=:SNR/1VJ17%_LGQ]H6IS4*31>$D6YB`/6!RET;-[N2\\+U0 M:TNR<&7\2SHJ[`8@+-:6FM!9?FJ36V2AGE/I%K0LTST]F3X!T8#S\L#CL1-1 MB"YSYPOF"MN<2?&JMU@@5+)-&0"3\_KXAI;+YIPAD_X=;LVFGKCN;Q:V>-=/:#^9N\_:;3 M*`M2R!2=T%%7W7QW5#,@PK>E']0%TXR6%*>3F"6TX`Q!;:^08.6LM3+F5"[R M-(,MG>TJ7BGB[T$*9SXAB+DOAF8]=$,(D$UX$['-?7Y>")Y%R>EVFP+,1#(7 M@CT/:-8V19N_<>#SM^L9=X18W$A/JB3L&-R]4NN%^@'R)S>PP7[UJY#]M`.G MYI5PU48%8MA5$WTC@]H;2@.D)'?#<]@1#\H'E%3?!Y2E,KAG$USR%8X?3C=% M8&VY6Z_()TVW7Q;,)+=596PX?\U$YEFN,D6,*\#:B/)_[R%%Q%#9#[.H=LZ3 MD9A])!,B-V5LR5J)>CG+DIY!,[Z-9I,OUB9-R(VXCIST-(N1UB8"Q%E.YW6L MV`],1#/-9^)ED2-1V=F<5.OG:`-?CW=?WO[]UY_Z<#3]BL\NC)?S<>^K MC1]JH\G-.;TX__WDVT/;9N;Y6'\Y-G^SBO=?I[?US\6SSY_NIF?]AS_,O3RM.@>L=>OM>O8;6B5Q[>]AXO;I^>ZBULG_2[[_3S MYXI5>IFPRO2WFQ;0Z_1\H%=^)I7^.1P/ZN,^JG[[4OSMH7'S[N>3`?O2^'YW M\EBO?M>-;W:3M7^_[W[JZ.VQW>FUFW^6>T_C<_-YVC[5_WCW\A9_NJL,*1@^ MEAJ_],ESNV--OH[:W=+YEX?&V=O)X^?'GWM/UB^P5KO_5)\\6?AFT++_UJJM MIIM\,D'GJ4$^S'3D=&H5Y/O*SSO$1<5(\1\B6A9FRF%?Y8%(;??B%-[HKB8) M4#)P-R/FOOJAFLXPB:>:]>NP09PIMY&VEE/+@^*=+LQP[AL&F7/*#>6:.$3@ MZ:9/:?4!A17`9C-B#J3,GDJ07KMEE0E8GOHL=NBIDYP`F%P?.&`BM[7Q]KCT M?#48FL2&]`Y8>C]PKR$P(#56<:_6E,87K"SB).E:(X44J$OB14"D4=IF8)$^.%LC ML(3[NAWQ:*+WEDJ.,Z#<4R!+F:.SY3ZH`J_6`4S(A]TFL,[/U MRX`_G"'W2=MC5[*)G0*Y_DS9V?"[@OE:C7ETH7LTGZ[2G'1K/<=-K!CHA^B! M.&$P6_3`6,$$^]>\=`=PRL=%)4V;!0+G-1J#T).=0U]7;BVHCRBR[!H<$H86 M;DN$"6",PG9V2&X@UIOAQ9%9FH$_]\!V!TE9_SY"%$JO#U"RCQ8=/6^/(!FU M2<0L"U),4]5<(PRX1LQ)U02A)S?\O'0=0L,)WZTS-A(7R#6ZBG,)AH/NK#;: MP/W*)F^86%-51$MPMPA#IC)!OAPL][6$]$A;D6*Z&2&7@9I\YC)3;XUN#7:4 M,[:&]YJ&VKHP)?$4"1.5+$I7/LKD8'L^RC9(<3TT8KNEM^#;+68=*)Y#5RI0X[HQP+3[Q]34_T,,-B=Y[1"S\/2G&YD35C-)IC<<:8H M`J:B_:8@H+PS2ZQS%'B/K%\X*0?.SU$>"7T6NQ3<4U6SO"Y!RGO=)S(-*P)* M^Z+-.@9:'$W#LMDXX:/XK M-Y'HBB'%E+<*W>IQL]+E9@6)2U]$C*1$PMH\#TN6["!3$QJ"N%]C*DQ\DF-%F4^9&>R)#D7A4)Q$Q3V$ MNX3.1-&QW1^WFT8?KB(Y7$5RN(KDHRCW!3R>&>DDSX2'9+R>&.DOP8V_:&DJ3F[I"#)C95 MR:XH24K0Z[ZE)([!^71 M+L)(Z:#"X2:,_>D926[&2&7J[55>:KMI+&]V:NK%(?$C)APR`E!2AK_]0\` MDC-\`4$`1!.D,U]V'4E$-W[=:*`;W8V__O?+.CAZ0C'VH_#'5V_^]/K5$0K= MR//#U8^O/CX'Q]]0"&*G01Y1XOMD7_V[\GZ M/XZ.C\ZB]>;!]8\NPX3\UDW\)T1^%I*!R7^3WS\FR>:'DY/GY^<_N>1/L>O' M"$=I["),?W!T?$PH'.V(G,6(DOCAZ#H*C\Z1>_3ZW=';MS]\]]T/;[XY^C@_ M.WK[^LUWV4?DB\`/?ULX&!V1N83XQUOLK_\ MX87^H/+WS]^POW[S_???G[#?[OX4^[P_),.^.?G']=6#^XC6SK$?XL0)74H` M^S]@]L.KR'42AFXG7T>M?T'_Z[CXLV/ZH^,W;X^_>?.G%^SM6"1_XR4[,N4! MOCO)?OF*`79T]-![U$AG3H!G?+#(T+)JR,Z\,?[R\IDR3<1E?()_>5) MZ[$(Q;$[P^/!)9/4:!1\S<^]]3/]G.R1!OH_@; M&38%7QOCL`*%@Q\O@NA9&<+B.\*5"9Y.'>SC:'E'##71'6;"9%CB?69N<=R0 M]<:T(X@PWA")4.'(L,7_T)R*I1ORIW21.8'G8Y=02&Y(:K4VOSHQ=-3*-L/$>9%=D_L_-P;* M?;1U@F1+U"'P7;I'DV4EOSCI&L+< MWEHBY"'R/WZ"`N+O\9>R*NL2(X+,Q`#K`_&:8K1,`XH/)HZ$XY+5@GWJH.EP MW368Z6-N4#-`"M:V\:FI/6*/1D1M9+YJ=#B5',D\X\P/ID%%C\9ER?&,>>SH MA?X3:;`O,9Y!PRQ'=K$E0R%B&M:F)U0?&61J=(.+-I3JAIQ[='2*/P2`A8D1 M3F+?39#'2#K/3NSI,"P8!X!K7-NE_9!8M#63\V*;_U('=>EAC!+A]YZ,GVPO]_N:#%?"[PONG-B59;#ESKRX\J:7Y=\QQCU_ M374H"H^)J^BD0?+J*"=39G@W!K&^)^23D_QO3IJ?#\1LM';\4)O7[.O2E@'! M[2,9@C@M"W2\HZS&,&^`\N(&@9A!<[Q&ZP6*%?&M?+H_OD&PZ02!&G/T@SU+ M>5B$`'I%B%?80B\)"CWD%8S1KW42-W:Z1<@%D5NA$=#LER@N2`3.`@4_ODKQ M\:;?WQ"K=()"A)<_(39J>/7;_*\F'\3 M4"GIEC[3N4\`R'#5ZZ](2;2+UC)%4%.4_)OEG&TEI%+$K4#$<7D>//C MJ]?D;YD._^"2#8@HV?OL5$[60;91[G]/CNC(^_%5$J>566K*XX&<$9S8CV8O M/JP>50CENX!QX7!MJE!8%7WD"JJ*4%->=7GH2B0G\S$D3J3K+WWDG>>[&(!4 M6HE59F!6.,WM62@9GF96!-0.6+>0S(KHE]>#"PE:0L5I#T9$%+!<2&]$*TE/ M3C/F^<\6.*%IM1"BJ5$`VVQJQRW];:<."33X^(ST_VC\Y,D)"%D\2\Z<.-X2)_>3$Z0@9S$YPN6)C5!8DNC) MK"2]A>2Z44HHWB,7$>KDF'*#DEQW0-:3B%[5(HQ06F*TX-`9%$9?^2VK(I%COBWQDW678PVCN^]SRYZ M`=->20RR7W%].;"#NVY82CT`4^US8(C5HR+=CDHO@> M9C^'V\AM@BU4L^;N+1>$UX.YE`M#=J)F!@ID0$N:-F2,WE3`41[(3M^\KR`' MB$4*J%E<5ZK*W"(_G7BEKM!"=+L\BY'G`XFI-+Y5E[V?:,HH`4;R\Y!:GK8X MCQT/TJ<7D9NLK(08PD4EFR5SL()K(69WH^HIMS8`H>*5]5QY:W6A*A*T- MF<$!`@^MTINB[$3XR<12^YI#8#MH/4XA5,T6^P<9L3B+UFL_6;/RQN@X8"MERX=JN9U*%D6PDLHJ`XP:GJ7)8Q3[7_;G,3CQ-2A.(9.S"S28 M_$T>U4N,T^'$E%.S&-O5ET^!5'>NDC'AW*8)?*+&1'!;5%MI"9Q M\FO%22:YPHQD@/$JV_U]@[?G4(@AZ"H(<@Z"$(>@B" M'H*@AR!H)>?G"84I`FVLV*`Q>K^^B8K>NO\`.IN3]/E]*I-V\N*#I!4?4O.Y0XM5LD[ MGX'NS>W$IF"#!%!!A6]QOMEE%B>\U#%``%9*LD MIK`(&K!TQE\U/06,".^T??(YL8-!Q-KYY0L/QFT0$1S_PN@`3";XJKF-HR"@ MK>102*QC0,C/O#4!B%K&Q']"@"*3I#P-ET,218GF<-H-1Y]\&F&XB.+S*%TD MRS0H6L_`W,8+Z$U"9&+$`.O@KM#*""8CN,C6]!J^$45H* M<(]8M<`\NB(HK-BC>0\H2;*K``@QR!$>L5>IB*!,89JZ-]\XL<^CQ*GUB>5Z M\BT?CMHNB2;<70'6WX'<%\Z`NHXE,N.W4%QP"F$8:BC%Y$[+F#(:N>3Y;CQ? MV=L_'K&!Z9IV@;*PP9#VLQ"8]?K(2%^&":)/IT.H?2NM\>M^.TR%:-J]=OV^ M3S=1&%47':`'TD%Q"OY\%VB%K`3Y55K"(H=FY*_"K*^;NYW'3HC)NB7P%">& M4_J(/`(J%E!_['3>YC3I%(8$7 M4#N:I"9A$5IQ*FZQ`4(3-RB!=0.J!"8AAQHF!?H&TVOH4;A"Y8[U-*"YN#0- M5\$5D!EEM&9-&H9"!,:[X!2M=XJZCE,'^R[$,N`3&JUD.O`IY&&\(7:=WKD? MI`E,<44;J4F8J%:<"LD('_I3-U:?R5'UD1"8/9&#Q@J5%FFY9$#!;BD../*P MABH\A93,ASIJG-RD=%JWRP8O8(9.C8$I.-R*D!:R%60XF)1LOO('*7A296'$ MJU8;U4*\G>5K@U=%<9IBO=)N%'(;*2/TT.P;>.F7W5M-&Z4H44)=JCA,`ZI0")R5@Q&'\D+L1M1 M/V3FAU?:-<_),&^C^)N#AWOP<.U[N)E.TM44A>Q%*6A/ETL03%H0+B\?,B"O MJD8,SNGE$QK`EY+Q=D5:6KE\E'UMWMVUGM MNG($`6JGEA.QZH`);49+$[4"')BETO+Z$YQ$Q`1M)C1+"Z<#,XD5HUD-6WW: M"4Y&+92FL73:8(+I+RWQB@S@6I(F;C$I2'Y9R4/9W8]:WQWZ8SYG)>LCZ3QQ MI"N*(=(/)IE@($@A,+WI'.XD9.\DA,9(WQ9E'8[+\<],^O<()['O)GDC^-FS M$V>1T8LH7B(_26.8TO#^3$TA/\L`])T=LS3/Z[^F63T=GD$8.-_:1H9I?-Z!ZYT2H3`-@[Q^`\CS[E&5YJG;VG#C=R7\&-G)K6 M#7D'U]U[:_C<10<_7@31\RL3MR.'*YW#E,H>Q99/GI,>:K1G?35`@)J[_S'"-3JZUQW`,67!*'<5AX]Z M:Z'K!ZA"=QZ1_Z2S8"T$R1'W=/L1TW>(^BTD*,H3$S6H$(`6[SDBGIKK,]\+ M8NU6QK>65PB\-,KKO`JHQ&E2+R2WCN+$_\*HW"XOP\0)5SXYZ,XP1C!M4SLH MVFMP/Z!LNU#O7*.'!KG3$+14AUWSC[&K"AA,_B/1P1@1 M`W".LO^_#(NS&=%4Y#]!W4!)T;5T8-)3Y5K71@E483+"VVD3_MF5\IX'$)]' MC0%[NRVDF+E0PW4>:#)"^W:'Y`-_*!F7"=HJ=H:0:`5(,&^U2?E`LBQCB>0)]IN$NZ<+;4#\]CQ!MY1*Y1MW@,`&MPJNE"OG7+IDR$K M_.>F?S?)TN\&D[L*3U^3M5851W?:I>ZE@HS3)^GQ@5Q!F.1OLN=TLU+J=*MU M4P(LZHD"]4EYX#KHFG^HO,)Y]M2.D00[('2V19J_^WOJ MQXAH!M&%9'L7.&%"+`LMF]M`/1BH0'TVHE9C.H;$EL-/+`N"?=HDQ^*;I?@`FLG M-DV!"<`#"]67E:1,_QPMP!=9@]Y78!^;&`)M<2U''@[K`QXH>=3'<:!4%*D* MNC"M%=XOE\A-;I?O7UP6&+PGAZ[;D#)%?!7Z?]2Y?'("!)3KJT1__-7G:G!* MW+CH]AGD4LS*V.MN*H18E>B/7ZQJ<,K$GL!ULU$CO`$NDA) M(BB9[#=(>P?Z'!J.EGWEPPT<&$KO%Y#3 MOU)FD-PN\WMLH"YI32)6]5M"<&5%YT`DYST/HM/DX..SVT+"`=Z@&-.<:MT6 M]/4W/"'UN966?DOMVH@[Z0[!_IZ8W09E72(4/=E:`FQ$&OZ0;C99AQ4G\'9+ M=QG%N-BGHJ5+=J$E=1UZ=>LI$2I\D;RW2TM(V%!1CPQ=7;>D&+!,9&\`,>@: MD:9MN:>?@MSK)R`Y:&4[T0RRGLHII=I)WMD0V_UT(1>(B%R?;+K&J*"K04C/ MN'X,.M! MC8$>P68I0J"+1I$#B[>L6EI17E2J8(]J4Z&5?7D2M.ZF0J/OPZR?%DKZ6TEU M0-`%T4;*\@8B%EZU2+\%JS%M&\U$;B=/.,H*7)-R&G>/R[QLQ=!LIKPJ&M31 M$)'KT<"F6@-1#%Y!;Z#%HEKKH-CWA8S&R`.M''GB5E-'9:0M?N.G%=-1 MK9&LY"IQ7OI$Q?*V4T-%Q=K)]:HQK8\*'!43T+,>%>L4:*T>5`#=F-R;^VCK M!,F6['N![](VTN$JNT34N3ZAJ5OY@*ST,1\P0T,AE;Y[#*U>NJW#MJBU&F^V M3SE*X!?I_C*0C.D",'M6(48;VK,S7&D_L)Z-M:C2[WKS%5Q'/[B/R$L#1+M1Y^/GL6:& M#JR1EZ5MU](KWE++(SJNR*C@SGJ_4`Y7U_++*1<-NO*?4(/LL*M+A16[BZWW M?;:V!$R_M$!=GC(S\O+G^H+20TTQ&4$-*^-EJ57R'S%:I@'5&7P1Q:QG!V8H M]A&:]*#3%Y\\?K+EJJ.[?"]MB'_D._B]S)O@#;G!=5*W6OBA>-&N`NJ(_*KZ M_61/Y^H/?K]>M:A<;/7VH8ZA+.X^QF[,U;`;EQ/6O,]6!/M>0=UV9Q3&NXLXJ*@(W,WMWBO^E"1\&GK"G;D'O7D!.Q7-^K?*EO M1]K2%J&'^N:OSJ`'%#_Y+N+S6)X%[=.Z"OTO9+JL:IWQ/Y"*FF;6;K\`?2TT M+C2@)H)[CODL,@QNV?Z)\PXEVR%-GC97TTI),B`%L'Y.->86=>;N$9F8[R;( M8VR2LUCM)Q]#V@[3EO*8Y7>RVR*$[+K[4`UZ'JXE8?3T*B>>B[$7?&WLRW`9 MQ6LF_=-M_LNAUJ,2*Q/*V=`%>T0QF6(.$1DPOXIT2U>1JAE-]2A]]793(>=. M8I!>SPKE8]X[S]=.0DY>3@#T"`F/D*5W(>0%PRVIKF(EFR.M+YO/4?P;?9\H M62(*$[)T\EY'/[["V1':5-[- MWK'.^W2=IIAVR<;Y41W/7GP0C1<3!`MZ/I(O8S==H&/R4UI6$85\!=!;(M4J M.R&D8*?&G,PYVS$`??6<`&C]5R&C8Z\RFY9>J"+=Y508%`B9SF7CDOGE]3"B M@)8#6CIID$`(@B+4>5)7=L&O_"5Z<'T4$E?@NG)Z$KC<^; M(-REW$6[(?P01S#.:2=-JR%I4R>%;F2!+L`$A&>NFZ[3@*QJ;[:F\;PO64/F M8870P&EK<66D#;X9?X4*T0/Z7`W>=:G!X+%R`\%QNDX$]:WG M*''\`+<3;8F4<^V1&3J:56Q]B',BX\8G.'#LV[C<"Z-K`.?><7'3-KEL7*!B MY"KD(<.PG4%SHXM)TC(W!0`5QQ4PL6?AQEDCN)"[*@N`$3&ID+S&PI$4.Q_Q M3M$/(7B8$+^6Z.W>`PPK?:E[`]VU?^+1&\3W*#N?XT=\`2DE$SNKM@P&)":$T?.=`#PJ?T0(3GEF!]^^I M']-\_)`JC?3U7-<(4Y6(%#K=L7^-.U+:81)Y<^0^AE$0K6C;258*K'!CVC'$ M="V;'$(2$7PM0S>/'0^MG?@W0.O6H&&Q=,R`06M"!O.:^.$N'#1R8/)B',#U M.]R-CT!G%3KV?%W0LOIT\5%1>AN(` M\?DNW(>:],AC]@KZH1.][Y2"G3C^/>UU`A6EWP]N+VL=:+64S7$)0[#4=48# MSL\I#P_FXDC%QQL*V4!:.H#6%VB8J'4-:KOQ:%FT02/)4[Q+_.N_'A\?_>_G MZT_?_M___L/=I"\_A]]][WUY][3Z>1M^/$^?/[R+OW_W][>_?IQO--OAMO5PVWJXU1OGK5Y'UYW#787%NPI#)9`% M'797U6`23$HBUG#!`60`U,(",V;7S M`@QYA<#((:^",7@E:O%*QA*D&8D474N=R@"#NVJP@QWZBCP7@6G^C/S5([W< M>T*QLT*PVM"+GVGA M=XZ>4!!MUM5GQY0MGO2(HU]46C!!9;`R?[G)-^#RZJ`XE>75!9SY'A.UA3V, MM*8OJ&X9=?>)&#A-+:*ZE;Y/0Z>%G"Y5V<2S M?N/#A5.YR6;&Q%SL4SW1M=4P]2H*5PF*U^=HD`&EYNS!DF'/G(V?.,$5KAO@C3QA3M'EDC!^;H<*B-Z&:1-G2M'1PY.`PH%QL]M$M[%V+=\)P@@Z^#4"*U9Y/ED6SYT+(7U(UJVX3!$N6* M%(GL+?3GD&Q.C_[F+G#"]P^W=^5'K=]GVQ!DRHD\$S;6!M@AKX&6-1.@MX_/&>&I0&><#3)Z)"N(+!Z\M^!-"I5:X[B94@,!MH=Y:YR M;J%<11$YN.LTC<`>PPUZ4M).$\23'!(;P7@4\!V11)D;;_`)2E#)22!J@L?4$!^O/J`B+/F!+3! MLK:X7$ M[U^()^YC=!<3LS5R+1.R;K%VS+K^B64*T_BF+_L74;Q$?I+&")-##=F]_#A+ M*;P,LQUQC,K8S;2U9P+L**&$%.'>5`=G?FJVLM^$[%4%CE1WIA]W5 MH7A:"^5]X1Y1*9"?TY>/**JI$\Q1O'X+ILL#3V.2&CRTJ"6JFVV?42\)SWZ( M??>3$Z2CM+3MS%K+RK!]"*T+K;M"VXJ:Y5:7:].?1 MN=8E7J=V7)1E_0_G6DO+--?*=P"N=8]C03O[;<>"-V,\`>I,XX]V`M02=:ZU M?QF;YU*:3/4P,7;UK'/[!];"AN!R9?N^0]D&OHR*=SGF[%K*H9,Q<2-5RUUG M(.E=2XE'LG'@R7*]:7URG-(?8E;Y.G]TPEP-;J+PB7"-O!$>K)69'\,:EM(F M(PJTA$+`/84,-[]/ M;'*CO$]3Y=U^5&U$>EN7*U#.UU`3^,K,L>KD#C:YEVI(7,.-3O_SF\>IVN8F M^P<=[A`O7$MA\&G0^_&OS$0KS>QP]-#6";DKP*'SD+/*S1AMHCCQPY4?+J-X MS1!:;/-?:D6"]AG[;(S[@L#EGL`59*6U%%WM.XE]8+&=#%&K,GX0<]1@`^KJ MM+7L644!^+7,"ACWKU0^U"D;K%-67AWFJI`/9IIB MLAE@G!L%#-X-D$L0;+T-;3L[<`5K'I63@;.750(CZOTG4N!J!6L%(;"+HS(9 M&"O8%,4H^OUI"0*FH7VIDX!"4X7F1S8;*'!7]*YA`F>",'W_Z..>#ZZ/0I7^ M%)R/1@LE;X(P[3_FCRAV-BA-?%<>2LY'HX62-T&XNJM9$+"X4&%OX#H[M%"R M^M)]JR"ZX#%=,)3U;PEQ%/@>[0N@T,2F\=%H-9LW0?/!]$./H$./H$./H$./ MH$./(,TNW_,H<0+YHU7IKZWNY4IVL#)'F;0#C5;?3RA,]V^BOI;`LOF-Y59( MJK($'T(!2NBH.0ROXJ^'@,80BE;58$1*?&ZSW'PWS' M8A>!4/<:!5O96MTZ5GE]IP8+W'-(C!#;-QZB`"3/M$["GKW1D4$)&K@[7Z'G M/7CT8B)KI`,TF?`V8*C"7HS"IO^@)D%9)*$Z:=W%T9-/[U$OHO@\2A?),@UF MKANE80*R%0GI349J8M2@ND>Q1\#)`1Q$,/O!IV'Z2F!TIU!K`OZ!L'L587+T M#NC=RCRZ(EADKWKOWV*'$(8<86MNHYJD)%'L[EZD?;K+>QH&\[)U\X=;.7M!WT^B$]Q8L,(1C=9R?-=/`$T7XV@)Y)G81%'[];VZJ) MWC5L8)(4&%@1#HH3D9`7;&+E^EFJ"-@%BL(?>;$VA^,)^#J%;4G0MN'=]54(.3YD.PAJM_[BE M]D2]@M2C#2!FB^@)U6OU10T`E<:;D+`TP.ITV;4WB<-S=H*^$SH:W>.A.M/5 ML7D_"]JJXBZ.7(0\9N/)O[W4I?<.,XP1T`6`).DIAFZD897L+CQ(UX\;LA6P MG9ZP@,D!`5.-/$>)XP?XE59@231B`S^!G9<;1W=7$HW.ZCER^>Z MQ[!Y?&JW`\66(X$!3,'XQ[R;<:U=G#3PXN_MED1UP]XQ>_,)\Y?A_!%=1R': M:JFY\/-Q:[AXYN;KSEDL>O_0F"K2K9^.7:7;YVP^1WX6)K[G!RGUY!Z0F\8$ M"H3W7C_UX-.$N8FWR_=.3%^6P7IOEJNMEDWK03>#ZFO*0QO:7! MQ2DV6KH.?EP&T3,NA6?T'.L2L3,RZ`49-/?E6U[B,>1CR]#5O3(JW6;=.3Y( M'4>=A-W=446*S>O!$E!@SF=QFP@GC]+X=J]JM6511@CB!$[L1Q!DE?M.B"_\ MT`E=Y$D?1SH&L'F[I@BY#!PP!_,S9^,3LE?(P>AV$>3)SS3_]M3!]6@FOU]. MQPB3TGTI2*2.[X/LS+3\[=D/`N9E$%]CY2\"PC:]R2E?DZBK1??`*KF\B.!+B]N.X1%Q0-=.4_T6AQ12$^8K1,`]I' M&4(\4G0M58/V%)LL7>+5`]2X[>$;9HU M\SR&EQ/LN,!\R4HO/N&0XQ:6'DI@%7`?0R<[)R*/\GZ)<4KCP(!%#1T4[1Z^ MY1=;%W#FGQK.-&<1Q??$%^`]!=RR?*I?6+RGD%T>(^S& M_B:[)__DQ#X].U$F./<2YDX[TO3';=+T(`5K5E1E@U%[V,3(\6[#,AMOX*4J MH#T5,R1D6E_:4 M]FUX7HU72@ND:[S1;UF*\'06O1ESJ#Z&*2VHS(^19]%Z[;-J]0M$=U>77E2O M0`YY^LQ8O<#OYVM)HIV+__OV)=I;_M`BG:*4]AZOL5A&FR]W3?`H.]TR60MR MXTPVO,2!I!"'^3QE'@/WB,Z.4+8671)P,.H=3A?50KZ"H(7)U7;E_Y[Z'N.) M_"/FM"1577?<$:>^`ODP%;(R^T21#!M9!RA3DBI&&[?#K(Q-(1[#KQ@*>*#I MBZ=I'/:3RVZ441LX:2@*,0AB%D9D4%#LMS;JHTQ2!@TH"AF8:H^\(WPA%'Y6 M5)/M;S1?E\5YR9^3Z4B?[GI0F(@]ZX-A(5C#H0L)I3(AVQX4)B+;/A@6LA7U M^1DP/X+UJKSRG06=B8]PKR8_+8-=*62L=PZA70C-'U@V/5WX^;`-?611KO16 M;IVYK38^CU&\C=0(NO>( M%%0H'97V/48%!),#+A*1U4X^/04DU\JG9Y.RTQ03LXQQWCT0@SX9BK:'I<9'WLNS85OX$PZ[WXL?SR MBZ0_;P9ZF(+&;I[N"$/D_S\Y08INESCE)T M]>EP;W0,/O+$(67[32!%8;8B)I-0K][)T'7)UQY[0[7M)5-^/D8!80EG#^]4.LVH"[QU0)5XO<0@FOK8.K)LR+YC`"BKSHW9 MRV.]>_.E8_J]X_;]`EL92[2G8A0.$MCB$K0;V)+34&YHBP\?6$2_1@XNR,4G M9+?IBY3.EJ74@A;,$YA<8C!AKU;AC"3^U4L^DN%\3=R'J[O8=]%'<@J.'YP`X=DJ1K)NA^Q(4Q&-$CJ2+5:41+,OS+E= MLHH=3&UWWCSE-LQF4+`F(2"U\2P%6=1EI`B3<5]]OVT2SFFM/?+.4Z8MK$B< MK5U\@Y[9KX#.Y%*4+08`](RB+*)FJ_!9`")_\X:L!-$6H0<4/Q&#SF?I)LH?'IL].[&'YQ%M%%_Z M/6W[?A,E/Z/D'KG1*J3=AEB=C:\B.+\1_3O M0/KH##R#J;C+M@0LTSEA9*HZ*:V>/3I@;\=TD2\\OUMYTW;5(.(M"5EV7.@'-:Y,ZLX^3 M\4ELYB/&3Z8UAG:$C,YGT3WE17W*^<0^L5E=YBWC+QP_9@%RD%T>C-?)Q17@ MI";1V4-?SW26UDU*@;M=9A'&V1/!A@:1R9GC`_D6YK5%*%ZGJ6<@4I-H43)8 MUECVKF-"WW7LW?]^]T;D,$WP1>3TRXO>+Y>(!D'0;GC:DI">NT):S9\I07*! MB`B=@%Z+IF2L;>6/0<[3!MBRFBX@H1R5<[,),73G2X&I"+LPGX7>%1DI*#V> M:DLW6OFQV\T50"O:D9=^2F80RWL?;9T@V9+S<$`.7&@3Q_<%-ZE451>&*2N)AX%/)0O=X[R5=)B]7+ MV`VGR!VJV`]5[(Q MSN6>&^!^9BEFJKUA\^<.4T2;,WF/GE"8@GB:-0JVKENTI-&&DNR;4,,4ZF4K M-D8;^BA2N.H==\D'O"\&A`RZM-+2]J:+<%DV)#TM%3L#!/\":A:;OG9)L*S; M(KPD3RN#J#F]RB%3(7M/K6VD3H\4SE@JKJSX>\T"5-Z@LCYK^[>#EIU*X;KK MU-(^7SO%IOW6Q?:4*\&TK#E M;"42,`YB#6J[_J$LVJ!UG%<1QI4%=[J]<6B3%)JX7OQX"V5R%*C#B+LL:D'`-;05D84QCIP3M&DLP(4(VO;TB M*&7=_3`9+J)<&\%.&WGS,QN9R]N[_.:'[X,U MBJ5!;'YC*1N^"T/.Y(S'VEA>0KKV0_0BGW-1^7L;5])=R-5F)'/AK&$+?6IN MY5-5JG\_1MAJ,Y)IAJ3G3>5=K.'N+:H$++\(P+FC*?M*-3"`TN3S9F6`D%<( MC!SR*AA`<>[+T$/KT%_Z+CMS?$@=6G&$`*_K.BA:/GUUA_W+,NI"#RZ^_8%P M5&(T2RC#LR!`*^0%V\MP29OW(._C)@JS_`\(66IP8:\;A'3J0A^,(5S#(G_G MBJ6U(90S(K&=MWUI*T5/*7ND==I`STGPQ7T1I:%W$R565Y2(B='+L@>^W:<[ M$Y+^&,;(I:2\V9IP`Y(%V4724@9S7R$VH9-]X4+)`E:I$E;O8O1KZF55U<6[ M1!+V4&XENY10!L]SZ-]X*KMK1=S*ZF;L)7*9>T5 M)0%D9^=+[:,DCQZ<(110FXH-%`$&UA:SW!RU]JP02%:$D-X4+*0<<)TM*XTM MJ;QUZE!KJB`W'4,H!$VFG:-F;P9,IO-\CC81]D$L7I7`E)9.#1J)1H7*)[M+ MUNDKEWO68$GB',?[:@*!A=8)RS3FTRE6;2XH:8@%'X_?I'3-OKM%G#+8[XE0 MU_0`)WN!Z=HCO'EUD& M"H--P;*KXB/9>*S'`>D>810_(<"W6UMI329RUHY6(1_!DQ:&!'03A>Z`,BJ1 M&_]V(P5:(2J#;U?,/(]AX01Y-T$:+.^Q^ZB--X5]2!&A0D9"]UU#3FSXV^6> MF_Q5[7OD(G^3D"EEO[B(XNXP&E]T?4E,Y/C<'\I"QN9>J4"U-[R4E([NPVV3 MD3N?`-"=PM(&0KQ0#X!(PQ^F$XORQMG6?<5XB4RN'IA:AR&"J`)RTSG6"$$K M1"4NE1FD?\AYY+)^\K/0RS((+\-E%*^9$5#OE4,3$8L12P,UD-*O?Q".KJ[C M^\S)>[3R:3N8,+EQU@)#HU:H41O55G*HC$RJA1MU.$P7'5!*\]BAKQ0\;->+ M*.B/>'4X*Z9"%>L:`N8KZ`IF:$V$N<7'1K-PWE&%MSI[\]GBE$8>5KCPL>L$ M/R,G?A]ZS;9\.FBWCFRQK$$%_79D#*0(PF)J,BD/.0&[Q,&A^YE='>,T(QQYE*N+P#&P`*K# M36*'K2%@]BW<"H%SA-W89Z_?&$2Z/.H43H]\."0R?'0M/NWQ25\@\-#+W]'6 MF)&O#6NO&%/#K-,3X=*;F:,KC4Q2D M8>+$VPL_0+$Q0=2'G=)R:$`B]7:HK@`8D3-RREU%L3%K5!UT4F?,&A[&7]/< M4_J,@N#O8?0BTR,#$U,3`S,5]L86(N>&UL550)``.+S696B\UF5G5X"P`!!"4.```$ M.0$``.V]:W/EMK$H^OU6W?^`X]Q*C>M('FELQ[&=Y-32:Z)$,]*6-/9V7*D4 M%XDET>8BE_G0:/G77SSX)MXD`6KVJ=K9(TM`=Z.[V6@T&MU_^3_/VP@\P30+ MD_BOGQU_(@P@!K):0HQBN_`NR0&9]`'1]^`-V^^^_KK M[XZ_!!_N3\&;H^.OZ20T(PKC7]=>!@%:2YS]];,6LN=U&GV1I`^OWQP=??FZ M&O@9'?G=,_Y%9_S'+\GHXV^__?8U^6L]-`M9`Q'8X]?__>[JSG^$6^\PC+/< MBWV,(`N_R\@OKQ+?RPEWI70![@C\7X?5L$/\J\/C-X=?'G_QG`6?_8UR#H"_ MI$D$;^$&$-*_R_<[^-?/LG"[BS!%Y'>/*=RP*8G2]#6>_SJ&#YCY&,NW&,OQ MGS"6/Y2_OD>Z`J^\-8P^`WCXA]M+[LJ^[0!LS7QME>0;F(9)<)=[:6Y$^&`^ M(M\N[>=Q,(+R>O;KO]ECNA&]`^V(\"^N$$$=4N%S#N,`!A6Q&(3@\R(8R,=< M`\:@$[\#-,+?:9)6,`GFOWY69(W7:QCE6?6;0_R;PZ/C\IO^@Q;>4A\K?G66 M5=E9+5Y1V1DSXC_1.B*&$TW&^PB,#S_BI(-J">#*K9X.=J_K__0DGX M6TM:^+]7:5=D7NI75*(?)2LK1[SV$V2@=_EA9Y&;--F:"3M/#'CSVEP13[WL M<14'^)_SWXKPR8L0OFR5GWIIND>[]@]>5+"_XI&:J(;X=5]FLRJC$DT<;<23 M@!<'P,<_P&9ZHWPN=$]+OFWE4^?%U.9B-]A?QPGK2$=:R+E;5[<$V&QZM'PR.#I%)@!OJ%E.U4@NN[82 M218]PD&]C)\0E"3=(Y!S:$T'OEUWLXV:HQO5D+!E5-QL8RPYM#5@L)BIO[D\ MR;U(Y$WT*6#Y?2^,B4?F._M-"G=>&)P_[V".`B!BN M-:%3#L`.3R+&!%;3R,'`M561R[-K7"0L,%>MMTD2?`RC:`XUJF';5ID*,4<] MJC\[=>3[C&_+NT._N6POXQPM.T2./S5&2%O.G_VHP->^<\I=":]-3T2%(*ZG M7TTM]YV>^7#DKZH+MNO'*O)AA,]"CIPE>+22F>,*`T360PI]"L31A"6X+D() M#:('S/6-]FGGXEO?JJXVI04,KD)O'49A'L)9`TM<9*\'5G%N56(3PE3Z!W#D2T2.\"GC9K#X:>S]KYSOEH;(=L>'0(3Q, M5?%@]J?J[&2EICRB!4^_V4K],0$YK(^4"J`U_@"4,]K&\@7+X&C<0.6OMGN+LYRO5DU95+Y5+2TY@QN(X`3WWG,+]KPQ,RE.NWZ^C!R.(E73 M0.X].\[J4A5B6Y.45FWJY?=MFH48+%>3G'D/BM'8Y9@@N=1$^]9TP=D6T)FW M+/MAVA9RX0:U'*U@2(.S(XU^;I)LMV&^)8G,<7":Q'D8/\#8GTD/1.@L/RWA M4\)[4-+,H&GN[3EN'R3(A=C)8YTN3_Q?9WNHQ$(S>7A#G)?'UP='2$_P>R1P_1 M_#V(D_)'$&89CDTE*4B*'+]!QA>WCHV40-R]_#@FMWI'EA&:=N.EUREYFQ<0 M\#H>KXN>L<*AWA\U51 MR*4Q*7MM)`1BMJH_\_EUP M+\D>84O!2FR6T\HY9&AJ%=U-G;IL<@'*5*FU\A'^/POR=>-BV-*F-DK7*M6B M15.O6+[94I2+(529AO49,?*8F<3SG@L&.&PJ4A^YX`R9Q`JG@6^&IX'N48`\ MDVD$]!WXZD\'1W_Z\\&?C_\$O!Q<^WFR1@[;E\<'M)@2'D^&O$'_^QH/^4<1 M[>N_N]Y>>0K2/[<.>#R-4MH\0JB@M>RS*9"DI-#*!P?'*J9S:%#ES?09%K*K M6T7*F.4V.F)#LW%H@J=\!;@U*)%3VB-9C[; M"?$YUR/YR8ZI3.R0^T(T2G*ND_+`7+=604`JWWG1C1<&E_&IMPMS+VIAG$/# M%+!:O0R2T\/+-ZXG`EP_X!!Y63Z=ZUS)U"7;R8I5X\28>Y];F'MA#(-S+\7U MX+*5[Q?;(L).W!G)5D^!WM]>;>>Y[%TFF28/VEC@YU"AJ9T-SN M-AP0$D#N#:*9-O3>#&CSR_3,0(SM8Q(%,,UPQ8A\/X=^,K`X24,>TB',\LI: MP\E;L6^^)R5"\KUS->/+K5N%F+G>Z3]_Q;JO;'I84:<3+\+E&-V&CL8PN?\X M8$(V2RJSLNEAE6$=,/D%*O/Q1*FLJSBP8PNE.&=XV:.1]LJD2347EEP=+=AJ MJLJ;DT'+YXWI]DMW\[I8_)SM`WBH;(=:.'1P2^O@T:#I%\#L#."JPHY0>-VB M.OQ%FX=5[KP(9K?P"<8%O(/I4^B3ZJVS>'`<5+:UAT,'+T:'0(0^ME'>.DDQ M)_<@*V]T54K4X@Q>P/'1V]0.-)4(_/BI%+IEL)^8@ M)H(C]7("\5XB.@5LX#"D8%,)U$2!U4!AR<;1@99F63`0,]D&>5B@2X/0VQU8 M!E=G)K9H>';!V"0TMT-9?KVI-J!Y+@0[&*S&R;NXN3=^&6D6X:MX%>YN_5AR MZM[S#=8ZAQ?W!--U(LM*ZE/"3D#28OM+8?K1B#P/#(OL]'?H)#K?M]B@L)YD MV$$O^1YW/*?-J38,Y#-4A^X"C4WS+7\@E-!C-V[3=G:QUQKWL$HPB5_29/?".%8!5MD@''@ M`O?TG5&]%#%;#STHD<5K>$DG'X`'.OV`*)_7@>#:;NE)O.-IJK-F^F.@@J.A M3A_+`>G+3B2Z3U5NHVI=W:3)4XC;BE\DZ5E2K/--$545+.8%O<9<&0X5^?9:58A98A[7O((/7G0!9RI-4P.W MZN/4:'E5I?'?2<"J[(SDU!H-)-"Y3.LL998<$&E5Z38)S)+27'8NG)_F)\JW M7ACCE*);2+*.[I.K,`\?/)RB>0?S/"*75G-\46J()_096$WF1_!$^$5F];!> M0Q`7:J0EXDZ?&64^3/:(MBND>]D7K4PA_VMO1/4_05(S](P6[5_*=+%RE/!D M\`I/_QR4`$">@`8$:&"X-=3SR\V@632^'+K>0>S/QP^E/Y^1FPR%VSS.1*NI MFWPZA-\X%6$#8Q;^R&05:>P)V>58V)]N'=M1LK\4:"7,7*CT6_FT!4N+JM[$H\* M?HW&B(34[\=,7>!8W2%/$EXG\1)5P]GC`=+,%J^FQ)3(ZHE[#Q.HR:Z M015A\6*-KZTNDA2&#S$ME.[O[U,OSCP?>SV50W0"-VC,3&^F=-#;CAEJT,91 MN!("\G[\1_1["/`&Y_J"P4#B;674Y8J#%AF:)+(.I`/)/9`3T`(<%+OB&W7C MT/A&%V@)M&YQ@/)''*4K@"9NNQ.D;GB&RHA>[WF`8WW,)\WE-%%X.25 M;CT\HLK:F\!<\H<*DSWZ5[D&+4&!>B(4J5![U>:^ZH\P?'A$8%;(*_$>X/MBB[:VZ\V@ MN-YLQDB/`!<[EQ:%4B-&ISF.DAE)O:V,^CPQ#L%S4)7J;Z4,J"X)=DN7:5*G M8";[.KH@%96)74%)A8PQKU%6ELVXWE"7D+2B&]1$F[-XBBX)=K54DSK>$Y6Z MQDJR`9WIH`RP,FJON"D79:0/W5I2^AP;U6V7`9Q_'X*((?\5>>W;D54:9NA3 M.BM2]/]OR*EYSIJ2-LBVFO)A84&2RUB_1`'R!BKP@E\*FJCA_)K"HJ8.D@PL M"&9,U@N#O#D_/A$Z!_7A!.3PJZ,/:K,R(M6.ZJ++1-DKBRY<^P1>S;"HG"5? M1H#8F0?#ITG%;VG/_J.W2[+O`06R0.=%+G:.RR)AD;%&VCCOV3C1J5:C53R^ ME652EQ-B4#JA2<]@$[):5I&618J@ZN]B#LKFC#XR#\J0KYNV=&F[,A3-+40? M>NCG9??%U4<%B*$EK6707*<1TX;.2'07SA,%/HI8?$67-,BE^A_QSXF0YUK2]<`7'ZS+46 M:'IHY1B_^?1#C'`)#>6$:M/J)7=3]I(KI[&4R-&&JB!2A79R7>TRMCK]%F+S MJ18'DUW[PR:"6TJ1#@;5Z*58(K'01!WBIK!)\@9>,]HG9>16CPZJ5/',UO7I M)5CEZ(2Y+G)<]`P7`;E!#BYN"3)0.2=62U?HFBW?!M9L[*W#J9<]7D3)Q\S2 M9<,0G_4*G@)BE)(BT"1`9C';T#B^3N#*DW.+P&:!>;KC&40JZX?DE#F'*G7@ MV]T3VZAY.5ZM(;1`Z#9)\_!W^@M:I7H'TWQ_`'9H8D[&X+-XO_2P$S5BR:ZM M-@,&&&^-+:[@W)L<\1#7M5QE&9RG&*@$H^6PM)@:WN;74Z6PG@8\,L]U!$Q) MJ)W]3LZ&Z4Y2ZF\TY62Q;JTZXAG4C/QD)'(T7QU&:8D_.76LUV;_0P1S/&K3 MWL`TA8'%=]DRE#:/)1):N'L]G=5ZEPW6=(9C]5(49W=KE[-@S(&C?)+5O868 M+;-DB,E!%1@V)>-OM]SE0'`%.$B$8"];UUW$!1'1F3@MO.@B29N;K*^.CG\] MW^ZB9`_3=U[N/S++CC&+66J!L^05ZM+%\P\I"/*D.FNI$P+SZM?/`2PA@2T& MY7@C-)5L5293FUU&)5-[J<=5AO%U3.J@X,_4B_=7B1*T;T>TXA4MDS2/^]C*N^![=U.X MOQ&&H]HXRK+M%5QRCCI;X@*5[:-T830EJ:V$;J(2@DIXI;$ MJT'."X,9ZQ=+<;J+J\E(XU:G(X/JVOKD,B-9 M1(UC50&+58[!A>E=OAMOCPWD?>H%EIV^#F8G=6;4:).Y?CLZMMYC*WI*ZH7]@-A5%IP_%YE(H;A/ M0Z9@Z8BP`\+J\-/0P.Z@IH(Z=8(2P#[.2-N5(,!Z#UX5&;F7_+S5`E?E_U:$*;PI$[=N<-H6VFO.JZ2M.716`[N3KICJ]/&> MK92/#3PRWIK3Q(M-Z3SC+CBQ% MZB2`)B5+H(V[<%7$+X;89:"K9. MTC3Y2)YQ%G$`4T#G@M5#"A?08%LJ4IZEA?!U]"W>ENW^]F5VM^,C<)$AP MZ>&^#J[&2_7)T18C%6?WI;!H^<8JU=;4-HHSN)[=6`WPV7Z2*2*&F]J0(9<] M(H\RH\2CK^W\,JP0X7,22-91^$"SJ"N0RS%=/!GSK!>3+9.?]2["&&W"KLYZ M+.S+.>LQJ).=]9HX;#LZNZD`+3XF*U`'A8,?CV&F![_SS0;Z^?7FO,PSOD4[ MU76,,>.Z[>@?'&)[\B+\D_B, M=4-$Z"S7?N!3PFWW4\T`>`H@]8;T9T[?%Q6Y'GU1X457-YKQ\8S%K M42,5O#:?L:L0Q+LU;4UM"AR!:O9R-$Y'V)U7R:J\&?6\BKY0V#>V.A M`,3B$W+!7`GUUOOX#AUGT]"+ M9LK:9R&RN>TQ*>#=17@?U2'"(Z:X#$X9+"CHUP_J!`)BJDGPS6:OULK05Z$<9@AF_4V28)YM:2+ MR9&6=(C@U;THQV`U"0K??1Q4+"RFI@S7::HI&,+',(I6<=`O3V;'']8CP')* MAA9Q''VK8)`@9@,%4#`R3]J%0AKI1%M/]=EF5.BG[8T%<(.^B1Q>A4]P@-30 M^5:#Z<@75R).R36O(!U&&-2P0*ESO1PE:Y;KKLX[8T_^@H_@;9K,X[%)<3KK MUBBCC*.G_RBB/?CR^`#@!3MM)J@JSK855%JTDYZ.*I2Q4EJO_3Q9PW0H$C?[ MU%Q".;)[LZ!"$JM"[H70:A\`,MEYEMY<0CJ>Q3:W>CFT:_=:MM8\*N;+'+T9 M;<?$A!A6CO)\I2P)4Q%A:O6/+DS.O:,4!*F MM1-\*M*8U+Z/.QR4%)D8<33UDY.,B1$FQ:/YD.]3+\XB8N9;E7D8\1MV[7`S MP/,Y^=R*DN;42FJ+^V5%;ES656T5[@E70ZS+"QC]-5 M)0Q6`B83$#I*7Q>DK#IB5]!:9=:-R?C4_FHL.[^SJ[9F?5]M4D<:XX4Y`G*E M'L>H4Z:3;0)&^6K<`/O_!!]EY#9G)RY6S,F3?_D2^0L#@G@"!X/!-7(8;-G MVSLJG]O5)LE9F:EXV[?.D^0D+"L)8436@4J2@8,#@KK`6(D%EC,)3O;OO%^2 M]#1"/)QKY]%!;[L`A09M@F3`'!X2$(SDK/4>$#"`P&'L7DMSFG@:H>@N,;EF M'MN^0;LFVB19^]I4%5?;"*S7/VECYQ5IHF.&6Y\CW6&*I%L1M;\H<_F?(H<[ MV>*&0M0%SQ[#W8S:($)G-VHKH(176K><`3I36&KCY+6[7)"=Q^V2Y9L\K?H1 MKC-DME9Q4%;J#4Z3&*NJLM^H]Q$B4/^ZK2\WAOU,*9=<;(/\633WGR8 MRS-X<=<]VWW(X*:(L-.<720IL57(;N&]S>@@KP#.R9%>3I?"X;X@0`"^?*&1)K"AQ@& M"TU]&`I5[=3>X\$,=D-:T%R5.%;*D#`$44 MBM-I8C:6C\8;)CD$]''-Y\6+T-F--PDH$?8Z'T:\78<0-$39UCD9`TR?Q]\B M@'"NJY4&N-4+_!HMM]H*+B/;N^MP4N"]S_Q.0??.*L9LG.^0G=H6V_GL1!>! M[5N*#G:.R,LQB_GZF2)I2W^X*/.`SSOO>6;Y=Q!8EW\;.T_^=,QRY,\224?^ M@T69RQ_7Y;=3ZX2#R7)-7"81O'*X:/`BB_V)A=8I@T9N+?RT M\*)92Y:*T%ENAL6GA'O_36>0ZC?5G`754U809:]?J)`!)E=5C*;HZB%EP60[ MJB$F@J,5Y01T^JUG+"(N+!=%%066+'F,'L`'+VK!+0M,:N@"!\#D#>)%5Y5B M6G@7E7@TV$!(.PQGKB(CZM+HJX-@N2.*/IYO=U&RAY#D4W24CJD<$Y5=ER*U M[+O00AV=`#6,(:;$#^`)`TEDNTVS#)\7^.VWIJR>#N%V9688>X5EQI] MDR8;2)CD11=P5H638'03$A:1Q._+6(_&QLRQ=JD)LAO`E:[:Z!EC"?<69A#1 MC]N?G,$G&"6DO_J8'4\9HO6,'4T"N;T8Z71BMH(&@'-'25>4O>U2BRWFIHP$ MAX<.VXRF3(+1A2D3DR2Z)7">]:,FO\%U@'BQXRZ9VGY_')#.*-E=L?X%^OE] M\@Y]IAXI_`T#N-V1QXH_%S7=LR\5@N3,ZB@1=404,/ M\5B`!Q\`/'SPDLV%E1/)JVV\N&L=TFY3RHP#A=+N/L$6D2.*N M--#63&)<_+F,M_'DPHJV,5<^)AV@OU?:<-GLQ69Y%`B]J]9>Y/C:CR<F5< M,*T/@4\G7A21L$?BL96*N0]Q)EH/<+'IX/8/K`<#,MIYPHE(UBH>63J M+D_\7Q^3*$`LQFV@\_W[))\U!46"T;(;*Z:&=V9J3?JCMTNR[P&="_!DUXT% M]43;+3(D9<;(-CGDS'^"C%APFFSQ!2NQ8^?TKM7H)*X&T=9%H0%M"N?R#,,Y M7&-`^,ZPAE1=4KM/BAHAY>$179UM8^Q>64^+5!I!.+'JSUX[;8#,NK7C$,)S MI$C1&:2!9.`2,K*E^XKC?34'7'VSV>=W#SCE<[KF-LWX(P MF5O9A^%JQIRQJ^0%HA+7'V/$Q\=P=X-XW6XCVPM#/84#PJ5LESD3K9S).J@Z85SN&KNCU_&B,^P=MBN\&!\`SR31RY"9[MS-)<2 M;@P+SP#U%%#-64AM8P51=EM*BQE@DLA^FF3Y]>84_3KTO0CM/DE*4@ON8/H4 MZM0Y5@1DUZ]7(XIWI$.3L8FKIH-F/J@`+&)CU9-A9;\T>#.JU$5$_@X#H96< MPW(I8K;JRNG1QMM_6WONC;2EM^96,06WM24- M)-TI,*'(%N-$XCL8H5\_O(4Q3+T(OR@-MFCCQ`Y]'C[!$M.,>09Z!-@.ENL0 MQVT[0F`<@!(*?83<@5.IZF*2$XRTHA-VUV;4"<5(& MDT>-2O""Q%D3FE"^BSQVQ4N'$0J)M!BA"!$SS*T?^21?B7\0U1@"5N)'*B)_R0NPV&Y_R, MI)?NGNG;)>3OG1J@G`]"GM[-2]-']PW()LATY= M+M;PP_\TOWS;6_EXR8V+YZWEI*^UO9#;JF<"[@R'`X^%%]W#=/MF-D-A>1DN MS(/=):H=(GE!'V>FP8TZ#PR"`UDM(:Q_B>@*XRST?_"B8I%>`9_8R5/2;!_. MN^L9\_V^Q(U=JH4SG;\97'<9P"W=`USQ>KEW;$,BY[ECF_G;&RR#\\VUQBUR MSYQ#W:;\VMA\=AC6:A'TTD[%JJ3/=TMB[Z,T./,J?JHO_F.U?I]9I M"M(L2QKU$;_P;YBCBS-]JBS&C\PZ[KWI)HC-4H_%D)SD'PM)4DA"3IO'^C0? MV2,0EI6)K"3!83JRG#?V@Y>T7%>KU#BI07G_Z,7EM_`^B9\0W3!88!Q%F_C9 M=H+YA,E7>2(YV18%Y8=-UDC:SDMP_EJ$\HF/#B=.]H;$1A M7D)[9Z*W"'1^YN7PP@O3Y5VC3;FNN?)AE[`G25<_9KOZ1.V%\I=@V92HR?)E M76%-O'K#O>__*O*RZ&JVRX7MEC\0^A>9-:Y+^W2>L(7<<S9 MNFGGTV:PWTGVB2:AGYC/J[LXNP7S%K-N1>OP29N'A;D&)A*T_D)%NHHRA_ZE M.@A#\E_6`S/]!7(L03WNDS4&7$VU\[FS!;'8#QH_BOG$7`6ME5GM&[:,-?]/ MMPQ:*F_5:*B+;\P)A!8WOO>>S\+,CY(,89VSMY8(G8NRUDQ*Q&6MT130S.$T M'G97UEHHRF%9:SX#3,I:WR9[+\KWJSBX"GWT39#W&AB-1M:)'(85,ZU$"J_H M)YT'T$10SP2E_BRB%9:RH.K^$$JL&!4+@0_8'-["79+F"/RL+?YXN.QZ`!PJ MN*4ZR7!0CV>JDIN"G&+1=6MO"A9MVF>F58FQ!_XRWB3IENS-:$.F?S2KOJD# MV$U%3@T*5:ITENJ6UNH6-@`/<(.1:H3[+7"\#C!J>NJRT_@:![<$*(L1D+JS M_G^$*5\$[M-X@.2"H$ M<3Z&]E32T\!KS<%?150$.%5JG3Q!Y]^%CL#;"JW,'P,7!#O#Q!=3;D76'CV# M`18U'&NA%KJ53INM<#A:G3SZ:S"U'F6L&8>1;]+$AS`@A@K]'!0^;F^QRC(X MSQ:OBMIJE$61*&Y1OEV(-8<<0P(:E7<=Z-64<-MBZ###-!C3ZFVGT<=P.,ER MS\(!`=R6\TU?0D9+'.M="+G!F3[(IW2`!O MHV@-7$;3>3[#ZZV#O;B1_2/)O609Z)JQQ18'D]W;0#81O#"2HAKI7$C69 M]1H(\I9KULTVSI(H#'"41Z-S[6"2[2ZU?0*X'6F;@>ZE+69XTV:6N;@Q)@$? M>>FA^0'&_G[.^SD>*EOMVR5TV02*\MG$0+=K\92=U+.=4 MFAX&JX>,+FZ.?JSN[L[O[YRK`EL2G>UAN)I1O@0!=UJD*??R=4H-Z".R&;%B M4L#;5N@HX)$YWSE];2H4T5`U6`L<<=+DZN;RZO+\\OP.K]V?@[O[Z])]_O[XZ.[^]^^,?_OSF M^)OOP?E_?;B\_\EMZHBNZ#L;E0Z+C*_=6E@LF#`!-IMVC$^&Q)A%S42W%DTN M-HXJ36S;[%HSL?VRE]FF:Z[:$RKS!,G$[UQGH&N9)`4C9*A'M_`)Q@6 MX+"I,WWDO-S:/<%&TW7W,!D8R[N9A!SA MON:WYW9-F3O+I2.KSD:GP@FCFTDO>[R(DH\DRZ5VJU8XU87&C=052!F4K"&*>%.N!]">GZ!'&,_44R!(@]L*3."0W'CG07MSF=967Y]/H_T) M^MYC$G]"!,J)/R$@2-&?""L(2_0G%$3']"=D;#'T)SHX+L+80Q9V"K42@7*B M5@*"%-5J4T%8HEHIB(ZI5C*VC+@Q./&R,+O>K'P_*4A.UQPW!4,D=M-W!_@Y MRD3&X>(&S4CP\SU\SL$)XN*OSDOX<(75OAU@+];TN="YE^*.<#AH2&(WF!N$ M&7/H"1^9Y1LE+B&\AF?E>'"#,[_Q#+;>N%`:J03;RB->N'D)B]*:W16[743* MGWE14U0U,#.F4S=#@UHG[" M$X*XL^.L2J:,VW;#846Z%`I1U0`.0)5E^#,!`A;DN>GJ0"=I3(=7QN;O;9($ M'\,H(B4LA4]P@-NN]=4AQ:$QUB!3R397\`X)0(;:BVVUGKHKEJENLYIL\@P&MW@^)#!31%A M?<850U;^;T68A:12U@AE4P9J7^U425-00`H*$%@``0-M:")E=*>)NM(>ZJ06 M_T:X`&=PG5MR6GFH;!_@.71PRY^M\T4>VR62ZU8WXZ]XQ#MT&C;/;KP]5DE< M+>DX)310@B.'I1(@:$%4.2XY>2D]3G\Z;ZE' M,-:\9VAMK(?(;!Z8I-@M-^U3)DQA[V>IL\C]='L&4M4#]K%'B5VFEY,D-]B^ M859!:_L)G)PD8;JXCF5U\CY.7=*=EW**;!EYU.ZC&7'ZD8"R?^81$Z1@[88* MMM2CMIH8A\<:!19-6B'@?9)#2Z9.';G;^@$4#``PUEL)%Y; M$\2E!T0\FR3^WNY\AUM?H#/_L.==TQ$O6T4$,AI]O6'WSR,--$[V-TB:-IU1 MFPMQY==:7*/"IM&&`S`@L$G*S*K#-48$2I)`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`$=&A5LUYH,>OA!R)9KYF19,=9+\OFWI?Q"G?WUJB= MI`?/6JJ6#E4\_ZP5'_3;%^5U)_0PILW0G57*-Q9HG:^ES2?#]U&#?=[(USJR MW.YR2(!&APWGOI;M1-ZW`LV^,8J)P!JTRO_GI= M>5OEL>8(8@JP66U#R"6#WZJ['*SVA-!%E%$N24$WYCX+IFGHTDY-46[@+H=A M=[>3TB/KUE).[&8QL1J^.^[3PI<6IS4+AQ6F^^$'4@09]I,>E!5'/'^&>Q"A MV@BIX:A,-6>82,/0%NOJHB2?2E7DRS>ZCKB,[Q_ANR2&>R/;(IQNUZR(2.&F MG0#DBP(R26Y-K.N'BFPJ]9"NWOC`W;2(TE4.[E3;IH-'".]LU0Q?TNXBDT1] MOA*MUKQR,&G<@%SENISU>9:'6R^')_M[-'_U',[BX2KAM>GKJA`D[.^!3U2M MNN;5;'SACN>#GS$$]\\==`3>*1*LRI\1"=3]FEJK+;ZS_YVV&O$-L!:$.H7N<,[:";?$P]^7=S,S7X9)[H](B@WL-TBZLC MS6D?V8BLOF5A4<`--Z&QAVBSW@(\^H!G\9QD%8E$ULD9XB[8N*W,+LR]Z`IZ M&;Q>1^$#449E/TLXW:X3+B*%6S^?3`%D#F@F.38UJG)I^L1(5C[FS5TWN!3" M[&3_WLN+E+P(KF-.QV'_.H$\;1/0P`M(8".GU@D-R''U5DS@]'2EEC M_M`E@-LXW(3T\>G;PDN].(=P3O=+B-&ZTR6BANMJ=2:!U4,*(4VT=1QUT!-K MUZN2,L+8E[H*\]*I5D2 M0/WM*'M+_1E3N\I"_ZB'G%=[[4R[Q M93+H?_&0/+U&D_`'_A7^`4OZJ]9WS0)HI1X'`S'O,\:C`!WF^AL6\!]+FK)2X@@"[A>?\V%Y\J!RT@^,#F;YW1-%R-T2=Z56S#&#XK"[$[WFYPJ8.;MZ72,8XC]+_5[V>YXNS+LX.9]A'3,,F3(9&[]%0Y68RK#%7*K M@C`J\O`)WD&_2$D!VR9#$><]:" M#!K0H(*-?@`MZ.!Z`QB]A2D*IX>SZ?2F=@$G8OJ(WA],"LZ?*06X$;OVYS!1 M)Y!)"+-:%7(2DC4_H@HZP'K:^8P2UF=T,/R.G'0,F5+K.OU#)A/!F#NDNB81 MS&Z\,)@G-M]%83T8WT$OK34%<7.;,'"=RL`4"[.:5&M=([IK(_\,9OE\.M"" M;_;68#*Z\ZTF`S`+5M`7X;FJ2:3)\I>N?-/T$EPT^\;)^&%XC`Z6! M8,<.*%"BFX-"*MZ3F4O+0AF(1YR(TN6`B1VY"F.49I,N3ZUN`AY6O7YS:&B9O&U,R7-#(ONWXO)D6^+AY!C,_#73F,VM/!;=;QT*!/U?&]@'(`6%+S_57"HYO4.GXZ,C(E"]'O$ M:[%MS#;7149@WNU2Z`77<1O9\?R:*\!M>>M3I4M59PD$0$$`I+<=I75:^EQ7 M^GPUE7#):(_L8GCGI0]AW`6NL&TJ`+'8PD%.C9I2`3J5KTT.MEUU<54[L2(W M)E">R]A/<9#O,J[N"3#TZ_@,;KPB4HGLZ\&SY9QI4:6H6A44_/:^O@,B^RO2 MMA*40^_.2+!LC5/AUPC/D'5F_1`7N+):>4H]3;;;,,>D7$#LCOKH)^]AEM.E M.3&6WRF:TJD;NJ-`Z]C(`6C@`@08-)!=OS`;K4>RL)XZ?Z>Z#'D7QIU`HLK% MF1H^XA5LOQ/E`SFX\!!18K3&I M19JNY:PA2:X]EF(KY6HA,Y`2WAGF$@@^DZOPMR(,"&;T0TK>#(XSD4R("S&6 M+-H,S68-"K1@.2OU;"AA!3O*99G9`R453*=%FDZGAA4TIS=O'*)&ZUX)9V'W M;1*!ZFA=FU%3WON6>$Z][/&D2.-QNE9#L7=5(J7%4+7P=(#G+RL'AB,N!4WJ M\&/"_;.".\Y8]:&X5*`>+9H*5"O.T"8M08$XXA(I$(L?8Q3H0JB?].4!=?AP MJB"Y^$7#AT7J^EK(KZ M-^\UJ[_,$2\:18_E*_`QM*J\&\@.`(5:;P75[(/FSNFRU5:G^K/S[(XIM*I3 M`GHLI\VKE$LQWR"TZ-\?O*A`7_)[F/?^[N8KD5)EM<+Y:'+'?BXE?$`0X/T' MH1@,:;UN7R_;2``:GT=0?S/%*-TG(F6BT6P22!]W2=#@:T M!%LSW-U14LSZNC@#?Y%F4=+R^@TN34B68FT0L+/&V!P5A`=)]GQI*I&]AY^)'^:IRN#&F;;!8;5 MR.*5Y2(-LNAL0*>7[R(.:!T7Y+@A&'1$!EZA$P[]M9NVM&9*T.GSH,XMP^+% M9=L_9&^)];W>$)0J[A9GIK5P$X<`GK=5=6Q$P\M=%-DYJE!83\Z2*/+2#.S0 MQIIA]G[NM*:66"RU*R9@@7$I/]*\K31_JSAH3&16]V_XXHJ[Y/\ M)YC?0C]YB/%SVG;OS5F^(RN$6_W>;*R(]UV6N$&)7/!!UA0`2L)!Y^_HSSG8 MPQPTZ`^Z_60=OQ&WJO"=S]R:>)=H#NAYX2))RU_A<;.\.K6\`LL7=W97-[NQ M(#7%6!:C;+&Y25+0(LCMON_DT[!B0?C"-[Y]G(W6%V4S[!9DF&T9KNS`I_F] M6_VTQX5@F&2LTA2WM29E`?;-D/+.E=!&8]?-2]SL.G^$Z?VC%Y=^2KV45H?V M'V'X\(A71X-)]:,&.%;>G1D>HN;^\[V,<]!JY./>8:%S/O!ASR5,\P_[?+.!^$X$U@U"<*D??`R*\5U\2EQ[;0?H1 MM([^>`A@DB%"0+?&XZ2T%_31R+1+]VL10HY88$&A!0FX0A05J8*"&!HH=N;`D`!T? M[,TUI:W)AGPT MDFBM8[9)MJI=)$4ORH0H;*5J<&S6(U"B2$V'0MRJO#6[KB?C,#"A);AJ#U;GR9@J MVGG9]+8ID#"?O1)@LUL=FT<&M[)7-:%5_>*`T17;4U3$V58L*0>FM5(S M-N(4H;/=#(5+B9ZI&K3?7(JA$K3>E"W>^.8R0Q1_/(.[)`MGV>:Z"&Q;H@YV MWFTA&0/*06ZU@BF.SMW=8$%F%20N28YHJ5+*;5=9LRQ696*@Y\BT,W+8A-6^ MTRO@=^7B\E9GV%)W:"\TNNMR)]LQ^6(B=*S]$F0OET53)5:X9I.&4^=(I;9> M#@/5TPU3(U2@V+J45Z"%:^G+F8"M*\,SC&U5T9!6I3.J[#`,LU#UNWZ"Z8^/ MH?_8!_UW+[M/3N"-%ZH8%@U@-@,NZF3QR[#A![@8`B`@AEH%$!20)^`$7WV$ M+CN"ZTNT58--AT]3G'%N80;3)\CL8#'U`:>'R^H]!X\*'4MV%7KKLBN9VYX[ MJF)D'W`8#!AS%3$`_!X1;E&=6NAJQPL2Q6@4! M>?KO167B/KX@'N%BZ<&SY6QI4<4KXE?#J)^.D$P`!1?,>@4_$Z'6=?VT>65: M;)M`N-XT",OBW[?0A^$N/TUB^H>+)&51H**-8U%8#`N,I96GMM1O0ZK:4N"J M$GT)&M2PR5LGIDX[K`P^D9[4"CX%HT=7A-;ZS+"SRB-7[<`R`UX7%:8GHUZI M$K6^R0<)/CSQO[1EE*V>7/=8Y:VG%=682\RR,03^G&W<80K0V76=!91PGW_0 M&70;X%]?.KF\E(NQA4^XRD6.V!2N([C*,IAG M]_BQR2PJHD>!3?.B1QI/P4H@V#%KP!P2.*`!!"@D\#.!M0`M-%*,CIKJS7;)M&G8WHL.MUF9#(O?^O%3KB*32&`0B0 M?[L.9XY1DK9J&W/0U*>[X"-K4+WWMG"^K5R7!+LZK4D=1YTOA+;Y`!!0@,`" M&!C3:7"AV(;ZT=9I$PZ:Q//?)DGP,8PB4C"OPN,1/&FWO MX%QO<-O@;9XC6WAYE4SPB.6$(!ARZ)0QZ:W'@C$L,K@I(GS&R#9)ZOF_%6%& M8O&S^`0R;$OT#B0T3VL;*3)`L)%0?!L?(X:Q9`.IJ%HF9E)%)DX_GKE\"A6, M"_4N%$BW^BTQ?8Z7^3U-XGJHRL?8";E*XH<#3`PP\`GK",BS2QU#I)BOP%F\0S2%N`*GDSA$.%3?"`,@LR:L:I M^BWCX-M[1S2*3HZZT889+:!<(TJ`@Q(Z:($?.B.V;>!RVO/+1E,ZI[2QWX:5H/-<_F(;C(VX72?"[[!\^GS_`P&([96)(`D=9Z25( MW21^$3X`7TKM_9^S1+/WW03*8Q(%,,UHBLY`-[.ZI8C?:DX`:5$!52]@&CP6 MCUR3$"QJ/%_"_J.W2[+OJVY;/(.9M=IJM)&!$IOSM(O)=:G3S7X2.1@EE(]% MK^-!3(?+6GG/R4BV^*5P+D%>VM?"=3:FE!*I9K)L5-_E'"@+M)AK)N#!&OYH,/:5.KZLH*O'C M`N3=-LVXRZN-'-$I";5<.7R612@DG6HT1&YPTG+Y%=:J\SG!Z]Q7LJ*^[$S6 MJ24W;R=S*2$<[\IB_W(-$I?7M5R=^/FZ`@X[ECL/`&";` MO(<(*CX=14F6[=!9'=O^\J2N&E65P[#7Z$5&"J_E"\P!G0A>X:F?`S291G%: M,1Z&RVZ]"8RJO.IV,$H<,=FM9=!U@HYJ<&Q6V5.B:)PVN;=.VB)4T2J&73*[ M+7S$SOMEO/)]7#H"&;^JXM>\^41*>&WNCRH$\>X7R52DC*"9#*K9O,0C5Y$( M'8%WKB)5^3-;DNATV=/6;Q@521J;K/D2DID-$Y5'WNW)$>ALI#K0K'EE&D2- MUC/FIKH\7>/NK+J\&A5G>42'BGLK2;H\5-:+F;#IX$86T6AYIJZC(Z58>IU3 MI;AD[G%RRD>FXED^+(BH,L@L7<#Q4$8LD'7#\H9`#6&<;DX*P>124$6.B M*LLX^ZE*2J(R8T]\PGR1T;E]=A\;BLD8D6"T`.NB)B-I!M#H5WM9HR32/5:QD& M2UN:JFHV,%\C>X6<>MG,07$N+D=]9[I4R'NLX?%+.;C+Y,;N!<)8LO(5_@&KQU:_+7%W;7HA4#)77(5ZQX5F;!53' MBQ7/MWC"%A*BJQ,L_W0)>L'U2.6KG]R1"Q*_P+EKQ'MA"&3E^VGA11=)>E<_ M!/OJZ/C7,ALY?>?E_F.K:_@10T`E#%+PA^;7T/1N#`?`$A#88DC5T[LOW+7K MTEAP7W[ZS)I^"U82*`Q(&XY6D+C5&I$EPE,O3??X%/CD106^T<5)R/DCEB0: MYT,D5PAS$'@Y+=JPCDJ'.,/G1@P[0,/3I'AX1/]ZY4A\P-QY>VS]B')$F*@O M')XEQ062JB36ZC/VH"'`C`OR.K\C+QWOG M7AJC72"[@=27E%B#%F@D]`HVWA$(<)Q;[#?@L3K!$D$KZ[UO)UQL`>-Y-%"7 MJ=CN8JMX@JGW`.^\"-ZDH0_+4DY<-:##08;&@QV>0,J<0XQBT`9Q M@/;%&[[\\%J(2#BC086.-34NER9V))OZ*C$)UVU[/0*BV62^39-L&@UY61HA MX(:&(DAY:M^THQ,S#!]B&B'S]V^],,9WUM?46<`G2"_>7R5>K"AT"JZLWNSO MP0,""/!K9+P[ARV8Z)<>X9 M;U+X2Q'0`DR53\@3+YZ,HTVM^]9=:WKM/+O\;I46V)>:!E<?FCT(\.GGC)FM$>G'0J07`R04N,. M3ZSJZ^[+4Y=C3H2:H>-U1&M=HIT`[13X?B<0>]"M6<1F9GAG)?.6X#R+US04 MDIP#+ESFR_@)?>VE)T]KI_'%T1HZV+3RIGBUN;<$N1;::,D`X4GTN;#+KO/./0,%9:G(C(>.K3C9Z2?H<8]_/#V`-12PQ6#( MJ6^/`"WLTV:O5D6X(CXY./2Q2"Q]A6;G,/6\FHW6[1%$:9$JPN-P9EERJ\S' M:']Y8=]<;WD:\NIR9"G;:4G<5?A;$0;8[)MY0978H@H.PQM:DOSZZ]60(YM5 M2]C]^@3>0O1#*DRD5)=GV@!;EM\C6+6)5`=,EXV>HAA<)OJYR./B\ZO\P]+#`$ MDHR8`:^"X30^K;C.OKRTV&,_B/J^V*YABO/B<1D+"&^\7)2Z08?3YP)T`MC1 M&6Z_'\XR^L(0KM;VYG2-#(]'BAG35WW9?8*.C-SK4QBCX5&$]QCL-9#C-NDS MY659XHX?$(&$@L>/>]`!'?&.)/B3^W&<1%)FTSS"#%8/)S/P M\3'T'Y%7&8,U!'Z$3CL$7T2`YPGZ-I.@\&FF!:G3VDX1S\B]_4.2!!G(DB@` M^,DF;3B3?0'*I>)Q@A3CP<@`>Z(@+)"_!>FN68XB4SA]?1*) MT,&.2-6Y.;:>"3(?Z=CV*3[H)3K:9CF+^C[#^2MT<51`^ZZ/__P`VR]*%-X: M73_!E/<$A2NP&EGO18_B&RZ0(*2"ET`./[99^#A0G?F$Y5KW3I/M-LPR?"-+ MWVE>Q[287N5UJ.F47X.IWWOBAK:TV&#EGRU$3:1+%HE?D5^.Q(I<>:QR/^*] MN*^+?_?0%G."_):0>\@I>U"2KYWNYT-3\.AE>#M?8^\M='HAKKY>AD"U..5@ M/RZKQ*WBH'0X+R"DK6IYPKN%3S`N('EAA_RJ05(CP)PC_XW?">&_(2>+I%I] M##/\RYCFA4F.*7VRGZ>O$,2`I1T1*B&4C#AT?D/&*7,$2,PU-\F.8X M20]Y>0A;OO\"K*(L(7-3&5W$22Q1(Y%G85!ZGW1[P9F[A'0O)M269%4>*2$& M3RTR>`#618Z<6+1A?8P/:J+*E^S=10R2@1U:)[ZP^YHK4POK1_@^0:0-&:;G M'C[G)Y'@U>!]*9(4@B#,_"C)<(TM)*M45`?2RTM9!I58T[J]&]6G@[*X0.:G M:)>MSAO4>I&J!EGX$(>;$!U5JL3$C)8L2/RRD$%+1_O0%Z0E0U;+M(4G'/NQ M@Z:EXB`]'6^JCQTX9$T%/:+PX^1,MT%HE;M?&SQ,XCV!72DB_;5?W<=_1__7V:4/6`XK@V=ON(N2DEN./?_KZW?&79^5(Y&C@ZDC8 M1VG\#NSZ(CJ)U8LA29%!L'"8D^3-9-37P=YZ#B$.P^V=OEU;IH(,/KE%4NGP ML\8%+ZKP!?(5FQ!'5L6F>=\8F=KYK*`O6D]?(/*UV[Z"DU%T+)"&H.;ABY;"L;4" MSJO-!MGE/`V?T8%6\@G40_%%(DOQ[?-\2/V`U;P%.B@@QB:%J>`=7KLMZ67, MXV.+/5/J)`Z)#E?#F.IKG[==J@=\92W*277$(2%,K64F";T`KAY;]3_8E;G$ MBEN5)B.30#-K"?Z':#U]YLO7;JUU`?I%Z"-2O'4FX7TY$N"A#(9;Y_>`\@&7 M.6NS7H>/20?+=,AX[$*M#=ELSWE#1]\LB4*<-!1(5+@UG0/.,M9 MF3W.9OGUIB7?),6M._9W92Z=C-M9#JXWH*W4)0!005B(CBNMY8-SG* MM#'-4)E!J2NY3TUN'1NFW,;F//X]N0HW\,X/83R@0M"_AC/1IE/&)H';]>SW M!.#1H!J^C,]9+("ZWB%_J0ZJ47*)81:@5&/\2^-[/S-*_8M[ACZIC'V]V:`O M.-7XY#@SK;2:%!#`^^*JT:`:[MZ-D3"_%KM@H2X.\P)ZF)]^@_QDF4/.RKRHEBWE?S0#,1H)F`3%U`$$RVKKXXU/C@Y`FUG#"6 M8=(5D(,/90X9'=O]>%0/)K(SB7W6RTXC@I.(9?UGT<'6^,4=N$W9;&_'O2JV M80R?)=I+![D_4G6H';!RN!3KRMHG@:FG=)##XB-:7#2+];U'0'"NY-^+.$AA M0/YSC___#>*%+` M:U(DC67LCK_]]ELB%(8;^FA."G`>E]'G/6YJ*D#XL2ECJ77(9XI%OGPHR[5F,KMS#+ MT]#/84""TA)+W8RFUR(+.?^S%]%GMFBI+DIB<,EA*76+\^3ZP_&]QUB.]W5< M^&EQOSL(4^FB*^M6[*B2+'Z,B29SS+YW=W,SC,#0! M@)/@:A`+B(IJRK!^Q:;!'>N%0S2(8[X\I+*K[O;)T\,UD5VR`4$%P^ECV-F% MUG.5#4V"X?=O.ZC3QUJ!PP=+L5V]&E``LLA+`T=<+2/V9AN-V`RT?RHI\O9L5 M,;^K2:!_?;>,6*)P37U9*##`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`)T,RME._$?5I;%D MI<:.)7QQ%V'LQ?X47UP-:?E?'&/1&E\-UDS7'JMP66I'C0$?/HV@U?ND?#\PN[NJ&+*J"1JZLB_,F=7EO=UX M%5/P9K[0?>IA+_INOUTGT7@?J`O.COT;X.6]EJ-C`!WD*);*Y7GEX@Q78BOE MK=+;.GY&+\FOR@P>X74;H&/!*SSZ<\=Q:L8"6-\G=YTV=P?R:;>2082)%Z`U MT+5I[1/.Y#!S<;;U>>@/K'P_*9!=1487^V[XD].-QU8@0`GC`!`HSAUHM<6J MN4U\-EDZU%:DG6]W4;*'Y<.5CS%,L\=PAY^NGM]=W[1W5TEPO0)4/;BJ0-%W MTZ\PM,\/NDY2/^#N1JS:'&!)V)"-NL^"V@?UBS#SO8@>UR_0[[+Q+@8?M)5H MLY`$6;"%3JAB+F2**SNN)*5^W(6]8(-:#4U(K\Q^O(6[),6;\5WNY5.HB1"Z M/<=41(8X,%O.`?4D0&NDLODD#V-Y^PZ%`T3'!XX=NB6._9"`?ME?27:OMO:6T0=E]4E:FN$F3'4SS M/7:OR9-I]%OR\H/;3Z6$`/*D*M4!*B`'Y("2']!'Y14DQV<2]26S++PNP^RF MDG@1S,K75N\A5V3E"+0O0]?"Z%',W%-9B[)[146?"O+82?_JF)&4"!;_VL3; M-B]5N1O!`\Q>D8\/&=P4$6X5RV5W50^(`CV,,%30@`44[@$8E*NAL`$&[CS@ M-88S3"F/YK3=3XJ3DG=);HBFR&*L(2T_BY&Q:):(=5EF=>LY]](8T9#=P)2< M<,["J$"ZQHUHEL-Q3(F>)P]`.<5ICC!G&BHN0SN-^SU9*AT7LJU]5T0$YRQ5Q>O:1ZE!5IW] MLY1,2-5A2KA:VR\GDBV\]YY++3V!,=R$7">\O'E&XZMO$;PJIWSN-E+&60CG M\HV_9LLV4.$VFGT/[8+'DAMHYY?/91$(Y&ML8):%2>Q%%[!3\X'MFI-9H#T- MX'D'8%#3R9G?+5H8V[.6L\+R<30BFQL,V.'FUBTHLXQ)-1MPX_U+>*VEMDBF MP#388]E&]8Y@-,9_O2&$ME^'(*)#7[D,*P6#NQ120-W7.0268W.GM6Z63`T8 M9_>;9.N:[DW;$J_(U.^YAL=.W4MU9%!3+[J,`_C\3[B?[#:]!];BVQ8F`9(+ M=#H8D-$`#7=VI2442N^ZG+%"DP25^(=KL1!'F29YGJ!2,:%T\.X0*:^S(--XNP$;I(4UF<1F)T_(V5, M4K0A>.G^,H=;G'J.N)`C9!$M"`(1F;*S&I# M"SL@Z,D;@Q8!H*+`\;X\(V_YQ\491?G24G-:GDO/PRDS0>!-&OI<5WZV%]T# M%[,B!Q!Z7,?1+;%=W?.92>*C,A1OX4.(BW#%^7MO.T%PDPG56NXJ"[O8CVK& M`CS8X08KDD?7C6*LS_()=7"B$MJ>KMU8P.FE33GW\QTNSVJ@^!;NRB22Z\U5 M&"-R-JV87W)6O?+_8%A&.(JVV M.`/X]_J$^X8AH3(5X8J7BM`"!]KPW'XQ^NMGB=24B]9?F>NZGN_".$G)BU;J M8J[BH`N%/GA]!_/')*"W\$2SISI5E*^7*7S00G`PQ8'CA1PW3(4PT?%CG`XX MKMQ6/82[A3X,GW!2N>EKP0:":]=?994H#86Z]3!J`>*4 M#_H6MP5LN;)DK%Q/J%S6V=UU6O>XB"+R@/$QB0*89M1N*%Q4U[G3^=ZYJR=; MCN0J6\`"JY:2.B>RN^S2=6-<7+O+[Q5=4P\793L)S_-`";E1[8'3\D1FLQGXVX MW8ELC2YB+[-4WOF!E-U93I%P2@^K0OB+"B=K\GW2>+*1S&T:CE8[K?L$^6%( M#F&$7_`T!ZC[9&3M\!8._/ZLQH)?-G5K^^`_CZ@R[F;/GY"#3)=A<@F-JV2+ MOH!M$A,7D1O,'9T+(L)A,TU;3HXD383,I!5A#AB)7RX+=*B+LY=%(N/&BRK, MW7K,+[OJLUJ-X1._W%5D^QR7NUH2M^Q<:O?`Y.FE[*ZC!0VTP#G?3;49H'G9 M(>*BU<*MS!`+Z]:J/?*/WB[)OJ_\]U6>I^&ZR+$F8\_IQG/7D)F_+N8GS%G] MJ%2*'Y*H0-).]Q?(/THGJ_+4!VL]+[5'@-CAJ`<#.GH!!9TX\%Y0VCZ@6R'=_,2 MG+M<9MA_D5*2P?NH=E2H*%H&V_=R,FHBH24)'!B-6^Q,.AE,US M'`L596M57TFTN'S:JG[%0V/YU3-?V86/NP+?W(6QQ*O""MO):C3;2-ISD0X; M%GMVD\W1(9J=K\%8EUDMQ/I=TAG,_#3=A5WZ>*PUUET? M-)$T!B_)^JO[9&Y9Z_XFO>#?6YS0CXN27'AA6O>@7DS/FT$\F-!+"L``3/&@ MQ]:+VO@GE)K=^UM=;=(^US8A,P2,E*=M)T\.C>C&R]9$=N5$;$F_?@VC/*M^ M@TWJURV3RL%@US'OX.:8TWH0^)D,^[=;)YI[V@-`-[Y,/;0B67U',ZK(AU$ M=F]/&!3PE*0<`G[&@Q9B,U@B8BK'8(&-'U:N!*G/KY6NHU^A_\(>!S'>_S]0 M2P,$%`````@`Y#N(1RM)4.?\-@``VW<#`!0`'`!E;GHM,C`Q-3$P,S%?<')E M+GAM;%54"0`#B\UF5HO-9E9U>`L``00E#@``!#D!``#M?>MSW+:2[_=;=?\' MK??+W=IR9#O)<9Q*SM;HY>@<2:,=C>R3;&VE."1F!)M#3`A2TOBOOP`?,WR` M))X$:<^7>T?/8(00Q3\^N+U=Z]>'('`11X,5K^^ MN+][.;D[O;Q\\5]_/SKZO__GEW][^?+H/0A`Z$3`.UILC^#I_XO6_W'T\N@4 MK3=W+CRZ#"+R6S>"CX#\+""$R7^3WS]$T>;GX^.GIZ?O7/*GV(4AP"@.78#I M#XY>OB0_3FS<\__OCSZ^^/[N>G1V]>O?XQ M_8A\XUZ$_G?7J^^/\#U^D?_GS,_U!Z>^? MOD_^^O6[=^^.D]_N_A1#UA\2LJ^/_W5]=><^@+7S$@8X<@*7,L#P9YS\\`JY M3I2@VRG74>-?T/]ZF?_92_JCEZ_?O/S^]7?/V'OQ]Q2YHZ-?0N2#&5@>):+_ M'&TWX-<7&*XW/I4H^=E#"):_O@#!EY<4PM>O4A+_3G[P9_@GT1A&/O0H]B>. M3T=R]P!`].*($KZ?79;&0+Y!5'G'])?'C=\>&Q?OSULG!$'T`"+H.CY6D;9* MRHSPEV2&K<%=1/Z])MQ$!:Y^?IS/';U2TCD=@@<08#*;4YZBDK)()-+JD/7N M@>CJ`?D>\5[G?\4PVLX)B3A*&,/^.2*5#IA,' M0XR6M\3_$MM)/!./2*S/]$V.&S+?$NOP$<8;HA&J'!ZQV!_J,[%X0_Z43C+' M]R!V"9>8_#T*<3[YT-(E"EH2!7'Y'3&"FE1^2=9A0CB$@$O&XI]K0_(]0MX3 M](FG):$%62-7<.$#!V,0<%G.#6V3H+G\OZBG^N#:F)ZX8Q\*Z@ MLX`^C(@6R*"G9$D*3^.0+DZ%W_`(*41/WY1..`B*6OM&WT2.D/NYY.VY9FO] MJ^._ZQ$H70PCYYEW3N[_7!LH,[1U_&A+S,&'+EVCR;3B7N:;/];DM>[`BOK# M$&Q02)S\BDMAU6]T+N64(-D;<=IR^0-]9K/SS7/J=D0=>O:11I?9XIGY)>PF MH@M`$6_(+[\$54VSI.HR^65N^%*C:=3=)[]TC=_J6Z&JSD)`./:7.J%S'X`7 M^P`M839YMVYJ27/>X*2+A+ZUM<#(`^1_8`1\LM]C3V51T3DH&AF)!M%[DC7& M8!G[%!],-A*.2V8+AG2#)B-U%S'=8:Y?<4`"WK;VJ:XU8H\&HCXRFS4RDG)2 MTB]XL@^FN4*/IEM)>);LV,$S_2>0$)^#GD;'S,=VL26D`'$-:]T#JE(V,C2Z MP*$-Y;HA<8^,3;%)&/`P(`E+Y\D)/1F!6^@8D!I75FD8$(^V3O2\ MV&:_E$&=FZRV,3&S7&=D.PCYLMVMWVMS/B*I+0'AI>CVL\$1&`4'%7U>II"7 M$A"1\94NVZCN-02D:OI4F]G6-AHBMMGXL;;4[2[O(R`6XRM=<#6F?03$ZZ2A M4I0R1@%S,[Y3M[0RY,1WN)/#."?UH>[E?UWBD:OT^EVY3 M.#ZZ(L*4Q`3/$2#;/2\7E)*5.7!.>1%N/G)+#'QZ$H_"G+[O+(#_ZXL8OUPY MSN;/W7GJ='D!`T(..OXM2C<_DP4)7!PW*F.8B9:;I*#@I?L`_9UE+T.TEC.\"#7K%H5D&4IK>)3- MY8[X92>$:/(,S>JAQ&@OMDTUE*8*$_`R.CIPSPC>!R0\=^$2`N\,K1T8&,&^ MD=D^`K6L`I;YE331C%>FC5>I-H8PF&Y[*KB\3/PWF?ARYC1)]A4F%ZT*AX$@ M75LZBFA702D8RA$1>@G"$'A7*9"-0B42)6A+S_54CNQ^L[:=*4Q$8;NHDQY/Y:^5E7(L]$:\,K4^;?^HXY\F,]$QK;T1Z! M=O8X9)IXV[GJJFTQ"S.GUT_IC<936J)B^_`%S$^[#+-_F1A34M"UDPV M%+B&H_H:HX&KKP&=3%_OK,4@YH(/NQIIM<9ZQ*$OU)#21:%V@BR;]8H%DRE( M;MZ#.7EH32'S0ZDCFZ6J[1Y2S"W='U/17Q$G#1%1**6<%=?/0\4SF3MK8C5B7K2C:RC/7+WN956P#,]M+IJ)> MFR"TF(&NEIJ:/CUH5.I(M=J(GX[TM:9HJ)\HR+X>.VRY/>#1F1R5U-Q9QG/N M/!?D,[OY[^0YXI6T&T\-1Q9:O&X/"9Y&[8Y3MVT(:DB,*^Q8"MT_C+K=`>2# M6BVXP=U:S@R=HO4:1NND'"?P*ATN].NKC=V(/6LKBK9.0_I-\[4G]L:I5H[L MGN))B'0Y1LHO$=!8\2&+C=TJ7Q5E,D'3I?!J;.!9!DN2&@D!]3-=;Q3DP?27-^*Q<%2*I_1"Y8!\,Z= M,"`+.YZX;KR.?7KKD.RIH&LF&<_!=;PJYX$T5[E*=E?Z]'HO3]K#J][%]@IA M6B4Q79+]M*&TKY`((XZ?A='.34,I1:PIJNXGFK:?3I2<$NT!M=8THY':"!LU M$;;GL@95=\,J?RS+*K[]Y;C:6"!OT=!'PX%JS_A#_X%#_X%#_X%#_X%#_X%# M_X$A#*;__@/E=!M9'J=APLM+\C>W(+Q+WW*N/;*HTMBE1,IG+;6*E,B\.*=SAIW`[3(P_:ZN*_"%O>\C; M'O*V8\W;SL`C"&)@M'-LC<Z5D$GA7R2LE MX`+D3]B7],5\W:/EXV$KH6W4>JYFJ\^;'J:,S=G2;7A-LZ4X4=1KZN1N)PT"B[8X\5QD46W>E4SF2 M1?$.^892RV46XYA)-6!T9)(E]U`8D-'1EO=GQ"O[*&E2FDUP,QNJ-H9CF%T= MD%F[0PM\GS;`!`'QTCX1;N*M80"IAX[@(S"H4D[.8]F'<>)H]U8M>H28('>! MPC,4+Z)E[.?-I\P43+3P&XE>VS'3TWU4\EH'6#D^B9K-M)W8$1^#;RU`H>/6 MK&27;`<&],[(#"372N;H"D9PE8!U!Z(H?=W7A*[X&(^BZH$30YFKLN]2)0?$ M5*+L;\5U7=O+S.ENDB-5TO#A@-/"34-5N+.J=>N]OZ1E=--=8#,&3\B$1^$N MJ8K*DHMUJ1R9#;'3).P)T_SQL#=K;:/.%:&2\)!^=@@G[7M2R2Z#"!#@C#U! MQ.0UAOG3#%2N.Z6B._G><3%(:)7L)`%=! MVHC2W+XE7Y0OR!C3+FHQ ML^1+(HZ?&+5)3VY.W`%'OKUH M*[=!B420GJX0.ZDSAW@"`K`TT^>GB=5(?$LC4KD.1=(_3=M0.27>@,CL/JC, M8"0*JZ"2%U7TVW^T),1MTF&$5I'3`G*!;1`/E2''U5PHY`JR4JN4]^?*[TB= M.!BZ)J82F]$(UL$&A'*MV6A>5A7I#/IQ9.864A.KD?C"1J1R]J%_1FBY34DFS^AJ#GCK-<8F@X3[:X?_I/(_I$`;(&*@;)X^4-#7V'10H@N,H.9T$S%\"%A\\)B MDX3-QXID'4_^RW>*AXR3$&(2DY_%(?G?6T`\EV>R@7X?8MMQKB*3IW;H;UJ1 M&NY%RS;OJ8[+I'6UL;.TDY8UBU;D]+5I[W$+G>0!2OWFYX3,&Q1^KV7WW/?3 M:CR,#SOE;V2G+/J&G<']<N@\4`/KXH>E],I/A:#8X;+BJW9#A-[AR_XRA7[X35SFFAG.)") MS*N4#O3TS.OJ0VGF=-/`:6Q3I0FP2DI);KYTOXMD<.YP,Q]&`IE[&ON@^ M,ZXQ-JS.A0X?PQA/_TG:;_<]/ MH'`)8!2'9KH=J`LU[`,8C>#K:(\GN9/[%*^89Z:11['GB:=QV&E#;6MUB8^,CWSJMKK=]3 MW%(AM(,?+GST]$+YT&JZS&D9;4S;RN_P&,LW>M["/F186U0F:IQ& M*M"K%S7%5%9*O="\2>!"'Y2$FR/RGW2H29];$KB>;.\Q?1=0;3J:XFQEQ96Q M!&/0VZR2/P.$HPL3S$W,_!)]2P=AAN=,T4N4X=3CTB5SZVL41O!+(@F]J$CV MUBM(HH`)QL!,:_`.CK8BNQZUWX6YEHE^:!,_!E/@ZC&OU35CTVBNMB M:67Y[W5%Z(!?SY?;WRT!>&U$[D/S#[$[%V!"+FOV?&+X:KA!%%4\943T/R@%"L])7>RC7Y#0#S,&4C__S+(8TMBZ@`^FCICX^)K)Z$C9>B5 MEL`TJFA([]++" MY_+-=;M]T:VSI0YH'CI>SVM^B;.]0SV#?KZ,K;4]>ZN@80Q*`\V6IAT:A=_U M9AXB,GT]JX2H,FR5$7/MC3DWQL:O6*C*-]+=B%X=R==`5]LAR=:76#0G`>ZV M@ABUNA11,U!_,U*A)BQ]C4]+35@;J='4A+7BH:A&/F"A"S7Q'&J4\1@&P6>36L$8Q1]KC^LKB/<"Z+8"M_8J!O_;V`@4-B M21WK;QNIT:R_K7A8/.(A!N4"X*4FB7%,A`339:&EFJ&RK0ZFPZC=YC#B2C%6 M%Y:VZKE9(E*CQ40^(H&9FJQF9H,XKU70;@4Z#8NN9/^[31;B39?&M=G,;(S: M;('.^L%+T=**D]<1]!B*61#&,<87H\A,HO[$$)D0:6+8*MP MQJ(C4WF^7`(WFB[/G]TDA3LC;F,:4.GI(T_D_^C._-'Q@:&Z>2'^0XZQY0#5 MX`#D&CHSY4G;OE0W^2;4+L1_#&H7`U37I->H^PEQ66&X)=[)6"S=*XA='^$X M!',BQ(E/^S$:[.33QDX^/DKPF"ZS^AA#'73K3"P[00[5%><%`R0M-X'[,WL2 ML<.DSH",&I,YB.F5%OE'B*H/UINT^T9>T@VAJA1W-M"'^'MFMCOC="FQ%/4W M0S:RF7`7;S9^LA0ZOK=S`TL4XGR)1$N7+(!+NC>6;_-6X)+OM,_3'YAM]\;# M5R6PI@2+3/:>%!N=1MR\;<\J$AGRA6+[15JY%,BVSTH)B=2 M&SN50O\:5:.SII6?]4T)ATK+];EMX.GKMM7/I'B/D/<$?3_ID)KW%7'2OB+R M6>^<*MG%5;N5]#-OQ`10R.]S,3(ZN00EL-J(4LHNBI-/%.[1+5+T7G=V.T1^ MD:*G7OW,LP9.\DM3F:#1B=/$ROJ"U*Z^YH^L*+:W1AQV4'F13PYQ34^_ M]S,!D[E6GF0J#YV4[ZJEG?COXL4GX$9S=$WF-B6PG0$/K#>)Z@U.1#6!9+,4 M5:X]34H>MK8GH!8+J3W.TL-T['=-9+R6HOJ86HG:#8J,QH8='%7ZRS$I]S3# M^)E;[OG/H^_V9VX:41W=7$IOMT;.LUKN+VNUV%?NKYF=4I./*E7#N;\6?M:W M6APJK=S-;P%O;)NN&=HZ?K0E:ZT/7?JH6;!*3V>%SYLR2LDU](Q2"I7`%:!N M&N)&WTBSP>3%!!N`'7,#3ZV8!XW1>?8[L**G5"'8T![9P4K>O6>49CDEH[%1 M$R_YYZ4J%/N*ACC8VMYO="FV%`3QP#BR6H-3E%0+@<#--_:2-D:[@^R);4U. MD"96*O69%9J%8^T>1E#D9G5CT*'$XF1H`VQDW[95#L#2`']-1Y89;:@2*<^E0*L`_XSRPA`&, MP!5\!#6V_4Y`$5%LST?E^@%I'5AX1:\H*[^!,+>PW*3LW@&35B\_5'W?W-]+ M=H_!,O:IL>$+%"8-FC"DX*JHDYOHZ!7+#Y^F1Y"&5_BP7VR_W?J'O4'4D>MS MW>SD;OEJD6"1@PBL(]OY50^'E;=_WWB!P]Y4F,C*K6,=I.RN7MKJ%?BATS'' M;%8J[";9H59AI_/B0VVG"$?YDU[)*VY9Z\Y)&-)N%NDU'3^AG+SYR7[NC5+! M)TEWSS[7OCX'8KU-@7`5A1U]:THH*9AW]B`=N`/A(W0!>P3%,=+NXZL`?B%@ M)+?QD]'U9,*ZA;7=.T7>2K6KS=YCQ/M!L4>1P#1-5F><]8;:]NDWI:4:6R&9 M!CWHZ9"JQ8X65?EG@(P=NA'PDI&0<+#RD_N`MFBV96%ZY1WQ`FQ">YHZB=FI MC5'>^HZ\1&9O&17:E\$2A>L$\Y-M]LN^IJR0*+8/8(1*:63A'EF"*1\G6L+\ MU-KIV(1(*.;^@=,!8C*Q$1OUZ8_0+* M2-G:L.W$^8C"S_1-0N0";%9S94Z6`@I%Y570TK')45/?!0P@)D.B1VMFU5?F M-$[U5=#2L;M04]\-,%LK1NF/4U4),MI>%+,3!N2E)3XM+6'63*E%!:VE*Y)! M`A]-/?MJGN(;^W5/"FML*_&3[;7S"86G/K&'JVHC5+W>0$*.`7@-(?.6+^\J M+>,*:<>\8]])C.G#$CC;T>#),S2BUG:&EE/14G.\?`VU%0`%;8JXK/D"B[!G0M!0`+G:[!><#WJQ_C(>AZ2$T/6 M>.5W"]5'H,8\L>56Q4*HKG`*?]',]WV(S.Q_.WE:UJA*E%+4:S>V\KF.AO[\ MNFU@XKKQ.O;I6TZ3-Y_G:!33SH$NW M[K]VQ1<>>!%YP*FL^GGU$54Q"VCQ2_/0";"?PNY]BG&4[`88P21S@R-)V/I6 M4E7ULH!*O/#480BZ[*!LQ.Q!J!D$%X>1[R64`99_"DKM.%78H'N.$EO,9;S6 MH@!^9B=O=3D2(]D(,R$%7S[B*[>+';Z9(?RDZ>VXGC(2O5M&2T[BJ[:3%OPS MRWFGF)(P;$!DW]R[L60IB:_:,#)<\[R4=$ZSK'X[90K:ZQ*T%")HK#QHZ5QS M!B('^K@+CF[1U7D(QQ$J+&MV;VAH5^6"`MLE!=TU!!ILI5I.H-VI%QV8J>H" M$?;65*MM8G-Z_3KP&NH06OCMN=TX:V"N4D%4!,MI!HFIP:E@-N#ER@?)KBL1 MW7FR2A]T]5DI,K"^AU-4406NBD>5TL`IV?VC-0AG(,T'X`>X,:B/-G;CGCZM M0);K-(04]1$L,)$K:57S5PQ#>E\OH&;`72_41<'V49DD\)W`*)1)JQV,I`W$ M:3;,?0B0CU:TJWC2U$2@QJN#A-6=I*3&NG&1.-)BJDS*%(Q1C\V`%4ZBOH[H5]-F\E"G-R0M*Z7'];6?.M3H?8U&8JY8S]RYVK=5GV?# M*A0+]6P]'[/#(4X:S-(;>WB)0J?:8%8E,=[_/C.^_+VOPW?O?WGFT_W\RWVWSZZ7U[Y_XB.;W]_OKJ\.?[QYK?KYQ\?[O_;GYP] MW$2WB^W'33![.UO]\>G"?3[Y8WUZC;_\=7D!3D__+=SYXW:QFL_^-5G]\?C6__P\_][] M[Y^^_!#\=GVR"9W-Q]?3OSV@S_-%]/1[/%^^?OOA?OKC#T_W'W^,EQOWYNFW M&?[+^>/#TS0Z0=?_>W1Z-WOYTDIMB\QL%PV_.V>=G@.(&6U):.IX84_<3@V2 M`2]77"`+V.G(72;DS.W5B^2M;M-K)E?#M++_5DG)7Y,@9AVOS<%:9F`])=\* M;@4,+3>BKYUGPP"7&`PYK!8YG#D<%C\#1T6'XXJ>SRJ M5"G=.!RDZ#I(>5,[2!'31'*X5IN@QI32QF[<4Z85R,)!LQ4K-+28:\\#E7'2 M'][EN86ED?987'Q'K'_)U'81=%MM._,"D)9)_A'`U0,]DWD$H;,"9DU%29XQ M'(M(6I&:GO0U"NKS#"5[,LRO/&"];L5,H;YH^6).%]:31,]>AQ>=U,K>4Z^+0J@)Z6 M1UQDVVVD@[D-T1)@3,!S_`M@5+,='&TM5V):[8)-_F@^4KCRG$DU(Z"1`3], M`N\,/`(?;>A];!6WRDW12KPJY&;YP=%5[RN_TZX/S."\[.`XCGG9!9NN@F`E M9]N//L>NRFXMBC2H&4[#QQ0;4]K8%!7I>(EFQ4ZG%9)I[ZBA>BH`;E"P8JX^O496$1S\O>F M3G69?&PY9BTSL^B[V2CJ*9BJTC9W!-O`R?+)0YN%MNE`2X/Q8J[B#D21G[3I MYKZ&UOKYP'%M'[K&9*+<8;:S@32T`0X&TX4/5^E)K,'C[%:&=EN>\4Z1#M`4 M#TTO`TR(^\GV$CEL73!G2<.'5D^DNR!M&JR^2[,C7A8U!(H:BIJJ4AA+(A1Y M6#%:;8%Y+;50@D];8M[&-A3OWNMU"^_U@F?Z3Y!O1B4WHNR7J,]3VE+;43Z* MHC.C_MYQS5(X8.(8AQ8^,FN0*F>1K:H^7M9?Q1(R8.HD-%F2CO>6\K=SDOHC M,I3DW6W3CV/5F-G:RFJ=TLR7LNJX:NF;4Z!J;D?+X&*]GK_38$L1.P.FZH96 M,(FW:=PHL1-RF^H^9^C8549H:Z7K,(9 M`4W(;\@>0;A`UFKZ..%:;`DQ``E@)O=G)]M<+?IW:@S:TG'NCN/.4$#X"%W` M%F#B)^229RUFP$6K`'[)FX.?(MS+,\@Z!=50SZ MMC.T_8Q.IX5S:*=ASRJD'FH6T^4I^1%TDV(F%-*_VF9VQK^QXB1D_;4K+N!Y M4=&U_97K,,(L/LW6`8.=1SC8VN[:*SB_N)#4TO[A#OCDQZOW@.Q`')^V!_;6 MQ,CH2AW!1Y"Q-'C2+B;`R/0HB&[URN:]OXVF;8 MX$VRTY5^@W;:I5#YR^;ZWJZ_VY6%M`]W(3S<&:`'4N3G]+$[BG;L^',0KM\8 ML^2>AS'"`*%O16<6_K>1AP679%PPP-#]X/CQ($/=9F&_4=];55EFB6_U^%HK M!IFM'S1'/=P4;%W(;R@%R]!09G<_:5KCK5O>V'(`O*)_8SE8;HUF]OO.\@Y+ M(7!I'FI3X/)ZB!&JS#"^K0A52M'Y&4/OG:`UCK8JO2?K-&6E-;;HO2 M!UZL8*'OFHIP=S4MJ:YPZ-C5"RLJ%]X21.6J*]HI68FRT@M.M,])&-,?XJ0A MQ/S!"3*CN4'!(Q$;>`.,^X6%MS_?N8Q)2[0EKEF])1M#M>/*^OR>D([.G`A< M.#`<7HY%Y[BLG]D,T?@YS$%W+*MR)8I2AE()R#M<6B;VE7EY MH9$=8AQ)BY`O>?&'.RDJF_B!U6K))&@.MMVD6/F*EGJ*=JAFW#F/1VOAG,'[ MP;E+F83^&IO>+X2"%<4A!!L41C!8P6")PG7"9+'-?JE^232E,\N97.Z9$$6E MOY2[."I"6.FD0XAE#_VO^,60=KO-'*Y,]JOBXFN[Q$K"H-D-J`3,R60?HF^Z MN93PE)9N'77H'77H'77H'77H'77H'243CQQZ1PV]=Q2?1N?TX5!N[UC\ZY&` M6AJ@MF=R9>=-+NU)C$G\C'$6T6#C#UDP&=J-'C0%?1V8:GA@*B-H+L8K,[#> MWXO+2LL.JP20TDN,A6A%(&JK?V1[1\.+(6N\^IZR$(+^"B[!G0M!(!(P,SX: M"_2L\6I_PX)S&7X@2_T&Q!%T^:%G?#06Z%GCU?ZDHG#?QR0!G8ML+GAMX#06 MW74!5@BR)/;Q`48^]&@A@L">O?;16+!DC5?^E-K^,SJZ8SNNO+?2!FA&=LI! MO'^W_16'P=6_L?MHD\#I0/I^4VW(VI[\E-T8.3[`F5QY=NH&1":\;Q,K:V%W MHP669D(30/*:4[Q!6!#H/4)>'^K:\;&5>Q!6U1X9^9C>EPQL9FCK^-%V$GA7 MQ%H"#"X`2),F/"ZN^>-!@M\V6/F87M\4Z6%VC&IB%.>$3,1/LWJR$?]T`V@F M-5CEF521M;_E8]L94=$XH`T'2RF(?"CIR56^T)F8.14.=E*AW998>B2V`HK. M9P$5M)2L<7?(-W*SH,K"UAR3T50!&!VKO_[3U=[/54!$E,O+X[RP4G-NTKI^S9$CQ`3]"Y0>(;B1;2,_8GKHCB(C"R(K?Q&HMMV MS.1/?]7[05Z!E>.3/8D1U>V)C\&_%J#0E>J44LE[!P97"),=B4_3KW-T!2.X M2O"Z`U'D)PE<$^KB8VPI@RNF2TX,)>ZME"\ESM75G3PZE7:73\9E*EHM\;"2 M%Q:/5W#Q=3MA"DNFKN M%"YT48DNR$!IBUX8Q,0ZL\4>!9FDZ=\1>0&^A@$*DZO+J8LBP7.92GJS^1I$ M#XC\AMYA3HI_S'CW_L2W75,D&1[WJF&%&P;EL%O*F,\`X>G"]%H=V/@@44_@ M3=84LB_)STU8(1??406,8HAJ:"PC=IV?V7.!F*@?>[09U&2!'D'UTG/;+7XA M>N/:)0MBI>/1H,.[\WKO^LM8>[^OR5>/?.1.?-+F*+2IU6V(7`"\9*TA__9B MEYY-33`&A@Y_.%F/:^H+`RN?^:QF`OKI'7-#EJ,D+O%)7$+"&4SM^PQ$#O3Q M"X4][KD3T@9.Z^=CF#;MX]=W M=U?P>'/_YJJH1AH_'<<\:1ZYQB8G0P]:."/K:L\C02.;!!'TH!_3G>(=<.,0 M1A#@??Z!YA+B%)SILA8!KVGU(8<]ZN!B)?87VMY0K6G!4\.]1\D\'5/Z\^=4 M^O2(0=`>-*7QM`AF)\,C;$.:M:'K?D9/+8/CS28MK71\#V*7@!:']`P+YRL' M6KH.?ECZZ`F7TD%RV^@"NU-"]H*0/4]_T/`*HJ8=-0]?M7/?Y+3OUH%&[BY5 M65B_'RB@Q_H!:@$J';Y7UACS(UES2BO0MQV82RNLB%'O=\]H2W?']].N?$Z` M+V#@!"[PN$.A#@*6#R$$E=*%AH;[9((]=IP-I*4&P,%@NO"S0[)N(F(P)Q`20R"AT8\=[E,1+268U[*8MU!D4%U\K20+!:54Z#.$"4\N+ M#,VL*".#!U8\?*T>[(I8-)_RBH@J=8PM1+TE?U`LT4M?1S37TI&;M^W02%:/ M_."R_>>P78W0`>.M20OV:3!"%S!1U`-,^XQ M6,8^;1UL0G=Z@+?JE`]0C0?O/6ZWZ+;^UME2IZ*A]NX,+*)^]E(-G&0: MAP=@NCPENH+1A>-"'T;;\^<-3*]77*,@HLUT?@<.7T-Q;F)6(Z)V/:7]Q?EA ML9E29 M^0\"I^/OA,1LU7//W5:2EK,)-R8%'AW6)<4SSS`;OC71P MM+W5X9^K7=!I2/\*SLP%"F=D3Y;NK+@F7OF+H7O)V@BU].:2CK?VCQ"?`>R& M<)-6"WQP0DBC.BHHXVQ$7Q3&S7_H>I4#5R]I(M`=D<'QID%1TM?F M5=_">SRNE!].#1ENS:"5CG,G!# M>AQ[&>3%#%2L:7`&ED[L\Q01B-$;NF,51"?3WD_]+Z>L@/D^B.F5VRQ$/D7K M-4SZ)5P`NOZ[%.R5D0A57IC!;TPTX)T9R3N[1F):[^-4Y3XET/N;/,S,!0Q* MF0N>J@(^.B/,X3'`R)6EDL#1YFYG@)ZJ$L&L9>]:)!BXOF5QS0U`J8Q/VSR] M@G_%T$M$)O$&9V,16)15E$ND-JFJ5,:HHAH2N8J4.E_) MJ.BBU7;2JUSI6DN+M).D//ES,E3N(%2!PSC\I`J$N=[[R_1PF*,.K2MP&(?6 M52#,M:Z4(>JOQ"9I/WL%G04=*0180YU-E>0D2-O#X;MX\0FXT1Q=.X%'"9`@ MT0/KY/C"9#F.FD"BH6<#HKR7&UH_EVQ37R=W)7")H9.$U=V*%FO;=;)OU)N. MRPMW#RB,YB!<4S=D\K8"FY&=)U,X9D.I2Q8;(R/PF[MVT,3*^A%6JPFVZJ&Q M6Y:..Y+%M%)D-+[]V)KA;MH"FV)]IQ28D:7"Y*#.PO$CRF6'[YLP20 MTJ6S4_(?T$T:]O-[(L9'MA<#7@Q9X]7^1O@`IW#WQJ10'*HR>XNK+KZ(Z38] M2^/DW:OS4H]]HZS\-R8FNY(\5I\DXMA&EFZH*@&OY=Z&(8.Y38'_X/@QF"YO M0%3YO1VSZ91J2!M`1BQ]:$F#,,Q$SJ:W2*>18'$4C7E;>KYJX;A@3 M-O0QY:;GBME])MD?#G[6-0U81V^>'EOWT5ZN#\@G,N/T$:E"*EMR1U:E>(,B MH_=&.SA*N*1&5'C3T1T$A)-QC?1$,M(<1`:PB>*QGN0=I0X=:6G`LMN/I!QH M[TX4]))>8#*TDU[@FPW,!`,;-AUIZ0IEJRSJHP&L\->$%U9XT'IDO"$@:KVQ"ZX)Y$K>&=XP,\686` M=_?`2\G>8X%"ZN,&1L,^74AC^WLZTV5R@0=CVFDK[3(S#=*1Y6)SZ$V,WL`< M)%-U@@CUWF:W%&'3E@+`.XL3(TNNO*?5'S?@*?F5H=B6B_-(IJHHGMIZ]O*G M9+(7I8CK2!Q)]G(+3TZFX4M+89>88AJ'K:6G@^2L*[[SF??S2/U$MDJ;F'#= M3$#MG3_..K9P)V1"P]JCUN?/+L!D@_-\ M`@*PA!$U)/8CS&E;?#H&^B)OD@TVDEU0$LA*%D)NZBHBKZ']@YS!K#<^V@)P M!$'LI:P);Y!V2.!DRP"3,*3=ZI/ZQ.W^3[+JF614*63[SD@X*2F8/SA!MD+L M0"@\F%IY`GK7U^$4!23XT80\"7C>DV_-U".9DG6,EFA$9SH:XQSU66:7/ED:T2=+-5P5WSV`VL^[ M#&WLY->6\^42T`0/V)&G/2-IY!?0_@&IK407@&C:\>GQ=4PO(Y?^V$@\KT$L MR]4I'.91BMUU*,+>O0,>\9/JATG@71%*?N'Y8%L&U"B/[<;*!DRG&7M--0S] M>/`9VCI^M"7!NT\VN`$FH7KZ0KS\>^8928I-3C+%A^W,F?N];AKB,ZMKJ+Q% MT'QT1!.>751K(8F"A%>5PNC^)R:WC=!IR:FX:F7TX>JULG[XYHKX'>S7:N64 MARO8/5[!ID_&W;D0!"[@OX+-^&@HM$H70 M_FGY2VUG?&]#,#\;II=DIA'8P];S,)V4-\U&,0./((B-;#XK'$:DK":,1A7C M9YXN!!OZ^E:PTI"JR4C.PLI\O$+;E9=14<%7L&[\_T/+`.X!*Z"2[O8X<640"#JW('1]N'G&HJ MZX)3RP)T!:.LS_&I@XT%I@PNUI8B,8_'@*?<]U(#ZF9[G3?RLOMX3[/A->/? MUN=<[,)RWM^`^_BD^L60P:N-3F/KOBAX#E8!`><4&".OW`% M7\)P*%3HF*)0'/&>+$Z% MW7-:O($GO@]6P/.WE\&2-@0!WOT&!>DAJ8E=E804MK(17$=ZQ4V7#,)ZCIS% M+"(_`D\+5@'(!.5P'TU?#B@)R]10XXCU=-/7.2$O4!QX-RBR.A_;A!C.CD9B M,K:BJZ/CGQY;N`]"X%)QO,F:2&RD"*.+I96H5E7-=>`T=/43TFA9(#**VQ!\ MBKWT/F7^,`R'J^6C,VPE<6*AI^V?]+RCIPTSX-/VNW.TSUPUO9&A;_9U,Q[Z MNBH(HX[6?XKG!GMQS'G6%F[#GJ\\<&GH#*COI&B9Z\$>.8/H+PXP-T'ZHR_>;@.3H! MMP[DF3D"Q(8=@(N@HJG%DFKX-B,HAH_`X%N@C;P&/O6ZL]1B@=WX(G`&9+DR>WS88.)Y23M@Q\^:L]$3#H7U3HS>P*>?(#BY^I2>/!!4 M7\)ZNMQ+FCT0/0,N@)N(##7]Q04*N_.2;(VJLAA^Z*^.8JYZI32(:/2S>XI* MR$YI:-`T4+Y`R0#?@3L"0V#G5J.4@+]"+G(*)5^ MS\`*4CI!=..L6[R36`EXA:H=CR2B@W)Q>!44Q19_E/`\=&B?^KOM>H%\=9C+ MY"RY#!F`*S@H77^F]'(9Z*TI=5A+U*QDGV0P+6-0OKDGCFB6\+B`V'7\WX$3 MG@=>O4>:#+J-E*WM6V30;L9'UW6^H\'*R^1&M$!6<"@4 M?<@MD#MZ9P"[(4Q>)=$(;Y'J>,(\-BB%L@S9,"]S1H"^.N33W@;/_P1;;3Z[ M0M;60;."EZX"4RBT$*TU*U!-5^1=1\'D504-UX-;J8_(I;2C5"R\4%H/3-]+:+/F+`-Y$?H0H:D2J60<@J(Q\%^8D&_]Y$>$1+:R,VQ0(#R56U3#M_6=@`\D72 MXXGA6^`IE@>TMSS_Y9C2I(\W)O_Y_P%02P,$%`````@`Y#N(1S_[5>`J$P`` M1M```!``'`!E;GHM,C`Q-3$P,S$N>'-D550)``.+S696B\UF5G5X"P`!!"4. M```$.0$``.U=77/B.-:^WZKW/WASLSVUFR:09#))37H+".DPDX0,D/[:VIHR MM@!U&XF6[`3RZU])ML'8EF03.JW>\=8#(!1B M=+Y7?WVP9P'D8!>BR?G>_6"_.6AWNWO_?F-9__>W7_^^OV^]!0@0VP>N-5I: ML/W*G_UD[5MM/)L/'&AUD<_>.CY\`.P98@VSO]G[J>_/SVJUQ\?'UPXK2AU( M`,4!<0#E#ZS]?=:#M>JD30#OXLRZPU\#VX!@"=\]BLB)ZAH+9^5X" MT&)$O->83&JN3VK^<@YJK`0@T-FS?)M,@']KSP"=VP[8J`;0$^;8:QQ+_>"P M'K?O0?0EOX/&P<%AC;\>V13$Q1>9\H^'HG3]]/2T)M[&10.ZS_'15>FQ34>B M;/Q&@-D_J.^OX3">B9KO?;AYGH@F%F590VZ_JI\ M4C/'M?!ELBA4Z!$BZMO(`7MOPH%C67P@V`AAW_;9:'X3/8V>S^<0C?&;^!E[ MRC5[%K/1!V-+Z/J,BWF^1^%L[G&.Q+,I`>/S/::Y_5AI?WKVZ#4#&I>PB4.P M!]0\UN8$SYE)0$948AB(!C*U-Z7EKVNL3^!=KQ'OU6*KV8E(7"36)V46 M*QA+2[8CL5PP?G&Q6)\0P3RA=D>78WLO+A?KTPF\/+8VA>*%ATP,B__COM_- M]T"B239-4.Q!ESO\ENUQDQY,`6!^`+I"XC_)G](R;Q+JC/M>Z_X-\T%L\AFP MX27F!3Y1]6X'O>ON17/8N;!:S>OF;;MC#:XZG>'@UUJZNI73>D"!VT-OQ+_3 M@S=J(2JBKKLY0M(U-1VG:$C57E%1V^`BJ:N=L?3GG4V8"J;`APP4+4):NHJ6 MPT9Q#JU7FXW_E$-JQ6B&T2Y;\LW`2L>6T=:[ MM'IWG7YSV&4%*D,L2!M?=1,P!8BR]79(CHRZO*(YBMD@[Z@X>>W>S5V_<]6Y M'73?=:SN+?N[8[VZ[@T&E05*J1Q,F:^:8L]EX5?G:P#]):_8P.0PR:*BE([` MXT($]46G/_B'U?GCOCO\F&N&%759*[3I]-+#CU+3B]_G"[+! MV,\E3*XYN+(NKWOO*W^I8JIE4TCQ^"XA<9*HO-?:!G(BB:G(+Y/,RFV9Z[TN@8$QJ[)SQVF&<;,\^VL>PO5[&`3SQ-2O1BK`LT8,5=9%\F\=R1;&@6.A,0F/FG<[4 MCM),A8QHF*CL;;4(]+'S92/WL+'2R[[-YG8V^#C.+.423?S#"ANIIA_54HV' M,KZ]2"_5UH]U-O%S=JDFPB-1NS('E?;[>&E[_I*Y=@\Z/)7*EDV9K*N\D#[6 MJ6JWP(3'@`3,,?&9PC:\5OJ=SF`R.86H!6O51&4U MFEPI5Q)`3FHZWWRAF3HR68"-VI4I%`CNASS`D(7XT4MM,-E0A?K6J["9O$V? MRA[T(7^6(7UAM=TT2L;^2@8K`DM'H5E&MZBM7S@T,DF%TC&IBOF*^-S8-$NN MI(3>JV9R"IE(5>U;*XID$6N6)&D97>:GD18U*:*MXVV+C-H?/K>KKS3*3 MV=AB%U&Z7TK75%-;J21R8UL!(,Q6YSM MJ"-.Z*JK?UE19]5,N4VTF&.\!4IK%SF93(LN8E0:945CQB8CZ,"##R`_JI>9 M:(&:&HL]S*1OBK*;,>(8S+Y`4^P8034:,J.A!/W;\%TZ_R/EN\@ID8KA#,.L MEW'@<1NA;&EC.RQ&I$(.%=>Z2CK6,^F@+5D/<5@"B%B9):%4!E[DF%#.+)WS M5ATH'6;20\DS0W^YR$A\(_Z?]S?OCO[[GP_./%A\1,>G[M/)P^3C$MU?!(]O M3\CIR>^-S_?#)?5.'IRG`^\WOW;W<7'=O:T=WU[=+(ZG]W]XS8OIK7\W6KZ? MH_Y)?_+I\Z6S:'V:M6_HT]?N)6BWG-;]T>3]Z?6G3]T!6C:FXU^_O+/QLS^J[W]:;QOMO^ MZKB?EWTZ_/UN?#5RA@_+T638_]"G]Q^63V_!@>OCQMU_K?:@'WT) MO^5@C5+%7BIMF9.TSA31#-M,OFR+K'3",\6U/=WYG?^U`;\EL>EL=(XKDA71 M$)M)LN6DJ_]B3FE+CM9S/N8JC`)BE2T6K*%A,)-Z4S"86A2(;N/076^,%=.R MK8F\[)NTD'X3\#";8\O=GJCB]3)F*9+/_*(#E]]<`Q`5,,""_Q,HC+-`/5TJ MYC![]$A):,I.!8)]`<%*8K`B$)6Y[F`$C):L80!],-MV+*1;T(Z*[`=1NQP5 M_%XG#LCBB"H746B`][[MG*P#Z_J":6Z+4ZXJ$G MEZ(G+[:1%-&85_;05?9` M3V5C)5Y4S\P%=@(^=IO([3#5^FR'#"E+Z#DZR,04 M<8,6:]$*F[02;?YU,NV_UC8NC!5/PV<;E\N&S]EC..,.R$*YUP1++JVUPAN+ MK[$CVE-4X7_MQ_7V^:/]>F/_L/YZ0=W5-:DE87#!PZL_R\&(ZVT%0WU9L02( M`)&L.;'MN:A8`YY/5VWMK]M:(2JIF>SUST64DZ[%57/*55/_^?E`DI^7%6#=$UW:+7\[UX3N^-X\.#RV@CL#EBD:WML'[# M*W'%E=!G/-I%DR[/E[&G>Y8=E3K?\TG`;[,5I>9,>.P.13TW()'C1/QLW(C? M%_`&FW%^]>')3A6J*7F#03IV0,%+0`6*G(V<_7C!%0`2WE]60L2C[# M,T;"XD@+"BPN%VWQO8!V8BN@$^X$&"AV,;S)Y6;-T(N(P_F@YRD!?2 M!D\<]\0.P1W?(#!1;!G$`MZYOTJ1BU::(D%NH(QJG%)!H]PEB]NNX\QEF((V M1D0]PMJ;0OXJS.CTXY1/(CYM+:.7Q@B])6PIS<+GAVHSS4,KH"EGHEO@A[6N M,:5W;$;#LQE&PL,9(UL1C(KPYCV`DRFSZ.8#(/8$)&K37N#SL)[_V)(QTI:$ MJV0W7*1D;Y[GBC1&X$(@E6+&%WS32X)GO3G_>2RN(OXK6&8M'PL#50SGIOLY MH#Y_0(>X#QR,'.B!#1L98O8G[^N.X`?H`K>U9!$'BQY-ULVWDDN^^FI/6;0) M:+)Z&'8B(Z.KDG"+6PQ/J5!#1T5AH`J+V6CC$B*;C2SSA54!50C;!P\`!>NR M!]]=JBPBN4FNAG:TB#%(#`4T_1RN#G"#^:L M'LNA+6-9WY^_'$BJ,$X^A+^_*"IL"G\A'\`&B*0"IPRWRPS9[R]G2;A*;YG. M4X!+L/IAK:28+"8"ODV6>8*.;8]J)`W?C<(?Q3O?`W-B^,XT:,U?L M4E)(R6;5652/PNT"9_G6AHC',STD?JZ9?P1@HR7_HMC@05YT]P!44(&N6U(L[%#L/!;'G:^Q`H(?Q/ZS(^? M;ZF"76>-USBWV'D6!Q,-D[0PVD+G*.3[NV;+7AAW(2WDWL5IK.P:M`J)+^4' M-(;$1C0\")?(;S$\E)KKXK:41S[[*0ZPS/A^S)-HL#?.;_V'5%0AP50Q@/XB M,>T=1B\<%KC^V935)$XP$OO?:ST]7Q:%]3VG\7BKGG[W&&HW4DA-L$SSVON2 M?LAQI9-J1R-,WLV/.=:*R*,]J@8FMI>86:-34SOPZ^&I;'_7H8X&MVIS+JS9 M!Q38Q)FRA?,%>``>GL\VCXG]*"HH+(@F19>]X*;HM2O&.)OGR:'?(MBB:7-< MRO,E4$44LBM9RMT18LQ(VHT\\L#[F M#*4B\8Q\Z$*/=?,`HMPPLYC"$=X.1SY?O']DZOJC(W\ZME<"JL.6\5IJN*^)2VVMA0O`C]X?,5I0#$@N+%>XC=<.\44)_7[J$+,+8#SS=,4AW: MDH9Z`Q&SEAD%<[=O3OWO)T]@UDE\J]=99\#B/ M.9=H[2\.&+'B`0&[<)??4"O/D*ND&TTI_,=5V3/D4JA,DI$U+>)3PE2>9\BX%7.*/?[C"8A_'M27JZU7!=A(T5^7^^#F0WY[@2_@9*K+["](2!I!_A]TE.&:D9W MSXCTWF73)M!B>+7GY*7US9E-BR-5NJD[VQ=K_C@C?I%(?$:&PIZ\\(R2ATGQ M57W.E;6FC4LY1M4.8DXE=#]"N$&EA2:?K/=QHU<@=V?=@_YF9G5)BJ())4:(W7C<8 MI3/[P`%P[C.O%[ZXQ"2O!X,-Y-FBR9UA,I8O104?P#(\1F4H=B>5_E!^*C]Y M`_@"(_45HHMY3/;"^0P5//FW%>,Q4QB;SQ==Y)@C2PXJ%3-Q_LT<`5*(-+=H MY9W,,T86)3SIP&I[$$&'56,0S1$E"THN`$84>Y`'RJXY`F1!*02@S`\F1,:L M6#1D$"O%@$H%[:`G?`W'8,!B'6228!)@JG5N9P$<<5J[-QXSV8E! MPDB0*:[I&$[!#5MC+1-7/ILCCQ*>0JC-D^,&B9,+3'UJ2.1$W"%PI@A[>+*, M[QPQ1BHM1+5\!OJ$?'\@$2"80006YF#?P"-/!K)"/@#H*D`N"XK$GTO^7W[? MNS'"%$&I_MS2,(=6T(,E=I*,DT`&3;VM_@6B#G-\YGBM+":5FTK]6(`Y=$B` M*:\8@3Z"1YT&'CW@X MQ0%E,TS'XU?>&K4>4:%3N=Q$O4L6G9DJ4PJ;TA_=1X=>4A.0,6*I\2E_0V1$ M65-LMA&7XA%^8`CY)B4N=0CEUI4ZEF1DS*_'*/_T3O$SO<9<4EX(Y,KTQ&_A MAK\$&@[9_P=02P$"'@,4````"`#D.XA'3\X[,,*.``"A#PD`$``8```````! M````I($`````96YZ+3(P,34Q,#,Q+GAM;%54!0`#B\UF5G5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`.0[B$=R/`]A2`T```2M```4`!@```````$```"D M@0R/``!E;GHM,C`Q-3$P,S%?8V%L+GAM;%54!0`#B\UF5G5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`.0[B$=1UQ/0B34``'!-`P`4`!@```````$```"D M@:*<``!E;GHM,C`Q-3$P,S%?9&5F+GAM;%54!0`#B\UF5G5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`.0[B$`Q0````(`.0[B$`Q0````(`.0[B$<_^U7@*A,``$;0```0`!@```````$```"D M@2)L`0!E;GHM,C`Q-3$P,S$N>'-D550%``.+S696=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`%`(``)9_`0`````` ` end XML 22 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814

Contingencies (Details)
$ in Thousands
1 Months Ended 3 Months Ended

Oct. 31, 2015

USD ($)

Jul. 31, 2015

USD ($)

Apr. 22, 2014

USD ($)

Nov. 30, 2012

Jun. 30, 2004

Oct. 31, 2015

USD ($)

Apr. 30, 2014

USD ($)

Jun. 20, 2014

USD ($)

Contingencies (Details) [Line Items]

Gain Contingency, Patents Allegedly Infringed upon, Number 6

Number of Licensee Patents 4 4

Gain Contingency, Patents Found Not Infringed upon, Number 1

Gain Contingencies Prejudgement Interest $ 12,500

Gain (Loss) Related to Litigation Settlement $ 170 6,800

Estimated Litigation Liability, Current 10,000 $ 10,000

Affymetrix Inc [Member]

Contingencies (Details) [Line Items]

Payments for Legal Settlements 6,800

Perkin Elmer [Member]

Contingencies (Details) [Line Items]

Escrow Deposit $ 7,000

Luminex [Member]

Contingencies (Details) [Line Items]

Litigation Settlement, Amount $ 7,100

Siemens [Member]

Contingencies (Details) [Line Items]

Litigation Settlement, Amount 9,500

Royalty Revenue $ 1,000

Agreement [Member] | Affymetrix Inc [Member]

Contingencies (Details) [Line Items]

Litigation Settlement, Amount $ 5,100

Proceeds from Legal Settlements 4,300

Litigation Settlement, Expense $ 800

Subpoena [Member]

Contingencies (Details) [Line Items]

Investigation Period The time period initially covered by the investigation was from 2004 through 2011

Estimated Litigation Settlement Amount $ 2,000

Period Over Which Settlement Amount Has to Be Paid 5 years

Estimated Litigation Liability, Current 400 $ 400

Estimated Litigation Liability, Noncurrent 800 800

Additional Payment of Litigation Settlement Amount $ 1,500

Percentage of Additional Payment of Litigation Settlement Amount over Additional Capital Receipt 20.00%

Indemnification Agreement [Member]

Contingencies (Details) [Line Items]

Gain Contingency, Unrecorded Amount $ 48,500 $ 48,500

Minimum [Member] | Siemens [Member]

Contingencies (Details) [Line Items]

Litigation Settlement Period 2015

Minimum [Member] | Subpoena [Member]

Contingencies (Details) [Line Items]

Litigation Settlement Period 2004

Amount of Additional Capital Receipt Condition for Litigation Settlement $ 10,000

Maximum [Member] | Siemens [Member]

Contingencies (Details) [Line Items]

Litigation Settlement Period 2019

Maximum [Member] | Subpoena [Member]

Contingencies (Details) [Line Items]

Litigation Settlement Period 2014

X

- Definition
Additional payment of litigation settlement amount.
+ References
No definition available.
+ Details

Name: enz_AdditionalPaymentOfLitigationSettlementAmount

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of additional capital receipt condition for litigation settlement.
+ References
No definition available.
+ Details

Name: enz_AmountOfAdditionalCapitalReceiptConditionForLitigationSettlement

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_ContingenciesDetailsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Estimated litigation settlement amount.
+ References
No definition available.
+ Details

Name: enz_EstimatedLitigationSettlementAmount

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gain contingencies prejudgement interest.
+ References
No definition available.
+ Details

Name: enz_GainContingenciesPrejudgementInterest

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Investigation period.
+ References
No definition available.
+ Details

Name: enz_InvestigationPeriod

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Litigation settlement period.
+ References
No definition available.
+ Details

Name: enz_LitigationSettlementPeriod

Namespace Prefix: enz_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of licensee patents.
+ References
No definition available.
+ Details

Name: enz_NumberOfLicenseePatents

Namespace Prefix: enz_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of additional payment of litigation settlement amount over additional capital receipt.
+ References
No definition available.
+ Details

Name: enz_PercentageOfAdditionalPaymentOfLitigationSettlementAmountOverAdditionalCapitalReceipt

Namespace Prefix: enz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period over which settlement amount has to be paid.
+ References
No definition available.
+ Details

Name: enz_PeriodOverWhichSettlementAmountHasToBePaid

Namespace Prefix: enz_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_EscrowDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of entity's patents that another entity has allegedly infringed.
+ References
No definition available.
+ Details

Name: us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of entity's patents that another entity was found not to have infringed.
+ References
No definition available.
+ Details

Name: us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355

+ Details

Name: us-gaap_GainContingencyUnrecordedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 55

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6396582&loc=d3e15243-108350

+ Details

Name: us-gaap_LitigationReserveCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_LitigationReserveNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of judgment or settlement awarded to (against) the entity in respect of litigation.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for the settlement of litigation or for other legal issues during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_PaymentsForLegalSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received for the settlement of litigation during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromLegalSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=enz_AffymetrixIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=enz_PerkinElmerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=enz_LuminexMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=enz_SiemensMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=enz_AgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=enz_SubpoenaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net income (loss) per share
3 Months Ended

Oct. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]
Note 2 – Net income (loss) per share

Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three month period ended October 31, 2014, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive.

For the three months ended October 31, 2015, approximately 125,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. For the three months ended October 31, 2014, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 482,000.

For the three months ended October 31, 2015 and 2014, the effect of approximately 374,000 and 142,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income taxes (Details)
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Income Tax Disclosure [Abstract]

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 1.90% 3.40%

Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent 34.00%

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories (Details) - Schedule of inventory, current - USD ($)
$ in Thousands

Oct. 31, 2015

Jul. 31, 2015

Schedule of inventory, current [Abstract]

Raw materials $ 1,109 $ 1,013

Work in process 1,984 2,002

Finished products 4,489 4,381

$ 7,582 $ 7,396

X

- References
No definition available.
+ Details

Name: enz_ScheduleOfInventoryCurrentAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 26 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Supplemental disclosure for statement of cash flows (Details) - USD ($)
$ in Thousands
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Supplemental Cash Flow Elements [Abstract]

Income Taxes Paid $ 27 $ 26

Interest Paid 41 69

Installment Loans Financed Amount 38 $ 19

Capital Lease Obligation Cost Basis $ 157

X

- Definition
Capital lease obligation cost basis.
+ References
No definition available.
+ Details

Name: enz_CapitalLeaseObligationCostBasis

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Installment loans financed amount.
+ References
No definition available.
+ Details

Name: enz_InstallmentLoansFinancedAmount

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814

Royalty and licensing income (Details) - USD ($)
$ in Millions
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Royalty and licensing income (Details) [Line Items]

Patent Expiration Date Apr. 24, 2018

Life Sciences [Member]

Royalty and licensing income (Details) [Line Items]

Royalty Revenue $ 0.4 $ 1.0

X

- Definition
Patent expiration date.
+ References
No definition available.
+ Details

Name: enz_PatentExpirationDate

Namespace Prefix: enz_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_RoyaltyandlicensingincomeDetailsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=enz_LifeSciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Goodwill and intangible assets (Details) - USD ($)
$ in Thousands
3 Months Ended

Oct. 31, 2015

Jul. 31, 2015

Goodwill and intangible assets (Details) [Line Items]

Goodwill $ 7,452 $ 7,452

Intangible Assets, Amortization Period [Member]

Goodwill and intangible assets (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life 4 years

X

- References
No definition available.
+ Details

Name: enz_GoodwillandintangibleassetsDetailsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_IntangibleAssetsAmortizationPeriodMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($)
$ in Thousands
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Indefinite-lived Intangible Assets [Line Items]

July 31, 2015 $ 27,838

July 31, 2015 (21,683)

July 31, 2015 6,155

Amortization expense (423) $ (431)

Amortization expense (423) $ (431)

October 31, 2015 27,741

October 31, 2015 (22,034)

October 31, 2015 5,707

Life Sciences [Member]

Indefinite-lived Intangible Assets [Line Items]

July 31, 2015 27,838

July 31, 2015 (21,683)

July 31, 2015 6,155

Amortization expense (423)

Amortization expense (423)

Foreign currency translation (97)

Foreign currency translation 72

Foreign currency translation (25)

October 31, 2015 27,741

October 31, 2015 (22,034)

October 31, 2015 $ 5,707

X

- Definition
The amount of finite lived intangible assets amortization of translation adjustments.
+ References
No definition available.
+ Details

Name: enz_FiniteLivedIntangibleAssetsAmortizationOfTranslationAdjustments

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of finite lived intangible assets translation adjustments.
+ References
No definition available.
+ Details

Name: enz_FiniteLivedIntangibleAssetsTranslationAdjustmentsGross

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=enz_LifeSciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Basis of Presentation
3 Months Ended

Oct. 31, 2015

Disclosure Text Block [Abstract]

Basis of Accounting [Text Block]
Note 1 – Basis of Presentation

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of October 31, 2015, the consolidated statements of operations, comprehensive income (loss), and cash flows for the three months ended October 31, 2015 and 2014, and the consolidated statement of stockholders’ equity for the three months ended October 31, 2015 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2015 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2015 has been derived from the audited financial statements at that date. The results of operations for the three months ended October 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2016.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($)
$ in Thousands

Oct. 31, 2015

Jul. 31, 2015

Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]

Finite-lived intangible assets, Gross $ 27,741 $ 27,838

Finite-lived intangible assets, Accumulated Amortization (22,034) (21,683)

Finite-lived intangible assets, Net 5,707 6,155

Patents [Member]

Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]

Finite-lived intangible assets, Gross 11,027 11,028

Finite-lived intangible assets, Accumulated Amortization (10,879) (10,871)

Finite-lived intangible assets, Net 148 157

Customer Relationships [Member]

Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]

Finite-lived intangible assets, Gross 12,190 12,243

Finite-lived intangible assets, Accumulated Amortization (7,621) (7,398)

Finite-lived intangible assets, Net 4,569 4,845

Website And Acquired Content [Member]

Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]

Finite-lived intangible assets, Gross 1,016 1,020

Finite-lived intangible assets, Accumulated Amortization (1,016) (1,020)

Licensed Technology And Other [Member]

Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]

Finite-lived intangible assets, Gross 515 518

Finite-lived intangible assets, Accumulated Amortization (443) (441)

Finite-lived intangible assets, Net 72 77

Trademarks [Member]

Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]

Finite-lived intangible assets, Gross 2,993 3,029

Finite-lived intangible assets, Accumulated Amortization (2,075) (1,953)

Finite-lived intangible assets, Net $ 918 $ 1,076

X

- References
No definition available.
+ Details

Name: enz_GoodwillandintangibleassetsDetailsScheduleofintangibleassetsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=enz_WebsiteAndAcquiredContentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=enz_LicensedTechnologyAndOtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($)
$ in Thousands
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share-based Payment Arrangement $ 111 $ 98

Cost of Clinical Laboratory Services [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share-based Payment Arrangement 1 1

Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share-based Payment Arrangement 1

Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Share-based Payment Arrangement $ 110 $ 96

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=enz_CostOfClinicalLaboratoryServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Oct. 31, 2015

Jul. 31, 2015

Current assets:

Cash and cash equivalents $ 30,642 $ 18,109

Accounts receivable, net of allowances 12,763 12,109

Other accounts receivable 6,650

Inventories 7,582 7,396

Prepaid expenses and other 1,780 2,222

Total current assets 52,767 46,486

Property, plant and equipment, net 8,132 7,948

Goodwill 7,452 7,452

Intangible assets, net 5,707 6,155

Other assets 338 353

Total assets 74,396 68,394

Current liabilities:

Loan payable 3,013 3,013

Accounts payable – trade 9,450 8,762

Accrued liabilities 12,357 11,297

Other current liabilities 969 886

Total current liabilities 25,789 23,958

Deferred taxes 37 37

Other liabilities 1,357 1,793

Total liabilities $ 27,183 $ 25,788

Commitments and contingencies

Stockholders’ equity:

Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding

Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,068,816 at October 31, 2015 and 46,062,065 at July 31, 2015 $ 461 $ 461

Additional paid-in capital 325,077 324,966

Accumulated deficit (280,248) (284,682)

Accumulated other comprehensive income 1,923 1,861

Total stockholders’ equity 47,213 42,606

Total liabilities and stockholders’ equity $ 74,396 $ 68,394

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment reporting (Details)
3 Months Ended

Oct. 31, 2015

Segment Reporting [Abstract]

Number of Reportable Segments 3

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 3 months ended Oct. 31, 2015 - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

AOCI Attributable to Parent [Member]

Total

Balance at Jul. 31, 2015 $ 461 $ 324,966 $ (284,682) $ 1,861 $ 42,606

Balance (in Shares) at Jul. 31, 2015 46,062,065

Net income for the period ended October 31, 2015 4,434 4,434

Vesting of restricted stock (in Shares) 6,751

Share-based compensation charges 111 111

Foreign currency translation adjustments 62 62

Balance at Oct. 31, 2015 $ 461 $ 325,077 $ (280,248) $ 1,923 $ 47,213

Balance (in Shares) at Oct. 31, 2015 46,068,816

X

- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a-c)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities - USD ($)
$ in Thousands

Oct. 31, 2015

Jul. 31, 2015

Accrued liabilities [Abstract]

Legal fee expense $ 4,999 $ 4,183

Payroll, benefits, and commissions 4,717 3,907

Professional fees 491 678

Research and development 300 300

Other 1,850 2,229

$ 12,357 $ 11,297

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal.
+ References
No definition available.
+ Details

Name: enz_AccruedLegalLiabilitiesCurrent

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: enz_AccruedLiabilitiesAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.
+ References
No definition available.
+ Details

Name: enz_AccruedResearchAndDevelopmentLiabilitiesCurrent

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Goodwill and intangible assets (Tables)
3 Months Ended

Oct. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Indefinite-Lived Intangible Assets [Table Text Block] The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows:

Gross Accumulated
Amortization Net

July 31, 2015 $ 27,838 $ (21,683 ) $ 6,155

Amortization expense — (423 ) (423 )

Foreign currency translation (97 ) 72 (25 )

October 31, 2015 $ 27,741 $ (22,034 ) $ 5,707

Schedule of Intangible Assets [Table Text Block] Intangible assets consist of the following:

October 31, 2015 July 31, 2015

Gross Accumulated
Amortization Net Gross Accumulated
Amortization Net

Patents $ 11,027 $ (10,879 ) $ 148 $ 11,028 $ (10,871 ) $ 157

Customer relationships 12,190 (7,621 ) 4,569 12,243 (7,398 ) 4,845

Website and acquired content 1,016 (1,016 ) — 1,020 (1,020 ) —

Licensed technology and other 515 (443 ) 72 518 (441 ) 77

Trademarks 2,993 (2,075 ) 918 3,029 (1,953 ) 1,076

Total $ 27,741 $ (22,034 ) $ 5,707 $ 27,838 $ (21,683 ) $ 6,155

Schedule of Useful Lives For Acquisitions [Table Text Block] At October 31, 2015, information with respect to intangibles assets acquired is as follows:

Useful life
assigned Weighted average
remaining useful life

Customer relationships 8-15 years 5 years

Trademarks 5 years 2 years

Other intangibles 10 years 4 years

X

- Definition
Tabular disclosure of intangible assets by either major class or business segment.
+ References
No definition available.
+ Details

Name: enz_ScheduleOfIntangibleAssetsTableTextBlock

Namespace Prefix: enz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of useful lives for acquisitions.
+ References
No definition available.
+ Details

Name: enz_ScheduleOfUsefulLivesForAcquisitionsTableTextBlock

Namespace Prefix: enz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b),(d)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Liabilities (Details) - USD ($)
$ in Thousands

Oct. 31, 2015

Jul. 31, 2015

Other Liabilities (Details) [Line Items]

Other Liabilities, Current $ 969 $ 886

Accrued Legal Settlement 1,200

Capital Lease Obligation [Member] | Clinical Labs [Member]

Other Liabilities (Details) [Line Items]

Capital Leases, Future Minimum Payments, Interest Included in Payments 23

Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments 579

Other Liabilities, Current 274

Installment Loans [Member] | Clinical Labs [Member]

Other Liabilities (Details) [Line Items]

Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments 534

Other Liabilities, Current $ 289

X

- Definition
Accrued legal settlement.
+ References
No definition available.
+ Details

Name: enz_AccruedLegalSettlement

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: enz_OtherLiabilitiesDetailsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount necessary to reduce net minimum lease payments to present value for capital leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=enz_CapitalLeaseObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=enz_ClinicalLabsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=enz_InstallmentLoansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Liabilities (Tables)
3 Months Ended

Oct. 31, 2015

Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]

Schedule of Other Liabilities [Table Text Block] Other liabilities consist of the following:

October 31,
2015 July 31,
2015

Accrued legal settlement $ 807 $ 1,220

Capital lease obligations, net of short term 305 210

Installment loans, net of short term 245 363

$ 1,357 $ 1,793

X

- Definition
Tabular disclosure of other liabilities not separately disclosed on the balance sheet.
+ References
No definition available.
+ Details

Name: enz_ScheduleOfOtherLiabilitiesTableTextBlock

Namespace Prefix: enz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesAndSharesSubjectToMandatoryRedemptionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 41 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Cash flows from operating activities:

Net income (loss) $ 4,434 $ (3,729)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Depreciation and amortization of property, plant and equipment 527 507

Amortization of intangible assets 423 431

Provision for uncollectible accounts receivable 704 541

Deferred income tax benefit (3) (24)

Share-based compensation charges 111 98

Accrual for share-based 401(k) employer match expense 166 145

Foreign exchange loss 129 422

Changes in operating assets and liabilities:

Accounts receivable (1,376) (482)

Other receivables – settlements 6,650

Inventories (210) 107

Prepaid expenses and other 442 182

Accounts payable – trade 682 (1,157)

Accrued liabilities, other current liabilities and other liabilities 474 204

Total adjustments 8,719 974

Net cash provided by (used in) operating activities 13,153 (2,755)

Cash flows from investing activities:

Capital expenditures (505) (264)

Security deposits and other 15 5

Net cash used in investing activities (490) (259)

Cash flows from financing activities:

Net proceeds from issuance of common stock 2,322

Proceeds from borrowings under Credit Agreement 22,461 22,360

Repayments under Credit Agreement (22,461) (22,360)

Installment loan and capital lease obligation payments (125) (115)

Net cash (used in) provided by financing activities (125) 2,207

Effect of exchange rate changes on cash and cash equivalents (5) (57)

Increase (decrease) in cash and cash equivalents 12,533 (864)

Cash and cash equivalents - beginning of period 18,109 17,455

Cash and cash equivalents - end of period $ 30,642 $ 16,591

X

- Definition
Accrual for share based 401k employer match expense.
+ References
No definition available.
+ Details

Name: enz_AccrualForSharebased401kEmployerMatchExpense

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_AdjustmentsToReconcileNetIncomeLossToNetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_CashFlowsFromFinancingActivitiesAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_CashFlowsFromInvestingActivitiesAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_CashFlowsFromOperatingActivitiesAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_ChangesInOperatingAssetsAndLiabilitiesAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of foreign currency gain loss on intercompany loan during the period.
+ References
No definition available.
+ Details

Name: enz_ForeignCurrencyGainLossOnIntercompanyLoan

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net change during period in security deposits and other.
+ References
No definition available.
+ Details

Name: enz_IncreaseDecreaseInSecurityDepositsAndOther

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ProceedsFromLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_RepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 42 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares

Oct. 31, 2015

Jul. 31, 2015

Preferred Stock, par value (in Dollars per share) $ 0.01 $ 0.01

Preferred Stock, shares authorized 25,000,000 25,000,000

Preferred Stock, shares issued 0 0

Preferred Stock, shares outstanding 0 0

Common Stock, par value (in Dollars per share) $ 0.01 $ 0.01

Common Stock, shares authorized 75,000,000 75,000,000

Common Stock, shares issued 46,068,816 46,062,065

Common Stock, shares outstanding 46,068,816 46,062,065

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 43 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income taxes
3 Months Ended

Oct. 31, 2015

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]
Note 10 - Income taxes

At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.

The Company’s effective tax rate provision for the three months ended October 31, 2015 was 1.9% compared to 3.4% for the three months ended October 31, 2014. The tax provision for the periods was based on state, local and foreign taxes, net of the benefit for amortization of foreign intangibles. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

The Company files a consolidated Federal income tax return. The Company files combined returns with California, Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
3 Months Ended

Oct. 31, 2015

Dec. 02, 2015

Document and Entity Information [Abstract]

Entity Registrant Name ENZO BIOCHEM INC

Document Type 10-Q

Current Fiscal Year End Date --07-31

Entity Common Stock, Shares Outstanding 46,069,000

Amendment Flag false

Entity Central Index Key 0000316253

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Filer Category Accelerated Filer

Entity Well-known Seasoned Issuer No

Document Period End Date Oct. 31, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q1

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_DocumentAndEntityInformationAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Royalty and licensing income
3 Months Ended

Oct. 31, 2015

Royalty And Licensing Income [Abstract]

Royalty And Licensing Income [Text Block]
Note 11 – Royalty and licensing income

The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended October 31, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $0.4 million and $1.0 million respectively, which is included in the Life Sciences segment.

X

- References
No definition available.
+ Details

Name: enz_RoyaltyAndLicensingIncomeAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of royalty and licensing income at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period.
+ References
No definition available.
+ Details

Name: enz_RoyaltyAndLicensingIncomeTextBlock

Namespace Prefix: enz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Revenues:

Clinical laboratory services $ 17,090 $ 15,822

Product revenues 7,687 8,002

Royalty and license fee income 400 1,000

Total revenues 25,177 24,824

Operating expenses:

Cost of clinical laboratory services 10,332 10,130

Cost of product revenues 3,611 3,695

Research and development 867 791

Selling, general, and administrative 10,225 10,285

Provision for uncollectible accounts receivable 704 541

Legal fee expense 1,601 2,466

Legal settlements, net (6,800)

Total operating expenses 20,540 27,908

Operating income (loss) 4,637 (3,084)

Other income (expense):

Interest (40) (69)

Other 54 19

Foreign exchange loss (130) (472)

Income (loss) before income taxes 4,521 (3,606)

Provision for income taxes (87) (123)

Net income (loss) $ 4,434 $ (3,729)

Net income (loss) per common share:

Basic (in Dollars per share) $ 0.10 $ (0.08)

Diluted (in Dollars per share) $ 0.10 $ (0.08)

Weighted average common shares outstanding:

Basic (in Shares) 46,068 44,564

Diluted (in Shares) 46,193 44,564

X

- References
No definition available.
+ Details

Name: enz_NetIncomeLossPerCommonShareAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of goods sold or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: enz_OperatingExpensesTotal

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_OtherIncomeExpenseAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Also the revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets.
+ References
No definition available.
+ Details

Name: enz_RoyaltyAndLicenseFeeIncome

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_WeightedAverageCommonSharesOutstandingAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs related to services rendered by an entity during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Goodwill and intangible assets
3 Months Ended

Oct. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]
Note 5 – Goodwill and intangible assets

At October 31, 2015 and July 31, 2015, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452.

The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows:

Gross Accumulated
Amortization Net

July 31, 2015 $ 27,838 $ (21,683 ) $ 6,155

Amortization expense — (423 ) (423 )

Foreign currency translation (97 ) 72 (25 )

October 31, 2015 $ 27,741 $ (22,034 ) $ 5,707

Intangible assets consist of the following:

October 31, 2015 July 31, 2015

Gross Accumulated
Amortization Net Gross Accumulated
Amortization Net

Patents $ 11,027 $ (10,879 ) $ 148 $ 11,028 $ (10,871 ) $ 157

Customer relationships 12,190 (7,621 ) 4,569 12,243 (7,398 ) 4,845

Website and acquired content 1,016 (1,016 ) — 1,020 (1,020 ) —

Licensed technology and other 515 (443 ) 72 518 (441 ) 77

Trademarks 2,993 (2,075 ) 918 3,029 (1,953 ) 1,076

Total $ 27,741 $ (22,034 ) $ 5,707 $ 27,838 $ (21,683 ) $ 6,155

At October 31, 2015, information with respect to intangibles assets acquired is as follows:

Useful life
assigned Weighted average
remaining useful life

Customer relationships 8-15 years 5 years

Trademarks 5 years 2 years

Other intangibles 10 years 4 years

At October 31, 2015, the weighted average useful life of amortizable intangible assets is approximately four years.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories
3 Months Ended

Oct. 31, 2015

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]
Note 4 - Inventories

Inventories consist of the following:

October 31,
2015 July 31,
2015

Raw materials $ 1,109 $ 1,013

Work in process 1,984 2,002

Finished products 4,489 4,381

$ 7,582 $ 7,396

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accrued Liabilities and Other Current Liabilities (Tables)
3 Months Ended

Oct. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block] Accrued liabilities consist of the following:

October 31,
2015 July 31,
2015

Legal fee expense $ 4,999 $ 4,183

Payroll, benefits, and commissions 4,717 3,907

Professional fees 491 678

Research and development 300 300

Other 1,850 2,229

$ 12,357 $ 11,297

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment reporting
3 Months Ended

Oct. 31, 2015

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]
Note 12 – Segment reporting

The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.

Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. Legal settlements, net represent activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the products covered by the settlements.

Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2015.

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2015 Clinical
Labs Life
Sciences Therapeutics Other Consolidated

Revenues:

Clinical laboratory services $ 17,090 — — — $ 17,090

Product revenues — $ 7,687 — — 7,687

Royalty and license fee income — 400 — — 400

17,090 8,087 — — 25,177

Operating expenses:

Cost of clinical laboratory services 10,332 — — — 10,332

Cost of product revenues — 3,611 — — 3,611

Research and development — 667 $ 200 — 867

Selling, general and administrative 5,286 3,059 — $ 1,880 10,225

Provision for uncollectible accounts receivable 708 (4 ) — — 704

Legal fee expense 9 (22 ) — 1,614 1,601

Legal settlement, net — (6,800 ) — — (6,800 )

Total operating expenses 16,335 511 200 3,494 20,540

Operating income (loss) 755 7,576 (200 ) (3,494 ) 4,637

Other income (expense)

Interest (19 ) 14 — (35 ) (40 )

Other 4 39 — 11 54

Foreign exchange loss — (130 ) — — (130 )

Income (loss) before income taxes $ 740 $ 7,499 $ (200 ) $ (3,518 ) $ 4,521

Depreciation and amortization included above $ 397 $ 530 $ — $ 23 $ 950

Share-based compensation included in above:

Cost of clinical laboratory services $ 1 — — — $ 1

Research and development — $ — — — —

Selling, general and administrative 10 5 — $ 95 110

Total $ 11 $ 5 — $ 95 $ 111

Capital expenditures $ 437 $ 68 $ — $ — $ 505

Three months ended October 31, 2014 Clinical
Labs Life
Sciences Therapeutics Other Consolidated

Revenues:

Clinical laboratory services $ 15,822 — — — $ 15,822

Product revenues — $ 8,002 — — 8,002

Royalty and license fee income — 1,000 — — 1,000

15,822 9,002 — — 24,824

Operating expenses:

Cost of clinical laboratory services 10,130 — — — 10,130

Cost of product revenues — 3,695 — — 3,695

Research and development — 548 $ 243 — 791

Selling, general and administrative 5,066 3,150 — $ 2,069 10,285

Provision for uncollectible accounts receivable 530 11 — — 541

Legal fee expense 91 1 — 2,374 2,466

Total operating expenses 15,817 7,405 243 4,443 27,908

Operating income (loss) 5 1,597 (243 ) (4,443 ) (3,084 )

Other income (expense)

Interest (27 ) 2 — (44 ) (69 )

Other 2 (8 ) — 25 19

Foreign exchange gain — (472 ) — — (472 )

Income (loss) before income taxes $ (20 ) $ 1,119 $ (243 ) $ (4,462 ) $ (3,606 )

Depreciation and amortization included above $ 357 $ 560 $ 1 $ 20 $ 938

Share-based compensation included in above:

Cost of clinical laboratory services $ 1 — — — $ 1

Research and development — 1 — — 1

Selling, general and administrative 9 $ — — $ 87 96

Total $ 10 $ 1 — $ 87 $ 98

Capital expenditures $ 254 $ 10 $ — $ — $ 264

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Liabilities
3 Months Ended

Oct. 31, 2015

Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]

Other Liabilities Disclosure [Text Block]
Note 8 – Other Liabilities

Other liabilities consist of the following:

October 31,
2015 July 31,
2015

Accrued legal settlement $ 807 $ 1,220

Capital lease obligations, net of short term 305 210

Installment loans, net of short term 245 363

$ 1,357 $ 1,793

As of October 31, 2015, future minimum payments under the capital leases, net of interest of $23 aggregates $579, including a short term debt portion of $274 included in other current liabilities. Future minimum payments under the installment loans aggregate $534, including a short term portion of $289 included in other current liabilities. A total of $1.2 million was recorded in other current liabilities and in other liabilities as accrued legal settlement which is further discussed in Note 13 - Contingencies.

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesAndSharesSubjectToMandatoryRedemptionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Loan Payable
3 Months Ended

Oct. 31, 2015

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]
Note 6 - Loan Payable

On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and Healthcare Finance Group, LLC (the “Lender). The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. If the amount of borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%. In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the Credit Agreement. At October 31, 2015 and July 31, 2015, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million.

The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. In July 31, 2013, the lender modified various financial covenants relating to fiscal 2014. As of October 31, 2015, the Company is in compliance with the financial covenants.

The Credit Agreement includes customary affirmative and negative covenants and events of default. The terms of the debt covenants include:

o The minimum balance the Company must borrow at any time is $2.0 million. At October 31 2015, the loan balance was approximately $3.0 million, with an additional availability of $2.4 million.

o The Company must maintain a Minimum Liquidity, as defined in the Credit Agreement, of not less than $3.0 million. At October 31, 2015, the Company’s Minimum Liquidity was $11.0 million.

o The quarterly Cash Burn, as defined in the Credit Agreement, must be greater than zero. During the three months ended October 31, 2015, the Cash Burn was positive in the amount of $1.4 million.

As of October 31, 2015, the Credit Agreement was amended to redefine Cash Burn and add a definition for Liquidity (the “amendment”). Under the amendment, the determination of Cash Burn during a fiscal quarter excludes capital expenditures provided that Liquidity exceeds $7 million as of the last day of the fiscal quarter. As of October 31, 2015, Liquidity as defined was $33.1 million.

Based on its current level of Minimum Liquidity and Cash Burn, the Company believes it will continue to be in compliance with the financial covenants in future periods; however there are no assurances of such compliance. Based on our ability to comply with financial covenants in the past, our ability to obtain covenant waivers previously, and our expected future performance, we believe we would be able to cure a non-compliance event and obtain a Lender waiver. The Company currently believes that the Lender would be willing to negotiate and provide waivers to the Company in the event of non-compliance with covenants, although there can be no assurances. In addition, the Company believes the effects of non-compliance with the covenants would not have a material effect on our financial condition and liquidity due to cash provided by operating cash flows and funds available under the Company’s Controlled Equity Offering program.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accrued Liabilities and Other Current Liabilities
3 Months Ended

Oct. 31, 2015

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Note 7 – Accrued Liabilities and Other Current Liabilities

Accrued liabilities consist of the following:

October 31,
2015 July 31,
2015

Legal fee expense $ 4,999 $ 4,183

Payroll, benefits, and commissions 4,717 3,907

Professional fees 491 678

Research and development 300 300

Other 1,850 2,229

$ 12,357 $ 11,297

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity
3 Months Ended

Oct. 31, 2015

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]
Note 9 – Stockholders’ Equity

Controlled Equity Offering

On March 28, 2013, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sales Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to the Company’s Registration Statement on Form S-3 which was declared effective on August 5, 2010 and a prospectus supplement, dated March 28, 2013, and more recently under the Company’s current Registration Statement on Form S-3 which was declared effective on August 13, 2013 and a prospectus supplement dated August 1, 2013, filed by the Company with the Securities and Exchange Commission (the “SEC”).

On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus supplement dated December 31, 2014.

During the three months ended October 31, 2015, the Company did not sell any shares of Common Stock under the Sales Agreement. For the three months ended October 31, 2014, the Company sold an aggregate of 505,829 shares of Common Stock under the Sales Agreement at an average price of $5.38 per share and received proceeds of approximately $2.6 million, net of expenses of $82.

Share-based compensation

The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2015. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

Three months ended
October 31,

2015 2014

Stock options $ 104 $ 85

Restricted stock 7 13

$ 111 $ 98

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

Three months ended
October 31,

2015 2014

Cost of clinical laboratory services $ 1 $ 1

Research and development — 1

Selling, general and administrative 110 96

$ 111 $ 98

No excess tax benefits were recognized during the three month periods ended October 31, 2015 and 2014.

Stock Option Plans

The following table summarizes stock option activity during the three month period ended October 31, 2015:

Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value (000s)

Outstanding at July 31, 2015 1,358,104 $ 3.04

Awarded — $ —

Exercised — $ —

Cancelled or expired (6,000 ) $ 3.61

Outstanding at end of period 1,352,104 $ 3.04 2.2 years $ 964

Exercisable at end of period 785,188 $ 2.87 1.8 years $ 664

As of October 31, 2015, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.4 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is eleven months.

The intrinsic value of in the money stock option awards that are vested at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that vested.

Restricted Stock Awards

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the three months ended October 31, 2015 is as follows:

Awards Weighted
Average
Award Price

Outstanding at July 31, 2015 21,501 $ 8.84

Awarded — $ —

Vested (6,751 ) $ (2.10 )

Forfeited (1,500 ) $ (2.86 )

Unvested at end of period 13,250 $ 4.04

The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of October 31, 2015, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately twenty-one months. The fair value of the awards that vested during the three months ended October 31, 2015 and 2014 was $21 and $35, respectively.

The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,309,000 shares as of October 31, 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Loan Payable (Details) - USD ($)
3 Months Ended

Oct. 31, 2015

Jul. 31, 2015

Debt Disclosure [Abstract]

Line of Credit Facility Expiration Month and Year December 2016

Line of Credit Facility, Maximum Borrowing Capacity $ 8,000,000

Line of Credit Facility Additional Borrowings Capacity 4,000,000

Unamortized Debt Issuance Expense $ 281,000

LIBOR Rate Period 3 months

Debt Instrument, Description of Variable Rate Basis three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%

Debt Instrument, Basis Spread on Variable Rate 1.25%

Debt Instrument Margin on Variable Rate 4.00%

Debt Instrument Increase in Interest Rate on Default 3.00%

Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.50%

Long-term Line of Credit $ 3,013,000 $ 3,013,000

Line of Credit Facility Minimum Borrowings 2,000,000

Line of Credit Facility, Remaining Borrowing Capacity 2,400,000

Line of Credit Facility Minimum Liquidity Requirement 3,000,000

Line of Credit Facility Minimum Liquidity Current 11,000,000

Line of Credit Facility Minimum Cash Burn 0

Line of Credit Facility Cash Burn Current 1,400,000

Line of Credit Facility Minimum Cash Burn Excluding Capital Expenditures 7,000,000

Line of Credit Facility Cash Burn Current Excluding Capital Expenditures $ 33,100,000

X

- Definition
Debt instrument increase in interest rate on default.
+ References
No definition available.
+ Details

Name: enz_DebtInstrumentIncreaseInInterestRateOnDefault

Namespace Prefix: enz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt instrument margin on variable rate.
+ References
No definition available.
+ Details

Name: enz_DebtInstrumentMarginOnVariableRate

Namespace Prefix: enz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
LIBOR rate period.
+ References
No definition available.
+ Details

Name: enz_LiborRatePeriod

Namespace Prefix: enz_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line of credit facility minimum cash burn excluding capital expenditures.
+ References
No definition available.
+ Details

Name: enz_LineOFCreditFacilityMinimumCashBurnExcludingCapitalExpenditures

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line of credit facility additional borrowings capacity.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityAdditionalBorrowingsCapacity

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line of credit facility cash burn current.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityCashBurnCurrent

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line of credit facility cash burn current excluding capital expenditures.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityCashBurnCurrentExcludingCapitalExpenditures

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line of credit facility expiration month and year.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityExpirationMonthAndYear

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line of credit facility minimum borrowings.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityMinimumBorrowings

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line of credit facility minimum cash burn.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityMinimumCashBurn

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line of credit facility minimum liquidity current.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityMinimumLiquidityCurrent

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line of credit facility minimum liquidity requirement.
+ References
No definition available.
+ Details

Name: enz_LineOfCreditFacilityMinimumLiquidityRequirement

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_UnamortizedDebtIssuanceExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 56 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories (Tables)
3 Months Ended

Oct. 31, 2015

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block] Inventories consist of the following:

October 31,
2015 July 31,
2015

Raw materials $ 1,109 $ 1,013

Work in process 1,984 2,002

Finished products 4,489 4,381

$ 7,582 $ 7,396

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment reporting (Tables)
3 Months Ended

Oct. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block] The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2015 Clinical
Labs Life
Sciences Therapeutics Other Consolidated

Revenues:

Clinical laboratory services $ 17,090 — — — $ 17,090

Product revenues — $ 7,687 — — 7,687

Royalty and license fee income — 400 — — 400

17,090 8,087 — — 25,177

Operating expenses:

Cost of clinical laboratory services 10,332 — — — 10,332

Cost of product revenues — 3,611 — — 3,611

Research and development — 667 $ 200 — 867

Selling, general and administrative 5,286 3,059 — $ 1,880 10,225

Provision for uncollectible accounts receivable 708 (4 ) — — 704

Legal fee expense 9 (22 ) — 1,614 1,601

Legal settlement, net — (6,800 ) — — (6,800 )

Total operating expenses 16,335 511 200 3,494 20,540

Operating income (loss) 755 7,576 (200 ) (3,494 ) 4,637

Other income (expense)

Interest (19 ) 14 — (35 ) (40 )

Other 4 39 — 11 54

Foreign exchange loss — (130 ) — — (130 )

Income (loss) before income taxes $ 740 $ 7,499 $ (200 ) $ (3,518 ) $ 4,521

Depreciation and amortization included above $ 397 $ 530 $ — $ 23 $ 950

Share-based compensation included in above:

Cost of clinical laboratory services $ 1 — — — $ 1

Research and development — $ — — — —

Selling, general and administrative 10 5 — $ 95 110

Total $ 11 $ 5 — $ 95 $ 111

Capital expenditures $ 437 $ 68 $ — $ — $ 505

Three months ended October 31, 2014 Clinical
Labs Life
Sciences Therapeutics Other Consolidated

Revenues:

Clinical laboratory services $ 15,822 — — — $ 15,822

Product revenues — $ 8,002 — — 8,002

Royalty and license fee income — 1,000 — — 1,000

15,822 9,002 — — 24,824

Operating expenses:

Cost of clinical laboratory services 10,130 — — — 10,130

Cost of product revenues — 3,695 — — 3,695

Research and development — 548 $ 243 — 791

Selling, general and administrative 5,066 3,150 — $ 2,069 10,285

Provision for uncollectible accounts receivable 530 11 — — 541

Legal fee expense 91 1 — 2,374 2,466

Total operating expenses 15,817 7,405 243 4,443 27,908

Operating income (loss) 5 1,597 (243 ) (4,443 ) (3,084 )

Other income (expense)

Interest (27 ) 2 — (44 ) (69 )

Other 2 (8 ) — 25 19

Foreign exchange gain — (472 ) — — (472 )

Income (loss) before income taxes $ (20 ) $ 1,119 $ (243 ) $ (4,462 ) $ (3,606 )

Depreciation and amortization included above $ 357 $ 560 $ 1 $ 20 $ 938

Share-based compensation included in above:

Cost of clinical laboratory services $ 1 — — — $ 1

Research and development — 1 — — 1

Selling, general and administrative 9 $ — — $ 87 96

Total $ 10 $ 1 — $ 87 $ 98

Capital expenditures $ 254 $ 10 $ — $ — $ 264

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity (Details) - Schedule of stock option plans
$ / shares in Units, $ in Thousands
3 Months Ended

Oct. 31, 2015

USD ($)

$ / shares

shares

Schedule of stock option plans [Abstract]

Outstanding at July 31, 2015 | shares 1,358,104

Outstanding at July 31, 2015 $ 3.04

Cancelled or expired | shares (6,000)

Cancelled or expired $ 3.61

Outstanding at end of period | shares 1,352,104

Outstanding at end of period $ 3.04

Outstanding at end of period 2 years 73 days

Outstanding at end of period | $ $ 964

Exercisable at end of period | shares 785,188

Exercisable at end of period $ 2.87

Exercisable at end of period 1 year 292 days

Exercisable at end of period | $ $ 664

X

- References
No definition available.
+ Details

Name: enz_ScheduleOfStockOptionPlansAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 59 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Net income (loss) $ 4,434 $ (3,729)

Other comprehensive income (loss):

Foreign currency translation adjustments 62 108

Comprehensive income (loss) $ 4,496 $ (3,621)

X

- References
No definition available.
+ Details

Name: enz_OtherComprehensiveIncomeLossAbstract

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a-c)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 60 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Supplemental disclosure for statement of cash flows
3 Months Ended

Oct. 31, 2015

Supplemental Cash Flow Elements [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]
Note 3 - Supplemental disclosure for statement of cash flows

For the three months ended October 31, 2015 and 2014, income taxes paid by the Company were $27 and $26, respectively.

For the three months ended October 31, 2015 and 2014, interest paid by the Company was $41 and $69, respectively.

For the three months ended October 31, 2015 and 2014, the Company financed $38 and $19 respectively, in machinery and transportation equipment under installment loans.

During the three months ended October 31, 2015, there was a total of $157 in capital lease agreements. During the three months ended October 31, 2014, the Company did not enter into any capital lease agreements.

X

- Definition
The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net income (loss) per share (Details) - shares
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Weighted Average Stock Options [Member]

Net income (loss) per share (Details) [Line Items]

Antidilutive Securities Included In Computation Of Earnings Per Share Amount 125,000

Unvested Restricted Stock [Member]

Net income (loss) per share (Details) [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 482,000

In the Money Stock Options [Member]

Net income (loss) per share (Details) [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 482,000

Outstanding Options [Member]

Net income (loss) per share (Details) [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 374,000 142,000

X

- Definition
Antidilutive securities included in computation of earnings per share amount.
+ References
No definition available.
+ Details

Name: enz_AntidilutiveSecuritiesIncludedInComputationOfEarningsPerShareAmount

Namespace Prefix: enz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_NetincomelosspershareDetailsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=enz_WeightedAverageStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=enz_UnvestedRestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=enz_InTheMoneyStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=enz_OutstandingOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 108 227 1 false 40 0 false 4 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.enzo.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.enzo.com/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.enzo.com/role/ConsolidatedBalanceSheet_Parentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.enzo.com/role/ConsolidatedIncomeStatement CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.enzo.com/role/ConsolidatedComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.enzo.com/role/ShareholdersEquityType2or3 CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.enzo.com/role/ConsolidatedCashFlow CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 007 - Disclosure - Basis of Presentation Sheet http://www.enzo.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Net income (loss) per share Sheet http://www.enzo.com/role/Netincomelosspershare Net income (loss) per share Notes 9 false false R10.htm 009 - Disclosure - Supplemental disclosure for statement of cash flows Sheet http://www.enzo.com/role/Supplementaldisclosureforstatementofcashflows Supplemental disclosure for statement of cash flows Notes 10 false false R11.htm 010 - Disclosure - Inventories Sheet http://www.enzo.com/role/Inventories Inventories Notes 11 false false R12.htm 011 - Disclosure - Goodwill and intangible assets Sheet http://www.enzo.com/role/Goodwillandintangibleassets Goodwill and intangible assets Notes 12 false false R13.htm 012 - Disclosure - Loan Payable Sheet http://www.enzo.com/role/LoanPayable Loan Payable Notes 13 false false R14.htm 013 - Disclosure - Accrued Liabilities and Other Current Liabilities Sheet http://www.enzo.com/role/AccruedLiabilitiesandOtherCurrentLiabilities Accrued Liabilities and Other Current Liabilities Notes 14 false false R15.htm 014 - Disclosure - Other Liabilities Sheet http://www.enzo.com/role/OtherLiabilities Other Liabilities Notes 15 false false R16.htm 015 - Disclosure - Stockholders' Equity Sheet http://www.enzo.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 016 - Disclosure - Income taxes Sheet http://www.enzo.com/role/Incometaxes Income taxes Notes 17 false false R18.htm 017 - Disclosure - Royalty and licensing income Sheet http://www.enzo.com/role/Royaltyandlicensingincome Royalty and licensing income Notes 18 false false R19.htm 018 - Disclosure - Segment reporting Sheet http://www.enzo.com/role/Segmentreporting Segment reporting Notes 19 false false R20.htm 019 - Disclosure - Contingencies Sheet http://www.enzo.com/role/Contingencies Contingencies Notes 20 false false R21.htm 020 - Disclosure - Inventories (Tables) Sheet http://www.enzo.com/role/InventoriesTables Inventories (Tables) Tables http://www.enzo.com/role/Inventories 21 false false R22.htm 021 - Disclosure - Goodwill and intangible assets (Tables) Sheet http://www.enzo.com/role/GoodwillandintangibleassetsTables Goodwill and intangible assets (Tables) Tables http://www.enzo.com/role/Goodwillandintangibleassets 22 false false R23.htm 022 - Disclosure - Accrued Liabilities and Other Current Liabilities (Tables) Sheet http://www.enzo.com/role/AccruedLiabilitiesandOtherCurrentLiabilitiesTables Accrued Liabilities and Other Current Liabilities (Tables) Tables http://www.enzo.com/role/AccruedLiabilitiesandOtherCurrentLiabilities 23 false false R24.htm 023 - Disclosure - Other Liabilities (Tables) Sheet http://www.enzo.com/role/OtherLiabilitiesTables Other Liabilities (Tables) Tables http://www.enzo.com/role/OtherLiabilities 24 false false R25.htm 024 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.enzo.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.enzo.com/role/StockholdersEquity 25 false false R26.htm 025 - Disclosure - Segment reporting (Tables) Sheet http://www.enzo.com/role/SegmentreportingTables Segment reporting (Tables) Tables http://www.enzo.com/role/Segmentreporting 26 false false R27.htm 026 - Disclosure - Net income (loss) per share (Details) Sheet http://www.enzo.com/role/NetincomelosspershareDetails Net income (loss) per share (Details) Details http://www.enzo.com/role/Netincomelosspershare 27 false false R28.htm 027 - Disclosure - Supplemental disclosure for statement of cash flows (Details) Sheet http://www.enzo.com/role/SupplementaldisclosureforstatementofcashflowsDetails Supplemental disclosure for statement of cash flows (Details) Details http://www.enzo.com/role/Supplementaldisclosureforstatementofcashflows 28 false false R29.htm 028 - Disclosure - Inventories (Details) - Schedule of inventory, current Sheet http://www.enzo.com/role/ScheduleofinventorycurrentTable Inventories (Details) - Schedule of inventory, current Details http://www.enzo.com/role/InventoriesTables 29 false false R30.htm 029 - Disclosure - Goodwill and intangible assets (Details) Sheet http://www.enzo.com/role/GoodwillandintangibleassetsDetails Goodwill and intangible assets (Details) Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 30 false false R31.htm 030 - Disclosure - Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets Sheet http://www.enzo.com/role/ScheduleofindefinitelivedintangibleassetsTable Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 31 false false R32.htm 031 - Disclosure - Goodwill and intangible assets (Details) - Schedule of intangible assets Sheet http://www.enzo.com/role/ScheduleofintangibleassetsTable Goodwill and intangible assets (Details) - Schedule of intangible assets Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 32 false false R33.htm 032 - Disclosure - Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions Sheet http://www.enzo.com/role/ScheduleofusefullivesforacquisitionsTable Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions Details http://www.enzo.com/role/GoodwillandintangibleassetsTables 33 false false R34.htm 033 - Disclosure - Loan Payable (Details) Sheet http://www.enzo.com/role/LoanPayableDetails Loan Payable (Details) Details http://www.enzo.com/role/LoanPayable 34 false false R35.htm 034 - Disclosure - Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities Sheet http://www.enzo.com/role/AccruedliabilitiesTable Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities Details http://www.enzo.com/role/AccruedLiabilitiesandOtherCurrentLiabilitiesTables 35 false false R36.htm 035 - Disclosure - Other Liabilities (Details) Sheet http://www.enzo.com/role/OtherLiabilitiesDetails Other Liabilities (Details) Details http://www.enzo.com/role/OtherLiabilitiesTables 36 false false R37.htm 036 - Disclosure - Other Liabilities (Details) - Schedule of other current liabilities Sheet http://www.enzo.com/role/ScheduleofothercurrentliabilitiesTable Other Liabilities (Details) - Schedule of other current liabilities Details http://www.enzo.com/role/OtherLiabilitiesTables 37 false false R38.htm 037 - Disclosure - Stockholders' Equity (Details) Sheet http://www.enzo.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.enzo.com/role/StockholdersEquityTables 38 false false R39.htm 038 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense Sheet http://www.enzo.com/role/ScheduleofsharebasedcompensationexpenseTable Stockholders' Equity (Details) - Schedule of share-based compensation expense Details http://www.enzo.com/role/StockholdersEquityTables 39 false false R40.htm 039 - Disclosure - Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item Sheet http://www.enzo.com/role/ScheduleofsharebasedcompensationexpensebylineitemTable Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item Details http://www.enzo.com/role/StockholdersEquityTables 40 false false R41.htm 040 - Disclosure - Stockholders' Equity (Details) - Schedule of stock option plans Sheet http://www.enzo.com/role/ScheduleofstockoptionplansTable Stockholders' Equity (Details) - Schedule of stock option plans Details http://www.enzo.com/role/StockholdersEquityTables 41 false false R42.htm 041 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock awards Sheet http://www.enzo.com/role/ScheduleofrestrictedstockawardsTable Stockholders' Equity (Details) - Schedule of restricted stock awards Details http://www.enzo.com/role/StockholdersEquityTables 42 false false R43.htm 042 - Disclosure - Income taxes (Details) Sheet http://www.enzo.com/role/IncometaxesDetails Income taxes (Details) Details http://www.enzo.com/role/Incometaxes 43 false false R44.htm 043 - Disclosure - Royalty and licensing income (Details) Sheet http://www.enzo.com/role/RoyaltyandlicensingincomeDetails Royalty and licensing income (Details) Details http://www.enzo.com/role/Royaltyandlicensingincome 44 false false R45.htm 044 - Disclosure - Segment reporting (Details) Sheet http://www.enzo.com/role/SegmentreportingDetails Segment reporting (Details) Details http://www.enzo.com/role/SegmentreportingTables 45 false false R46.htm 045 - Disclosure - Segment reporting (Details) - Schedule of segment reporting information, by segment Sheet http://www.enzo.com/role/ScheduleofsegmentreportinginformationbysegmentTable Segment reporting (Details) - Schedule of segment reporting information, by segment Details http://www.enzo.com/role/SegmentreportingTables 46 false false R47.htm 046 - Disclosure - Contingencies (Details) Sheet http://www.enzo.com/role/ContingenciesDetails Contingencies (Details) Details http://www.enzo.com/role/Contingencies 47 false false All Reports Book All Reports In ''CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONSOLIDATED STATEMENTS OF OPERATIONS'', column(s) 1 are contained in other reports, so were removed by flow through suppression. enz-20151031.xml enz-20151031_cal.xml enz-20151031_def.xml enz-20151031_lab.xml enz-20151031_pre.xml enz-20151031.xsd true true XML 63 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity (Details) - USD ($)
3 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Jul. 31, 2015

Dec. 31, 2014

Stockholders' Equity (Details) [Line Items]

Common Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.01 $ 0.01

Maximum Offering Price Under Sales Agreement $ 20,000,000 $ 20,000,000

Percentage of Commission Payable on Equity Offering 3.00%

Proceeds from Issuance of Common Stock $ 2,322,000

Excess Tax Benefit from Share-based Compensation, Financing Activities $ 0 0

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 400,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 11 months

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized $ 100,000

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms 21 months

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 21,000 $ 35,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares) 1,309,000

Common Stock [Member]

Stockholders' Equity (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares) 505,829

Average Sale Price of Stock (in Dollars per share) $ 5.38

Stock Offering and Commissions Expenses $ 82,000

X

- Definition
Average sale price of stock.
+ References
No definition available.
+ Details

Name: enz_AverageSalePriceOfStock

Namespace Prefix: enz_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum offering price under sales agreement.
+ References
No definition available.
+ Details

Name: enz_MaximumOfferingPriceUnderSalesAgreement

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of commission payable on equity offering.
+ References
No definition available.
+ Details

Name: enz_PercentageOfCommissionPayableOnEquityOffering

Namespace Prefix: enz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options of non vested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: enz_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: enz_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock offering and commissions expenses.
+ References
No definition available.
+ Details

Name: enz_StockOfferingAndCommissionsExpenses

Namespace Prefix: enz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: enz_StockholdersEquityDetailsLineItems

Namespace Prefix: enz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Contingencies
3 Months Ended

Oct. 31, 2015

Loss Contingency [Abstract]

Contingencies Disclosure [Text Block]
Note 13 – Contingencies

On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company could be reduced or be subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. The Company has moved for reconsideration of that decision by the panel and for en banc rehearing by the full Court. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company.

As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The litigation in the United States District Court for the Southern District of New York between the Company and Molecular Probes, Inc. terminated on May 11, 2015, with a settlement in favor of the Company in the amount of $170. Through October 31, 2015, the Company’s former legal counsel, Greenberg Traurig LLP (“GT”), was also engaged in litigation against the Company in the United States District Court for the Southern District of New York concerning GT’s request for a charging lien against another matter relating to its representation of the Company in the Roche and other cases.

On April 22, 2014, the Company as plaintiff finalized and executed a settlement agreement with Affymetrix, Inc. to settle patent litigation actions before the U.S. District Court, Southern District of New York (the “Agreement”) in the amount of $5.1 million. Under terms of the Agreement, Affymetrix paid to the Company $4.3 million and paid to the Company’s attorneys $0.8 million.

On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of GT’s requesting a charging lien for fees allegedly owed for past services rendered to the Company as referenced above. Because the settlement proceeds were held in escrow, and the amount the Company would ultimately receive was indeterminable, the Company has not included the settlement in the financial statements as of or for any periods through October 31, 2015. Any applicable amounts will be recognized when so distributed. On December 3, 2015, the Company entered into a Settlement Agreement with GT pursuant to which the Company and GT resolved their respective claims against each other. The escrow referred to above will be distributed in accordance with the terms of the Settlement Agreement, upon the entry by the Court of the Stipulation, Order and Judgement.

In 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. As of October 31, 2015, the Company carried a balance of $0.4 million as other current liabilities and $0.8 million as a non-current liability. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004-2014.

On July 2, 2015, the Company as Plaintiff executed a settlement agreement with Luminex Corporation with respect to an action between the Company and Abbott Laboratories and Abbott Molecular, Inc (Defendants) and Luminex Corporation (Intervening Defendant) before the United States District Court for the District of Delaware for alleged patent infringement. Luminex paid the Company a total of $7.1 million as consideration for this agreement and the dismissal of the litigation against Luminex.

On July 20, 2015, the Company as a Plaintiff finalized and executed a settlement agreement with Siemens Healthcare Diagnostics Inc. (“Siemens”) to settle a patent litigation lawsuit before the U.S. District Court for the District of Delaware in the amount of $9.5 million. Under terms of the agreement, Siemens will also pay the Company additional royalties of $1.0 million per annum on sales of its molecular products manufactured and/or sold in the United States during the its fiscal years 2015 through 2019 if sales of such products exceed a contractual amount. The net settlement amount was included in other receivables in the consolidated balance sheet as of July 31, 2015 and was received in August 2015.

On October 9, 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in an infringement action brought by the Company regarding its US Patent no. 7,064,197. The case was originally brought by the Company in the United States District Court for the District of Delaware. This settlement is included in statement of operations under Legal settlements, net within the Life Science segment.

The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

X

- References
No definition available.
+ Details

Name: us-gaap_LossContingencyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Name: us-gaap_LossContingencyDisclosures

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Contingencies (Details) $ in Thousands	1 Months Ended					3 Months Ended
Contingencies (Details) $ in Thousands	Oct. 31, 2015 USD ($)	Jul. 31, 2015 USD ($)	Apr. 22, 2014 USD ($)	Nov. 30, 2012	Jun. 30, 2004	Oct. 31, 2015 USD ($)	Apr. 30, 2014 USD ($)	Jun. 20, 2014 USD ($)
Contingencies (Details) [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number					6
Number of Licensee Patents	4					4
Gain Contingency, Patents Found Not Infringed upon, Number				1
Gain Contingencies Prejudgement Interest						$ 12,500
Gain (Loss) Related to Litigation Settlement	$ 170					6,800
Estimated Litigation Liability, Current	10,000					$ 10,000
Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements	6,800
Perkin Elmer [Member]
Contingencies (Details) [Line Items]
Escrow Deposit								$ 7,000
Luminex [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount		$ 7,100
Siemens [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount		9,500
Royalty Revenue		$ 1,000
Agreement [Member] \| Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount			$ 5,100
Proceeds from Legal Settlements			4,300
Litigation Settlement, Expense			$ 800
Subpoena [Member]
Contingencies (Details) [Line Items]
Investigation Period						The time period initially covered by the investigation was from 2004 through 2011
Estimated Litigation Settlement Amount							$ 2,000
Period Over Which Settlement Amount Has to Be Paid							5 years
Estimated Litigation Liability, Current	400					$ 400
Estimated Litigation Liability, Noncurrent	800					800
Additional Payment of Litigation Settlement Amount						$ 1,500
Percentage of Additional Payment of Litigation Settlement Amount over Additional Capital Receipt						20.00%
Indemnification Agreement [Member]
Contingencies (Details) [Line Items]
Gain Contingency, Unrecorded Amount	$ 48,500					$ 48,500
Minimum [Member] \| Siemens [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period		2015
Minimum [Member] \| Subpoena [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period						2004
Amount of Additional Capital Receipt Condition for Litigation Settlement						$ 10,000
Maximum [Member] \| Siemens [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period		2019
Maximum [Member] \| Subpoena [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period						2014

Income taxes (Details)	3 Months Ended
Income taxes (Details)	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	1.90%	3.40%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	34.00%

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Oct. 31, 2015	Jul. 31, 2015
Schedule of inventory, current [Abstract]
Raw materials	$ 1,109	$ 1,013
Work in process	1,984	2,002
Finished products	4,489	4,381
	$ 7,582	$ 7,396

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Income Taxes Paid	$ 27	$ 26
Interest Paid	41	69
Installment Loans Financed Amount	38	$ 19
Capital Lease Obligation Cost Basis	$ 157

Royalty and licensing income (Details) - USD ($) $ in Millions	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Royalty and licensing income (Details) [Line Items]
Patent Expiration Date	Apr. 24, 2018
Life Sciences [Member]
Royalty and licensing income (Details) [Line Items]
Royalty Revenue	$ 0.4	$ 1.0

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
July 31, 2015	$ 27,838
July 31, 2015	(21,683)
July 31, 2015	6,155
Amortization expense	(423)	$ (431)
Amortization expense	(423)	$ (431)
October 31, 2015	27,741
October 31, 2015	(22,034)
October 31, 2015	5,707
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
July 31, 2015	27,838
July 31, 2015	(21,683)
July 31, 2015	6,155
Amortization expense	(423)
Amortization expense	(423)
Foreign currency translation	(97)
Foreign currency translation	72
Foreign currency translation	(25)
October 31, 2015	27,741
October 31, 2015	(22,034)
October 31, 2015	$ 5,707

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Oct. 31, 2015	Jul. 31, 2015
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,741	$ 27,838
Finite-lived intangible assets, Accumulated Amortization	(22,034)	(21,683)
Finite-lived intangible assets, Net	5,707	6,155
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,028
Finite-lived intangible assets, Accumulated Amortization	(10,879)	(10,871)
Finite-lived intangible assets, Net	148	157
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	12,190	12,243
Finite-lived intangible assets, Accumulated Amortization	(7,621)	(7,398)
Finite-lived intangible assets, Net	4,569	4,845
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,016	1,020
Finite-lived intangible assets, Accumulated Amortization	(1,016)	(1,020)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	515	518
Finite-lived intangible assets, Accumulated Amortization	(443)	(441)
Finite-lived intangible assets, Net	72	77
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	2,993	3,029
Finite-lived intangible assets, Accumulated Amortization	(2,075)	(1,953)
Finite-lived intangible assets, Net	$ 918	$ 1,076

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 111	$ 98
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	1	1
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement		1
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 110	$ 96

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 31, 2015	Jul. 31, 2015
Current assets:
Cash and cash equivalents	$ 30,642	$ 18,109
Accounts receivable, net of allowances	12,763	12,109
Other accounts receivable		6,650
Inventories	7,582	7,396
Prepaid expenses and other	1,780	2,222
Total current assets	52,767	46,486
Property, plant and equipment, net	8,132	7,948
Goodwill	7,452	7,452
Intangible assets, net	5,707	6,155
Other assets	338	353
Total assets	74,396	68,394
Current liabilities:
Loan payable	3,013	3,013
Accounts payable – trade	9,450	8,762
Accrued liabilities	12,357	11,297
Other current liabilities	969	886
Total current liabilities	25,789	23,958
Deferred taxes	37	37
Other liabilities	1,357	1,793
Total liabilities	$ 27,183	$ 25,788
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,068,816 at October 31, 2015 and 46,062,065 at July 31, 2015	$ 461	$ 461
Additional paid-in capital	325,077	324,966
Accumulated deficit	(280,248)	(284,682)
Accumulated other comprehensive income	1,923	1,861
Total stockholders’ equity	47,213	42,606
Total liabilities and stockholders’ equity	$ 74,396	$ 68,394

Segment reporting (Details)	3 Months Ended
Segment reporting (Details)	Oct. 31, 2015
Segment Reporting [Abstract]
Number of Reportable Segments	3

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 3 months ended Oct. 31, 2015 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2015	$ 461	$ 324,966	$ (284,682)	$ 1,861	$ 42,606
Balance (in Shares) at Jul. 31, 2015	46,062,065
Net income for the period ended October 31, 2015			4,434		4,434
Vesting of restricted stock (in Shares)	6,751
Share-based compensation charges		111			111
Foreign currency translation adjustments				62	62
Balance at Oct. 31, 2015	$ 461	$ 325,077	$ (280,248)	$ 1,923	$ 47,213
Balance (in Shares) at Oct. 31, 2015	46,068,816

Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities - USD ($) $ in Thousands	Oct. 31, 2015	Jul. 31, 2015
Accrued liabilities [Abstract]
Legal fee expense	$ 4,999	$ 4,183
Payroll, benefits, and commissions	4,717	3,907
Professional fees	491	678
Research and development	300	300
Other	1,850	2,229
	$ 12,357	$ 11,297

Other Liabilities (Details) - USD ($) $ in Thousands	Oct. 31, 2015	Jul. 31, 2015
Other Liabilities (Details) [Line Items]
Other Liabilities, Current	$ 969	$ 886
Accrued Legal Settlement	1,200
Capital Lease Obligation [Member] \| Clinical Labs [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Interest Included in Payments	23
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	579
Other Liabilities, Current	274
Installment Loans [Member] \| Clinical Labs [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	534
Other Liabilities, Current	$ 289

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ 4,434	$ (3,729)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment	527	507
Amortization of intangible assets	423	431
Provision for uncollectible accounts receivable	704	541
Deferred income tax benefit	(3)	(24)
Share-based compensation charges	111	98
Accrual for share-based 401(k) employer match expense	166	145
Foreign exchange loss	129	422
Changes in operating assets and liabilities:
Accounts receivable	(1,376)	(482)
Other receivables – settlements	6,650
Inventories	(210)	107
Prepaid expenses and other	442	182
Accounts payable – trade	682	(1,157)
Accrued liabilities, other current liabilities and other liabilities	474	204
Total adjustments	8,719	974
Net cash provided by (used in) operating activities	13,153	(2,755)
Cash flows from investing activities:
Capital expenditures	(505)	(264)
Security deposits and other	15	5
Net cash used in investing activities	(490)	(259)
Cash flows from financing activities:
Net proceeds from issuance of common stock		2,322
Proceeds from borrowings under Credit Agreement	22,461	22,360
Repayments under Credit Agreement	(22,461)	(22,360)
Installment loan and capital lease obligation payments	(125)	(115)
Net cash (used in) provided by financing activities	(125)	2,207
Effect of exchange rate changes on cash and cash equivalents	(5)	(57)
Increase (decrease) in cash and cash equivalents	12,533	(864)
Cash and cash equivalents - beginning of period	18,109	17,455
Cash and cash equivalents - end of period	$ 30,642	$ 16,591

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Oct. 31, 2015	Jul. 31, 2015
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	46,068,816	46,062,065
Common Stock, shares outstanding	46,068,816	46,062,065

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Oct. 31, 2015	Dec. 02, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		46,069,000
Amendment Flag	false
Entity Central Index Key	0000316253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Oct. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Revenues:
Clinical laboratory services	$ 17,090	$ 15,822
Product revenues	7,687	8,002
Royalty and license fee income	400	1,000
Total revenues	25,177	24,824
Operating expenses:
Cost of clinical laboratory services	10,332	10,130
Cost of product revenues	3,611	3,695
Research and development	867	791
Selling, general, and administrative	10,225	10,285
Provision for uncollectible accounts receivable	704	541
Legal fee expense	1,601	2,466
Legal settlements, net	(6,800)
Total operating expenses	20,540	27,908
Operating income (loss)	4,637	(3,084)
Other income (expense):
Interest	(40)	(69)
Other	54	19
Foreign exchange loss	(130)	(472)
Income (loss) before income taxes	4,521	(3,606)
Provision for income taxes	(87)	(123)
Net income (loss)	$ 4,434	$ (3,729)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.10	$ (0.08)
Diluted (in Dollars per share)	$ 0.10	$ (0.08)
Weighted average common shares outstanding:
Basic (in Shares)	46,068	44,564
Diluted (in Shares)	46,193	44,564

Loan Payable (Details) - USD ($)	3 Months Ended
Loan Payable (Details) - USD ($)	Oct. 31, 2015	Jul. 31, 2015
Debt Disclosure [Abstract]
Line of Credit Facility Expiration Month and Year	December 2016
Line of Credit Facility, Maximum Borrowing Capacity	$ 8,000,000
Line of Credit Facility Additional Borrowings Capacity	4,000,000
Unamortized Debt Issuance Expense	$ 281,000
LIBOR Rate Period	3 months
Debt Instrument, Description of Variable Rate Basis	three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%
Debt Instrument, Basis Spread on Variable Rate	1.25%
Debt Instrument Margin on Variable Rate	4.00%
Debt Instrument Increase in Interest Rate on Default	3.00%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Long-term Line of Credit	$ 3,013,000	$ 3,013,000
Line of Credit Facility Minimum Borrowings	2,000,000
Line of Credit Facility, Remaining Borrowing Capacity	2,400,000
Line of Credit Facility Minimum Liquidity Requirement	3,000,000
Line of Credit Facility Minimum Liquidity Current	11,000,000
Line of Credit Facility Minimum Cash Burn	0
Line of Credit Facility Cash Burn Current	1,400,000
Line of Credit Facility Minimum Cash Burn Excluding Capital Expenditures	7,000,000
Line of Credit Facility Cash Burn Current Excluding Capital Expenditures	$ 33,100,000

Stockholders' Equity (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	3 Months Ended
	Oct. 31, 2015 USD ($) $ / shares shares
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2015 \| shares	1,358,104
Outstanding at July 31, 2015	$ 3.04
Cancelled or expired \| shares	(6,000)
Cancelled or expired	$ 3.61
Outstanding at end of period \| shares	1,352,104
Outstanding at end of period	$ 3.04
Outstanding at end of period	2 years 73 days
Outstanding at end of period \| $	$ 964
Exercisable at end of period \| shares	785,188
Exercisable at end of period	$ 2.87
Exercisable at end of period	1 year 292 days
Exercisable at end of period \| $	$ 664

Net income (loss) per share (Details) - shares	3 Months Ended
Net income (loss) per share (Details) - shares	Oct. 31, 2015	Oct. 31, 2014
Weighted Average Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Included In Computation Of Earnings Per Share Amount	125,000
Unvested Restricted Stock [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		482,000
In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		482,000
Outstanding Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	374,000	142,000

Stockholders' Equity (Details) - USD ($)	3 Months Ended
Stockholders' Equity (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014	Jul. 31, 2015	Dec. 31, 2014
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01		$ 0.01
Maximum Offering Price Under Sales Agreement	$ 20,000,000			$ 20,000,000
Percentage of Commission Payable on Equity Offering	3.00%
Proceeds from Issuance of Common Stock		$ 2,322,000
Excess Tax Benefit from Share-based Compensation, Financing Activities	$ 0	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	11 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 100,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms	21 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 21,000	$ 35,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	1,309,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)		505,829
Average Sale Price of Stock (in Dollars per share)		$ 5.38
Stock Offering and Commissions Expenses		$ 82,000